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1 Abstract 
Protein phosphorylation is a post-translational modification that plays a significant role in many cell 
processes and regulatory pathways. In eukaryotic cells, six percent of total protein phosphorylation 
occurs on the nitrogen atoms of the imidazole moiety of histidine. While phosphate esters (P-O bond) 
are relatively stable to hydrolysis, phosphoramidates (P-N bond) hydrolyze easily. Hydrolysis of 3-
phosphohistidine 7 (pHis) is even faster under acidic conditions, since the protonated imidazole behaves 
as an excellent leaving group. Therefore, research focused on phophorylated histidine containing 
proteins is complicated by the lack of analytical techniques that are compatible with pHis’s inherent 
instability. Following the success of phosphotyrosine antibodies, attempts have been made to raise 
antibodies specific for pHis containing peptides. However, pHis itself cannot be used for immunisation as 
the phosphoramidate is hydrolyzed before a strong immune response can be realized. Therefore, a new 
pHis analogue 63 was designed and synthesized. This mimic closely resembles pHis’s electronic and 
structural properties under physiological conditions, due to the conserved imidazole ring, while the P-N 
bond is exchanged for a stable P-C bond. In order to raise antibodies the pHis mimic should be 
incorporated into a peptide. Therefore, the mimic was decorated with protective groups suitable for 
Fmoc-based SPPS (65). 
 
 7 63 65 
Various routes have been investigated to synthesize 65. The successful retrosynthetic strategy involved 
coupling of compound 66 with an Alloc/allyl protected aspartic acid to yield amide 119. Compound 66 
was made via a nine step sequence, which included the activation of compound 113 as a triflate 
followed by substitution with TMGA. A dppe promoted aza-wittig ring closing reaction of the amide was 
used to form the imidazoline. Aromatization of the imidazoline was realized by base induced elimination 
of the tosylate to yield 136. Several protecting group manipulations gave final compound 65 in 22.7 
percent yield over 15 steps. 
 
 113 66 
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The resulting compound 65 was used to synthesize several peptides, of which two have been employed 
to raise antibodies. These antibodies successfully recognized natural pHis, both in dot blot tests with 
pHis containing peptides, as well as in cell lysates. These antibodies can be used in the near future to 
study the biological functions of pHis. 
In order to study the related enzyme PHPT1, responsible for phophohistidine dephosphorylation, a 
library of 5-phosphonic acid imidazoles with various substituents on C-2 has been synthesized to act as a 
starting point for the development of a PHPT1 inhibitor. The synthetic strategy described for the 
synthesis of mimic 65 was applied to generate this compound set.  
The antibodies, inhibitors and other tool compounds described in this thesis provide an invaluable 
toolset to increase the understanding of phosphorylation. 
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2 Zusammenfassung 
Die Proteinphosphorylierung ist eine posttranslationale Modifikation, die eine entscheidende Funktion 
in vielen zellulären Prozessen und regulatorischen Signalwegen erfüllt. Sechs Prozent der gesamten 
Proteinphosphorylierungen in eukaryotischen Zellen geschieht an den Stickstoffatomen der 
Imidazolgruppe von Histidin. Während Phosphatester (P-O Bindung) relativ hydrolysestabil sind, 
werdenPhosphoramidite (P-N Bindung) leicht hydrolysiert. Die Hydrolyse von 3-Phosphohistidin 7 (pHis) 
geschieht unter sauren Bedingungen noch schneller, da protoniertes Imidazol eine exzellente 
Abgangsgruppe darstellt. Aus diesem Grund wird die Untersuchung von phosphoryliertenHistidinen 
innerhalb von Proteinen durch das Fehlen von analytischen Methoden, die mit der inhärenten 
Instabilität des pHis kompatibel sind, erschwert. Dem Beispiel der erfolgreichen Phosphotyrosin-
Antikörper folgend, wurden Versuche unternommen Antikörper zu generieren, die spezifisch pHis 
innerhalb von Peptiden erkennen. pHis selber kann jedoch nicht für Immunisierungen verwendet 
werden, weil das Phosphoramidit hydrolysiert wird, bevor eine starke Immunantwort realisiert werden 
kann. Deshalb wurde ein neues pHis Analogon 63 entworfen und synthetisiert. Das Analogon imitiert die 
elektronischen und strukturellen Eigenschaften von pHis unter physiologischen Bedingungen aufgrund 
des konservierten Imidazolringes, während die P-N Bindung durch eine stabile P-C Bindung ersetzt 
wurde. Um Antikörper zu generieren, sollte das pHis Analogon in einen Peptid integriert werden. Daher 
wurde das Analogon mit Schutzgruppen versehen, die den Einsatz in Fmoc SPPS erlauben (65). 
 
 7 63 65 
Zur Synthese von 65 wurden verschiedene Syntheserouten untersucht. Die erfolgreiche 
retrosynthetische Strategie beinhaltet die Kupplung von Verbindung 66 mit Alloc/Allyl geschützter 
Asparaginsäure, um das Amid 119 zu erhalten. Verbindung 66 wurde in einer Neun-Stufen-Synthese 
hergestellt, die eine Aktivierung von Verbindung 113 als Triflat, gefolgt von einer Substitution mit TMGA, 
beinhaltete. Ein dppe-vermittelteAza-Wittig Ringschlussreaktion des Amids wurde zur Bildung des 
Imidazolins eingesetzt. Aromatisierung des Imidazolinsdurch Eliminierung des Tosylates unter basischen 
Bedingungen ergab 136. Verschiedene Manipulationen der Schutzgruppen ergaben die finale 
Verbindung 65 in 22.7 Prozent Ausbeute über 15 Stufen.  
 
 113 66 
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Verbindung 65 wurde zur Synthese verschiedener Peptide eingesetzt, von denen zwei zur 
Antikörpergenerierung verwendet wurden. Diese Antikörper erkennen erfolgreich natürliches pHis, 
sowohl in Dot-Blot Tests mit pHisinnerhalb von Peptiden, als auch in Zelllysat. In naher Zukunft werden 
diese Antikörper für die Untersuchung der biologischen Funktionen von pHis eingesetzt werden. 
Um das in Beziehung stehende Enzym PHPT1, das für die Dephosphorylierung von Phosphohistidin 
verantwortlich ist, zu untersuchen, wurde eine Bibliothek von 5-Phosphonsäure Imidazolen mit 
verschiedenen Substituenten an C2-Position synthetisiert, die als Ausgangspunkt für die Entwicklung von 
PHPT1 Inhibitoren dient. Die beschriebene Synthesestrategie für Verbindung 65 wurde zur Generierung 
dieser Bibliothek angewendet. 
Die Antikörper, Inhibitoren und andere Hilfsmittel, die in dieser Dissertation beschrieben werden, 
gewährleisten einen wertvollen Ansatz, um das Verständnis von Proteinphosphorylierung zu erweitern. 
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3 List of Abbreviations 
AA amino acid 
Ac acetyl 
ad (NMR) apparent doublet 
All allyl 
Alloc allyloxycarbonyl 
aq. aqueous 
ATP adenosine triphosphate 
Bn benzyl 
Boc tert-butoxycarbonyl 
br  broad 
Bu butyl 
Bz benzoyl 
°C degrees Celcius (centigrade) 
calc. calculated 
CAN ceric ammonium nitrate 
Cbz benzyloxycarbonyl 
CDI carbonyldiimidazole 
m-CPBA meta-chloroperoxybenzoic acid 
CTAN cerric tetrabutylammonium nitrate 
d (NMR) doublet 
DABCO 1,4-diazabicyclo[2.2.2]octane 
dba dibenzylidene acetone 
DBU  1,8-diazabicyclo [5.4.0]undec-7-ene 
dd (NMR) doublet of doublets 
DDQ 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 
DCC N,N-dicyclohexylcarbodiimide 
DCM dichloromethane 
DIAD diisopropyl azodicarboxylate 
DIB (diacetoxyiodo)benzene 
DIC diisopropyl carbodiimide 
DIPEA diisopropylethylamine 
DMAD dimethyl azodicarboxylate 
DMAP 4-dimethylaminopyridine  
DMB 2,4-dimethoxybenzyl 
DMBA 2,4-dimethoxybenzaldehyde 
DMF N,N-dimethylformamide 
DMP Dess-Martin periodinane 
DMSO dimethyl sulfoxide 
DMTSF dimethyl(methylthio)sulfonium tetrafluoroborate 
DBP dibenzylphosphite 
dppa diphenylphosphoryl azide 
dppe ethane-1,2-diylbis(diphenylphosphane) 
dppf 1,1'-bis(diphenylphosphino)ferrocene 
dt (NMR) doublet of triplets 
e.e. enantiomeric excess 
EDC 3-(ethyliminomethyleneamino)-N,N-dimethyl-propan-1-amine 
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EDT ethane dithiol 
equiv equivalents 
ESI electrospray ionization 
Et ethyl 
et al. et alia (and others) 
Fmoc 9-fluorenylmethoxycarbonyl 
h hours 
HATU 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate 
methanaminium 
HBTU O-benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate 
HOAt 3-Hydroxytriazolo[4,5-b]pyridine 
HOBt N-hydroxybenzotriazole 
HPLC  high performance liquid chromatography 
HRMS high resolution mass spectrometry 
iPr isopropyl 
IR infrared 
HMDS bis(trimethylsilyl)amine 
KLH keyhole limpet hemocyanin 
LCMS high performance liquid chromatography mass spectrometry 
m (NMR) multiplet 
Me methyl 
MeCN acetonitrile 
min minutes 
mp melting point 
MS mass spectrometry 
Ms mesyl 
m/z mass to charge ratio 
NDPK nucleoside diphosphate kinases 
NBS N-bromosuccinimide 
NMP 1-methyl-2-pyrrolidone 
NMR nuclear magnetic resonance 
Ns 4-nitrobenzenesulfonyl 
o ortho 
OSu hydroxysuccinimide 
p phospho 
p para 
Pbf 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl 
PCC pyridinium chlorochromate 
PEG polyethyleneglycol 
PEPPSI pyridine-enhanced precatalyst preparation stabilization and initiation 
Ph phenyl 
PHP phosphohistidine phosphatase 
PMB 4-methoxybenzyl 
ppm parts per million 
PPTS pyridinium p-toluenesulfonate 
PTM posttranslational modification 
PyBrOP bromo-tris-pyrrolidino phosphoniumhexafluorophosphate 
q quartet 
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quant. quantitatively 
Rf retention factor 
rt room temperature 
s singlet (NMR) 
sat. saturated 
S-Phos 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl 
SPPS solid phase peptide synthesis 
t (NMR) triplet 
TBS tert-butyldimethylsilyl 
tBu tert-butyl 
Tf trifluoromethanesulfonyl 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TIPS triisopropylsilane 
TLC thin layer chromatography 
TMGA N,N,N’,N’-tetramethylguanidinium azide 
TMP 2,2,6,6-tetramethylpiperidine 
TMS trimethylsilyl 
TPAP tetrapropylammonium perruthenate 
TPS 2,4,6-triisopropylbenzenesulfonyl 
Tr trityl (triphenylmethyl) 
Ts p-toluenesulfonyl 
VS,max local surface maximum 
VS(r) surface electrostatic potential 
XantPhos 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene  
X-Phos 2-dicyclohexylphosphino-2’,4’,6’,-triisopropylbiphenyl 
 
Amino acids 
Ala  alanine (A) 
Arg  arginine (R) 
Asn  asparagine (N) 
Asp aspartate (D) 
Cys cysteine (C) 
Gly glycine (G) 
Glu glutamate (E) 
Gln glutamine (Q) 
His histidine (H) 
Ile isoleucine (I) 
Leu leucine (L) 
Lys lysine (K) 
Met methionine (M) 
Phe phenylalanine (F) 
Pro proline (P) 
Ser serine (S) 
Thr threonine (T) 
Trp tryptophane (W) 
Tyr tyrosine (Y) 
Val valine (V) 
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5 Introduction 
Diseases are often related to aberrant function of the biological machinery. In order to understand these 
diseases knowledge of the particular malfunction and the underlying mechanisms is of crucial 
importance. Using this knowledge, eventually ways can be found to alter the malfunction or the specific 
pathway, usually by a small molecule. In this regard, post-translational modifications (PTMs) are of 
particular interest, since PTMs are responsible for all structural changes proteins undergo after 
ribosomal synthesis.  
Posttranslational modifications are essential for protein function, and about five percent of the 
eukaryotic genome is dedicated to enzymes effecting PTMs. Several types of PTMs are known, the most 
well-studied are: acylation, alkylation, glycosylation, oxidation and phosphorylation.[1] Of these five, 
phosphorylation is arguably the most widespread and investigated post-translational modifications in 
eukaryotic organisms. In the human proteome alone, more than 500 kinases responsible for 
phosphorylation are known, divided over several sub-groups.[2] 
PTMs in general, and phosphorylation in particular, induce conformational changes in proteins, thereby 
changing their function. In the case of phosphorylation the conformational change is induced by the 
introduction of an anionic phosphate, which changes the local hydrogen bonding pattern. Additionally, 
the presence of an anionic phosphonate changes the electrostatic properties of the protein. Often, 
phosphorylation acts as an on/off switch, changing the protein from an inactive to an active 
conformation. Phosphorylation has been shown to be involved in numerous diseases, most prominently 
various forms of cancer, by constitutively activation of its target protein. Therefore, kinase inhibition has 
become a common strategy in the pharmaceutical industry, spearheaded by the success of Gleevec, an 
inhibitor of tyrosine kinase that is used in the treatment of leukemia and other types of cancer.[3] 
Understanding the effects and causes of protein phosphorylation is of critical importance and many 
techniques have been developed to aid in their study. Whereas O-phosphorylation has been widely 
studied, the effect of N-phosphorylation remains unclear. The short life-time of such N-phosphorylated 
enzymes hampers the studies. In order to understand N-phosphorylation, a chemical biology approach 
could be pursued.  
Chemical biology is the science of understanding biological processes through the use of synthetic 
chemistry.[4] Organic chemistry is employed to synthesize tool compounds that can be used to 
investigate and manipulate biological systems. A recent example of this strategy by the group of 
Hedberg involves the synthesis of a solid phase peptide synthesis (SPPS) ready adenylylated tyrosine 
building block. This building block was used to synthesize peptides that were used to raise antibodies 
specific for adenylylated tyrosine. These antibodies can be used to investigate the functions of this 
PTM.[5] 
In this thesis, efforts towards the understanding of N-phosphorylation of histidine will be described. For 
this reason, a stable phosphorylated histidine analog has to be designed and synthesized. Before the 
design and synthesis of this analog will be described, a short overview of the current state of research 
will be given, divided in a biological background of phosphorylation and synthetic strategies to obtain 
imidazoles.   
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5.1 Phosphorylation 
The first phosphorylated protein was discovered in 1906 by Levene and coworkers. It took many years of 
work before the phosphorylated amino acid was identified to be serine.[6] Since then, it has been 
discovered that about 30 percent of the proteins in mammalian cells are phosphorylated at any time.[7] 
80 percent of all phosphorylation occurs on the hydroxy functionalities of three amino acids: serine, 
threonine and tyrosine.[8] While O-phosphorylation is the best studies type of phosphorylation it is not 
the only type. To date six more amino acids are known to be phosphorylated: arginine, aspartate, 
cysteine, glutamate, histidine and lysine.[9] Since phosphohistidine (pHis) is the focus of this work it will 
be discussed in more detail. 
5.1.1 O-phosphorylation 
The most common form of phosphorylation is O-phosphorylation, which occurs on the residues of 
serine, threonine and tyrosine. Serine is by far the most commonly phosphorylated amino acid followed 
by threonine. Tyrosine phosphorylation is quite rare; however, since anti-phosphotyrosine antibodies 
can detect phosphotyrosine very well, it has been extensively studied. 
 
 1 2 3 
Figure 1: O-phosphorylated amino acids pSer (1), pThr (2) and pTyr (3). 
There is a wide range of kinases and phosphatases linked to these amino acids and their 
phosphorylation has numerous biological functions. For an overview of this field one can turn to several 
excellent literature sources.[7, 8b, 10] 
5.1.2 N-phosphorylation 
As mentioned before, N-phosphorylation represents a significant amount of all protein phosphorylation 
in organisms. Besides histidine, there are two other basic amino acids that get phosphorylated: Arginine 
and Lysine (figure 2). Little is known about these phospho-amino acids due to the instability of the 
phosphoramidate bond. Several of the kinases and phosphatases that have these amino acids as 
substrates have been found and some reports exist on proteins containing pArg and pLys.[11] 
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 4 5 
Figure 2: N-phosphorylated amino acids pArg (4), and pLys (5). 
Not many proteins that contain Arginine or Lysine residues that are phosphorylated are known. The few 
that are known include: Histones H1 and H3,[12] Myelin basic protein[13] and VP12, a basic internal core 
protein of the virus Plodia interpunctella.[14] 
Regrettably, little is known about the biological function of both these phosphorylated amino acid. 
While their abundance does not rival that of phosphohistidine, they might still be involved in important 
processes and should be investigated further. 
5.2 Phosphohistidine 
Compared to the O-phosphorylated amino acids, pHis was discovered fairly recently in 1947, when 
Severin and coworkers synthesized pHis for the first time.[15] It was identified for the first time in a 
biological setting in 1963 by Boyer, who discovered pHis in rat liver mitochondria.[16] Subsequent 
research revealed that pHis is of crucial importance in prokaryotes, which have two-component histidine 
kinase signaling pathways that enable these organisms to react to different kinds of stimuli (paragraph 
5.2.2). In eukaryotes, pHis has been found in high concentration, in the slime mold Physarum 
polycephalum pHis makes up six percent of all phosphoamino acids of its basic nuclear proteins.[17] The 
importance of pHis in higher eukaryotes has not been sufficiently studied to date as pHis’s chemical 
properties (its instability) make it difficult to study. There are two biologically relevant phosphohistidine 
isomers, 1- and 3-pHis (figure 3, 6 and 7), of which 3-pHis is the more stable one. 
 
 6 7 
Figure 3: 1- and 3-pHis at pH 8.[18] 
Recently, pHis has been discovered in several proteins of higher eukaryotes. Among these proteins are: 
Rat ATP-citrate lyase,[19] KCa3.1 ion channel,[20] β-subunit of G proteins[21] and the N-terminus of histone 
H4.[22] These instances of histidine phosphorylation were discovered by studying histidine phosphatases 
and kinases and mutational studies. Additionally, there was a recent publication describing a possible 
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connection between a phosphohistidine phosphatase and certain lung cancer cell migration and 
invasion properties.[23] 
5.2.1 Phosphatases and kinases 
In vertebrates only one type of histidine phosphatase and one type of histidine kinase are known. These 
two enzyme types are the Nucleoside diphosphate kinases (NDPK’s), which phosphorylate histidine and 
Phosphohistidine phosphatase (PHP), which removes the phosphate from pHis.[24] NDPK’s are found in 
almost all organisms, while PHP is restricted to higher eukaryotes, it is one of the smallest enzymes 
known with a weight of 14 kD. 
5.2.1.1 NDPK’s 
Of the nine known isoforms of NDPK only two, NDPK-A and NDPK-B, have been known to phosphorylate 
histidine. NDPK’s influence various processes in the cell, such as nucleotide metabolism, regulation of 
tumor metastasis, cell differentiation and cell motility. They are not exclusively histidine kinases but also 
phosphorylate aspartate, serine and threonine in some proteins. As histidine kinases they target the 
proteins mentioned in the previous paragraph, except for the histone: Rat ATP-citrate lyase, KCa3.1 ion 
channel and β-subunit of G proteins. It is not known which protein phosphorylates the histone H4 
histidine. NDPK’s mode of action involves autophosphorylation on a histidine, using ATP, followed by 
transfer of the phosphate to the target protein.[25] 
5.2.1.2 PHP 
PHP has been first identified by Zetterqvist in 2002,[26] and the first structure was obtained by Hallberg 
and coworkers in 2006.[27] These studies showed that the protein is not similar to any known 
phosphatase. As mentioned before, it is unusually small (14 kD) and it is not completely clear whether 
its active form is a monomer or a trimer.[24] Mutational studies have shown that Arg45, His53 and His102 
are important for the phosphatase function and may contribute to the mechanism of action.[27-28] The 
substrates of this enzyme are the same as for the NDPK’s. 
On the other hand, several other phosphatases and kinases are known to occur in prokaryotes.[29]  
5.2.2 Two component system 
The phosphohistidine kinase two component signaling systems are ubiquitous in prokaryotes (bacteria) 
and to an extent in lower eukaryotes (fungi and plants). These systems play a large role in the 
interaction between an organism and its environment. The systems are used as sensors that can sense a 
variety of external variables including: temperature, pH, osmotic pressure and availability of 
nutrients.[30] A well-known example is ethylene induced fruit ripening in plants, which is regulated by 
histidine kinase activity of ethylene receptors.[31] 
The two component signaling system comprises five active domains, divided over two proteins. These 
two proteins are: (1) a histidine kinase, containing an extracellular sensing domain, a histidine substrate 
domain and a kinase domain. (2) the response regulator, containing the aspartate substrate domain and 
the effector (figure 4). The substrate domain on the histidine kinase also doubles as a dimerization 
domain; the kinase proteins are always present as dimers when active.  
27 
 
 
Figure 4: schematic representation of the two component signaling system. 
When the sensing domain senses an event, the two monomers phosphorylate each other’s histidine 
residue, using ATP.  The resulting unstable phosphoryl group is then transferred to an aspartate on the 
response regulator protein. This in turn activates the effector, resulting in a cell response, such as 
change in flagella motion or a change in transcription.[32] 
There is a variety of two component systems, including those with more components, but each is 
dependent on the easily transferred phosphoryl group on histidine. For a more in depth look on 
phosphohistidine kinase two component signaling systems there are excellent reviews by Stock,[33] 
Dhillon[34] and Grefen[31].  
5.3 Properties of Phosphohistidine 
As mentioned before, the biological function of phosphohistidine is dependent on the ease with which it 
can transfer its phosphate group. While this property is useful in its biology it has made pHis difficult to 
study. This section will discuss the reasons behind the pHis instability and some attempts made to 
circumvent it and analyze the biological functions of pHis. 
5.3.1 Phosphohistidine Nomenclature 
The numbering of the phosphohistidine isomers is somewhat confusing. In the literature isomer 6 is 
designated as the 1-isomer while compound 7 is the 3-isomer. However, according to the IUPAC rules 
the naming should be reversed as the substituent on the imidazole should always have the lowest 
possible number when the nitrogen substituent is the same (figure 5: 6b). To avoid confusion when 
comparing to the literature the conventional naming will be used for phosphohistidine (making 6a 1-
pHis), all other imidazoles will be named according to IUPAC rules. 
 
 6a 6b 
Figure 5: 1-pHis using conventional (literature) numbering (6a) and using IUPAC numbering (6b). 
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5.3.2 Phosphohistidine stability 
The lifetime of phosphohistidine is dependent on its environment; in outside of a small pH range (pH 8 – 
9.5), it is highly unstable. This makes it difficult to measure or analyze phosphohistidine, unlike the O-
phosphorylated amino acids mentioned before. There is a stark difference in stability between 
phosphate esters and phosphoramidates. The ΔG° of hydrolysis of a phosphoester is between -6.5 and -
9.5 kcal mol-1, while for a phosphoramidate the ΔG° of hydrolysis is between -12 and -14 kcal mol-1.[33] 
This is due to the fact that phosphoramidate nitrogens are basic. Therefore they are protonated at 
acidic-, and even at neutral pH, greatly improving their leaving group ability. When considering the 
reasons behind this one might expect enhanced stability from donation of the nitrogen lone pair into 
the P=O π*-orbital, thereby giving some double bond characteristics to the P-N bond. However, the 
donation of the nitrogen lone pair, is not a major contributor to the phosphoramidate electronic 
structure. Since the phosphorus d-orbital is involved in the P=O π-bond and overlap between this d-
orbital and the lone pair orbital of the nitrogen is very poor. Therefore, the lone pair is not donated to 
the phosphorus and there is little or no double bond characteristic in the phosphoramidate bond (figure 
6). 
 
Figure 6: canonical resonance structures of a phosphoramidate. 
In the case of pHis the effect is even more pronounced, as donation from the nitrogen lone pair to the 
phosphorus would break the aromaticity of the imidazole (figure 7: A). Additionally, the acid sensitivity 
of pHis is even greater than for other phosphoramidates, though the phosphoramidate nitrogen in pHis 
is not basic, due to the aromaticity loss upon protonation at that nitrogen. The other nitrogen on the 
imidazole however, is basic. Its protonation not only leads to a reduction of the electron density on the 
phosphoramidate, making it more electrophilic. It also makes the imidazole an excellent leaving group 
as the ejected imidazole is a neutral species (figure 7: B).[32c] Therefore, pHis’s reactivity is closer to that 
of an acyl transfer reagent, like CDI or even an acyl chloride, than a phosphate ester or an amide.[35] 
 Figure 7: donation of the nitrogen lone pair leads to loss of aromaticity (A). Protonated imidazole is an excellent leaving group (B). 
Due to their general instability and their acid sensitivity 1- and 3-pHis have very short half-lives under 
normal acidic phospho-protein partial digestion conditions. In 1M HCl at 49°C 1- and 3-pHis have a half-
live of 18 and 25 seconds respectively,[36] compared to 18 hours for phosphoserine and 
phosphothreonine and 5 hours for phosphotyrosine.[37] Both pHis isomers are stable under basic 
conditions, because the imidazole is not protonated under those conditions.  
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The inherent instability of phosphohistidine makes it an excellent phosphoryl transfer residue, a 
function for which it is extensively used in biological systems. 
5.4 pHis analysis 
A myriad of methods is used to detect phosphorylated proteins, including: partial acid hydrolysis, mass 
spectrometry, sample fractionation, 31P NMR, gel separation, affinity purification and immuno-based 
techniques.[11, 32b] However, most of these methods use acidic conditions, and are therefore not suitable 
to be used for the detection of acid labile phosphohistidine. Not only the detection of pHis complicated, 
its instability also requires special measures during sample preparation and work-up. For example a 
study on the tryptic digests of CheA, a part of the bacterial two component signaling system, used a 
combination of HPLC-ESI-MS and element mass spectroscopy under acidic conditions. Initially 40 
percent phosphorylation was measured, but after one hour the fraction of phosphorylated peptide had 
fallen to 10 percent.[38] 
It is possible to perform partial alkali hydrolysis of a peptide to preserve pHis, but pSer and pThr are not 
stable under those conditions and are lost. Trypsination also produces protein fragments containing 
intact pHis, however most methods to analyze the fragments require acidic conditions. Moreover, these 
methods cannot differentiate between 1- and 3-pHis.  Additionally, due to pHis’s instability one cannot 
be completely sure no sample degradation has taken place before measuring, leading to a problem with 
underestimation of the amount of pHis present.  
These problems could be solved with the availability of a pHis specific antibody, as was the case when a 
phosphotyrosine-specific antibody was raised.[39] However, raising antibodies specific for pHis is very 
difficult, for the same reasons that make its detection difficult, its instability. If pHis is introduced in an 
animal for the purpose of antibody generation (see chapter 5.5), it decomposes before a strong immune 
response can be realized. A non-hydrolysable mimic of pHis would help to generate these antibodies 
and some compounds have been tested, with limited success. 
Several non-hydrolysable mimics have been synthesized; among them are a pyrrole analog 8,[32c] a furan 
analog 9,[40] a thiophosphoryl analog 10[41] and a triazole analog 11.[42] Of these four, only two have been 
reported to be used in attempts to raise antibodies specific for pHis (8 and 11). Antibodies raised using 
pyrrole analog 8 were selective for the analog but did not show any affinity for pHis containing peptides. 
During the course of the thesis the triazole analog 11, designed and synthesized in the group of Muir, 
was incorporated into a peptide using SPPS. The resulting peptides were immunized in rabbits and 
antibodies were obtained that were specific for pHis containing peptides. However, they did not report 
on the affinity of their antibodies for pHis. Therefore, it is not sure if their antibodies are qualitatively 
good enough to study histidine phosphorylation. 
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Figure 8: non-hydrolyzable phosphohistidine analogs. 
The reason why the analogs mentioned above are not successful in raising high affinity antbodies for 
pHis is that although they are structurally similar, their electronic properties are widely different. A more 
in depth look at these analogs will be given in chapter 7. 
This thesis will describe the design and synthesis of a pHis analog that resembles histidine both 
electronically and structurally. This will be achieved by conserving the imidazole of pHis and synthesizing 
an imidazole containing mimic. The design of this analog will be discussed in chapter 7. 
5.5 Antibody generation 
Antibodies are powerful tools in biochemistry and biology. Their high specificity and binding affinity 
ensures their use as reagents in protein recognition. Antibodies are generally raised using native or 
recombinant proteins, however, it is also possible to use peptides, including phosphorylated peptides, as 
haptens in antibody generation. Peptides themselves are too small to generate a significant immune 
response. Therefore, they are usually attached to a carrier protein, most commonly keyhole limpet 
hemocyanin (KLH). The peptides can be attached to the carrier protein by coupling with an exposed 
amino acid on the protein surface. Several bond types can be used for the conjugation of peptides to 
their carrier proteins, coupling using a thiol on a cysteine that is incorporated on one end of the peptide 
is ideal. Using other residues (amino, hydroxyl, carbonyl) has the disadvantage that they present a much 
larger fraction of the amino acids in proteins, encouraging multipoint attachment.  
Designing the right peptide to generate antibodies that can recognize the target protein is of critical 
importance in antibody generation. A greater chance of obtaining antibodies with a good titer can be 
realized if the peptides are from a part of the protein sequence that is on the surface, hydrophilic and 
flexible. Furthermore, it is important to choose sequences at the N- or C- terminus of the protein 
because these regions are usually on the surface of the protein. Ideal peptide length has been shown to 
be between eight and 20 amino acids. Longer peptides might lose specificity while antibodies raised 
with shorter peptides might not recognize the protein. Acylation of the N-terminus and and a C-terminal 
amide are also important to better mimic the protein. Other variables to consider are peptide stability, 
ease of peptide synthesis and conjugation and immunogenicity of the host animal.[43] 
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After the peptides have been designed, synthesized and attached to the carrier protein, they are 
injected into the host animal. A wide variety of animals are used for this purpose, such as mice, rabbits, 
chickens, pigs, cows and horses. Animal selection is mainly based upon the amount of antibody required 
and the cost. The peptides are injected together with an adjuvant, which is a mixture of chemicals 
designed to illicit a strong immune response. A commonly used adjuvant is Freund’s complete adjuvant, 
which contains cell membranes of mycobacteria tuberculosis, paraffin oil and mannide monooleate. 
Since it is highly toxic (immunogenic shock) to the host animal, other adjuvants have been used as 
replacement recently.[44] After the initial injection, several booster injections can be administered to 
maintain a strong immune response. The time it takes to raise antibodies depends on the animal used; 
usually there are several points of serum collection finalized by the terminal bleed at the end. 
 The collected serum is purified by affinity purification. In the case of phospho-peptides two affinity 
columns are used; first a column functionalized with the phospho-peptide is used to obtain only 
antibody that recognize the correct sequence. Second a depletion step is performed over the native, un-
phosphorylated peptide to remove all antibodies that bind the non-phosphorylated peptide. 
This workflow typically results in high titer, polyclonal antibodies that can be used in biochemical 
experiments to detect the presence of their respective antigen. 
5.6 Solid Phase Peptide synthesis 
Solid phase peptide synthesis (SPPS) is the default method for the synthesis of peptides. The method 
was pioneered by Merrifield in 1963.[45] The method involves the immobilization of an amino acid on a 
resin, followed by a stepwise build-up of the peptide chain. The advantage of having the growing 
peptide chain attached to a solid resin is that after each coupling step all reagents can simply be washed 
away. Since many peptides are quite long (between 10 and 50 amino acids) and require many coupling 
steps, purification by any other method becomes impossible. To prevent side reactions the amino acids 
are protected using a range of protecting groups. The correct choice of these groups is of critical 
importance; the right protecting groups should be removed at the right time. There are two main 
methods of peptide chain protection, the Fmoc- and the boc-method. The Fmoc method is the most 
widely used method at the moment and was used for all peptides described in this thesis; thus it will be 
the focus of this paragraph. 
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The Fmoc method refers to the protecting group that protects the N-terminus of the peptide. The first 
amino acid is connected to the resin at the C-terminus, this can be done using a variety of linkers, which 
can impart different functionality to the C-
terminus upon cleavage. The peptide 
synthesis starts with deprotection of the 
Fmoc group on the terminal amino acid using 
a base (usually a piperidine solution). The 
resin is washed, a second Fmoc protected 
amino acid is added together with a coupling 
reagent, which extends the peptide by one 
amino acid. Finally, the peptide is washed 
and sequence can be started again (figure 9). 
When the desired peptide is synthesized it 
can be cleaved from the resin, in the case of 
the Fmoc method this is usually done with an 
acidic cleavage step. If the protecting groups 
on the amino acids are well chosen, they will 
also be cleaved during this step. The group 
on the C-terminus of the peptide after 
deprotection is determined by the linker – 
resin combination that is used. Since the peptides in this thesis were needed for antibody generation a 
tentagel resin with an S-RAM linker was used, yielding an amide at the C-terminus after peptide 
cleavage.[46] 
After cleavage and global deprotection the peptide is first roughly purified by ether precipitation, which 
removes most of the organic impurities. Then the peptide is purified by preparative HPLC. The overall 
yield of a peptide synthesis sequence is very much dependent on the amino acid sequence and length. 
5.7 Imidazole review 
Compared to other five membered heterocycles 1H-imidazoles have some unique properties due to the 
fact that it contains two nitrogens. The properties include its basicity, ability to form hydrogen bonds 
and leaving group ability. 1H-Imidazoles are present in a variety of natural products but is most well 
known as the defining structural feature of the amino acid histidine.[47] They are used, among others,  as 
pharmaceuticals,[48] ionic liquids,[49] and organometallic chemistry (mostly as N-heterocyclic 
carbenes).[50] In this chapter, first the properties of 1H-imidazoles will be discussed, followed by some 
synthesis strategies used to make them. 
5.7.1 Imidazole properties 
Imidazoles are five membered aromatic heterocycles containing two nitrogen atoms in a 1-3 
relationship. There are three isomers that are called imidazoles, 1H-imidazoles (12), 2H-imidazoles (13) 
and 4H-imidazoles (14) (figure 10). There are large differences between these three compounds, most 
notably, 2H- and 4H-imidazoles are not aromatic, while 1H-imidazoles are. This imparts stability to 1H-
imidazoles, in fact unsubstituted 2H- and 4H-imidazoles have not been synthesized as they rearrange to 
 
Figure 9: Fmoc SPPS flowchart. 
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the 1H-imidazole isomer immediately. 2H- and 4H-imidazoles that have large substituents on C-2 and C-
4 respectively, or are part of ring systems can be synthesized and are used in dyes, semiconductor 
chemistry and as reactive intermediates.[51] However, they are not as important and widely studied as 
their 1H-imidazole counterpart.  
 
 12 13 14 
Figure 10: Imidazole numbering 1H-imidazole (12), 2H-imidazole (13) and 4H-imidazole (14). 
The atom count of imidazoles start at the substituted nitrogen, proceeds to the other nitrogen via the 
shortest path and continues to the final carbon. Imidazoles that have a hydrogen substituent at the 
nitrogens are present as a mixture of tautomers. If these imidazoles have a substituent on the four or 
five position they are designated as 4(5)-substituted imidazoles (figure 11). 
 
 15a 15b 
Figure 11: 4(5)-methyl imidazole. 
Compared to other five membered heterocycles imidazoles have a high boiling point of 256°C. This is 
due to the formation of hydrogen bonds between the individual imidazole molecules (figure 12: A). The 
imine nitrogen of imidazole is basic (pKa 7.0) and can easily donate to an N-hydrogen of another 
imidazole (figure 12: B). Imidazole is such a strong base because the positive charge of the protonated 
imidazole can be shared over both nitrogens (figure 12: C).[52] 
 
Figure 12: A: pKa of several positions on the imidazole. B: hydrogen bonding in imidazoles. C: Charge sharing in protonated imidazoles. 
This ability of imidazole, to accept a proton and then release a proton, is exploited in numerous enzymes 
where histidine is a part of the active site. One of these enzymes is serine protease, an enzyme that 
breaks peptide bonds in proteins.[53] In figure 13 it is shown how, during the cleavage of the peptide, the 
imidazole acts as both a proton acceptor and a donor. 
34 
 
 
Figure 13: Breaking of a peptide bond in the active site of serine protease. 
Imidazoles are also nucleophilic at the nitrogen and will quickly methylate on both nitrogens in the 
presence of an excess of methyl iodide. Imidazoles can be easily deprotonated at the nitrogen by 
sodium hydride or similar bases, as the pKa of that proton is only 14.4. N-protected imidazoles can be 
metalated using lithium or magnesium reagents, preferentially at C-2, if that position is not eligible for 
deprotonation, C-5 is preferred. Imidazoles are electron rich and are thus easily halogenated and 
nitrated. Halogenated imidazoles have been extensively used in halogen-metal exchange reactions and 
metal catalyzed couplings.[52, 54] 
5.7.2 Imidazole synthesis 
While there are many synthetic methods to make imidazoles, there is not a condensed set of methods 
that allows access to most imidazoles, like there are for, indoles or pyridines, for instance. Therefore, 
there are many different routes and every imidazole synthesis requires its own synthetic plan. In this 
chapter various methods for imidazole synthesis will be discussed that are of historical significance or 
important to this thesis. The initial discovery of the method will be mentioned along with selected 
examples of their use in modern organic chemistry. 
5.7.2.1 Debus-Radziszewski synthesis 
Debus discovered the reaction of a 1,2-diketone 16 and an aldehyde 17, in the presence of ammonia to 
synthesize 2,4,5-substituted imidazoles 19, the method was later elaborated by Radziszewsk (figure 
14).[55] The mechanism likely involves attack of ammonia on all the carbonyls, followed by attack of the 
diimine on the imine to yield 18. This intermediate can then close by elimination of one equivalent of 
ammonia and tautomerization yields the imidazole 19. This method suffers from mediocre yields (50 – 
60%), however a wide variety of building blocks can be use, yielding many differently substituted 
imidazoles.[56] The yields and reaction times of this reaction have been be improved by the use of 
microwave irradiation[57] or catalysts[58], where yields between 85 – 99 percent can be obtained for 
selected examples.  
 
 16 17 18 19 
Figure 14: Debus- Radziszewsk synthesis. 
Recently, a variation of this reaction was reported using α-keto aldehydes 20 instead of 1,2-diketones 16 
(figure 15). The obvious problem of self-condensation of the α-keto aldehydes was solved by careful 
35 
 
optimization of the reaction conditions. In acetic acid, DCM and DMF compound 22 was the major 
product, but using methanol at room temperature yielded a mixture of 21 and 22 in an 8:1 ratio and 
reasonable to good yields.[59] 
 
 20 17 21 22 
Figure 15: Debus type synthesis using α-keto aldehydes. 
Another useful variation is the Gridnev modification of the Debus synthesis, which uses an amine to take 
the place of one of the ammonia equivalents (figure 16). In this way also 1,2,4,5-substituted imidazoles 
are accessible.[60] This method has been used recently to synthesize imidazoles with optically active 
substituents on the N-1 position, without loss of enantiopurity during the reaction.[61] 
 
 23 24 17 25 
Figure 16: Gridnev modification. 
5.7.2.2 Kunckell synthesis 
The Kunckell synthesis, first reported in 1901,[62] involves the reaction between an α-haloketone 26 and 
an amidine (figure 17). In its original form it provides access to the same substitution pattern as the 
Debus synthesis. 
 
 26 27 28 19 
Figure 17: Kunckell imidazole synthesis. 
Useful variations include the Webber synthesis, which exchanges the amidine for acetyl guanidine 29 
(figure 18). This method gives access to 2-amino imidazoles after deprotection of the amine.[63] The 
acetyl group has also been changed for a boc, leading to higher yields in some examples.[64] 
 
 26 29 30 
Figure 18: Webber’s modification. 
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The α-haloketone 26 can also be changed for compounds with a similar reactivity pattern. For instance, 
recently 2,3-epoxy- and 2,3-aziridine aldehydes (31 and 32) were reported to work well in this reaction 
(figure 19). Using optically pure aldehydes yielded products 33 with good ee’s in average to good yield. 
The 2,3-epoxy- and 2,3-aziridine aldehydes were made in situ from α,β-unsaturated aldehydes and 
hydrogen peroxide or TsNHOTs in the presence of a pyrrolidine organo-catalyst.[65] 
 
 X = O 31, NTs 32 27 33 
Figure 19: use of 2,3-epoxy- and 2,3-aziridine aldehydes. 
5.7.2.3 Van Leusen synthesis 
The van Leusen synthesis is a multi-component reaction between a toluenesulfonylmethyl isocyanide 34 
(usually TosMIC, R2 = H), an amine 24 and an aldehyde 17 (figure 20). In this reaction initially the amine 
and aldehyde react to form a Schiff base. The isocyanide is then added, which attacks the Schiff base 
leading to ring closure to the imidazoline. The imidazoline is then aromatized by the elimination of the 
tosylate, yielding a 1,5- and some 1,4,5-substituted imidazole.[66] This method is used extensively in the 
pharmaceutical industry for a synthesis of pharmaceutically active imidazoles,[67] and has also been used 
in solid phase synthesis.[68] 
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 17 34 24 35 36 37 
Figure 20: van Leusen imidazole synthesis. 
One modification of the van Leusen synthesis involves the reaction between a toluenesulfonylmethyl 
isocyanide 34 and an aldehyde 17 to form a 4-tosyloxazoline. Then the amine is added to yield the 
imidazole (figure 21).[69] This method gives regioselective access to 4-, 1,4- and 4,5-imidazoles, 1,4,5-
imidazoles are difficult to make using this method as a mixture of regio-isomers is usually obtained. 
 
 17 34 38  37 
Figure 21: Modified van Leusen imidazole synthesis. 
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5.7.2.4 Aza-wittig strategy and imidazoline aromatization 
There are several synthetic strategies for imidazoles based on the Aza-wittig reaction, the reaction of an 
iminophosphorane and a carbonyl group. Molina et al. published the use of an aza-wittig reaction to 
produce 2-aminoimidazoles 43 (figure 22).  Triphenylphosphine (PPh3) and the azide 39 are mixed at 0°C 
to form the iminophosphorane 40 by the expulsion of molecular nitrogen. The iminophosphorane reacts 
with isocyanate 41 to yield a carbodiimide 42, which ring closes at room temperature to form the target 
2-aminoimidazole 43. The reaction works with both aryl and alkyl isocyanates but the other substituents 
are restricted to a rather small set. The iminophosphorane was isolated in one case but in all other cases 
the reaction was performed in one pot.[70] 
 
 39 40 41 42 43 
Figure 22: Aza-wittig reaction with isocyanates. 
Very recently, Nie et al. reported the use of an aza-wittig reaction between azides (44) and aldehydes 
(17) to yield 1,2,4-substituted imidazoles (47) (figure 23).[71] Mixing the iminophosphorane 45 and the 
aldehyde 17 at room temperature did not result in any product, but upon heating to 80°C the reaction 
proceeded smoothly to yield a range of substituted imidazoles, presumably going through intermediate 
46. The substituent on the imine moiety of 44 (R1) is limited to phenyl or 4-chlorobenzene; however 
aldehydes with a wide range of aromatic groups were successfully used. In all cases the intermediate 
iminophosphorane was isolated as a crystalline solid. 
 
 44 45 17 46 47 
Figure 23: Aza-wittig reaction for the synthesis of 1,2,4-substituted imidazoles. 
In line with the work of Molina et al. similar iminophosphoranes were allowed to react with isocyanates 
to give carbodiimides, which could be continued to imidazoles with either amines or ethers at C-2 using 
amines or alcohol respectively (figure 24). The 2-oxo-imidazoles 51 were not stable and all oxidized at 
the benzylic position to yield a final benzoyl group a C-4.[72] 
 
 48 41 49 X = NR4 50, O 51 
Figure 24: Aza-wittig reaction with isocyanides to synthesize 2-amino- or 2-oxo-imidazoles. 
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The aza-wittig reaction has been widely used in the synthesis of five membered dihydro-heterocycles 
like oxazolines and thiazolines by reaction of iminophosphoranes with esters or thioesters, respectively. 
These dihydro-heterocycles can then be aromatized to their unsaturated analogs by various methods. 
The synthesis of imidazolines by this method is less investigated, mostly due to the low reactivity of the 
amide bond in this reaction (figure 25).  
 
 52 53 54 
Figure 25: Aza-wittig imidazoline synthesis. 
The first time an aza-wittig reaction was used to synthesize an imidazoline was in 1985, in this instance 
the low reactivity was overcome by heating the reaction to 180-250°C.[73] Unfortunately, these 
conditions are not suitable for many functional groups. To enhance the reaction rate, Loos et al. used a 
sulfonamide to activate the amide group of compound 52 (R1 = Ts). The electron withdrawing character 
of the tosyl group increased the electrophilicity of the amide, allowing the reaction to proceed at a more 
agreeable 80°C.[74] The reaction is heavily influenced by the substituents on the phosphine, where 
triphenylphosphine showed the best reactivity.[75] 
Once an imidazoline-ring is created, using an aza-wittig reaction or other reactions, it needs to be 
dehydrogenated to make an imidazole. One popular method for the aromatization of all kinds of 1,3-
azolines is dehydrogenation using bromo trichloromethane (BrCCl3) and DBU (figure 26). This method, 
first discovered by Williams et al.[76] likely involves deprotonation of the imidazoline C-4, followed by 
bromination. The imidazoline then eliminates hydrogen bromide to become aromatic. This method is 
extensively used for the aromatization of sensitive imidazolines due to its mildness and functional group 
tolerance.[74, 77] The only requirement is that the imidazoline has a strong electron withdrawing group at 
C-4, ideally an ester. If such an electron withdrawing group is absent, the C-4 hydrogen is not acidic 
enough and deprotonation does not occur, retarding the reaction. 
 
 55 56 57 
Figure 26: Dehydrogenation of imidazolines to imidazoles using bromo trichloromethane and DBU. 
Recently, a similar reaction, using trichloroisocyanuric acid, instead of bromo trichloromethane, showed 
good results in aromatizing 2-imidazolines, without an ester at C-4. However, no substituents other than 
at C-2 are tolerated in this case.[78] 
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 Many other reagents have been used to dehydrogenate imidazolines including MnO2,
[79] BaMnO4,
[80] 
Pd/C,[81] Zn-Al2O3,
[82] DMSO/(COCl)2,
[83] KMnO4,
[84] IBX,[85] (Diacetoxyiodo)benzene (DIB),[86] O2
[87] and 
Magtrieve.[88] 
5.7.3 Additional Imidazole Syntheses 
There are an enormous amount of other imidazole syntheses, however their detailed discussion is 
beyond the scope of this thesis. Some examples from the recent literature (2002 – present) include (1) 
by rhodium catalyzed transannulation of 1,2,3-triazoles with nitriles,[89] (2) by treatment of imidazolones 
with phosphorus oxybromide or -oxychloride,[90] (3) by 1,5-electrocyclization of azavinyl azomethine 
ylides,[91] (4) by gold catalyzed hydroamination of fluorinated N’-aryl-N-propargyl amidines,[92] (5) by the 
Wallach reaction,[93] (6) from β-ketoamides,[94] (7) from two different isocyanides or formamides,[95] (8) 
from nitriles and amines,[96] (9) by palladium catalyzed cyclization of O-
pentafluorobenzoylamidoximes,[97] (10) from thioamides,[98] (11) from thioiminoether hydrobromides,[99] 
(12) by the Bredereck synthesis,[100] (13) by nickel catalyzed nitrile cyclization,[101] (14) by SeO2 mediated 
oxidation of 1,3-diazabuta-1,3-dienes,[102] (15) from 2-azido acrylates and nitrones,[103] (16) from (N-
acylated)α-aminonitriles,[104] (17) from allenes, imines and nitriles,[105] (18) by cross-coupling of 
aldimines,[106] (19) from keto-oximes, aldehydes and ammonia,[107] (20) by the Lantos-Eggelston 
synthesis (hetero-Cope rearrangement),[108](21) from 3-N,N-(diemthylamino)-2-isocyanoacrylates[109] 
and (22) from 2-bromo-isocyanoacrylates and amines.[110] 
For older imidazole syntheses (pre-2002) there are some excellent reviews available.[51d, 111] 
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6 Aim of the Project 
Selective antibodies that recognize 3-phosphohistidine would be valuable tools to understand the 
epigenetic importance of 3-phosphohistidine. The aim of the main project described in this thesis is to 
provide a tool set to raise such antibodies. To this end several steps were undertaken: 
1. The design of a stable 3-phosphohistidine mimic. 
2. The synthesis of the 3-phosphohistidine mimic. 
3. Incorporation of the 3-phosphohistidine mimic in peptide that can serve as a antigen. 
The design of the 3-phosphohistidine mimic had to take into consideration both the electronic and the 
structural aspects of phosphohistidine. The mimic has to be stable under physiological conditions to 
enable the raising of antibodies. In order to incorporate the 3-phosphohistidine mimic in a peptide, the 
synthetic building block needed to be suitable for SPPS. The synthesis of the mimics should minimize 
synthetic steps and maximize yields, especially since multi gram quantities of the final compound are 
required for SPPS. Finally, the peptides needed to be well designed so antibodies could be raised 
successfully. 
After coupling of the peptide to a carrier, antibodies can be raised to investigate phosphohistidine 
function. The raising of the antibodies as well as some of the subsequent studies are being performed in 
the group of Robert Schneider. 
6.1 Side projects 
Several side projects were also pursued in parallel with the work described above: 
Toward potential phosphohistidine phosphatase inhibitors: The aim of this project was to use chemistry 
developed in the 3-pHis analog project to synthesize a small library of 4-phosphonic acid imidazoles. This 
library might serve as a starting point for the development of an inhibitor for PHP. 
1-phosphohistidine project: This project is analogues to the 3-pHis project, where the aim is to generate 
antibodies for 1-pHis. It involves the same key steps as discussed above. 
Adenylylated histidine project: This project is also analogous to the pHis projects but the aim was to 
generate a mimic for adenylylated histidine in order to raise the relevant antibodies. 
Nδ-Methylarginine project: The aim of this project was to synthesize an SPPS building block that enabled 
the synthesis of peptides containing an arginine methylated at the N2 position. 
Piperazine probe project: The aim of this project was to investigate the feasibility of a proposed 
synthesis for a probe that was to be used for exploring the relation between phosphorylation and 
lipidation in proteins. 
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7 Design and synthetic consideration of pHis mimic 
To achieve the goal of raising antibodies specific for phosphohistidine it would be necessary to design a 
pHis mimic that is stable under most conditions and that can be incorporated into a peptide, preferably 
using SPPS. 
To design an analog of pHis that not only had similar structural but also electronic features it was clear 
that the imidazole ring should be conserved. The properties of the imidazole are unique among five 
membered heterocycles and cannot be easily mimicked. Importantly, imidazole is a base with a pKa 
around 7.0. Thus the imidazole is protonated at physiological pH (7.2-7.4).Protonation of the imidazole 
has a profound impact on its electronic structure. To compare unprotonated vs. protonated 
phosphohistidine the surface electrostatic potentials (VS(r))of their respective heterocyclic cores were 
calculated at the PCM-B3LYP/6-31+G(d) level by electron density contour using Gaussian 03 and the 
HS95v09 program (figure 27) in collaboration with prof Tore Brink at the Royal institute of technology, 
Stockholm, Sweden. 
 
 58 59 
Figure 27: calculated surface electrostatic potentials of the pHis heterocyclic core unprotonated (58) and at pH 7.2 (59). 
Figure 27 shows pHis with an unprotonated (58) and protonated imidazole moiety (59). It is quite 
striking how different their VS(r)’s are. The phosphate has a strong negative potential in both cases; 
however, the phosphate in 59 also shows a surprisingly strong local surface maximum (VS,max) located at 
the hydrogen of the OH group. Thus the OH group of pHis under physiological conditions is a good 
hydrogen bond donor, even though the phosphate overall is negatively charged. Furthermore, the VS(r) 
over the imidazole ring of 59 has two positions with a high VS,max at the N-1 and C-4 positions, whilst 58 
does not. Overall the imidazole ring is more positive in 59 than in 58.  
Taking these differences into consideration the two pHis homologs were compared to the cores of the 
pHis mimics that were synthesized by other groups (figure 28). 
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 60 61 62 
Figure 28: calculated surface electrostatic potentials of several non-hydrolysable analogs at physiological pH. 
At first glance it is clear that these mimics have similar electronic properties to unprotonated imidazole 
58. They also have a fully negative phosphonate; the OH group on the phosphonate is no hydrogen bond 
donor due to its high electron density. Also the VS(r) over the heterocyclic rings are highly negative, they 
are more negative than 58 and certainly than 59. Therefore, it is not surprising that compound 60 failed 
to raise antibodies specific for pHis, since it does not resemble the electronic structure of pHis at 
physiological pH at all. It is also surprising that the triazole mimic 62 did produce antibodies that 
recognized pHis. However, using the same logic it can be deduced that they should not have a high 
affinity. 
The antibodies produced using a peptide containing a mimic with heterocyclic core 62, showed some 
cross reactivity with pTyr and, to a lesser extent pThr and pSer.[112] However, the cross reactivity was 
only seen in the antibodies obtained from one of three rabbits. Antibodies generated using compound 
63 might also show some cross-reactivity with other phosphorylated amino acids. To which extent this 
would be an issue has to be determined using affinity experiments using non-pHis phospho-amino acids. 
Thus, it is clear that the imidazole ring needs to be conserved in the analog to mimic pHis correctly 
under physiological conditions. Additionally, to ensure a stable compound, the labile phosphoramidate 
P-N bond has to be exchanged for a stable phosphonate P-C bond. Both these goals can be achieved by 
simply turning the imidazole ring relative to its substituents (figure 29). 
 
 7 63 
Figure 29: Design of a better pHis analog by turning the imidazole ring. 
Surface electrostatic potential calculations were performed on this proposed mimic 63. The results are 
compared with protonated pHis (figure 30). It can be clearly seen from the pictures that the two 
compounds are very similar, not only structural but also in an electronic sense. In contrast to the other 
analogs, the OH group on the phosphonate has a similar VS,max for pHis (63 kcalmol
-1) as for the imidazole 
analog (58 kcalmol-1). This means that the phosphonate OH can be a hydrogen bond donor even though 
the phosphonate is negatively charged overall. Additionally, the VS(r) over the imidazole ring is very 
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similar. Both structures have a positive potential at the protonated nitrogen. The only difference 
between 63 and pHis is seen at C-4. pHis has an additional high local VS,max at C-4, while the mimic has a 
much less pronounced positive potential at that point. Nevertheless, it is clear that the pHis analogue 63 
should make an excellent mimic of pHis that should give antibodies selective for pHis. 
 
 59 64 
Figure 30: calculated surface electrostatic potentials of the pHis core (59) and the non-hydrolysable analog 64 core at physiological pH. 
With the basic design of the pHis established, the next step was the incorporation of these design 
principles in a SPPS building block. Therefore, 63 had to be synthesized with protective groups amenable 
for solid phase peptide synthesis. Firstly, it should have an Fmoc protecting group on the amino acid 
amine moiety, to allow its use in Fmoc based SPPS. Secondly, the other protecting groups on the 
building block should preferably be acid labile, so they can be cleaved during the global deprotection 
and cleavage step, when peptide synthesis is finished. Taking these constraints into consideration 
compound 65 was envisioned as a good building block. 
 
 65 
This compound has two benzyl groups as protecting groups for the phosphonate. More common groups 
on phosphonates are methyl or ethyl groups, however these are much harder to cleave, requiring TMS 
bromide or even stronger reagents. The benzyl groups, on the other hand, are easily cleavable using TFA 
and a scavenger. A disadvantage of benzyl protecting groups is that they can also be removed by strong 
nucleophiles and (very) strong bases; however, these conditions can be avoided during the synthesis of 
compound 65. 
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Several options could be considered as protecting group ‘R’ on the imidazole. Trityl is used in SPPS for 
histidine and would be a good choice as a protective group for analog 63, since it is stable and easily 
cleaved with acid.  Another possibility could be a boc group, even though they are less stable on 
imidazoles, they should remain stable as long as the pH stays basic. 4-Methoxybenzyl and 2,4-
dimethoxybenzyl are two other protecting groups that have been used during these studies. Finally, a 
tosyl protecting group could be used. However, cleavage of the tosyl group would require different 
conditions than the acidolytic cleave of the peptide.[113]  
The Fmoc group, however, cannot be used for the entire synthesis as basic conditions are expected to 
be employed. Additionally, the carboxylic acid moiety also needs to be protected to avoid side reactions. 
Several protecting groups were considered but finally the Alloc and allyl ester groups were chosen for 
the amine and acid respectively. The main advantage of these two protecting groups is that they are 
stable under most acidic and basic conditions. They are both cleaved in the presence of palladium(0) 
and a scavenger, usually in high yield. After their removal an Fmoc group can be used to make the 
building block SPPS ready. 
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8 Research toward a non-hydrolysable 3-phosphohistidine analog 
In order to obtain the non-hydrolysable 3-pHis mimic, a versatile route toward the synthesis of 65 
needed to be developed. Even though there are many syntheses towards imidazoles (chapter 5.7), only 
a few publications exist about phosphonic acid imidazoles.[114] Therefore the synthesis of the 3-
phosphohistidine mimic is not as straightforward as one might expect. Many different synthetic 
strategies can be considered to synthesize compound 65 and many different routes have been pursued 
during the studies reported in this thesis. Below is a graphical abstract of the different routes toward the 
pHis mimic that are reported in this work. They can be roughly grouped by those that started with a fully 
formed imidazole that was to be substituted and those routes that formed the imidazole during 
synthesis. The routes are briefly described below. 
8.1.1 Routes that included imidazole synthesis 
 
8.1.1.1 Aza-wittig route 
 
 
 65 
 
 66 67 68 
The Aza-wittig route was the route that eventually provided 65 in good overall yield, amenable to scale 
up into preparative amounts. It started with dibenzylphosphite and 4-methoxybenzyl amine and 
involved an aza-wittig ring closing reaction-aromatization as central, imidazole forming step. The major 
challenges were the oxidation/aromatization of the imidazoline and selection of a suitable protecting 
group for the imidazole (chapter 8.2). 
8.1.1.2 Alternative Aza-wittig route 
 
 65 
 
 69 70 71 
The alternative Aza-wittig route would also close the imidazole using an aza-wittig reaction, but 
introduced the amino acid part much earlier in the synthesis. This route was one of the first attempts 
and failed due to an unstable intermediate (chapter 8.3.4). 
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8.1.1.3  Negishi route I 
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 66 72 73 74 
The first part of the Negishi route involved the synthesis of the imidazole by Aza-wittig after a 
formylation of the tosylamide. Then the imidazole would be iodinated and a Negishi coupling would be 
performed to obtain the target compound. Regrettably, the yield of the imidazole obtained using the 
Aza-wittig strategy was to low too make this strategy feasible (chapter 8.3.1). Later on, a different route 
to iodo-imidazole was devised, which allowed the exploration of the Negishi reaction itself (chapter 
8.4.2). 
8.1.1.4 Aldehyde route 
 
 65 
 
 
 75 67 76 
This route was pursued in an attempt to circumvent the oxidation of the imidazole by having all atoms 
at the desired oxidation state before ring closure. The route started with dibenzylphosphite and (tert-
butyldimethylsilyloxy)acetaldehyde. This route failed due to an unstable intermediate (chapter 8.3.2). 
8.1.1.5 1,3-Dithiane route 
 
 
 65 
 
 77 78 79 
The 1,3-dithiane route was analogues to the aldehyde route except that it did not have an unstable 
aldehyde intermediate but a dithiane instead. This route failed due to a failure of the synthesis of 
intermediate 77 (chapter 8.3.3). 
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8.1.2 Routes starting with an imidazole 
8.1.2.1 Metal catalyzed & Halogen-metal exchange 
 
 65 
 
 80 X = Br (81), I(82) 83 84 
This imidazole substitution was chronologically the first strategy that was pursued. Several attempts 
were made to phosphorylate imidazoles at the C-4 position, including halogen metal exchange and 
metal catalyzed couplings. Regrettably all these reactions did not work (chapter 8.4.1). 
8.1.2.2 Negishi route II 
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 85 86 73 74  
This second part of the Negishi route started after a successful route toward the imidazole was 
developed. Many conditions were investigated to couple these two iodo compounds but none worked 
(chapter 8.4.2). 
8.1.2.3 Aziridine opening route 
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 73 87 65 
Finally, it was attempted to use halogen metal exchange to synthesize the C-2 anion of the imidazole, 
followed by nucleophilic ring opening of an aziridine (chapter 8.4.3). 
Although the routes depicted above are reported separately in this thesis, many were pursued in 
parallel, sometimes coming to a halt and later being picked up again. Chemistry discovered in one route 
was often used in other routes. Therefore, the different paragraphs will refer to each other frequently. 
Now the routes will be discussed separately, starting with the synthesis that was finally successful to 
yield 65, using the aza-wittig reaction to assemble the imidazole. 
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8.2 Aza-wittig strategy 
As mentioned above, the strategy presented in this chapter led to the successful synthesis of 3-pHis 
analogue 65 (figure 31). The retrosynthetic analysis involved the formation of the imidazoline 88 via an 
aza-wittig reaction, followed by the adjustment of the heterocycle’s oxidation state. The required 
precursor for the aza-wittig reaction 89 was expected to be available by an amide coupling reaction of 
compounds 67 and 90. Key challenges for this route were expected to be the synthesis of compound 90 
and oxidation of the imidazoline. 
 
  
 67 
 
 
 65 88 89 90 
Figure 31: Retrosynthetic analysis of compound 65. 
Compound 67 could be easily synthesized via a literature procedure.[115] Compound 90 should be 
available by nucleophilic ring opening of aziridine 91 with an azide.[116] The aziridine should be accessible 
via a reaction with chloramine-T (figure 32).[43] 
 
 90 91 92 
Figure 32: Retrosynthetic analysis of compound 90. 
8.2.1 Synthesis toward compound 90 
The synthesis toward 90 started with dibenzyl vinylphosphonate 92, which was easily obtained by 
bubbling acetylene through a solution of dibenzylphosphite 80 and 
tetrakis(triphenylphosphine)palladium(0) in THF (scheme 1) until all of the dibenzylphosphite was 
consumed.[116] 
 
 80 92 
Scheme 1: Synthesis of dibenzyl vinylphosphonate 92.Reagents and conditions: acetylene, tetrakis(triphenylphosphine)palladium(0) (0.05 
equiv), THF, rt, 7h, 72%. 
Next, attempts were made to react 92 with chloramine-T 93 and silver nitrate to obtain aziridine 91. 
Kumar et al. reported that chloramine-T and silver nitrate react to form a nitrene, which should react 
with alkenes.[117] Unfortunately, these reaction conditions were not successful in providing intermediate 
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91. Using rigorously dry reaction conditions or silver tetrafluoroborate, as a more soluble silver source, 
also did not produce the target compound (scheme 2).  
 
 92 91 93 
Scheme 2: Unsuccessful aziridation strategy. Reagents and conditions: chloramine-T (1 equiv), silver nitrate or silver tetrafluoroborate (1 equiv), 
THF, rt. 
Since the nitrene conditions did not yield the desired product, it was decided to synthesize the aziridine 
via a multi-step synthesis starting with aminohydroxy compound 94 (scheme 3). This compound might 
then be submitted to ring closing conditions to yield the aziridine 91. Sharpless et al. had shown that 
vinyl phosphonates could be aminohydroxylated using chloramine-T and osmium tetroxide,[118] in line 
with the more well-known Sharpless dihydroxylation.[119] However, in their case only aryl substituted 
olefins could successfully be oxyaminated.  It was gratifying to see that our vinyl phosphonate 
performed well using this reaction conditions, giving up to 50 percent yield. During acidic work-up and 
solvent evaporation of the reaction it was noticed that the aminohydroxide 94 was decomposed. A final 
basic wash during the work-up and low temperature (30°C) evaporation of the solvent were essential to 
prevent any decomposition of the product. 
 
 92 94 
Scheme 3: Aminohydroxylation of dibenzyl vinylphosphonate 92. Reagents and conditions: chloramine-T (1.25 equiv), osmium tetroxide (0.01 
equiv), benzyl triethylammonium chloride (0.05 equiv), CHCl3, water, 60°C, 16h, 50%. 
To facilitate ring closure to the aziridine, activation of the hydroxyl moiety was attempted in two ways; 
via the mesylate and via a mitsunobu reaction. The mesylate formed quickly and was isolated in high 
purity. However, the ring closing reaction using potassium carbonate did not yield any product. 
Conversely, the Mitsunobu reaction gave the aziridine in a single step and high yield. The product of the 
Mitsunobu reaction was contaminated with triphenylphosphine oxide (PPh3O) and diisopropyl 
hydrazine-1,2-dicarboxylate. The PPh3O was easily removed by column chromatography but the 
hydrazine eluted in the same fractions as the product. This problem was solved by using 
dimethylazodicarboxylate (DMAD) instead of diisopropylazodicarboxylate (DIAD) for the activation of 
the triphenylphosphine. The hydrazine product from DMAD had a different Rf and was thus easily 
separated on column together with PPh3O. The reaction conditions used to obtain the aziridine are 
summarized in table 1. 
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Table 1: Synthesis of aziridine 91. 
 
 94 91  
# Reagents Result 
1 MsCl,a K2CO3
b 96% mesylate of 94 
2 PPh3, DIAD
c 100% conversion 
3 PPh3, DMAD
d 93%  
a: methyl sulfonylchloride (2 equiv), triethylamine (3 equiv), DCM, -10°C to rt, 75 min, 96%. b: potassium carbonate (5 equiv), DMF, rt, 16h, 
trace. c: triphenylphosphine (1 equiv), diisopropylazodicarboxylate (1 equiv), THF, 0°C to rt, 2h, not isolated.d: triphenylphosphine (1 equiv), 
dimethylazodicarboxylate (1 equiv), THF, 0°C to rt, 2h, 93%. 
With the aziridine in hand a nucleophilic ring opening with sodium azide in DMF was performed.[120] The 
reaction proceeded uneventful and in good yield, providing key intermediate 90 as a single regio-isomer 
(scheme 4). 
 
 91 90 
Scheme 4: Aziridine ring opening. Reagents and conditions: a) sodium azide (1.25 equiv), DMF, rt, 16h, 78%. 
8.2.2 Amide coupling I 
Next, sulfonamide 90 needed to be coupled to Alloc/allyl protected aspartic acid 67. Due to the electron 
withdrawing character of the tosyl group, the amine was expected to be a weak nucleophile. Therefore, 
several strong activators were tested to activate acid 67 (table 2). The initial trial used the preformed 
HOAt-ester of 67 and DBU, conditions that were successful for other tosylamides (see chapter 8.3.4).[121] 
However, amide 89 was not detected in the complex mixture of products that resulted from the 
reaction. Changing amino acid protecting groups from allyl ester/ Alloc to tert-butyl ester/ boc to mimic 
more closely the conditions from chapter 8.3.4, did not yield any different result. These results, coupled 
with the discovery that 90 slowly decomposed in the presence of DBU, led us to consider other 
activation strategies (table 2). 
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Table 2: Amide coupling conditions. 
 
 95 R = Et, 90 R = Bn 67 96 R = Et, 89 R = Bn 
Reagents and conditions: 67 (1.1equiv), Activator (1.1 equiv), base, rt, 16h. 
# Activator Base (equiv) DMAP (equiv) Solvents Tosylamide Result 
1 HOAt DBU (1.5) ― DCM 90 Decomposition 
2 HATU DBU (2) ― DCM, DMF 90 Decomposition 
3 HATU Cs2CO3 (4) ― DCM, DMF 90 No reaction 
4 HATU ― 2  DCM 90 Tracea 
5 DIC Cs2CO3 (1.1) 1.1 DMF 90 No reaction 
6 PyBrOP DIPEA (2.2) 1.1 DCM 95 Tracea 
7 PyBrOP DIPEA (3) 1.25 DCM 95 0 – 42% 
a: The mass was detected on the LCMS but the compound was not isolated. 
HATU is used as coupling reagent for a wide range of amide coupling reactions including SPPS strategies; 
therefore it might be successful in promoting this coupling. In these reactions the ester was activated in 
situ by the addition of base and coupling reagents for 
five minutes, after which the tosylamide was added. 
Using DBU as a base did not yield any product before 
the starting material decomposed (table 2: entry 2). 
Since the tosylamide was not stable to DBU a 
replacement was considered. Cesium carbonate was 
expected to perform better, as an inorganic base it 
might not decompose starting material 90. While the tosylamide was indeed stable under these 
conditions, no product was obtained (table 2: entry 3). HATU with 2 equivalents of DMAP seemed to 
yield traces of product. Unfortunately, these conditions could not be optimized to obtain a satisfying 
amount of product (table 2: entry 4). DIC with DMAP did also not yield any product (table 2: entry 5). At 
this time supplies of dibenzyl vinylphosphonate ran out, as well as the starting material to make it, 
therefore, diethyl vinylphosphonate was temporarily utilized while exploring the chemistry of these 
compounds. The final coupling reagent that was tested in this reaction was PyBrOP. PyBrOP is a 
phosphonium based coupling reagent that does not require pre-activation of the acid. Under these 
conditions a moderate yield was obtained (table 2: entry 7) but the reaction was poorly reproducible 
and yielded inconsistent amounts of product. Since large amounts (multi-gram) of this compound were 
needed, another, more reliable strategy was considered. 
8.2.3 New strategy 
Looking closely at 90, one can notice that, not only is the amine deactivated by the tosyl group, there is 
also considering steric hindrance from the bulky benzyl protecting groups on the phosphonate. 
Additionally, the phosphonate serves as an electron withdrawing group, which might have an additional 
deactivating effect on the amine. To test these hypotheses, and to successfully perform the amide 
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coupling, it was decided to switch the tosylamide and the azide moieties (figure 33). In doing so any 
negative influences from the phosphonate would be minimized, leading to a facile amide coupling and, 
after deprotection of the imidazole ring, the same final product would still be obtained.  
 
 90 66 
Figure 33: Switching azide and tosylamide groups. 
As the aziridine 91 had high selectivity to open at C-3 it was not suitable as an intermediate for the 
synthesis of 66. Therefore, a new synthesis was designed starting from diethyl vinylphosphonate 100 
(figure 34). After dibromination of diethylvinylphosphonate 100, both bromines would be substituted 
with sodium azide.[41, 44] The azide beta to the phosphonate, would then be selectively reduced with one 
equivalent of triphenylphosphine, followed by tosylation.[26, 115] 
 
 97 98 99 100 
Figure 34: Retrosynthetic analysis of 97. 
The bromination of diethyl vinylphosphonate proceeded smoothly.[122]The substitution reaction 
however, did not produce desired product 98. Instead, the beta bromine eliminated to form diethyl (1-
bromovinyl)phosphonate 101. This reaction would be expected under basic conditions. However, it was 
surprising that the elimination took place with only sodium azide present. At this point it was decided to 
focus on a different route that used conditions previously successful in this project. 
 
 98 
 
 100 99 
 101 
Scheme 5: Synthesis toward 97. Reagents and conditions: a) bromine (1.02 equiv), CHCl3, rt, 3h, quant. b) sodium azide (8 equiv), DMF, rt, 16h, 
quantitative. 
8.2.4 Azide introduction 
The new strategy relied on the previously described product of the Sharpless aminohydroxylation, 94 
(paragraph 8.2.1). The alcohol could be activated and then substituted by an azide nucleophile. The key 
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transformation of this route was the activation of the hydroxyl function followed by its substitution 
without interference from intramolecular aziridine formation. 
 
 97 94 
Figure 35: New retrosynthesis of 97. 
Initially, some sulfonyl chlorides were used to activate the alcohol followed by substitution with sodium 
azide (table 3). Activation with the sulfonyl chlorides went smoothly in all cases. However, problems 
became immediately apparent when the methyl sulfonyl activated alcohol did not react with sodium 
azide (entry 1). The tosyl activated alcohol yielded an unidentified product (entry 2) and the o-
nitrobenzene sulfonyl activated alcohol mostly formed the aziridine along with some unidentified 
byproducts (entry 3). 
Table 3: Azide formation I. 
 
 102 97 
Reagents and conditions: a) Sulfonyl chloride (2 equiv), triethylamine (3 equiv), rt, 2h. b) Sodium azide (4 equiv), DMF, rt, 16h. 
# Activator result 
1 Mesyl No reaction 
2 Tosyl Unidentified products 
3 2-Nosyl Aziridine formation 
 
To prevent aziridine formation it was decided to protect the hydroxylamine 102 as compound 103 
(scheme 6). This compound contains an oxathiazolidine that simultaneously activates the hydroxyl 
moiety and protects the tosylamide.[10a, 123] After substitution of the alcohol, the protecting group should 
leave the reaction as gaseous sulfur dioxide.[124] 
 
 102 103 
Scheme 6: Synthesis toward 103. Reagents and conditions: a) thionyl chloride (1.4 equiv), pyridine (2.5 equiv), THF, -78°C to rt, 6h, 93% (NMR 
yield). 
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Synthesis of the oxathiazolidine was fairly straightforward. Reaction with thionyl chloride and pyridine in 
THF yielded the product in 93 percent yield. Interestingly, substituting pyridine for 2,6-lutidine yielded 
no product. This result emphasizes that an acyl transfer reagent (in this case pyridine) is required to 
drive the reaction. Purification of the oxathiazolidine proved to be problematic; the compound 
decomposed during silica flash column chromatography. Therefore, it was used as the crude mixture in 
all subsequent reactions. The oxathiazolidine was submitted to various reaction conditions in order to 
obtain azide 97, summarized in table 4. 
Table 4: Azide formation II. 
 
 
 103 97 
Reagents and conditions: azide (5 equiv), solvent, rt, 16h. 
# Azide Solvent Result 
1a NaN3 DMF 102 
2 TMSN3 THF 102 and an unidentified by product 
3 b TMSN3, TBAF THF TMS adduct of 102 
4c Bu4NN3 THF 102 and an unidentified by product 
a: reaction was done at 60°C. b: 0.25 equiv TBAF was added. c: 2.5 equiv azide were used, reaction was stirred for four hours. 
As can be derived from the table, sodium azide in DMF did not yield desired product 97 but instead 
returned alcohol 102 (entry 1). Presumably, the azide was not reactive enough and subsequent aqueous 
work-up decomposed 103 to its precursor, 102. Therefore, different azide sources that were more 
soluble in organic solvents were considered. TMS-azide (entry 2) resulted in 102 along with an 
unidentified byproduct. Adding a catalytic amount of TBAF was expected to promote the substitution 
reaction by scavenging the TMS cations, thereby creating a more soluble tert-butyl ammonium azide in 
situ. However, added TBAF (1M in THF) yielded a surprising quantitative amount of TMS-ether adduct of 
102. It seems that TBAF catalyzed the decomposition of the oxathiazolidine to 102, which then reacted 
to the silyl ether with TMS-azide.  
A possible mechanism for the formation of 104 is outlined in figure 36. In this proposed mechanism the 
fluorine anion attack the electrophilic sulfoxide that is further activated by the electron withdrawing 
effect of the tosylamide. The alkoxide attacks a TMS group, freeing an azide to attack the sulfoxide and 
free the tosylamide. The sulfurazidous fluoride can be attacked by a second equivalent of azide, freeing 
the fluorine to start the catalytic cycle again. Finally, an aqueous work-up with sodium bicarbonate 
removes the labile TMS group on the tosylamide, while leaving the TMS group on the alcohol. The 
diazidosulfoxide reacts further to form hydrazoic acid and sulfur dioxide. 
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Figure 36: Possible mechanism for the decomposition of the oxathiazolidine by catalytic fluorine. 
In order to increase the reactivity of the oxathiazolidine so it would react with one of the azide sources. 
Attempts were made to synthesize oxathiazolidine 106 with a sulfonyl group instead of a sulfoxide. 
However, attempts to synthesize such a compound, through direct synthesis from alcohol 102 with 
sulfuryl chloride or 1,1-sulfonyldiimidazole failed (table 5). Also oxidation of the sulfoxide 103 with 
RuCl3.3H2O/NaIO4 did not produce any 106 (not shown).
[125] A likely explanation is that the compound 
was not stable under the reaction conditions due to its high reactivity.[126] 
Table  5: Protection of 102 with a sulfonyl group. 
 
 
 102 106 
# Sulfonyl source (equiv) Base (equiv) Solvent Temp. (°C) Result 
1 Sulfuryl chloride (1.4) Pyridine (2.5) THF -78 to -41 Decomposition 
2 1,1-sulfonyldiimidazole (1.5) NaH (3) DMF 0 to -41 Decomposition 
 
Since the oxathiazolidine strategy was unsuccessful, a more conventional protecting group was needed. 
The Boc group seemed appropriate since it is generally easy to introduce. More importantly, it is also 
easy to remove under acidic conditions and stable to the basic conditions used in the synthesis. The Boc 
group was introduced reacting mesylate 107 or tosylate 108 (table 3) with Boc anhydride in the 
presence of a catalytic amount of DMAP, yielding 109 and 110 respectively (scheme 7). 
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 R = Ms 107, Ts 108 R = Ms 109, Ts 110 
Scheme 7: Boc protection of tosylamides. Reagents and conditions: Boc anhydride (1.2 equiv), DMAP (0.1 equiv), DCM, rt, 3 h, 109: 77%, 110: 
49%. 
The Boc protected mesylate was allowed to react with sodium azide in DMF, however only starting 
material was recovered (table 6: entry 1). When sodium azide was substituted for N,N,N’,N’-
tetramethylguanidinium azide (TMGA) in MeCN, an azide source that has been reported as successful in 
similar systems,[114b, 123, 127] also no reaction took place (entry 2). The tosylate did not do better, at room 
temperature and at 40°C no reaction took place in the presence of TMGA. At even higher temperature 
(80°C) decomposition of the starting material into an unidentified mixture of compounds occurred, 
possibly due to attack of TMGA on the benzyl protecting groups (entries 3-5). 
Table 6: Azide formation III. 
 
 
 R = Ms 109, Ts 110 111 
Reagents and conditions: azide (1.5 equiv), MeCN, 16 h. 
# R Azide Temp. (°C) Result 
1a Ms NaN3 rt No reaction 
2 Ms TMGA rt No reaction 
3 Ts TMGA rt No reaction 
4 Ts TMGA 40 No reaction 
5 Ts TMGA 80 Decomposition 
a:3 equiv of sodium azide were used, DMF was used as the solvent. 
The results summarized in table 6 indicate that the mesylate and the tosylate do not possess sufficient 
leaving group ability to allow substitution by the azide anion. Additionally, the Boc protecting group 
might retard the reaction through steric hindrance. Therefore, it was decided to change the Boc group 
to a PMB protecting group, which is less bulky than the Boc-group, and to change the activating group 
on the alcohol to a triflate, which is a better leaving group.[128] Optimization of the PMB introduction is 
summarized in table 7. 
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Table 7: PMB protection of tosylamides. 
 
 102 R = Et, 94 R = Bn 112 R = Et, 113 R = Bn 
Reagents and conditions: p-methoxybenzyl halide, base, additive, solvent, rt, 16h. 
# PMB-X (equiv) Base (equiv) Additive (equiv) Solvent Tosylamide Yield (%) 
1 Cl (1.1) Cs2CO3(1.1) ― MeCN 102 63 
2 Cl (1.5) Cs2CO3(1.1) ― DMF 94 55
a 
3 Cl (1.1) K2CO3(1.1) KI (0.1) Acetone 94 No reaction 
4 Cl (2.5) K2CO3(1.1) ― Acetone 94 No reaction 
5 Cl (2) K2CO3(2.5) Bu4NI (0.1) Acetone 94 53
a 
6 Br (2) K2CO3(2.5) ― DMF 94 75
a 
7 Br (2) Cs2CO3(2.1) ― DMF 94 80
a 
8 Br (2) Cs2CO3(2) ― DMF 94 91 
a: NMR yield. 
The PMB group was installed by stirring 102 in acetonitrile in the presence of p-methoxybenzyl chloride 
(PMBCl) and cesium carbonate, although in modest yield (entry 1). In an attempt to increase the yield of 
the reaction a small optimization study was carried out. Switching solvent to DMF did not improve the 
yield of the reaction (entry 2). Finkelstein conditions initially showed no conversion; however, when 
tetrabutylammonium iodide was used instead of potassium iodide, a modest yield was seen (entries 3-
5). Switching from PMB-Cl to PMB-Br and back to DMF as a solvent gave an immediate rise in yield 
(entry 6). Finally, returning to cesium carbonate as a base gave the product in 91% yield on a 0.5 mmol 
scale (entry 8).  
Introduction of the triflate was uneventful; stirring 112 in DCM in the presence of triflic anhydride and 
pyridine gave triflate 114 quantitatively. Submitting the triflate to the TMGA conditions provided the 
azide in good yield (scheme 8). The lower yield for 117 compared to 116 is most likely due to slow 
decomposition of 115 by nucleophilic attack of the guanidine on the benzyl protecting group. Therefore, 
it was essential to monitor the reaction closely and quench it as soon as all starting material was 
consumed. 
 
 R = Et 112, Bn 113 R = Et 114, Bn 115 R = Et 116, Bn 117 
Scheme 8: Synthesis of 116. Reagents and conditions: a) triflic anhydride (1.5 equiv), pyridine (2 equiv), DCM, -15°C, 10 min, quantitative. b) 
TMGA (1.1 equiv), MeCN, 0°C to rt, 2-16h, 116 90%, 117 70%. 
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The deprotection of the tosylamide 117 was performed by oxidation of the PMB group (table 8). DDQ 
was initially investigated to remove the PMB group but no reaction occurred (entry 1). CAN was 
considerably more successful, giving 71 percent isolated yield after a few hours an acetonitrile: water 
mixture (entry 2). Upon switching back to the benzyl protecting groups on the phosphonate, a complex 
mixture was obtained that gave only a modest yield of product (entry 3), presumably due to the slight 
sensitivity of the benzyl groups to oxidation. A solvent switch to 1,4-dioxane containing 10 percent 
water yielded a much cleaner mixture and gave the compound in 85 percent yield (entry 4). 
Table 8: PMB deprotection of tosylamides. 
 
 
 R = Et 116, Bn 117 R = Et 97, Bn 66 
Reagents and conditions: oxidizer (3 equiv), solvent, rt, 8h. 
# Oxidizer Solvent (ratio) Tosylamide Yield (%) 
1a DDQ DCM: H2O (10: 1) 116 No Reaction 
2 CAN MeCN: H2O (5: 1) 116 71% 
3 CAN MeCN: H2O (5: 1) 117 56% 
4 CAN 1,4-dioxane: H2O (9: 1) 117 85% 
a: 1.2 equiv DDQ was used and the mixture was stirred 20 hours. 
8.2.5 Amide coupling II 
With compounds 66 and 97 in hand the amide coupling was reinvestigated. The PyBrOP conditions 
proved to be the most successful when using 90 as a coupling partner. Therefore, the same conditions 
were used for this amide coupling, using both 66 and 97. After minor optimization, coupling occurred 
fast and in a reproducible 79 percent yield of 119 (table 9: entry 2).  
Table 9: Amide coupling. 
 
 
 R = Et 97, Bn 66 67 R = Et 118, Bn 119 
Reagents and conditions: 67, PyBrOP, DMAP, DIPEA, DCM, rt, 4h. 
# 67 equiv PyBrOP equiv DMAP equiv DIPEA equiv Tosylamide Yield (%) 
1 1.1 1.1 1.1 2.2 97 73a 
2 1.2 1.2 1.2 2.4 66 79 
a: NMR yield. 
A summary of the route described so far is given in scheme  9. Although feasible on a small scale (up to a 
few hundred milligram), some of the transformations require undesirable reagents (explosive acetylene, 
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non-commercially available, unstable 4-methoxybenzyl bromide), or were low yielding. Additionally, 
flash column chromatography was required after every step. To facilitate scale up, different routes were 
explored to allow multi-gram synthesis of 66 in a higher yield, preferably using purification by 
crystallization. 
 
 
 
 80 92 94 113 
 
 
 
 
 
 
 66 117 115 
Scheme 9: Synthesis of 66. Reagents and conditions: a) acetylene, tetrakis(triphenylphosphine)palladium(0) (0.05 equiv), THF, rt, 7h, 72%.b) 
chloramine-T (1.25 equiv), osmium tetroxide (0.01 equiv), benzyl triethylammonium chloride (0.05 equiv), CHCl3, water, 60°C, 16 h, 50%.c) 4-
methoxybenzylbromide (2 equiv), cesium carbonate (2 equiv), DMF, rt, 3 h, 91%. d) triflic anhydride (1.5 equiv), pyridine (2 equiv), DCM, -15°C, 
10 min, 98%. h) TMGA (1.1 equiv), MeCN, rt, 2h, 70%. f) CAN (3 equiv), 1,4-dioxane: water 9:1, rt, 6.5 h, 82%. 
8.2.6 Alternative routes to intermediate 66 
Some constraints existed in designing different routes to 66, the introduction of the azide via triflation 
and substitution seemed to be the only chemistry that worked well for this transformation and thus 
could not be changed. The azide introduction also only worked with a PMB group on the tosylamide 
and, while its introduction could be done at a different point in the synthesis, its removal could not. 
Therefore, the last three steps in the previous route toward 66 (scheme 9) were not changed. Thus, 
compound 113 became the focus of a new synthesis strategy. Two additional potential routes towards 
compound 113 were undertaken going via intermediate 122. The retrosynthetic analysis is given in 
figure 37.  
 
 
 120 121 
 
 113 122 
 123 124 125 
Figure 37: Retrosynthetic analysis of compound 113. 
Synthesis of 113 via 122 could be realized in line with a literature procedure. Bendikov et al. reported on 
the synthesis of alpha hydroxyl phosphonates by nucleophilic attack of a TMS activated 
dibenzylphosphite on an aldehyde.[129] Dibenzylphosphite occurs as the phosphonate (phosphorus V) 
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tautomer, however the phosphite (phosphorus III) tautomer is a better nucleophile due to its free 
electron pair. To obtain the phosphite tautomer, the phosphonate can be deprotonated and trapped 
using triethylamine and TMS chloride to provide 127 (figure 38). 127 can then be reacted with aldehyde 
122 to provide 113. This reaction then results in the trimethylsilyl ether adduct of 113, which should be 
easy to deprotect. Thus, the target of the strategy became aldehyde 122. 
 
 80 126 127 
Figure 38: Activation of dibenzylphosphite with TMS chloride. 
Two alternative strategies toward aldehyde 122 were evaluated, one route starting with ethanolamine 
and one starting with p-methoxybenzyl amine (figure 37). Both routes use cheap commercially available 
starting materials. The ethanolamine route began by tosyl and PMB protection of the amine. Oxidation 
would then yield the aldehyde 122. The p-methoxybenzyl amine route started by tosylation of the amine 
yielding 125. A reaction with 1,4-dibromobut-2-ene (124) should afford an alkene that could be 
dihydroxylated using Sharpless conditions and then oxidatively cleaved affording the aldehyde 122. Of 
the two new routes the first, ethanolamine route was the shortest; however, it was expected that most 
intermediates in the second p-methoxybenzyl amine route were solids and might be suitable for 
purification by crystallization.  
For the new first route, ethanol amine was tosylated and subsequently PMB protected using PMB 
chloride, in good yield. A swern oxidation yielded aldehyde 122 in excellent yield. Although 122 is 
unstable at room temperature, it could be stored for several months at -20°C under argon before 
significant decomposition was observed. Nevertheless, the aldehyde was always used in the next 
reaction as soon as possible. The reaction of 122 with activated dibenzylphosphite proceeded smoothly 
to give phosphonate 129 in 88 percent yield, containing a silyl ether (scheme 10). 
 
 
 121 128 120 122 
 
 
 
 113 129 
Scheme 10: Synthesis of 113 starting with ethanolamine. Reagents and conditions: a) ethanolamine (1.1 equiv), 4-toluenesulfonyl chloride (1 
equiv), triethylamine (1.9 equiv), DCM, 0°C to rt, 16h, 83%. b) p-methoxybenzyl chloride (1.05 equiv), cesium carbonate (1.1 equiv), DMF, rt, 2h, 
83%. c) oxalyl chloride (1.1 equiv), DMSO (2.4 equiv), triethyl amine (5 equiv), DCM, -78°C to rt, 2h, 95%.d) dibenzylphosphite (1.2 equiv), 
chlorotrimethylsilane (1.44 equiv), triethyl amine (1.44 equiv), DCM, -20°C to -78°C to rt, 17h, 88%. e) potassium fluoride (2 equiv), methanol, 
rt, 30 min, 94%. 
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Next the removal of the silyl ether was explored (table 10). Removal of the silyl ether was first 
attempted using citric acid in methanol, a method that worked well on similar compounds (see chapter 
8.3.2), but not in this case (entry 1). Since acidic removal did not seem to work, basic removal with 
potassium carbonate was attempted but again there was no conversion to the free alcohol (entry 2). It is 
well known that silicon has a strong affinity for fluorine thus two fluorine reagents were tested in the 
removal of the silyl ether. HF.pyridine yielded mostly starting material and an unidentified byproduct. 
Similar results were obtained using potassium fluoride in THF: water 9:1 (entry 3 and 4). However, 
potassium fluoride in methanol gave the target alcohol 113 quickly, in high yield and purity (entry 5).  
Table 10: TMS deprotection of phosphonate 129. 
 
 
 129 113 
# Reagent (equiv) Solvent Result 
1 Citric acid (2.5) MeOH No reaction 
2 K2CO3(3) MeOH No reaction 
3 HF.Pyridine (0.2) THF: water 9:1 129 and unidentified byproduct 
4 KF (3) THF: water 9:1 129 and unidentified byproduct 
5 KF (3) MeOH 94% 
 
This sequence, although two steps longer than the original vinylphosphonate route, led to target 
compound 113 in 54 percent overall yield. It also circumvented many of the undesirable reagents and 
conditions of the vinylphosphonate route. However, still almost every step in the sequence required 
chromatographic purification. Therefore, yet another route was investigated. 
The second new route started with p-methoxybenzyl amine, which was tosylated using tosyl chloride 
and triethyl amine.[129] Tosylamide 125 was allowed to react with half an equivalent of 1,4-dibromobut-
2-ene (124, scheme 11), yielding alkene 131 in excellent yield. Sharpless dihydroxylation of the alkene, 
using osmium tetroxide and NMO, gave the 2,3-dihydroxyl compound 123, which was oxidatively 
cleaved using periodic acid to yield aldehyde 122. The aldehyde was then allowed to react with the 
activated phosphonate in the same manner as before (scheme  11). 
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Scheme 11: Synthesis of 113 starting with p-methoxybenzyl amine. Reagents and conditions: a) 4-toluenesulfonyl chloride (1 equiv), 
triethylamine (2 equiv), toluene, 0C to rt, 2 h, 94%. b) 125 (2 equiv), 1,4-dibromobut-2-ene (124) (1 equiv), cesium carbonate (1.2 equiv), DMF, 
rt, 2h, 91%. c) osmium tetroxide 5 wt% in water (0.05 equiv), N-methylmorpholine-N-oxide (3 equiv), chloroform: water: tert-butanol 20:2.5:1, 
50C, 16h, 97%. d) periodic acid (1.1 equiv), 1,4-dioxane, 0C to rt, 1h, 84%. e) dibenzylphosphite (1.2 equiv), chlorotrimethylsilane (1.44 equiv), 
triethyl amine (1.44 equiv), DCM, -20°C to -78°C to rt, 17h, 88%. e) potassium fluoride (2 equiv), methanol, rt, 30 min, 94%. 
This final sequence, although one step longer than the ethanolamine route and three steps longer than 
the vinylphosphonate route, gave a total of 58 percent yield of 113 over six steps (table 11). More 
importantly, until the introduction of the phosphonate all compounds were solids that were easily 
precipitated or crystallized in high purity, eliminating the need for column chromatography.  
Obviously, the p-methoxybenzyl amine route was superior to the other two as it had a higher overall 
yield, more robust chemistry and easier purification protocols. This method was used to synthesize 
compound 113 for the entirety of the project; more than 125 grams were produced in total. 113 could 
then be transformed to azide 66 via the triflate/TMGA method described before (scheme 9). 
Table 11: Numerical comparison of the three strategies for the synthesis of 113. 
# Strategy Steps Yield 113 (%) 
1 Vinylphosphonate route 3 32 
2 Ethanolamine route 5 54 
3 p-methoxybenzylamine route 6 58 
8.2.7 Aza-wittig ring closure and aromatization 
With a consistently high yielding route to 66 available and an amide coupling that was performing well, 
attention was focused on the aza-wittig ring closing reaction. Initial exploration of this reaction was 
performed using 96, although only a small amount was available. Two solvents, THF and 2,6-lutidine, 
were reviewed, of which the latter should perform better according to literature.[74] The reaction was 
executed, by dissolving 96 and triphenylphoshpine (PPh3) in the solvent at 0.045 M and -20°C. The high 
dilution was used to prevent intermolecular reactions. After addition of PPh3 the iminophosphorane 
forms almost instantaneously and, after the mixture stopped bubbling, the Schlenk was closed and 
heated to 80°C for six hours to bring about the ring closure (scheme 12). 
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 96 132 
Scheme 12: Initial aza-wittig tests. Reagents and conditions: triphenylphosphine (1.5 equiv), solvent, -20°C to 80°C, 6 h. 
Surprisingly, THF showed a much cleaner reaction profile (1H- &31P-NMR) than 2,6-lutidine, thus THF was 
chosen for all subsequent reactions. A problem became clear during the purification of the reaction; 
both the triphenylphosphine (PPh3) and triphenylphosphine oxide (PPh3O) byproducts were inseparable 
from 132 by flash column chromatography. It was hoped that, upon switching to 119 as a starting 
material, with benzyl protecting groups on the phosphonate, this problem might be solved. 
 
 119 68 
Scheme 13: Aza-wittig using 119. Reagents and conditions: triphenylphosphine (1.5 equiv), THF, -20°C to 80°C, 6h. 
The aza-wittig using 119 as starting material was performed under identical conditions as for 96. No side 
products were observed except PPh3O and some residual PPh3. Purification was again a problem 
however; both PPh3O and PPh3 remained in the material, in essentially unchanged amounts after 
column chromatography. Several different chromatography conditions, as well as precipitation 
conditions, were investigated, but removing the side products completely proved impossible.  
8.2.8 Oxidation 
The next step in the synthesis was the oxidation of 68 to 133 (scheme 14). It was decided to continue 
with crude 68 as its oxidation should change its behavior on column substantially, allowing separation. It 
was expected that PPh3O would not interfere in the oxidation reactions as it is not a reductor. PPh3 is a 
reductor and therefore might quench the oxidator used to oxidize 68, however the PPh3 was only 
present in small amounts (5-10%) and should be easily compensated for by adding a super 
stiochiometric amount of oxidizer. Many different oxidizing agents are known in literature. In order to 
oxidize the imidazoline to the imidazole, at first oxidizers that were reported for heterocyclic systems 
were investigated (chapter 5.7.2.4). All oxidation trials were performed on small scale (10-20 mg) and 
monitored by TLC, if the TLC showed conversion LCMS and NMR analysis was also performed. Therefore, 
several entries in the result sections of the following tables are marked as ‘conversion’ and further 
explained in the text. 
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 68 133 
Scheme 14: Oxidation of imidazoline 68 to imidazole 133. 
8.2.8.1 Oxidation with electrophilic halogens 
A common way to oxidize imidazolines to imidazoles uses BrCCl3 and DBU (chapter 5.7.2.4).  According 
to the literature, an imidazoline with an ester at C-4 is deprotonated at that position by DBU. The 
resulting negative charge attacks the electrophilic bromide, followed by elimination of hydrogen 
bromide to yield the imidazole. Since phosphonates are also electron withdrawing it was expected that 
this method would also work in this case. Initial tests with BrCCl3 and DBU gave no reaction, even upon 
heating. Other sources of electrophilic halogens were also reported in literature as useful reagents in 
this reaction. Therefore, several were investigated in this reaction (table 12). 
Table 12: Oxidation I, electrophilic halogens. 
# Lewis acid (equiv) Base (equiv) Solvent Temp. (°C)a Result 
1 BrCCl3 (1.5) DBU (3) DCM 0 to 70 No reaction 
2 CCl4 (9.5) DBU (5) MeCN 0 to 70 Decomposition 
3 NBS (1.5) DBU (3) DCM rt No reaction 
a: All reactions were performed in a closed vial. 
Reactions with carbon tetrachloride did not show any conversion until the mixture was heated to 70 
degrees for several hours, after which all 68 had decomposed (entry 2). Also no conversion of the 
starting material was seen when N-bromosuccinimide was used as the bromine cation source (entry 3).  
A possible explanation for these results could be the substituent pattern of the imidazoline. The 
phosphonate might not be as electron withdrawing as the ester groups that are usually on that position 
in literature examples, which could lead to a less activated proton at C-4. Also steric shielding by the 
benzyl groups might be a problem, as the large protecting groups might block DBU’s access to the C-4 
proton.  
8.2.8.2 Oxidation with the Kharash-Sosnovsky reaction 
The Kharash-Sosnovsky reaction has been used to oxidize imidazolines, oxazolines and thiazolines and 
various other heterocycles with electron withdrawing groups, to their respective aromatic 
heterocycle.[130] Therefore, it was thought that the method might be adapted to imidazolines with a 
phosphonate at C-4. To this end imidazoline 68 was dissolved in benzene and copper(I)bromide, 
copper(II)acetate and tert-butyl peroxybenzoate were added, after stirring four hours at 80°C a trace of 
product 133 was detected by LCMS. Thus, attempts were made to optimize the conditions and obtain a 
useful yield of 133 (table 13). 
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Table 13: Oxidation II, Kharasch-Sosnovsky. 
 
 
 68 133 
# Cu(I) (equiv) Cu(II) (equiv) Peroxide (equiv) Solvent Temp (°C) Result 
1 Cu(I)Br (1.1) Cu(II)(OAc)2 (1.1) tBuOOCOPh (1.5) PhH rt to 80 Trace 133
a 
2 Cu(I)Br (1.1) Cu(II)(OAc)2 (1.1) tBuOOCOPh (3) PhCl 90 Decomposition 
3 Cu(I)Br (1.1) Cu(II)(OAc)2 (1.1) tBuOOCOPh (3) DCE 84 Decomposition 
4 Cu(I)Br (1.1) Cu(II)(OAc)2 (1.1) tBuOOCOPh (2) PhH 80 Decomposition 
5 Cu(I)OAc (1.1) ― (BzO)2 (2) PhH 80 Trace 136
a 
a: detected by LCMS. 
However, changing the solvent, temperature or the amount of peroxide did not result in a higher yield 
of 133. Only when copper(I)acetate was used as copper source and benzoyl peroxide as peroxide a small 
amount of tosyl eliminated product 136 was detected by LCMS. Due to its lack of success this method 
was not further investigated. 
8.2.8.3 Oxidation with Manganese based oxidizers 
Manganese dioxide has been reported for the oxidation of heterocycles including imidazoles, and was 
investigated next (table 14). The manganese dioxide was activated before the reaction by co-
evaporation with toluene to remove residual water. [79] 
Table 14: Oxidation III, manganese oxidizers. 
# Manganese oxidizer (equiv) Solvent Temp (°C)a Result 
1 MnO2 (10) THF 70 No reaction
b 
2 MnO2(10) CHCl3 70 No reaction
b 
3 MnO2 (10) toluene 70 No reaction
b 
4 MnO2 (10) DCM 70 No reaction
b 
5 n-Bu4NMnO4 (1.1) MeCN rt Decomposition 
6 n-Bu4NMnO4 (1.1) CHCl3 rt Decomposition 
7 n-Bu4NMnO4 (1.1) DCM rt Decomposition 
8 Mn(OAc)3. 2 H2O (4) AcOH rt to 60 Decomposition 
9 Mn(OAc)3. 2 H2O (4) benzene 100 No reaction
c 
a: All reactions were performed in a closed vial. b: Stirred for 16 hours. c: Stirred for 2 days 
Manganese dioxide in various solvents gave no reaction (entries 1-4). Since it is a relatively mild oxidizer 
some manganese compounds with a higher oxidizing potential were investigated. Tetrabutylammonium 
permanganate was selected since it dissolves in organic solvents due to its highly soluble counter-
ion.[128a] This permanganate, however, was found to be too harsh leading to complete decomposition at 
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room temperature, using only 1.1 equivalents (entries 5-7). Manganese(III) acetate also did not yield any 
product (entries 8-9).[131] 
8.2.8.4 Oxidation with selenium dioxide 
Selenium dioxide is an oxidizer known for the oxidation of allylic alcohols and it has been reported as an 
oxidizer of 1,4-dihydropyridines.[132] Thus imidazoline 68 was subjected to these conditions (table 15).  
Table 15: Oxidation IV, selenium dioxide. 
# Equivalents SeO2 Solvent Temp. (°C) Result 
1 1.5 1,4-dioxane 60 to 40 Trace, many side products 
2 1.5 Pyridine rt No reaction 
3 1 1,4-dioxane:pyridine 10:1 40 Trace, did not go to completion 
4a 3 1,4-dioxane 60 12% 
5 1.5 1,4-dioxane 40 20% 
a: 3 A molsieve was added. 
Selenium dioxide in 1,4-dioxane gave a surprising result, on LC-MS the correct mass for compound 134 
could be identified, among other side products. The 31P-NMR (entry 1) showed a single diastereomer, 
suggesting that a stereocenter had been destroyed, as one would expect when the imidazoline was 
aromatized. However, only an impure, small amount of product could be obtained, which was 
insufficient for a full characterization.  
In order to obtain enough isolated compound, optimization studies were performed. Selenium dioxide 
has also been used with pyridine as a solvent.[133] However, changing the solvent to pyridine did not 
yield any product (entry 2). Mixing pyridine and 1,4-dioxane produced mixture containing some of the 
target compound but mostly unreacted starting material was recovered (entry 3). Performing the 
reaction in 1,4-dioxane with addition of 3A molsieve led to a 12% isolated yield after purification. It was 
very gratifying to see the PPh3O byproduct from the previous, aza-wittig reaction, was easily removed 
from the product (entry 4). Lowering the temperature from 60 to 40 degrees improved the yield even 
more (entry 5). Unfortunately, the analytical data showed that the stating material 68 was oxidized at 
the amino acid side chain instead of the imidazoline, yielding compound 135 (figure 39). 
 
 
 133 
 68 
 
 
 135 
Figure 39: alternative product for the reaction of 68 with selenium dioxide. 
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A possible mechanism for this reaction (analogous for the selenium dioxide allylic oxidation 
mechanism),[134] is shown is figure 40. Initially, selenium dioxide and compound 68 undergo an ene-
reaction, to form intermediate A. This intermediate then undergoes a [2+3] sigmatropic rearrangement, 
followed by a tautomerisation and a second ene-reaction, to yield compound 135 and selanediol. After 
elucidating the structure of 135 further investigations into this reaction were ceased. 
 
 
 
 68 A B 
 
 
 
 135 C 
Figure 40: Selenium dioxide oxidation, possible mechanism. 
8.2.8.5 Oxidation with hypervalent iodine reagents 
Since its re-introduction by Nicolaou IBX has found many uses as a mild oxidizing agent, among which 
the oxidation of imidazolines to imidazoles.[85] The initial trials with IBX were encouraging (table 16); 
conversion was noticed after 16 hours at 45°C, however much starting material remained (TLC). 
Increasing the temperature to 60°C for three hours yielded a mixture showing three new signals in the 
31P-NMR in addition to some unreacted starting material (entry 1). Increasing the amount of IBX to two 
equivalents ensured the reaction went to complete conversion (entry 2). Using more than two 
equivalents resulted in decomposition of the products (entry 3). Attempts to select for one of the three 
products were not successful, and the products were inseparable. Therefore, it was impossible to 
identify these products. Using Dess-Martin periodinane (DMP) instead of IBX in either DCM of CHCl3, 
yielded no product (entries 4 and 5). Further investigation into this reaction was not done as at this time 
a more promising method was found (vide infra). 
Table 16: Oxidation V, hypervalent iodine reagents.a 
# Hypervalent iodine reagent (equiv) Temp. (°C) Result 
1 IBX (1.5) 45 to 60 Conversion 
2 IBX (2) 60 100% Conversion 
3 IBX (10) 60 Decomposition 
4b DMP (1.1) rt No reaction 
5c DMP (1.1) rt No reaction 
a: DMSO was used as the solvent. b: DCM was used as the solvent. c: CHCl3 was used as the solvent. 
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8.2.8.6 Base induced aromatization 
Since the oxidation seemed a bigger challenge than expected, another strategy was envisioned. Instead 
of oxidizing the imidazoline, it might be possible to aromatize it by base induced aromatization. To 
achieve this; a base would abstract a proton from C-4, which would lead to elimination of the tosyl 
protecting group, the imidazole would then be obtained after tautomerisation (figure 41). 
 
 135 A B 136 
Figure 41: Base induced aromatization mechanism. 
Thus, several bases were screened (table 17); DBU was not strong enough a base to deprotonate the 
imidazole. DBN also did not show any conversion until the mixture was heated; then the reaction 
mixture contained only decomposed starting material (entry 3). The absence of a 
reaction at room temperature indicated that there was a reactivity problem. This 
could be solved in two ways: increase the acidity of the proton at C-4 or use a 
stronger base. First it was attempted to increase the acidity of the C-4 proton by 
adding lewis acids; these could coordinate to the imidazole and the phosphonate, 
thereby decreasing the electron density on C-4 (figure 42). Silver was initially 
investigated as a chelating agent. Silver carbonate, which could both act as base 
and chelator, did not show any reaction (entry 4). Silver tetrafluoroborane and trimethylsilyl triflate, a 
strong lewis acid, also did not result in any reaction (entries 5 and 6). Therefore a look at the second 
option, using a stronger base, was required.  
Using strong base has the disadvantage that it might induce racemization of the amino acid by 
abstracting the alpha proton. However, it was expected that the proton on the Alloc carbamate was 
more acidic, and its removal would strongly deactivate the alpha proton on the amino acid. Later this 
was found to be the case (vide infra). 
 
 
 
 
 
 
 
 
Figure 42: lewis acid 
coordination 
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Table 17: Base induced aromatization. 
 
 135 136 
# Base (equiv) Solvent Temp. (°C) Result 
1 DBU (15) DMF rt No reaction 
2 DBU (33) ― rt No reaction 
3 DBN (41) ― rt to 60 Decomposition 
4 AgCO3(6) DCM rt No reaction 
5 DBU (3) AgBF4 (1.5) DCM rt No reaction 
6 DBU (3) TMSOTf (1.5) DCM 0 No reaction 
7 NaH (1.1) DMF rt No reaction 
8 KHMDS (2) THF -78 to 0 0 - 72%a 
9 Zn(TMP)2 (2.2) THF -78 Trace 
a: NMR yield. 
 
The first strong base that was used was sodium hydride, however no reaction occurred (entry 7).Upon 
addition of KHMDS to compound 135 in THF some product was formed. 
Regrettably, there was also a lot of side product formation and the reaction was 
not reproducible. Sometimes the reaction gave good yield (up to 72 percent), 
while other times no product was recovered. Zn(TMP)2 was tested as a ‘softer’ 
alternative for KHMDS, but only traces of product were detected by NMR.  
8.2.9 Aromatization of an electron deficient imidazoline 
Convinced that the base induced elimination strategy could work, attempts were made to test if the 
reaction went better with a more electron deficient imidazoline. To that end compound 138 was 
synthesized, this imidazoline has an ethyl ester on the 2-position and therefore is much more electron 
deficient (scheme 15). Its synthesis was straightforward, 66 was dissolved in DCM with chloroethyl 
oxoacetate in the presence of DMAP and DIPEA to furnish the amide. The amide proved to be unstable 
to basic conditions and was thus quickly cyclized to the imidazoline with PPh3 yielding 138 as a mixture 
with PPh3 and OPPh3.  
 
 66 137 138 139 
Scheme 15: Synthesis of 138. Reagents and conditions: a) chloroethyl oxoacetate (2 equiv), DMP (1 equiv), DIPEA (2 equiv), DCM, rt, 1 h, 45%. 
b) triphenylphosphine (1.5 equiv), THF, -18°C to 80°C, 6h, assumed quant. c) DBU (15 equiv), DMF, 0°C, 5 min, 139 quantitative  
 
           Zn(TMP)2 
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Imidazoline 138 was submitted to base induced aromatization conditions (DBU in DMF), which led to 
immediate quantitative formation of 139. It seemed that the deprotonation reaction was very fast and 
working quite well using electron deficient imidazolines.  
It was clear that reducing the electron density of the imidazoline was very 
effective in promoting the base induced aromatization. Therefore, a way was 
sought to decrease the electron density on the imidazoline, while still allowing the 
other chemistries to work. A possible solution was found in exchanging the tosyl 
group for a nosyl. Due to the nitro group on the 4 position a nosyl is significantly 
more electron withdrawing than a tosyl. This should allow the use of weaker 
bases, like DBU, and circumvent the danger of racemization. A disadvantage was 
that, due to our synthetic strategy, the nosyl imidazole had to be synthesized starting with p-
methoxybenzyl amine instead of simply swapping the tosyl for a nosyl using imidazoline 68. 
 
 
 140 141 142 
 
 
 143 144 145 
Scheme 16: Synthesis of 146. Reagents and conditions: a) 4-toluenesulfonyl chloride (1 equiv), triethylamine (2 equiv), toluene, 0°C to rt, 2 h, 
90%. b) 1,4-dibromobut-2-ene (124) (0.5 equiv), cesium carbonate (1.2 equiv), DMF, rt, 2h, 98%. c) osmium tetroxide 5 wt% in water (0.05 
equiv), N-methylmorpholine-N-oxide (3 equiv), chloroform: water: tert-butanol 20:2.5:1, 50°C, 16h, 95%. d) periodic acid (1.1 equiv), 1,4-
dioxane, 0°C to rt, 1h, 92%. e) dibenzylphosphite (1.2 equiv), chlorotrimethylsilane (1.44 equiv), triethyl amine (1.44 equiv), DCM, -20°C to -78°C 
to rt, 17h, 57%. f) potassium fluoride (2 equiv), methanol, rt, 30 min, 93%. g) triflic anhydride (1.5 equiv), pyridine (2 equiv), DCM, -15°C, 10 min. 
h) TMGA (1.1 equiv), MeCN, rt, 2h, 76% over two steps. i) CAN (3 equiv), 1,4-dioxane: water 9:1, rt, 6.5 h, 85%. j) 67, PyBrOP (1.2 equiv), DMAP 
(1.2 equiv), DIPEA (2.4 equiv), DCM,0°C to rt, 3.5 h, 47%. k) PPh3 (1.5 equiv), THF, 80°C, 6 h, 88%. 
The synthesis of the nosyl imidazoline was similar to the synthesis of 68 (scheme 16). However, several 
reactions gave lower yield using a nosyl group than with the tosyl group. The phosphonate introduction 
gave the TMS-ether adduct of compound 145 in only 57 percent and the amide coupling between 144 
and 67 provided a modest yield of 47 percent. The latter low yield is most likely due to increased 
deactivation of the sulfonamide compared to the tosylamide, due to the stronger electron withdrawing 
properties of the nitro group. Additionally, the nosyl compounds had a lower solubility in most solvents. 
This lengthened some reaction times due to the higher dilution required. The overall yield to 143 was 23 
percent.  
143 was submitted to similar reaction conditions as imidazolines 135 and 138, the results are 
summarized in table 18. 
 
 
    Tosyl          Nosyl 
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Table 18: Base induced aromatization. 
 
 143 136 
# Base (equiv) Solvent Temp. (°C) Result 
1 DBU (7.5) DMF 0 No reaction 
2 Cs2CO3 (2) MeCN rt No reaction 
3 DBU (5) CCl4 (4) MeCN rt Decomposition 
4 DBU (1) HMDS rt No reaction 
5 DBU (3) TMSOTf (1.5) DCM rt No reaction 
6 Zn(TMP)2 (6.6) THF -78 Decomposition 
 
As clear from table 18, no satisfying results were obtained for the nosyl-imidazoline employing weak 
base. Thus, no noticeable difference was seen in ease of deprotonation between the tosyl and the nosyl 
imidazoline. DBU failed to deprotonate 143 (entry 1), as did other methods investigated for the tosyl 
imidazoline (entries 2-5). Also using the strong base Zn(TMP)2 no product was obtained (entry 6). It 
seems that the nosyl group cannot reduce the electron density of the imidazoline as sufficiently as a C-2 
ester. Thus, since the yield and handleability of the tosyl imidazoline and its precursors were better than 
for the nosyl analogues, the tosyl compounds were used in all follow up chemistry. 
8.2.10 Successful base induced elimination 
Some promising, but irreproducible results were obtained with the base induced aromatization strategy, 
using KHMDS (vide supra). To solve the reproducibility issues it seemed necessary to perform the 
reaction on pure 135 without any residual PPh3 and OPPh3. Therefore, another phosphine that did not 
have the same retention time as 68 was required. In the literature several phosphines have been tested 
in the aza-wittig reaction, but they display inferior performance compared to PPh3. It was thought that 
bis(diphenylphosphino)ethane (dppe) could be a good replacement for PPh3 from a purification 
standpoint as a di-oxidized dppe would be quite polar and thus easily removable by column 
chromatography. dppe has not been described in literature as a phosphine source in the aza-wittig 
reaction. However, upon testing dppe in the aza-wittig reaction it was found to perform similar to PPh3 
(scheme  17). 
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 119 135 
Scheme 17: Synthesis of 147. Reagents and conditions: dppe (1.5 equiv), THF, rt to 80°C, 8h, 98%. 
Using similar conditions as described for PPh3, dppe gave full conversion 
in six to eight hours at 80 degrees and, after oxidizing residual dppe with 
hydrogen peroxide, all side products were easily removed by filtration 
through a silica plug. Since the formation of the iminophosphorane was 
slower with dppe compared to PPh3, it was no longer necessary to cool 
the reaction mixture during phosphine addition. With pure 68 in hand the 
aromatization reaction was further optimized. 
Table 19: Base induced aromatization of pure 68. 
# Equivalents KHMDS Quencher (equiv) Temp. (°C) Result 
1 2 water -78 60% conversiona 
2 2.5 water -78 to -15 100% conversion 
3 3 TrCl (1) -78 to -15 136 recovered 
4 3 TsCl (2.1) -78 to rt 136 recovered 
5 3 TsCl (1) -78 136 recovered 
6 3 Boc2O (2) -78 Double addition 
7 3 AcOH / water -78 100% conversion 
a: determined by NMR. 
Using 2 equivalents of KHMDS the reaction only proceeded to 60 percent conversion (table 19: entry 1). 
Increasing the amount of KHMDS to 2.5 equivalents, in combination with a slow increase of temperature 
during the reaction to -15 degrees, led to full conversion (entry 2). Due to the polarity of the 
unprotected imidazole it was difficult to purify using column chromatography, the imidazole seemed to 
have a high affinity for the silica and much product was lost during purification. Therefore, in situ 
quenching of the deprotonated imidazole with various protecting groups was also investigated. 
Unfortunately, in situ quenching with a protecting group was not successful. The reagent was added 
after complete consumption of 68. Reactions with trityl- or tosyl chloride only yielded 136 (entries 3 to 
5). However, when boc anhydride was used to quench the reaction double addition of Boc was observed 
(entry 6). NMR and LCMS suggested the compound was 148, the 
compound was not isolated but this result did suggest that in situ 
protection was not a good strategy. 
Thus, a quench with water, followed by a conventional protection seemed 
the only way to go forward. Since 136 behaved so poorly during column 
chromatography it was decided to submit it to the next reaction after 
only an aqueous work-up. The optimized conditions involved the slow addition of three equivalents of 
 
Figure 43: dppe 
 
 148 
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KHMDS, driving the reaction to completion immediately. To prevent decomposition during the quench 
the mixture was transferred, by canula, to a stirring, ice cold solution of six equivalents acetic acid in 
water. This ensured that all KHMDS was quenched immediately. These optimizations provided 136 in a 
high yield and purity so it could be submitted to the next reaction without further purification. 
8.2.11 Protecting the imidazole: trityl 
As discussed before (chapter 7) a trityl group would be preferred for SPPS. Installing a trityl group on an 
imidazole is normally done by reaction with trityl chloride and an amine base. Attempts to synthesize 
149 are summarized in table 20. 
Table 20: Attempted synthesis of 149. 
 
 136 149 
# Equivalents Trityl chloride Base (equiv) Solvent Result 
1 1.5 Pyridine (10) DCM No reaction 
2 1.5 Pyridine (10) THF No reaction 
3 1.5 DIPEA (4) THF No reaction 
4 2.2 KOtBu DMF No reaction 
 
Protecting the imidazole using trityl chloride and 10 equivalents of pyridine did not lead to any 
conversion of the starting material, using either DCM or THF as a solvent (entries 1 and 2). Changing the 
base to DIPEA was also not successful (entry 3). It was thought that the bases were not sufficiently 
strong to deprotonate the imidazole. Therefore potassium tert-butoxide was used, however again no 
reaction was observed. Steric effects from the amino acid part and the benzyl group could be preventing 
the big trityl group from access to the imidazole, thus retarding the reaction. 
8.2.12 Protecting the imidazole: Boc 
Therefore, an alternative protecting group was required. The Boc group is known as an easily removable 
protecting group on imidazoles, due to its propensity to fall off if the imidazole becomes protonated. 
Since all the following reactions were under basic conditions Boc was deemed a suitable protection 
group. Introduction of the Boc group was achieved by stirring crude 136 with Boc anhydride in the 
presence of DIPEA. In contrast to in situ protection, no reaction of Boc anhydride with the carbamate 
was observed under these reaction conditions. Purification of the protected imidazole using column 
chromatography proceeded without problems. 
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 136 150 
Scheme 18: Synthesis of 150. Reagents and conditions: boc anhydride (1 equiv), DIPEA (1 equiv), 1,4-dioxane: water 1:1, 0°C to rt, 66%. 
At this time the enantiomeric purity of 150 was investigated, in order to analyze if the base induced 
aromatization compromised the stereocenter (vide supra). To this end a racemic version of 150 was 
synthesized, by using di-protected DL-aspartic acid as the acid partner for the amide coupling. Both L-
150 and DL-150 were injected on a chiral HPLC. Gratifyingly it showed that L-150 had an ee of 96%, 
proving that the KHMDS does not induce racemization by abstracting the alpha proton from the amino 
acid (figure 44). 
 
 DL-150 L-150 
150 S-enantiomer R-enantiomer 
 tR(min) Area % tR(min) Area % 
DL 26.75 49.5 28.98 50.5 
L 27.11 98.0 29.57 2.0 
Figure 44: Chiral HPLC data for compound 150. 
Next the Alloc and allyl protecting groups were removed using tetrakis(triphenylphoshino)palladium(0) 
in THF and morpholine as allyl scavenger. The reaction went to completion and showed the right mass in 
LCMS.  The mixture was not purified beyond evaporation of all volatiles, due to the polarity of the free 
amino acid. Fmoc protection was performed on the crude mixture using Fmoc-OSu and sodium 
bicarbonate in dioxane: water 9:1 (scheme 19).  
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 150 151 152 
Scheme 19: Attempted synthesis of 152. Reagents and conditions: a) tetrakis(triphenylphosphine)palladium(0) (0.1 equiv), morpholine (20 
equiv), THF, rt, 15 min. b) Fmoc-OSu (1.1 equiv), Sodium bicarbonate (1.1 equiv), 1,4-dioxane: water 9:1, rt, 16h. 
Unexpectedly, the reaction did not yield any of the target product, only starting material 151 was 
recovered. It was hypothesized that residual morpholine might be the cause of the failure by reacting 
with all the Fmoc-OSu. Therefore, the alloc and allyl deprotection was performed again but this time 
using phenyl silane as allyl scavenger. The crude reaction mixture was suspended in mesitylene and 
evaporated to dryness three times to ensure no more volatiles were present. However, once again the 
Fmoc protection did not work.  
Taking a closer look at the LCMS data from both the de-allylations and Fmoc protection something 
peculiar was noticeable. After the deallylation using phenylsilane there are two peaks visible in the 
LCMS trace, at 9.0 min (A) and 9.5 min (B) (figure 45, I). Both show the correct product mass of 516 
[M+H]+. However, when looking at the LCMS spectra of the same mixture after exposure to base only 
one peak of that mass is visible (figure 45, II). 
 
Figure 45: LCMS spectra of the product of the deallylation before (I) and after (II) the exposure to base. A = 153, B = 154. 
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It seems that upon exposure to base a reaction occurs that yields a product with the same mass but that 
is unreactive toward Fmoc-OSu. Most likely exposure of compound 153 to base induces an attack of the 
free amine of the amino acid on the carbamate and abstracts it from the imidazole through a six 
membered transition state to yield 154 (figure 46). While 154 was isolated, it proved impossible to 
obtain a good HMBC NMR spectrum to conclusively prove its structure, most likely due to its 
zwitterionic nature. However, the 31P-NMR shows a singlet at 6 ppm, this is a chemical shift that would 
be expected for the unprotected imidazole (between 5-15 ppm). This problem precluded the use of Boc 
as a protecting group. Even if the problem could be solved at this stage by careful pH control, the Boc 
scramble would retard peptide synthesis during removal of the Fmoc under basic conditions, due to 
capping of the peptide sequence with the Boc group. 
 
 153 A 154 
Figure 46: Boc rearrangement mechanism. 
8.2.13 Protecting the imidazole: p-Methoxybenzyl 
Since Boc protection was no longer a possibility, another protecting group was needed and the PMB 
group seemed to have the main qualities that were needed; stability under peptide coupling conditions 
and acid lability. It also did not have an electrophilic functionality that could be attacked by the amine 
after allyl deprotection. To install the PMB group p-methoxybenzyl chloride was used in conjunction 
with a base (table 21). The first base tested was DIPEA but no product was obtained after stirring for 
three days at room temperature (entry 1). Potassium carbonate in acetonitrile led to decomposition 
(entry 2), the same base in DMF gave quick formation of 155 but also led to decomposition if the 
mixture was allowed to age at room temperature (entry 3). Finally, 155 was obtained in 84 percent yield 
after three hours (entry 4). 
 
 
 
 
 
 
 
81 
 
Table 21: p-methoxybenzyl protection of 136. 
 
 136 155 
Reagents and conditions: p-methoxybenzyl chloride (1.5 equiv), base, solvent, rt, time. 
# Base (equiv) Solvent Time Result 
1 DIPEA (1.6) THF 3 days No reaction 
2 K2CO3 (5) MeCN 7 hours Decomposition 
3 K2CO3 (5) DMF 7 hours Decomposition 
4 K2CO3 (5) DMF 3 hours 84% 
 
Removal of the allyl and alloc protecting groups was done without incident using 
tetrakis(triphenylphoshino)palladium(0) in THF and phenylsilane. The reaction mixture was again co-
evaporated with mesitylene and used in the Fmoc protection without further purification. Fmoc-Osu 
and sodium bicarbonate in 1,4-dioxane: water 10:1 was successful in Fmoc protecting the amine yielding 
156 in 51 percent over two steps (scheme 20). 
 
 155 156 
Scheme 20: Synthesis of 156. Reagents and conditions: a) tetrakis(triphenylphoshino)palladium (0.1 equiv), phenylsilane (5 equiv), THF, rt, 1h. 
b) Fmoc-OSu (1.5 equiv), sodium bicarbonate (1.5 equiv), dioxane: water 10:1, rt, 16h, 51% over two steps. 
Having obtained a suitable protected Fmoc SPPS building block a cleavage test was performed to make 
sure all acid labile protecting groups could be removed by acidolytic cleavage. To this end a small 
amount of 156 was dissolved in TFA:TIPS:water 95:2.5:2.5 and stirred for 16 hours. Periodic LCMS 
samples showed that first one of the benzyl protecting groups was removed and then slowly the second 
benzyl group was removed. However, no matter how long the reaction mixture was allowed to age, the 
PMB group could not be removed using this method. This made it very unlikely that the PMB group 
could be removed after peptide synthesis; therefore a new protective group was again needed. 
8.2.14 Protecting the imidazole: 2,4-dimethoxybenzyl 
2,4-Dimethoxybenzyl (DMB) is structurally similar to PMB, only the extra methoxy group makes it more 
labile toward acidic- and oxidative cleavage.[128b] Oxidative cleavage provided a good alternative method 
for removal of the protecting group in case acidolytic cleavage did not work.[ref greene] To attach the 
DMB group to the imidazole, DMB chloride was synthesized in two easy steps from 2,4-
dimethoxybenzaldehyde (scheme 21).[135] Sodium borohydride was used to reduce the aldehyde to the 
alcohol, which was then transformed into the chloride by thionyl chloride. DMB chloride is a very 
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reactive compound, sensitive to nucleophiles and prone to polymerization, therefore the reaction was 
quickly worked up with ice cold solvents and immediately used in the next reaction. 
 
 157 158 159 
Scheme 21: Synthesis of 159. Reagents and conditions: a) sodium borohydride (1 equiv) EtOH, rt, 30 min, 98%. b) thionyl chloride (2.5 equiv), 
2,6-lutidine (2.5 equiv), chloroform, -15°C, assumed quantitative. 
The protection of 136 with DMBCl was optimized (table 22). First DIPEA in DCM was investigated but this 
led to a rather complex mixture of mostly 160. Switching to potassium carbonate in DMF and 1.2 
equivalents of 159 yielded the desired product in 62 percent isolated yield. The product still contained 6 
percent 160 that was inseparable using flash column chromatography or preparative HPLC. Increasing 
the amount of DMB chloride to 1.4 equivalents lowered the yield but no 160 was present in the final 
product. However, since both 160 and 161 yield the same product after deprotection 1.2 equivalents of 
DMBCl were used in subsequent syntheses of the compound. 
Table 22: 2,4-dimethoxybenzyl protection of 136. 
 
 
 160 
 
 136 
 
 161 
 
Reagents and conditions: 2,4-dimethoxybenzyl chloride, base, solvent, rt, 16h. 
# Equivalents DMBCl Base (equiv) Solvent Resulta 
1 1.5 DIPEA (1.6) DCM 160:161 (10:1)b 
2 1.2 K2CO3 (5) DMF 161 (62%)
c 
3 1.4 K2CO3 (5) DMF 50% 
a: yield over two steps. b: yield not determined, ratio determined by 31P-NMR. c: containing 6% 160 
Having obtained a suitably protected imidazole the next step was concomitant deprotection of the alloc 
and allyl groups, followed by Fmoc protection of the amine. Deprotection of the allyl groups and Fmoc 
protection were done similarly to the PMB imidazole, yielding 50 percent 162 over two steps (scheme 
22).  
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 161 162 
Scheme 22: Synthesis of162. Reagents and conditions: a) tetrakis(triphenylphoshino)palladium(0) (0.1 equiv), phenylsilane (5 equiv), THF, rt, 1h. 
b) Fmoc-OSu (1.5 equiv), sodium bicarbonate (1.5 equiv), dioxane: water 10:1, rt, 16h, 50% over two steps. 
162 was exposed to several peptide cleavage mixtures (table 23). Standard TFA:TIPS:water 95:2.5:2.5 
removed both benzyl groups but failed to remove the DMB group, heating the mixture to 80 degrees for 
several hours, after the benzyls were removed, did not result in any change (entry 1). In pure TFA the 
results were the same (entry 2). In TFA: EDT 1:1 very quick benzyl deprotection was seen. EDT 
(ethanedithiol) is a strong nucleophile that will quickly attack any electrophiles in the mixture, reducing 
side reactions during deprotection and improving its speed. However, these conditions also did not 
remove the DMB group (entry 3). Finally, the compound was dissolved in acetic acid with EDT present. 
No reaction occurred under these conditions until the reaction was heated to 60 degrees overnight, 
when slowly one of the benzyl groups was removed.  
Table 23: Acidic 2,4-dimethoxybenzyl deprotection conditions. 
# Cleave mix (ratio) Result 
1 TFA: TIPS: water (95:2.5:2.5) DMB on, two Bn removed 
2 TFA DMB on, two Bn removed 
3 TFA: EDT (1:1) DMB on, two Bn removed 
 
Clearly, DMB removal did not proceed as hoped, to ensure it would also not work on a peptide, a small 
peptide, Ac-FKH*KG-NH2 was synthesized. Standard cleavage mixture (TFA:TIPS:water 95:2.5:2.5) was 
enough to cleave the peptide from the resin and remove all protecting groups except the DMB group 
(table 24: entry 1). Changing the ratio of the cleavage mix (entry 2) or adding hydrobromic acid (entry 3) 
did not remove the DMB either. 
Table 24: Acidic 2,4-dimethoxybenzyl deprotection conditions from a peptide. 
# Cleave mix (ratio) DMB removed? 
1 TFA: TIPS: water (95:2.5:2.5) no 
2 TFA: TIPS: water (90:5:5) no 
3 TFA: TIPS: HBr (48% in water): water (80:5:5:10) no 
 
A different peptide (Ac-GAKRH*RKVLRGC-NH2) was exposed to TMSBr for several weeks, as well as to 
condensed HF, without any sign of DMB removal. At this point it was clear acidolytic cleavage was not 
possible for the DMB group, therefore oxidative cleavage was investigated.  
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Table 25: Oxidative 2,4-dimethoxybenzyl deprotection conditions. 
# Substrate Oxidizer (equiv) Solvent Resulta 
1 162 DDQ (3) CHCl3: water 9:1 No reaction 
2 162 CTAN (3) DCM Decomposition  
3 162 CAN (3) DMF: water 9:1 DMB removalb 
4 Ac-GAKRH*RKVLRGC-NH2
c CAN (3) DMF: water 9:1 No reaction 
5 Ac-GAKRH*RKVLRGC-NH2
c CAN (10) DMF: water 9:1 No reaction 
6 Ac-GAKRH*RKVLRGC-NH2
c CAN (30) DMF: water 9:1 No reaction 
a: determined by LCMS. b: also some benzyl removal.c: on tentagel S-RAM resin. 
First, oxidation of the DMB group was attempted on the SPPS building block 162 using DDQ, but no 
reaction was seen (table 25: entry 1). Cerric tetrabutylammonium nitrate, an analogue to CAN that is 
more soluble in organic solvents, decomposed 162 completely (entry 2). CAN in DMF: water 9:1 gave 
slow DMB removal (several days) with concomitant mono benzyl removal (entry 3). Encouraged by this 
result deprotection of the DMB group on a peptide was investigated. The peptide on resin, before global 
acidolytic deprotection, was subjected to 3, 10 and 30 equivalents of CAN in DMF: water 9:1. 
Regrettably, even after prolonged reaction times no reaction was observed. 
8.2.15 Protecting the imidazole: Trityl revisited 
Since the alternative protecting groups proved incompatible with SPPS, introduction of the trityl group 
was more thoroughly investigated. With this final failure to remove the DMB group it became clear that 
yet another protecting group was needed. Most likely, the lack of reactivity of trityl chloride (TrCl) was 
the limitation in the previous experiments. There are literature reports that TrCl can be activated by 
silver triflate (AgOTf).[136] The triflate can displace the chloride of TrCl, which precipitates as silver 
chloride; TrOTf, a strong electrophile was expected to be more reactive toward the imidazole. Thus, the 
imidazole was dissolved in DCM in the presence of TrCl and DBU and AgOTf were added. Immediately, a 
grey solid precipitated out of the solvent and compound 149 was obtained in 77 percent yield over two 
steps (from the imidazoline). 
 
 136 149 
Scheme 23: Synthesis of. Reagents and conditions: Trityl chloride (2 equiv), DBU (3 equiv), silver triflate (2.2 equiv), DCM, rt, 2 h, 77% over two 
steps from 68. 
Alloc- and allyl deprotection and Fmoc protection were performed according to the previously used 
protocol. Flash column chromatography of 65 gave low isolated yield, most likely due to a high affinity of 
the compound to the silica. As an alternative the compound was purified over C18 sep-pak cartridges. 
The compound was dissolved in water and a minimal amount of acetonitrile and loaded on the 
cartridge. Elution was done by a gradient starting with 100 percent water to 100 percent acetonitrile in 
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steps of 10 percent. The compound elutes between 70 and 90 percent acetonitrile and was isolated in 
96 percent yield. To date, more than 5.4 grams of 65 were synthesized using this method. 
 
 136 65 
Scheme 24: Synthesis of 65. Reagents and conditions: a) Pd(PPh3)4 (0.1 equiv), phenylsilane (5 equiv), THF, rt. b) Fmoc-OSu (1.5 equiv), NaHCO3 
(1.5 equiv), 1,4-dioxane: water 10:1, rt, 16h, 96% over two steps. 
65 was used in SPPS to synthesize a range of peptides in moderate to good yield, these peptides were 
used to raise antibodies against pHis. This is further discussed in chapter 9. 
8.2.16 Final synthetic route toward 65 
In conclusion, a 15 step synthesis toward 65 was realized (scheme 25), beginning with the tosylation of 
p-methoxybenzyl amine. The resulting tosylamide was allowed to react with 1,4-dibromobut-2-ene, 
yielding alkene 124, which was dihydroxylated with osmium tetroxide. The diol was oxidatively cleaved 
using periodic acid and the resulting aldehyde was subjected to TMS activated dibenzylphosphite, which 
after deprotection yielded the phosphonate 113. An azide moiety was introduced by activating the 
hydroxyl as a triflate and substituting it with TMGA. Removal of the PMB group with CAN led to amide 
coupling partner 117 that was coupled to 67 using PyBrOP and DMAP. Aza-wittig ring closing of the 
resulting amide was promoted by dppe, followed immediately by aromatization by base induced 
elimination of the tosylate. Protecting the imidazole with a trityl group and removal of the Alloc and allyl 
protecting groups was followed by the final Fmoc protection yielding 65 in 22.7 percent over 15 steps.  
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Scheme 25: Synthesis of 65 starting with p-methoxybenzyl amine. Reagents and conditions: a) 4-toluenesulfonyl chloride (1 equiv), 
triethylamine (2 equiv), toluene, 0°C to rt, 2 h, 94%. b) 125 (2 equiv), 1,4-dibromobut-2-ene (124) (1 equiv), cesium carbonate (2.4 equiv), DMF, 
rt, 2h, 91%. c) osmium tetroxide 5 wt% in water (0.05 equiv), N-methylmorpholine-N-oxide (3 equiv), chloroform: water: tert-butanol 20:2.5:1, 
50C, 16h, 97%. d) periodic acid (1.1 equiv), 1,4-dioxane, 0C to rt, 1h, 84%. e) dibenzylphosphite (1.2 equiv), chlorotrimethylsilane (1.44 equiv), 
triethyl amine (1.44 equiv), DCM, -20°C to -78°C to rt, 17h, 88%. f) potassium fluoride (2 equiv), methanol, rt, 30 min, 94%. g) triflic anhydride 
(1.5 equiv), pyridine (2 equiv), DCM, -15°C, 10 min, 98%. h) TMGA (1.1 equiv), MeCN, rt, 2h, 70%. i) CAN (3 equiv), 1,4-dioxane: water 9:1, rt, 6.5 
h, 82%. j) XX, PyBrOP (1.2 equiv), DMAP (1.2 equiv), DIPEA (2.4 equiv), DCM,0°C to rt, 3.5 h, 81%. k) dppe (1.5 equiv), THF, rt to 80°C, 8h, 98%. l) 
KHMDS 0.5M in toluene (3 equiv), -78°C , 30 min. m) Trityl chloride (2 equiv), DBU (3 equiv), silver triflate (2.2 equiv), DCM, rt, 2 h, 77% over 
two steps. n) Pd(PPh3)4 (0.1 equiv), phenylsilane (5 equiv), THF, rt. o) Fmoc-OSu (1.5 equiv), NaHCO3 (1.5 equiv), 1,4-dioxane: water 10:1, rt, 16 
h, 96% over two steps. 
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8.3 Other routes toward a 3-phosphohistidine mimic – Imidazole synthesis 
Besides the successful route described in the last paragraph, many different routes have been pursued. 
Here the other routes that were followed in an attempt to synthesize the 3-pHis mimic will be described. 
The routes are roughly divided into methods that relied on the construction of the imidazole and 
methods that started from the imidazole. First, the syntheses to construct the imidazole will be 
discussed, followed by the methods starting from the imidazole. All syntheses described here have failed 
at a certain point, which will be detailed in the text. 
8.3.1 Negishi I 
It was though that 65 could be prepared from the heteroaromatic phosphonate 73 and amino acid 
derivative 74. In this case, a Negishi coupling should lead to the final product (figure 47).[54b] The choice 
of protecting groups of compound 74 was determined by success of 74 in reacting with systems 
analogous to 73, containing a sulfonyl amide moiety at C-4 instead of the phosphonate.[137] The methyl 
ester can be easily removed using trimethyltin hydroxide.[138] Compound 74 should be easily available 
via a literature procedure,[139] whereas compound 73 had proved to be more challenging. Earlier 
attempts to make a phosphonic acid imidazole by addition of the phosphonate to the imidazole failed 
(chapter 8.4.1). Therefore intermediate 66, described in chapter 8.2 was employed. 
 
 
 74 164 
 
 
 65 
 
 73 66 
Figure 47: Negishi strategy. 
To this end azide 66, which is made via a nine step synthesis from p-methoxybenzyl amine (chapter 
8.2.6), was allowed to react with formic acid using DCC and DMAP with formic acid. However, this 
reaction did not produce any product.[140] It was thought that 1H-benzo[d][1,2,3]triazole-1-carbaldehyde 
72 could serve as a suitable formyl donor and was easily synthesized using benzyl triazole, formic acid 
and diisopropyl carbodiimide (DIC).[141] 72 was allowed to react with 66 in the presence of various bases 
and solvents, the results are summarized in table 26. 
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Table 26: Synthesis of amide 165. 
 
 66 72 165 
# Base (equiv) Equivalents 72 Solvent Temp. (°C) Result 
1 Cs2CO3 (1.2) 1.2 DMF rt 50% conversion 
2 NaH (1.2) 2 DMF 0 Decomposition  
3 NaH (1.2) 2 THF 0 76% yield 
 
The amide coupling was first performed using cesium carbonate in DMF, however after 6 hours at room 
temperature there was only 50% conversion (entry 1). Therefore, sodium hydride was tested, being a 
stronger base. Surprisingly, sodium hydride in DMF yielded an unidentified mixture of products (entry 
2). After a solvent switch to THF the reaction gave target compound 165 in good yield after only 30 
minutes reaction time (entry 3). 
Aza-wittig ring closing using dppe under standard conditions (see chapter 8.2.7) gave 87% yield of the 
imidazoline (scheme 26). Imidazoline 166 was then aromatized to the imidazole by base induced 
aromatization and quenching with trityl chloride. The in situ quench with trityl chloride gave about 50 
percent conversion to 167 during test reactions; the rest was the unprotected imidazole. 
 
 165 166 167 
Scheme 26: Formyl synthesis of 167. Reagents and Conditions: a) dppe (1.5 equiv), THF, 80°C, 6h, 87%. b) KHMDS 0.5M in toluene (2 equiv), 
THF, -78°C, 1 h. c) trityl chloride (1.5 equiv), THF, -78°C to rt, 2.5 h, 50 percent conversion. 
The in situ quench of the imidazole failed completely in case of the pHis analogue described in chapter 
8.2.11. The absence of a C-2 substituent on compound 166  most likely allows for in situ protection 
albeit in moderate yield.1  
While this route toward 167 did yield the product, it was in quite low overall yield. Since parallel work 
on a different route toward 167 was successful at this point, the formyl route was abandoned (see 
chapter 8.4.2). 
 
                                                          
1 At this time the introduction of the trityl chloride employing the DBU and silver triflate method was not yet 
developed. 
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8.3.2 Aldehyde route 
The problematic oxidation of the imidazoline to the imidazole described in chapter 8.2.8, let to the 
consideration of a different strategy where this oxidation step could be discarded. Key intermediate 168 
already possesses the right oxidation state and should therefore lead directly to 155 via attack of an 
amine on the carbonyl (Figure 2). The retrosynthetic analysis to obtain 155 is depicted in Figure 48. 
The final compound 155 can be made by ring closing of imine 168. The PMB was chosen as a protecting 
group because it should not deactivate the amine.2 The imine should be obtained by reaction of 76 with 
4-methoxybenzylamine. Aldehyde 76 should be available through the amide coupling of 67 and 75 
followed by deptorection and oxidation. 67 can be easily synthesized according to a literature 
procedure.[115] It was thought that 75 could be obtained from the corresponding azide, which should be 
available from precursor 170 by activating the alcohol followed by substitution. Finally, 170 should be 
made accessible through a reaction between dibenzylphosphite 80 and aldehyde 169. The TBS (tert-
butyl dimethylsilyl) group was chosen as a protecting group on 169 due to its stability to a wide array of 
conditions and its ease of cleavage with fluorine sources. 
 
 
 
 155 168 76 
 
 
 80 169 170 75 67 
Figure 48: Retrosynthesis 
Intermediate 170 was prepared in analogy to the strategy described in chapter 8.2.6. The phosphonate 
was activated by TMS chloride and then the aldehyde was added, yielding silyl ether 171. The TMS group 
was easily removed using citric acid in methanol, leaving the TBS group untouched (scheme 27).  
 
 80 169 171 170 
Scheme 27: Synthesis of . Reagents and conditions: a) TMS chloride (1.44 equiv), triethylamine (1.44 equiv), DCM, 0°C to -78°C to rt, 16 h, 69% 
b) citric acid (2.5 equiv), methanol, rt, 2 h, 98%. 
Next, the alcohol needed to be activated so it could be displaced by an azide. Initially, the 4-
nitrobenzenesulfonyl (4-nosyl) group was selected. Attempts that used 4-nosylchloride and pyridine did 
                                                          
2At this time the imidazoline was not yet oxidized to the imidazole using base-induced aromatization. Therefore, 
the problematic removal of the PMB protective group was not yet known.  
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not go to full conversion, even after extended reaction times. However, the 4-nosyl group was 
successfully introduced in high yield using DMAP. Attempts at aziridation of 4-nosyl compound 172 are 
summarized in table 27. 
Table 27: synthesis of azide 173 via 4-nosyl activated compound 172. 
 
 170 172 173 
Reagents and conditions: a) 4-nitrobenzenesulfonylchloride (1.1 equiv), DMAP (1.1 equiv), DCM rt, 3 h, 98%. b) azide, solvent, temperature, 16 
h. 
# Azide Reagent (equiv) Solvent Temp (°C) Result 
1 NaN3 (3) DMF rt Unidentified byproducts 
2 TMGA MeCN 83 Decomposition 
 
Exposing 172 to sodium azide in DMF resulted in a complex mixture containing several unidentified 
byproducts (entry 1). TMGA in acetonitrile at 83 degrees resulted in complete decomposition of the 
starting material. It is likely that, like in chapter 8.2.4, the TMGA removes the benzyl group as no 
phosphorus containing compounds were recovered. The 4-nosyl group did not seem to be a good 
activator for this kind of reaction, therefore other possibilities were investigated. 
In the literature an example employing DDQ and PPh3 to activate an alpha-hydroxyphosphonate 
(scheme 28: A), followed by successful substitution, was described.[142] In analogy to this report, 2 
equivalents of sodium azide, DDQ and PPh3 were mixed and compound 170 was added. After stirring for 
several hours, no conversion was observed. 
 
 170 A 173 
Scheme 28: Synthesis of azide 173 via PPh3 and DDQ activation. Reagents and conditions: DDQ (2 equiv), PPh3(2 equiv), NaN3 (2 equiv), MeCN, 
84°C, 3 h.  
The triflate group was selected as a stronger activating group. The hydroxyl moiety was activated as a 
triflate using triflic anhydride and pyridine in DCM to obtain 174 quantitatively. Gratifyingly, dissolving 
174 in acetonitrile in the presence of TMGA gave the azide 173 in high yield (Scheme 29). 
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 170 174 173 
Scheme 29: synthesis of azide 173 via triflate activated compound 174. Reagents and conditions: a) triflic anhydride (1.5 equiv), pyridine (2 
equiv), DCM, -15C, 2 h, 96%. b) TMGA (1.2 equiv), MeCN, rt, 15 min, 83%.  
With azide 173 in hand, the next goal was its reduction to the amine. 1.1 equiv PPh3 in 1,4-dioxane: 
water 10:1 smoothly reduced the azide. However, the product was contaminated with a large amount of 
PPh3O. Rather than spending time and effort in purifying the compound another method was used. 
Exposing azide 173 to a suspension of ammonium chloride and zinc powder in ethanol: water 3:1 gave 
the target amine 75 as a pure yellow oil after an aqueous work-up in 89 percent yield (scheme 30). 
 
 173 75 67 175 
Scheme 30: synthesis of amide 175 via amine 75. Reagents and conditions: a) ammonium chloride (2.5 equiv), zinc powder (3 equiv), ethanol: 
water 3:1, rt, 1 h, 87%. b) 67 (1.25 equiv), EDC (1.3 equiv), DMAP (0.1 equiv), DCM, rt, 1 h, 67%. 
The amide coupling between 75 and 67 proceeded smoothly. Using previously established conditions 
(PyBrOP, DMAP, DIPEA, Chapter 8.2.5), gave 175 in 66 percent yield. The coupling was also performed 
using EDC as activator and a catalytic amount of DMAP. These conditions furnished compound 175 in 
comparable yields. Since EDC is cheaper than PyBrOP this method was used in subsequent reactions.  
Subsequent removal of the TBS group using an excess of HF.pyridine in wet THF went in 99 percent yield 
(scheme 31). 
 
 175 176 
Scheme 31: Deprotection of 75. Reagents and conditions: HF.pyridine (9 equiv), wet THF, rt, 1 h, 99%. 
Next, the oxidation of 176 to the aldehyde was investigated (table 28). The swern oxidation (entry 1) 
was the first choice for the oxidation of 176 to 76. Regrettably, all the starting material decomposed and 
no product was obtained. The Parikh-Doering oxidation, a close analogue to the swern oxidation 
provided similar results (entry 2). Various other oxidants and conditions were investigated, but all 
resulted in decomposition of the starting material (entries 3-6). 
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Table 28: Oxidation of 76. 
 
 176 76 
Reagents and conditions: oxidizer, solvent, 0°C. 
# Oxidizer (equiv) Solvent Result 
1a (CO)2Cl2 (1.2), DMSO (2.4), Et3N (5) DCM Decomposition 
2 SO3.pyridine (3), Et3N (6) DMSO Decomposition 
3 DMP (2) DCM Decomposition 
4b TPAP (0.15), NMO (1.5) DCM Decomposition 
5b TPAP (0.15), NMO (2) DCM: MeCN 8:1 Decomposition 
6 PCC (1.5) DCM Decomposition 
a: reaction was done at -78°C to rt. b: reaction was done at rt and 4A molsieve was used. 
The reason why all oxidation methods failed is most likely due to the instability of the aldehyde that is 
formed. In an attempt to trap the aldehyde before it decomposed, PMB amine was added to a crude 
mixture of the swern oxidation, but no product was obtained. Since the intrinsic reactivity of the 
aldehyde seemed to exclude its isolation and the oxidation issues regarding the aza-wittig route were 
solved (chapter 8.2.10), this route was discontinued. 
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8.3.3 Dithiane route 
To prevent the problems aromatizing the imidazoline described in chapter 8.2.8, an effort was made to 
circumvent this step by making use of a precursor already at the right oxidation state (79, figure 49). 
Because it was known from previous experiments that an aldehyde on the beta-position of the 
phosphonate is unstable (chapter 8.3.2), a 1,3-dithiane was used instead. 1,3-dithianes are used as 
protecting groups for aldehydes and ketones, in analogy to acetals and ketals and can be hydrolyzed 
back to their respective carbonyl. In this case however, the intention was to substitute the 1,3-dithiane 
directly without unmasking the unstable aldehyde (figure 49).[143] 
 
 
 
 65 136 79 
 
 
 
 
 177 178 179 77 78 
Figure 49: retrosynthetic strategy for the 1,3-dithiane route. 
65 could be made from imidazole 136 via protecting group switches. 136 in turn should be available via 
amidine 79 by activation of the dithiane, using dimethyl(methylthio)sulfonium tetrafluoroborate 
(DMTSF)[144] or methylation, followed by substitution of the dithiane by the amidine nitrogen. Amidine 
79 would be synthesized by a simple coupling of amine 77 and thioamide 78.[145] Thioamide 78 can easily 
be prepared from L-asparagine using Lawesson’s reagent. Amine 77 could be prepared from aldehyde 
177 in three steps. Phosphorylation of 177 should provide alcohol 178, which should then be activated, 
substituted for an azide (179) and reduced to give 77.[146] 
Thioamide 78 was synthesized by protecting the amine and acid moieties of L-asparagine 180 with an 
Alloc and allyl group respectively. The resulting amide 181 was transformed to the thioamide using 
Lawesson’s reagent in excellent overall yield (scheme 32). 
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 180 181 78 
Scheme 32: Synthesis of 78. Reagents and conditions: a) Allyl chloroformate (1.05 equiv), water, rt, 7 h, quantitative. b) allyl bromide (1.2 
equiv), cesium carbonate (1.5 equiv), DMF, rt, 8h, 92%. c) Lawesson’s reagent (0.5 equiv), THF, rt, 4h, 88%. 
Aldehyde 177 was synthesized according to a literature procedure.[147] Introduction of the phosphonate 
was done in a similar way as in chapter 8.2.6. Dibenzylphosphite 
was activated using TMS chloride and triethylamine, after which the 
aldehyde was added. The yield for the phosphorylation of this 
aldehyde was not as good as for other aldehydes, with a maximum 
yield of 50 percent (scheme 33). Removal of the TMS group with KF 
in methanol went in quantitative yield, setting the stage for the azide introduction. 
 
 177 80 182 178 
Scheme 33: Phosphorylation of 177. Reagents and conditions: a) dibenzylphosphite (1.2 equiv), chlorotrimethylsilane (1.44 equiv), triethyl 
amine (1.44 equiv), DCM, -20°C to -78°C to rt, 17h, 50 %. b) potassium fluoride (2 equiv), methanol, rt, 30 min, 99%. 
Attempts to introduce the azide were done by activation of the alcohol, followed by substitution with an 
azide source. Several condition were used, a summary is shown in table 29.  
Table 29: Azide introduction. 
 
 178 179 
# Activator (equiv) Azide (equiv) Solvent Result 
1 OTf2 (1.5), pyridine (2) ― DCM Decomposition 
2 OTf2 (1.5), 2,6-lutidine (2) TMGA DCM Decomposition 
3 TsCl (1.2), Et3N (1.2) ― DCM No reaction 
4 dppa (1.2), DBU (1.1) ― Toluene No reaction 
5 PPh3 (1.05), DIAD (1.05) TMGA (1.5) THF No reaction 
6 PPh3 (1.05), DIAD (1.05) HN3 (3) THF No reaction 
7 PPh3 (1.05), DIAD (1.05) dppa (1.5) THF Decomposition 
 
 
            Lawesson’s reagent 
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Initially, triflate activation was attempted, using triflic anhydride and pyridine; however, a mixture 
containing several unidentified products was obtained (entry 1). Changing pyridine for 2,6-lutidine, 
followed by addition of TMGA as soon as the starting material was consumed, did not improve the 
reaction (entry 2). It was hypothesized that the triflate of 178 was too reactive and therefore the tosyl 
group, a weaker activating group, was introduced. However, the reaction with tosyl chloride yielded a 
mixture containing mostly starting material (entry 3). Next diphenylphosphoryl azide (dppa) was tested 
as both activator and azide source;[148] but again no reaction was observed (entry 4). Mitsunobu 
reactions were explored as an alternative activation strategy, using several azides.[146b, 149] However, 
these reactions either gave back the starting material (entries 5 and 6) or decomposition (entry 7). 
The reason for the failure of the azide introduction might be due to the low electrophilicity of the 
carbon alpha to the phosphonate. In the case of the triflate activation in chapter 8.2.4 it was assumed 
that the tosylamide lowered the electron density on that carbon promoting sufficient activation. This 
effect is absent in the case of the 1,3-dithiane. Therefore, it was thought that the activated alcohol 
might be successfully substituted if the dithiane was more electron withdrawing. To that end, attempts 
were made to oxidize both dithiane sulfurs to the sulfoxide (Table 30). 
Table 30: 1,3-dithiane oxidation. 
 
 178 183 184 
# Oxidizer (equiv) Solvent Result 
1 m-CPBA (2.1) CHCl3 Decomposition 
2 m-CPBA (2.2) CHCl3: EtOAc 2:1 Decomposition 
3 NaIO4 (2.1) 1,4-dioxane: water 2.3:1 183: 184 2:1
a 
4 NaIO4 (2.3) 1,4-dioxane: water 2.3:1 36% 183
b 
a: yield not determined. b: still contained 6% 184. 
Initially, m-CPBA was investigated as oxidizer; however, a complex mixture of unidentified products was 
obtained (entry 1).[150] Changing the solvent to include ethyl acetate did not change the outcome of the 
reaction (entry 2). After switching oxidant to sodium periodate,[151] a mixture containing mostly 183 and 
184, in a 2:1 ratio, was obtained (entry 3). The two analogues were challenging to separate, finally 183 
was obtained in 36 percent yield (entry 4), albeit contaminated with six percent 184.  
 
 183 185 
Scheme 34: Mitsunobu reaction with 183 and hydrazoic acid. Reagents and conditions: PPh3 (1.05 equiv), DIAD (1.05 equiv), HN3 2.5 M in 
benzene (3 equiv), THF, -40°C, 16 h. 
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A Mitsunobu reaction between 183 and hydrazoic acid was attempted (scheme 34). Hydrazoic acid was 
freshly prepared as a solution in benzene and 183 was added as a solution in DMF as it did not dissolve 
in THF. Regrettably, the reaction did not show any conversion. 
Due to the failure of the initial azidation and the low yield of the 1,3-dithiane oxidation, combined with 
its low reactivity in the Mitsunobu reaction, it was decided to not pursue this route any further.  
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8.3.4 Alternative Aza-wittig route 
This was chronologically the first strategy that required the synthesis of the imidazole, opposed to 
merely substituting an imidazole. The strategy is similar to the one presented in chapter 8.2. The main 
difference between this route and the one described in chapter 8.2 is the early introduction of the 
amino acid moiety and the aldehyde intermediate. The retrosynthetic analysis is shown in figure 50. 
Compound 65 can be accessed from imidazoline 186 by aromatization and protecting group changes. 
The imidazoline should be available from amide 71, using an intramolecular aza-wittig reaction. The 
azide can be made from 189 by activation of the hydroxyl function and substitution. Alcohol 189 should 
be available by a nucleophilic attack of a TMS activated phosphonate on aldehyde 188 (chapter 8.2.6), 
followed by deprotection. Aldehyde 188 can be liberated by hydrolysis of acetal 187, which in turn can 
be synthesized by an amide coupling between compounds 70 and 69. The protected amino acid 70 can 
be made using a literature procedure.[152] 
 
 
 
 65 186 71 
 
 
 
 187 188 189 
 
 
 70 69 
Figure 50: Retrosynthetic strategy toward 65 starting from acetal 69. 
This route features the Boc and tert-butyl ester as acid cleavable protecting groups. Acidolytic cleavage 
is not convenient, as it will also cleave the trityl group as well as the benzyl groups that should be in the 
final imidazole. Later, it was decided to use an Alloc and allyl group to protect the amine and the ester, 
respectively. These two protecting groups could be much more easily removed (chapter 7). 
Synthesis of 65 started with the tosylation of 190 to make 69. Simply combining 190 and tosyl chloride in 
DCM, in the presence of DMAP and triethylamine gave 69 in 93 percent yield (scheme 35). 
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 190 69 
Scheme 35: Tosylation of 190. Reagents and conditions: Tosyl chloride (1 equiv), DMAP (0.01 equiv), triethylamine (1 equiv), DCM, 0°C to rt, 16 
h, 93%. 
Next, 69 had to be coupled to 70. The coupling between 70 and 69 was initially attempted with DCC and 
HOBt. Regrettably, no reaction occurred (scheme 36). There were two potential explanations for the 
failure of this reaction. Either the tosylamide was not a good enough nucleophile to attack the HOBt-
ester of 70 or the HOBt-ester of 70 was not formed, due to unsuccessful activation by DCC. 
 
 70 69 187 
Scheme 36: Amide coupling of 70 and 69. Reagents and conditions: HOBt (1 equiv), DCC (1 equiv), THF, 0°C to rt, 16 h. 
A possible solution to both problems was found in the literature, where a premade HOAt-ester was 
successfully coupled with a sulfonyl amide.[121] In this way it is assured that the activated ester forms 
and, since HOAt is a better activating group than HOBt, a possible reactivity problem might also be 
solved. In line with this strategy, compound 70 was subjected to HOAt and EDC in DCM, yielding the 
HOAt-ester 191 in 93 percent isolated yield. Combining 69 and 191 in DCM in the presence of DBU gave 
the amide 187 in good yield. 
 
 70 191 69 187 
Scheme 37: Amide coupling of 70 and 69, via HOAt activated ester 191. Reagents and conditions: a) HOAt (1.3 equiv), EDC (1.5 equiv), DCM, 0°C 
to rt, 16 h, 93%. b) 191 (1.1 equiv), DBU (1.5 equiv), DCM, 0°C to rt, 1.5 h, 73%. 
With the amide in hand, the next step was the hydrolysis of the acetal. This reaction appeared to be less 
straightforward than expected. The conditions that were tested are summarized in table 31. 
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Table 31: Acetal hydrolysis. 
 
 
 187 188 
Reagents and conditions: reagent, solvent, temp, 16 h. 
# Reagents (equiv) Solvent Temp (°C) Result 
1 AcOH: water 9:1 (excess) ― rt No Reaction 
2 AcOH: water 9:1 (excess) ― 65 No Reaction 
3 AcOH: water 2:1 (excess) ― 90 deprotection of boc/tbu 
4 1M HCl (excess) THF 0 to rt No Reaction 
5 PPTS (1) Acetone: water 9:1 rt No Reaction 
6 PPTS (1) Acetone: water 9:1 57 No Reaction 
7 FeCl3.6H2O (3.5) DCM rt Decomposition 
8 FeCl3.SiO2 (1) Acetone rt No Reaction 
9 FeCl3.SiO2 (1) CHCl3 rt No Reaction 
10 H5IO6 (3.9) 1,4-dioxane: water 2.4:1 rt No Reaction 
11 DDQ (0.1) MeCN: water 9:1 rt No Reaction 
 
Initially, acid catalyzed hydrolysis with acetic acid was attempted, but dissolving compound 188 in a 
large excess of acetic acid and water did not produce any conversion, even upon mild heating (entries 1 
and 2). Upon heating to 90°C in acetic acid: water 2:1 both the Boc and tert-butyl group were lost, 
whereas the acetal remained (entry 3). The acetal was also stable to stronger acids (HCl[153] and 
PPTS[154]), even upon heating no reaction was observed (entries 4-6). Lewis acid ferric trichloride in 
DCM[155] led to complete decomposition of the starting material (entry 7). Silica gel with ferric chloride 
impregnated on the surface did not succeed in hydrolyzing the acetal, nor did periodic acid[156] or 
catalytic DDQ in acetonitrile: water 9:1.[157] 
Since acetal 187 seemed to be to unreactive toward hydrolysis, an alternative route to the aldehyde was 
considered. Aldehydes can be easily made by oxidative cleavage of an alkene using osmium tetroxide 
and sodium periodate. Therefore, aldehyde 188 might be available from allyl tosylamide 192, which in 
turn is easily made by amide coupling of 193 and 70 (figure 51). 
 
 188 192 193 70 
Figure 51: New retrosynthetic strategy toward 188. 
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Compound 193 was made according to a modified literature procedure.[158] Its coupling with 70 was 
performed in line with the previous amide coupling (scheme 38). 
 
 191 193 192 
Scheme 38: Amide coupling of 191 and 193. Reagents and conditions: 193 (1.1 equiv), DBU (1.5 equiv), DCM, 0°C to rt, 1.5 h, 78%. 
Unfortunately, amide 192 appeared to be difficult to purify. During silica column chromatography 
residual starting material 193 and amide 192 eluted in the same fractions and seemed inseparable. 
Eventually it was found that alumina was able to separate the two compounds and 192 could be 
obtained in 78% yield.  
Next, oxidative cleavage of 192 was attempted with osmium tetroxide and sodium periodate in the 
presence of 2,6-lutidine (scheme 39).[159] During the reaction quick conversion to one new product was 
observed, after 30 minutes all starting material was consumed. However, during work-up and 
subsequent evaporation the mixture turned from a clear solution to a brown and then black oil. Analysis 
of this oil revealed an unidentifiable mixture of decomposition products. Attempts to do the work-up 
and evaporation at low temperature and under an argon atmosphere could not prevent the 
decomposition to occur. 
 
 192 188 
Scheme 39: Oxidative cleavage of alkene 192. Reagents and conditions: osmium tetroxide (0.2 equiv), sodium periodate (4 equiv), 2,6-lutidine 
(2 equiv), 1,4-dioxane: water 3:1, rt, 30 min. 
It seemed that the aldehyde 188 did form during the oxidative cleavage reaction, but that it was too 
unstable to survive work-up. Such an unstable aldehyde could not be used as an intermediate in the 
synthesis of 65. Therefore, this route was not pursued any further. 
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8.4 Other routes toward a 3-phosphohistidine mimic – Imidazole 
substitution 
8.4.1 Metal catalyzed & Halogen-metal exchange 
The initial retrosynthetic strategy toward a stable 3-pHis analogue was build around the substitution of 
an imidazole. Introduction of the amino acid part was envisioned through a nucleophilic attack of an 
imidazole cuprate onto a β-lactone, which was easily available from L-serine.[45-46, 160] The required 
phospho-imidazole should be available through either a metal mediated coupling or through halogen 
metal exchange and attack on an activated phosphite.[161] The 4-halo-imidazoles were easily made from 
1-benzylimidazole according to literature procedure.[162] 
 
 
 
 155 194 84 83 
 
 
 X = Br (81), I(82) 80 
Figure 52: First retrosynthetic analysis toward non-hydrolysable pHis analog. 
As protecting group on the imidazole the benzyl group was selected since there was literature precedent 
for the 1-benzyl-4-iodoimidazole as well as for the 1-benzyl-4-bromoimidazole that were targeted. In 
addition, this benzyl group could be removed together with the phosphonate protecting groups after 
SPPS using hydrogenation. Both the bromo- and iodoimidazole were investigated to account for possible 
differences in reactivity.  
4-bromo-1-benzylimidazole 81 was synthesized according to a literature procedure.[163] The synthesis 
started with imidazole 195, which was tribrominated using molecular bromine; albeit at low yield. Most 
probably, addition of extra equivalents of bromine would have driven the reaction to completion. Since 
enough material was isolated, this has not been further investigated. Benzyl protection was realized 
using benzyl chloride, setting the stage for halogen metal exchange of the two most reactive bromines, 
at the two- and four positions, followed by quenching with water to yield 4-bromo-1-benzylimidazole 81 
in acceptable yield. 
 
 195 196 197 81 
Scheme 40: Synthesis of 4-bromo-1-benzylimidazole.Reagents and Conditions: a) Bromine (1.5 equiv), KHCO3 (3 equiv), DMF, 0-100°C, 5h, 32%; 
b) Benzylchloride (1 equiv), Na2CO3 (1 equiv), DMF, 130°C, 2 days, 82%; c) n-BuLi (2.4 equiv), Et2O, -78°C, 2h, then; d) water, 64%. 
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4-iodo-1-benzylimidazole 82 was synthesized in an analogues way; imidazole 195 was first diiodinated 
using molecular iodine, sodium iodide and potassium iodide in aqueous sodium hydroxide.[164] 4,5-
Diiodo-1H-imidazole 198 was benzyl protected using benzyl chloride and sodium hydride. Finally, the 
iodine on C-5 was selectively removed using a halogen metal exchange reaction with ethyl magnesium 
bromide and quenching with water, yielding 4-iodo-1-benzylimidazole82 in acceptable yield. The next 
step was phosphorylation of these 4-haloimidazoles.  
a) I2, KI, NaI,
2.3M NaOH
b) BnCl,
NaH
a) EtMgBr
b) H2O
N
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Scheme 41: Synthesis of 4-bromo-1-benzylimidazole. Reagents and conditions: a) iodine (1.0 equiv), potassium iodide (1.1 equiv), sodium iodide 
(2.3 equiv), 2.3M NaOH (aq), rt, 3h, 27%; b) benzyl chloride (1.1 equiv), NaH (1.1 equiv), THF, 0-65°C, 2.5 days, 94%; c) ethyl magnesium 
bromide 1M in MTBE (1.1 equiv), THF, rt, 3.5h, then; d) water (6.7 equiv), 78%. 
8.4.1.1 Metal catalyzed 
While literature concerning the phosphorylation of imidazoles is rather small, some precedent can be 
found. A halogen-metal exchange strategy had been successful in the past.[165] Metal mediated couplings 
of vinyl- and aryl-iodides and bromides might also be successfully adapted to our imidazoles.[166] A great 
advantage of metal-mediated formation of phosphorus – aryl bonds is that they use commercially 
available, stable phosphites as phosphorus source. They usually employ either a copper or a palladium 
catalyst, of which the former is especially attractive due to its low price and easy availability.[127b] 
The synthesis of several phosphonates from aryl- and vinyl-iodides and bromides, using CuI and proline 
or N,N’-dimethylethylenediamine (DMEDA) as ligand have been reported.[167] Iodides were reported to 
show superior reactivity compared to bromides. Therefore, coupling reactions between 4-halo-1-
benzylimidazole and dibenzylphosphite were investigated (table 32). 
Table 32: Copper mediated coupling reactions. 
 
 X= Br (81), I (82) 80 83 
Reagents and Conditions: 80 (1.5 equiv), CuI (0.1 equiv), Ligand (0.3 equiv), Cs2CO3 (2 equiv), toluene, 16 h. 
# Imidazole Ligand Temp. (°C) Result 
1a 82 Proline rt No reaction 
2a 82 DMEDA rt No reaction 
3b 82 Proline 110 Decomposition 
4 b 82 DMEDA 110 Decomposition 
5 b 81 Proline 110 Decomposition 
6 b 81 DMEDA 110 Decomposition 
a: 0.2 equiv CuI was used. b: the reaction was stirred for 3 days. 
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Initial trails with iodoimidazole 82 at room temperature did not show any conversion, regardless of the 
ligand used (entries 1 and 2). When the reactions were heated to reflux, starting material was consumed 
very slowly, over several days. Regrettably, no product 83 was recovered, as all starting material had 
decomposed. 
The halo-imidazoles seemed to be inert under the copper catalyzed reaction conditions; therefore, 
palladium-mediated couplings were investigated. Stawinski et al. compared different palladium(0) 
sources in coupling reactions between diethyl phosphite and bromo- and iodo-benzene.[168] They 
showed that Pd(OAc)2 and PPh3 was the best catalyst – ligand combination and that iodides are superior 
to bromides. The attempts to apply the palladium chemistry to the 4-halo imidazoles are summarized in 
table 33.  
Table 33: Palladium catalyzed coupling reactions. 
 
 X= Br (81), I (82) 80 83 
Reagents and Conditions: 80(1.5 equiv), Pd (0.1 equiv), L (0.3 equiv), NEt3 (1.2 equiv), toluene, 90°C, 1 day. 
# Imidazole Palladium source Ligand Result 
1 81 Pd(OAc)2 PPh3 No reaction 
2 82 Pd(OAc)2 PPh3 No reaction 
3 82 Pd(PPh3)4
a ― Decomposition 
a: 0.3 equiv [Pd] was used, mixture was stirred for 2 days. 
Tests with palladium(II)acetate and PPh3 were unsuccessful, both for the bromo- and iodoimidazole no 
conversion was observed (entries 1 and 2). Switching catalyst system to 
tetrakis(triphenylphosphine)palladium(0) and stirring for several days led to decomposition (entry 3). 
8.4.1.2 Halogen metal exchange 
At this point it seemed that the metal catalyzed coupling conditions could not successfully be adapted to 
our system, thus it was decided to try a halogen-metal exchange strategy. Dibenzyl phosphorylchloride 
200, which was easily prepared from dibenzylphosphite and N-chlorosuccinimide,[169] was used as the 
electrophile. Results from the halogen-metal exchange trials are summarized in table 34. 
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Table 34: Halogen metal exchange reactions. 
 
 X=Br (81), I (82) 200 83 
Reagents and Conditions: 
# Imidazole Base (equiv) Temp (°C) Resulta 
1 81 n-BuLi (2) -78 to rt Benzyl imidazole 
2 82 iPrMgCl.LiCl (1.2) 0 to rt No reaction 
3 82 iPrMgCl.LiCl (1.2) rt to -78 to rt Benzyl imidazole 
a: reaction monitored by TLC. 
Initially, bromo imidazole 81 and n-BuLi were mixed at low temperature, stirred for 20 minutes at low 
temperature followed by quenching with 200. Regrettably, only benzyl imidazole and starting material 
were recovered (entry 1). Clearly the combination of 200 and the lithium salt of 81 was not reactive 
enough. A Grignard reagent might perform better due to the better coordinating ability of 
magnesium.[170] This not only yields a more stable metalate, but might also bring the two reactants 
closer together due to coordination of the phosphite. Therefore, 82 was subjected to iPrMgCl.LiCl at 0°C, 
followed by addition of 200 and slow warming to room temperature. Again, only starting material was 
recovered. Increasing the initial temperature to room temperature, to ensure complete halogen metal 
exchange, followed by low temperature, careful quenching with 200 led to a combination of benzyl 
imidazole and starting material. At this point it was realized that 200 was likely not a good electrophile 
in this reaction and an alternative pathway was needed. 
8.4.2 Negishi II 
Although the synthesis of compound 167 was successfully accomplished using the formyl method 
(chapter 8.3.1) the yield was disappointing. Therefore an alternative route was developed that gave the 
same product but in higher yield and fewer steps, employing a halogen-metal exchange and a more 
reactive phosphor source. Instead of the dibenzylphosphoryl chloride 200, bis(diethylamino)phosphine 
chloride was used, a better electrophilic phosphor source. It was thought that the obtained intermediate 
202 could be converted to 167 in situ. This indeed resulted in a one pot synthesis of compound 167 
(scheme 42). This success allowed the investigation of the Negishi reaction (figure 53). 
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Figure 53: Updated Negishi strategy. 
8.4.2.1 One pot synthesis of compound 167 
The alternative, one-pot route toward 167 started with 1-trityl-4-iodoimidazole 85, thereby 
circumventing the nine steps of the aza wittig route to 66. 85 was dissolved in THF, cooled to 0°C and 
isopropylmagnesium chloride lithium chloride complex in THF was added, resulting in halogen metal 
exchange with the iodine (scheme 42). The reaction was stirred at room temperature for 20 minutes to 
ensure full conversion during this step. Then the mixture was cooled to -78 degrees and 
bis(diethylamino)phosphine chloride was added. This P(III)-compound is a much better electrophile than 
dibenzyl phosphorylchloride 200 that was previously used in a similar reaction (chapter 8.4.1.2).[169b] 
After stirring the reaction for several hours the THF was removed in vacuo and benzyl alcohol was 
added. After adding acetonitrile as solvent, the reaction mixture was cooled down and a tetrazole 
solution was added to catalyze the substitution of the diethylamino groups to obtain the benzyl 
phosphoester groups. After stirring overnight at room temperature, the mixture was again cooled to 0°C 
and hydrogen peroxide in water was added to oxidize the phosphite to the phosphonate. In four steps, 
this one-pot method gave 167 in 59 percent yield. 
 
 
 
 85 201 202 
 
 
 
 167 203 
Scheme 42: One-pot synthesis of 167. Reagents and Conditions: a) iPrMgCl.LiCl 1.3M in THF (1.05 equiv), THF, 0°C to rt, 30 min. b) 
bis(diethylamino)phosphine chloride (1.1 equiv), -78 to rt, 3 h. c) benzyl alcohol (5.05 equiv), tetrazole 0.3M in MeCN (0.1 equiv), MeCN, 0°C to 
rt, 12h. d) hydrogen peroxide 30% in water (3.85 equiv), -20°C to 0°C, 2h, 59% over 4 steps. 
The next challenge was to iodinate 167 on the 2 position of the imidazole. This was done by adding n-
butyl lithium to a solution of 167 in THF at -30°C.[171] After stirring the solution for 20 minutes to ensure 
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full deprotonation of the imidazole, iodine in THF was slowly added until the iodine color persisted. 
After work-up and purification 73 was obtained in 53 percent yield (scheme 43). 
 
 
 167 73 
Scheme 43: Synthesis of trityl protected 2-iodoimidazole 73. Reagents and conditions: Iodine (1.5 equiv), butyl lithium 1.6M in hexane (1.1 
equiv), THF, -30°C to -60°C, 30 min, 53%. 
The Negishi reaction itself requires an iodo-zinc species and an aryl- (or vinyl-)iodide. Zinc powder was 
activated using a catalytic amount of molecular iodine at about 300°C under vacuum. This activated zinc 
powder was added to compound 74 in DMF to prepare the iodo-zinc counterpart.[172] The mixture was 
then added to a solution of iodo-imidazole 73. Finally, the catalyst and ligand were added and the 
mixture was heated to 40 degrees. The results of the first attempts at the Negishi reaction are 
summarized in table 35. 
Table 35: Negishi reaction I. 
 
 73 74 204 
Reagents and Conditions: a) 74 (2.5 equiv), iodine (0.03 equiv), zinc (8.2 equiv), DMF, 300°C to rt. b) catalyst, ligand, additive, 40°C, 16h. 
# Catalyst (equiv) Ligand (equiv) Additive (equiv) Result 
1 Pd2(dba)3 (0.1) X-Phos (0.2) ― Beta elimination 
2 Pd2(dba)3 (0.05) S-Phos (0.1) ― Beta elimination 
3 Pd2(dba)3 (0.05) X-Phos (0.1) LiCl (2.5) Beta elimination 
4 Pd2(dba)3 (0.05) S-Phos (0.1) LiCl (2.5) Beta elimination 
5 Pd(OAc)2 (0.1) X-Phos (0.2) ― Beta elimination 
6 Pd(OAc)2 (0.1) S-Phos (0.2) ― Beta elimination 
7 Pd(OAc)2 (0.1) X-Phos (0.2) LiCl (2.5) Beta elimination 
8 Pd(OAc)2 (0.1) S-Phos (0.2) LiCl (2.5) Beta elimination 
a: reaction was performed at room temperature. 
Initially Pd2(dba)3 was used as palladium source and X-Phos as ligand, this combination has been 
reported as particularly suitable for Negishi reaction by the group of Buchwald.[173] However, in this case 
no product was obtained (entry 1); switching to S-Phos[174] did not change the outcome of the reaction 
(entry 2). Addition of lithium chloride, reported to enable difficult Negishi reactions by activation of the 
107 
 
zinc reagent,[175] also did not produce any product (entries 3 and 4). Reactions using palladium(II)acetate 
as palladium source did not fare better (entries 5-8).  
All reactions performed so far resulted in formation of dehydroamino acid derivative 205, along with 
reduced starting material. The occurrence of this compound indicated that after the transmetalation 
step, beta elimination (path I) was preferred over reductive elimination (path II), normally a quick 
reaction (figure 54).[176] Therefore, conditions had to be found that favor the reductive elimination over 
beta elimination. 
 
  
   
 205 167 
  
 
 A 
 204 
Figure 54: Negishi mechanism. Path I: beta elimination leads to alkene 205. Path II reductive elimination leads to the desired product 204. 
It is known that ligands with a larger bite angle induce a bias for reductive elimination over beta 
elimination. Two ligands with large bite angles were examined; 1,1'-bis(diphenylphosphino)ferrocene 
(dppf) (206) and XantPhos (207).[175] Furthermore, an ‘all-in-one’ catalyst system called PEPPSI-iPr (208), 
is also reported to strongly favor reductive elimination over beta elimination.[177] Thus, these 
compounds were tested in the Negishi reaction (table 36). 
 
 206 207 208 
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Table 36:Negishi reactions II.a 
# Catalyst (equiv) Ligand (equiv) Additive (equiv) Solvent Result 
1b Pd2(dba)3 (0.05) dppf (0.1) ― DMF Beta elimination 
2b Pd2(dba)3 (0.05) Xant-phos (0.1) ― DMF Beta elimination 
3 Pd2(dba)3 (0.05) dppf (0.1) LiBr (5) DMF Beta elimination 
4 Pd2(dba)3 (0.05) Xant-phos (0.1) LiBr (5) DMF Beta elimination 
5c PEPPSI (0.01) ― LiBr (3.2) THF: NMP 1:1 Beta elimination 
6d PEPPSI (0.1) ― LiBr (5) THF: NMP 1:1 Beta elimination 
a:Reagents and Conditions: a)74 (2.5 equiv), iodine (0.03 equiv), zinc (8.2 equiv), DMF or NMP, 300°C to rt. b) catalyst, ligand, additive, 40°C, 
16h. b: this reaction was performed at room temperature and at 40°C.c: this reaction was performed with 1.6 equiv 74 at room temperature. d: 
this reaction was performed at 60°C. 
Regrettably, in all reactions only the beta elimination byproduct was recovered. To examine the 
reactivity of the organo-zinc compound, a Negishi reaction with iodobenzene as aryl halide was 
performed. This reaction went quickly to completion and no beta elimination byproduct was seen. It is 
known that Negishi reactions on imidazoles are sensitive to steric bulk at the N-1 position.[178] Therefore, 
imidazole 73 was thought to be too sterically hindered, to be a good substrate for the Negishi reaction. 
The trityl protecting group on 73 gives substantial steric shielding to C-2, thereby interfering with the 
reductive elimination. PMB and Boc[179] were investigated as different protecting groups of imidazole 73 
to drive the equilibrium to reductive elimination product 204. 
The Boc group was introduced by removing the trityl group from 73 using acetic acid and 
trifluoroethanol (scheme 44). The unprotected imidazole 209 was not isolated but immediately used in 
the next reaction. 209 was dissolved in DCM in the presence of DIPEA and Boc anhydride was added. 
210 was obtained in 57 percent over two steps. 
 
 73 209 210 
Scheme 44: Synthesis of Boc protected 2-iodoimidazole 73. Reagents and conditions: a) acetic acid (82 equiv), trifluoroethanol (3.1 equiv), rt, 5 
h. b) Boc anhydride (1 equiv), DIPEA (1.1 equiv), DCM, 0°C to rt, 16 h, 57% over two steps. 
The PMB protected 2-iodoimidazole was synthesized by deprotonation of 211 using tert-butyl lithium 
and quenching the resulting metalate with iodine. A large amount of 5-iodoimidazole and 2,5-
iodoimidazole byproducts were recovered from the reaction, but could be separated from the desired 
product 212 by column chromatography. The large amount of 5-iodonation suggests a strong ortho-
effect of the phosphonate, where it would stabilize the metalate on the C-5 position by coordination of 
the lithium cation. The large amount of side products did result in a low yield of 16 percent of 212. 
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Scheme 45: Synthesis of PMB protected 2-iodoimidazole 212. Reagents and conditions: Iodine (1.5 equiv), tert-butyl lithium 1.5M in pentane 
(1.2 equiv), THF, -78°C, 1 h, 16%. 
Attempts to obtain the coupling products of these two imidazoles using the Negishi reaction are 
summarized in table 37. 
Table 37: Negishi reactions III. 
 
 212 R = PMB, 210 R = Boc 74 213 R = PMB, 214 R = Boc 
Reagents and Conditions: a) 74 (2.5 equiv), iodine (0.03 equiv), zinc (8.2 equiv), DMF or NMP, 300°C to rt. b) catalyst, ligand, LiBr (5 equiv), 40°C, 
16 h.  
# R Catalyst (equiv) Ligand (equiv) Solvent Result 
1 PMB Pd(OAc)2 (0.1) X-Phos (0.2) DMF Beta elimination 
2 PMB Pd(OAc)2 (0.1) S-Phos (0.2) DMF Beta elimination 
3 PMB Pd2(dba)3 (0.05) dppf (0.1) DMF Beta elimination 
4 PMB Pd2(dba)3 (0.05) Xant-phos (0.1) DMF Beta elimination 
5 PMB PEPPSI ― THF: NMP 1:1 Beta elimination 
6 Boc Pd(OAc)2 (0.1) S-Phos (0.2) DMF Beta elimination 
 
Unfortunately, all conditions yielded only beta eliminated products. Due to the continued failure of the 
Negishi this strategy was abandoned at this point. 
8.4.3 Aziridine 
As an alternative method to introduce the amino acid part to 2-iodoimidazole 73 a reaction with 
aziridine 87 was attempted. 87 was made according to literature procedure[180] and submitted to the 
metalate of 73 (table 37). 
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Table 38: Aziridine opening reactions. 
 
 73 87 215 
Reagents and conditions: a) base, THF, -30°C to -20°C, 1h. b) 87, CuBr.SMe2, -30°C to rt, 16 h. 
# Equivalents 73 Base (equiv) Equivalents CuBr.SMe2 Result 
1 3 iPrMgCl.LiCl (3.4) 0.3 Decomposition 
2 1.2 iPrMgCl.LiCl (1.4) 1.4 Decomposition 
3 1.2 n-BuLi (1.4) 1.4 Decomposition 
 
Regrettably, all the attempts led only to decomposition of the starting material. Initially, isopropyl 
magnesium chloride lithium chloride complex was used as base, but no product was obtained (entries 1 
and 2). Reactions with butyl lithium as base also led to complete decomposition (entry 3). At this point 
the route in chapter 8.2 was successful in delivering the final target compound 65, thus this route was 
not pursued any further. 
8.4.4 Follow-up studies 
Later, Martijn Eerland, a colleague, discovered that the iodination of the 1-trityl-5-phosphonic acid 
imidazole was highly favored towards the C-5 position. The ortho-effect of the phosphonate was much 
stronger than expected. Even with a bulky trityl group on N-1, C-5 iodonation was highly favored. It 
could only be circumvented by performing the metalation with tert-butyl lithium at -100°C and 
immediate quenching of the metalate with an excess of iodine as soon as addition of base was 
complete. The 2- and 5-iodo-1-tritylimidazole isomers have extremely similar spectroscopic properties, 
as can be seen from the 1H-NMR spectra in figure 55 (31P-NMR shifts 11.43 and 11.75 ppm respectively). 
Another difference can be seen in the proton NMR spectrum, where the benzyl protons of the 5-iodo 
imidazole have a more complicated splitting pattern, due to the restricted rotation of the benzyls by the 
iodine. 
 
 Figure 55: 1H-NMR spectra of 5-iodo-73 and 2-iodo-73. 
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This explained the failure of the Negishi- and halogen metal exchange reactions previously described. 
The Negishi reaction was tested again with the correct 2-iodoimidazole and the reaction went to 
completion, albeit delivering a low yield of the final product.3  
 
 
  
                                                          
3 unpublished results, manuscript in preparation. 
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9 Peptides and antibodies 
As the final target of the project is to obtain tools to deepen the understanding of the role of 
phosphohistidines, the 3-pHis analog building block will have to be incorporated in a peptide to raise 
antibodies. 
Using the building block described in chapter 7 several peptides were synthesized. These peptides were 
based on peptide sequences found in proteins that are known to phosphorylate on histidine (chapter 
5.2). The peptides were to be used as antigens for antibody generation; therefore the peptides had to 
be prepared as C-terminal amides with an acetylated N-terminus. These end groups make sure that the 
peptide resembles the ionization state of a regular protein, increasing the chance for successful 
antibody generation (chapter 5.5). All peptides had a C-terminal cysteine for ligation purposes. The free 
thiol of the cysteine is an excellent handle for selective modification. It can be used for coupling to KLH 
with a bifunctional maleamide linker. In addition the thiol can be used to immobilize the peptides on 
sepharose, which provides the material to purify the respective antibodies. 
The peptides were made by standard Fmoc based SPPS using HBTU as coupling reagent and HOBt as the 
activator (chapter 5.6). The peptides were synthesized on Tentagel resin functionalized with a RAM-
anchored Fmoc-(Trt)-cysteine-amide. The initial amino acids were coupled on an automated peptide 
synthesizer using 10 equivalents of amino acid relative to the amount of peptide. The precious pHis 
building block was coupled manually, using HATU/HOAt as coupling reagents. Two equivalents of pHis 
mimic were used and the reaction was performed at high concentration, using just enough solvent to 
dissolve the reactants and wet the resin completely. The remaining parts of the sequences were 
completed on the automated peptide synthesizer. 
Following the final Fmoc deprotection and acetylation of the N-terminus; the cleavage from the resin 
and concomitant global deprotection was achieved using a mixture of TFA, TIPS, EDT and water. After 
evaporation of the cleavage mixture the residue was triturated with diethyl ether, dissolved in water 
and lyophilized. The resulting fluffy white solid was further purified using prep-HPLC. 
Table 39 includes the peptides that were synthesized. Each peptide was synthesized in two versions, 
either containing normal histidine (H) or the pHis mimic (H*). Entries 1-5 are the peptides containing the 
mimic, entries 6-10 are their equivalents that contain a normal histidine. 
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Table 39: peptides synthesized using the pHis mimic and normal histidine. 
# Peptide sequence Yield (%) 
1 Ac-GAKRH*RKVLRGC-NH2 (216) 37 
2 Ac-VQFGH*AGAGC-NH2 (217) 53 
3 Ac-ADQELMTYSH*DNIIC-NH2 (218) 1.8 
4 Ac-FRQVLKH*RKLREQGC-NH2 (219) 50 
5 
 (220) 
42 
6 Ac-GAKRHRKVLRGC-NH2 (221) 70 
7 Ac-VQFGHAGAGC-NH2 (222) 78 
8 Ac-ADQELMTYSHDNIIC-NH2 (223) 9.8 
9 Ac-FRQVLKHRKLREQGC-NH2 (224) 55 
10 
 (225) 
34 
As previously mentioned, the peptide sequences were based on proteins that are known to be 
phosphorylated on histidine. The sequence length varied between 10 and 15 amino acids, which is in the 
optimal range to raise antibodies. The sequences were based on histone H4 (entries 1 and 6), rat ATP-
citrate lysase (entries 2 and 7), G-protein β-1 subunit sequence (entries 3 and 8), and KCa3.1 ion channel 
protein (entries 4 and 9). In addition, two probes were designed containing a His or pHis analog with a 
PEG linker (entries 5 and 10). It was thought that this peptide could be used to raise a more general 
antibody that would recognize diverse sequences containing pHis, opposed to the other peptide 
sequences, which were expected to be more selective towards specific proteins.  
Isolated yields for most peptides were moderate to good. The only exceptions are both G-protein β-1 
subunit sequences (entries 3 and 8), which yielded only 1.8 and 9.8 percent respectively. The reason for 
this low yield is the insolubility of this peptide. During sample preparation for prep-HPLC it was noticed 
that the peptide was poorly soluble in most combinations of acetonitrile and water. After purification by 
prep-HPLC and lyophilization, only a small amount could be recovered. 
Peptides 216 and 220 were used to raise antibodies, by the group of Dr. Robert Schneider, Max Planck 
Institute of Immunobiology and Epigenetics, Freiburg. They also performed all antibody purifications and 
blot tests. The antigen peptides were conjugated to Keyhole Limper Hemocyanin (KLH) carrier protein 
using the bifunctional linker N-hydroxysuccinimidyl-3-maleimidobenzoate (MBS). The conjugate was 
injected into two rabbits with Freund’s complete adjuvant. Over the next eight weeks, five booster 
immunizations were carried out. After final bleeding and serum isolation the antibodies were purified by 
selection over peptide 216 or 220 immobilized on sepharose, followed by depletion over peptide 221 or 
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225 respectively. This method resulted in about 6 mg of monoselective poly-clonal antibody from each 
animal. 
The antibodies were then tested for their affinity for the natural pHis containing peptides (figure 56). 
Peptide 221 was phosphorylated using potassium phosphoramidate and dot blots were performed to 
assess the affinity of the antibodies for the natural pHis containing peptides. The dot blots for anti-216 
antibodies are shown in figure 56. The blots clearly show that there is no backbone recognition, as non-
phosphorylated peptide 221 was not stained by the antibody. The phosphorylated peptide (221-P) on 
the other hand was stained even at very low concentration (0.19 pmol). 
 Rabbit 1 Rabbit 2 
 Elution 1 Elution 2 Elution 1 Elution 2 
 221 221-P 221 221-P 221 221-P 221 221-P 
 
Figure 56: Dot blots of anti-216 antibodies against peptide 221 and 221 containing a phosphorylated histidine (221-P), blots by the Schneider 
group.  
Anti-220 antibodies were tested in a similar manner; these antibodies should recognize only pHis and 
should require no other amino acids for recognition purposes. Thus, these antibodies were also tested 
against 221 and 221-P. Additionally, they were also tested against peptide 216 containing the pHis 
mimic (figure 57). 
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Figure 57: Dot blots of anti-220 antibodies against peptide 221, 221 containing a phosphorylated histidine (221-P) and 216, blots by the 
Schneider group. 
Again the blots clearly show that the peptide back bone is not recognized by the anti-220 antibodies as 
peptide 221 is not stained at any concentration. Phosphorylated 221 is stained, however the detection 
limit seems to be around 3 pmol, much higher than for the anti-216 antibodies. The anti-220 antibodies 
also recognize peptide 216 containing the pHis mimic.  
The antibodies were then used to investigate H4 histone histidine phosphorylation. To this end mouse 
hepatocytes were fractionated and analyzed by western blot using the anti-216 antibodies. The results 
are shown in figure 58. 
 A B C D 
 
 
 A B 
 
 
 
 
 
Figure 58: Western blots of (I) mouse hepatocyte nuclear protein fractions. A: Soluble chromatin fraction. B: Pellet/Insoluble chromatin 
fraction. (II) Fractionated mouse hepatocytes. C: Nuclear extract. D: Cytoplasm. Blots by the Schneider group. 
The first blot (figure 58: I) shows two mouse liver nuclear protein fractions: the soluble chromatin 
fraction (A) and the pellet or insoluble chromatin fraction (B). The Ponceau blot is used as a loading 
control. When comparing the loading control and the western blot one can see that the band for the H4 
histone is detected in fraction B but not in fraction A. This indicates that the insoluble histone fraction 
contains H4 histone proteins that are phosphorylated on histidine, while the H4 proteins of the soluble 
200 pmol
50 pmol
12,5 pmol
3 pmol
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fraction are not. Since the insoluble chromatin fraction contains a high concentration of DNA that is 
tightly wound around the histones, this result suggests that phosphohistidine has a function in the 
packing of DNA. 
A second striking result from both western blots (figure 58: I and II) is the detection of many proteins 
other than the H4 histone. This might be caused by cross-reactivity of the anti-216 antibodies with other 
phosphoamino acids. As mentioned in chapter 7, the antibodies produced by the Muir group showed 
cross reactivity with phosphotyrosine and to a lesser extent phosphothreonine and phosphoserine. The 
anti-216 antibodies might also recognize these phosphoamino acids to some extent. This question can 
be easily answered by experiments using versions of the histone H4 peptide 221 with the histidine 
exchanged for a phosphotyrosine, phosphothreonine or phosphoserine. Since the anti-216 antibodies 
do not recognize the backbone of 221 any recognition of the modified peptide indicates cross-reactivity 
with that particular phosphoamino acid. 
Other possibilty are the recognition of the phosphates of protein-DNA complexes or, more intriguingly, 
the detection of polybasic stretches. Preliminary experiments, performed in the groups of Prof. 
Bastiaens and Dr. Hedberg suggest that a large number of these polybasic stretches containing a 
histidine are encoded in the human genome. The occurrence of these polybasic stretches seems to be 
highest among membrane proteins. More experiments will be necessary to investigate this further. 
To investigate in which location in the cell proteins that are recognized by the anti-216 antibodies reside 
mouse hepatocytes were fixed and then stained (figure 59). The cells were first stained with DAPI, a dye 
that colors the cell nucleus (A – blue), the cells were then stained with the anti-216 antibodies (B – 
green). As expected the overlay (C) makes clear that the anti-216 antibodies stain the nucleus, with 
minor background in the rest of the cells. 
 
 A B C 
Figure 59: Immunofluorescent stained fixed mouse hepatocytes. A: DAPI stain. B: Anti-216 antibody stain. C: Overlay. 
Thus the pHis mimic that was designed for this project was successful in raising antibodies selective for 
phosphohistidine. The antibodies have a high affinity for peptides containing phosphohistidine. They 
have been successfully used to detect histone H4 in complex mixtures and in the future they can be 
used to investigate the function of histidine phosphorylation. 
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10 Toward potential PHPT1 inhibitors 
The aza-wittig approach was very successful in providing a large amount of the pHis analog that was 
needed for biological studies (chapter 8.2). To investigate the generality of the approach to synthesize a 
range of C-2 substituted 4-phophonic acid imidazoles a small library was synthesized, with the help of 
Momotaro Takeda. Such a library could provide a source of inhibitors for PHP (chapter 5.2.1.2). 
Inhibitors of this phosphatase could be used to study its function in vivo. To this end, it was planned to 
react azide 66 with a variety of acid chlorides, in the presence of DMAP, to yield the amide. The amide 
could then be cyclized to the imidazoline by aza-wittig reaction, followed by base induced 
aromatization. Finally, the imidazoles will be protected with a trityl group to aid in their purification and 
ensure stability during storage (figure 60).  
 
 66 226 227 228 229 
Figure 60: Strategy to obtain a small library of C-2 substituted 4-phophonic acid imidazoles 
Practically, the coupling procedure is straightforward, the azide, DIPEA and DMAP were dissolved in 
DCM under air. Once the DMAP was completely dissolved the acyl chloride was added dropwise, which 
led to the immediate formation of a white precipitate. The mixture was stirred for an hour at room 
temperature to ensure the reaction went to completion and the reaction was submitted to an aqueous 
work-up. Final purification was done by flash column chromatography (scheme 46). 
 
 66 226a-t 227a-t 
Scheme 46: Reagents and conditions: 226a-t (2 equiv), DMAP (1 equiv), DIPEA (2 equiv), DCM, rt, 1 h. 
Most of the amide coupling reaction went well, with yields up to 94 percent (table 40). On average the 
benzoyl chlorides gave higher yields than the alkyl substituted acyl chlorides, likely due to the activating 
properties of the benzyl group (entries a-k vs. l-r). The alkyl substituted acyl chlorides seemed to be 
somewhat sensitive to steric bulk, as 227a and 227b formed in higher yield than 227c and 227d. 
The low yield retrieved for compound 227e (42 percent) was mainly related to purification issues. 227e 
was inseparable by normal silica flash column chromatography from myristic acid, the hydrolysis 
product of the acyl chloride starting material. The similar behavior on column of these two compounds 
is most likely due to the long alkyl tail. Separation could be achieved when the crude mixture was 
dissolved in methanol and a large excess of sodium bicarbonate was added. After stirring this mixture 
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for two hours, some celite was added, the solvent was evaporated and the residue was loaded on a 
column. This ensured that the myristic acid was loaded on the column as a sodium salt, which had a 
much higher retention than 227e. 
Even though similarly long alkyl tails were present, purification of 227f and 227g was not as problematic. 
The yield of 227g was only 65 percent, but 23 percent of unreacted starting material 66 was recovered. 
This was due to impurity of freshly prepared 226g, still containing some of the corresponding alcohol. 
After optimizing the synthesis of the acyl chloride, 227f was obtained in a good 86 percent yield. 
Table 40: Synthesis of a small library of imidazoles. 
# R  Yield 227 (%) Yield 228 (%) Yield 229 (%)a 
a Me 91b 91 54 
b Et 91 87 74 
c 
 
76 85 78 
d 
 
74 93 57 
e CH2(CH2)11CH3 42 41
c 74 
f CH2(CH2)8C≡CH 86
d 100 72 
g CH2(CH2)12C≡CH 65 (85)
e 96 76 
h 
 
74 84 78 
i 
 
84 91 81 
j 
 
76 93 88 
k 
 
69 76 75 
l Ph 93 93 87 
m 
 
91 91 81 
n 
 
77 93 70 
o 
 
80 87 79 
p 
 
94 70 56 
q 
 
82 86 67 
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r 
 
94 72 ―f 
s Cl
O  
―g ― ― 
t 
 
―g ― ― 
a: over two steps.b: no DMAP was used.c: 25 percent 230 was recovered. d: 1.2 equivalent acyl chloride was used.e:>1 equivalents of acyl 
chloride was used. Yield based upon recovered starting material..f: total decomposition of the starting material.g: no reaction. 
Finally, oxalyl chloride (226s) and diethylcarbamoyl chloride (226t) did not yield any of the 
corresponding amide. Oxalyl chloride was used in an attempt to make the double coupled product. 
Upon submission of 66 and 226s the mono-coupling product likely did form but decomposed back to 66 
with the release of carbon monoxide and carbon dioxide.  Addition of the second equivalent of 66 was 
apparently to slow to yield the double coupled product even after longer reaction times. In the case of 
diethylcarbamoyl chloride it seems likely that no reaction ever occurred as the carbonyl was deactivated 
since it was part of an amine moiety. 
Next, compounds 227a-r were submitted to the aza-wittig reaction to obtain the imidazoline (scheme 
47). 
 
 227a-r 228a-r 
Scheme 47: Reagents and conditions: dppe (1.5 equiv), THF, 80°C, 16 h. 
The aza-wittig reaction was performed by dissolving compounds 227a-r in THF, followed by addition of 
dppe. The mixture was then heated to 50°C until bubbling stopped, indicating that iminophosphorane 
formation was complete. The reaction vessel was then sealed and heated to 80°C for 16 hours to 
perform the aza-wittig cyclization. Afterwards, the reaction was cooled to around 50°C and a one-to-one 
mixture of 30% hydrogen peroxide in water and saturated aqueous sodium bicarbonate was added to 
ensure complete oxidation of the dppe. After 30 minutes the mixture was worked-up with chloroform 
and saturated aqueous sodium bicarbonate. Final purification was performed by filtering through a silica 
plug. 
The aza-wittig reaction performed admirably, yielding over 80 percent 228a-r in almost all cases (table 
40). Notable is that 227p and 227r, bearing electron withdrawing substituents provided lower yields. 
Compound 228e was recovered in only 41 percent yield. However, additionally to compound 228e, 
compound 230 was recovered in 25 percent yield (figure 61). This compound likely formed during the 
work-up of the aza-wittig reaction. If the reaction had not gone to completion and there was still 
unreacted iminophosphorane left (figure 61: A), the iminophosphorane could have been quenched 
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during the aqueous work-up, yielding the amine. In this case, the tosylamide becomes an acyl donor as 
the amine attacks on the carbonyl (figure 61: B), resulting in compound 230. Why there was still so 
much (25 percent) unreacted iminophosphorane after stirring for more than 16 hours at 80°C is 
unknown. None of the aza-wittig reaction using the other amides yielded side products like 230. 228f 
and 228g, both containing long carbon chains, were recovered in excellent yields. 
 
 A B 230 
Figure 61: mechanism for the formation of compound 230. 
The base induced aromatization to provide the imidazole was performed using KHMDS (scheme 48, 
table 40). The imidazoline was dissolved in THF and cooled to -78°C, after which KHMDS was slowly 
added as a 0.5M solution in toluene. A color change from colorless or yellow to orange or red was 
observed during addition. Upon completion of addition, the reaction mixture was transferred by canula 
to a flask containing six equivalents of acetic acid in water to quench all reactive species (chapter 
8.2.10). After aqueous work-up and evaporation, the unprotected imidazole was not isolated but 
immediately used in the next step. The described conditions smoothly converted all substrates, except 
for compound 228r. Addition of KHMDS to 228r made the reaction mixture turn black immediately and 
complete decomposition of the starting material was observed after work-up. Presumably, the KHMDS 
reduced one or more of the nitro groups, resulting in a complex mixture of products. With this in mind 
the aromatization of 228q, bearing a single nitro-group, was performed with DBU in DMF instead of 
KHMDS. It was gratifying to see that the previously discovered fact, that the imidazolines with an 
electron withdrawing groups at C-2 were easy to deprotonate (compound 138, chapter 8.2.9), held for 
compound 228n. 
 
 228a-q 231a-q 229a-q 
Scheme 48: Reagents and conditions: a) KHMDS (3 equiv), THF, -78°C, 15 min. b) TrCl (2 equiv), DBU (3 equiv), AgOTf (2.2 equiv), DCM, rt, 1 h. 
Trityl protection, by stirring the crude unprotected imidazoles with trityl chloride in the presence of DBU 
and silver triflate, under air, was straightforward in all cases (scheme 48, table 40). All imidazoles were 
protected in reasonable to good yield, whereas imidazoles (229p and 229q) were obtained in moderate 
yields. This was most likely due to their electron withdrawing properties, decreasing the nucleophilicity 
of the imidazole.  
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In conclusion, the presented synthetic strategy can be used to generate tritylprotected 4-phosphonic 
acid imidazoles with a wide variety of substituents on the C-2 position. Aromatization to the imidazoles 
has been realized in general with KHMDS. In addition, it has been shown that imidazolines with electron 
withdrawing groups at C-2 can be aromatized under mild conditions (DBU). Imidazoles 229f and 229g 
containing a long alkyl chain with a terminal alkyne could be used to fashion molecular probes, using 
‘click chemistry’, also these two substituents performed well in the synthetic strategy presented 
here.[181] The potential inhibitors synthesized will be tested in a PHPT1 assay developed in the Hedberg 
group.[137] 
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11 Studies toward a 1-phosphohistidine analog 
As described in the introduction, histidine can be phosphorylated at both nitrogens of the imidazole, 
providing either 3-pHis or 1-pHis (chapter 5.2). In chapter 7 the design and synthesis of the 3-pHis mimic 
have been described. In order to obtain a stable 1-pHis mimic a similar design was used. To preserve the 
electronic and steric properties of natural 1-pHis, the imidazole was conserved whereas the positions of 
the substituents were changed (figure 62). 
 
 6 232 233 
Figure 62: 1-pHis, the stable analogue 232 and the SPPS building block 233. 
Compound 232 was derived following these design principles. As shown in figure 62, this analog 
maintains the 1-2 relationship of the phosphate and amino acid in 6, while the unstable 
phosphoramidate bond is exchanged for a stable phosphonate bond. In order to raise antibodies the 
stable pHis analog needs to be incorporated in a peptide (chapter 5.5). Therefore, SPPS building block 
233 needed to be prepared. The protecting groups of choice are the same as for the 3-pHis analog: 
benzyl groups on the phosphonate and an Fmoc group on the amine. The retrosynthetic analysis 
towards building block 233 is shown in figure 63. 
 
 233 234 235 
Figure 63: Retrosynthetic analysis of compound 233. 
Compound 233 should be available by the coupling of compound 234 and an activated serine 235. 234 
can be prepared by deprotection of its trityl protected analog 167, which has been successfully prepared 
before in order to obtain the 3-pHis analog (see chapter 8.4.2.1). The critical step of this synthesis would 
be the regio-selectivity of the serine addition. In general, a bulky group at C-5, the phosphonate in this 
case, leads to introduction of the alkyl on the opposite side of the ring, N-3. Thus, the steric bulk of the 
phosphonate is expected to interfere with the addition, favoring a 4-phosphonc acid imidazole instead 
of the desired 5-phosphonic acid imidazole. Several strategies, such as making use of directing groups or 
particular protective groups could be explored to obtain the desired regioisomers. The synthesis of 234 
and the coupling to 235 are detailed below. 
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11.1 Unprotected imidazole 
The synthesis of 234 involved the deprotection of imidazole 167 using TFA and TIPS. Compound 167 was 
synthesized as described in chapter 8.4.2.1. Compound 234 was submitted to an acid-base work-up and 
not purified further, as it was very polar and did not behave well during column chromatography. 
 
 167 234 
Scheme 49: Synthesis of compound 234. Reagents and conditions: TFA (1 equiv), TIPS (2 equiv), AcOH, rt, 20 h, 65%. 
Introduction of the amino acid part was initially attempted by a Mitsunobu reaction between imidazole 
234 and protected serine 236 (scheme 50).  
 
 234 236 237 
Scheme 50: Synthesis of compound 237. Reagents and conditions: PPh3 (1.18 equiv), DIAD (1.2 equiv), THF, 0°C to rt, 16 h. 
It was hypothesized that the phosphonate group could serve as a directing group to obtain the desired 
regio-isomer. The Mitsunobu intermediate would coordinate to the phosphonate oxygen, thereby 
selecting for the right product (figure 64: A). The main problem with this strategy is the propensity of 
the activated serine to ring close to the aziridine under Mitsunobu conditions (figure 64: B). In that case 
selectivity for the unwanted regio-isomer of 233 would be expected during aziridine ring opening due to 
the steric bulk of the phosphonate.[182] 
 
Figure 64: Mitsunobu considerations. A: Induction of selectivity due to coordination to the phosphonate. B: formation of the aziridine. 
 
Compound 234 and 236 were submitted to Mitsunobu conditions (scheme 50). Only a 1:1 mixture of 
products was obtained and attempts to isolate these products using column chromatography failed. A 
1:1 mixture of products is a much better ratio than one would expect if the reaction was governed by 
sterics alone. Therefore, it seemed that the induction of selectivity did work, but was insufficient to push 
the reaction to the desired regio isomer completely. Attempts to optimize the reaction did not change 
the ratio significantly, thus other strategies had to be considered. 
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11.2 Protected imidazole 
In the literature there are examples of enforcing regioselectivity during imidazole substitution by smart 
use of leaving groups.[183] A well-known example is the introduction of a methyl group on N-3 of 4-
substituted imidazoles. The natural selectivity of this reaction, like in our case, is for N-1. Therefore, N-1 
is first trityl protected, after which the compound is subjected to methyliodide or another methylation 
reagent to introduce a methyl group on N-3. Because the trityl group is good at stabilizing a positive 
charge it will fall off during the reaction, sometimes with the help of some acid and/or silver salt, 
yielding the imidazole with the desired substitution pattern (figure 65).[184]  
 
 238 239 240 241 
Figure 65: 5-substituted N-methyl imidazole synthesis. 
In analogy to this strategy, trityl protected imidazole 167 was submitted to various reaction conditions in 
order to obtain compound 242, as summarized in table 41. 
 
Table 41: Substitution of 167. 
 
 167 242 
# Electrophile (equiv) Reagents (equiv) Solvent Result 
1 
(1) 
236 
PPh3 (1.18), DIAD 
(1.2) 
THF No reaction 
2 
(1.1) 
243 
― MeCN No reaction 
3 
(1.1) 
244 
― MeCN No reaction 
4 
 (1.1) 
245 
― MeCN No reaction 
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Unfortunately, in all cases only unreacted starting material was recovered. Neither a Mitsunobu reaction 
nor an iodide was successful in activating the hydroxy function (entries 1 and 2). Using β-lactone 244 or 
aziridine 245 also did not result in the formation of any product (entries 3 and 4).  
A possible reason for the failure of these reactions might be the electron withdrawing properties of the 
phosphonate, which deactivate the imidazole. Additionally, there might also be a steric factor, the two 
benzyl protecting groups might shield the side of the molecule that should be substituted. Therefore, 
attempts were made to use 1-trityl-4-iodoimidazole 85 as a starting material. The rationale being that 
the iodine is weakly activating and much smaller than the phosphonate, allowing for substitution to the 
desired compound 249. This compound might then be subjected to the same conditions as discussed in 
(chapter 8.4.2.1, scheme 42) to introduce the phosphonate. Thus, compound 85 was allowed to react 
with various serine derivatives, the results are summarized in table 42. 
Table 42: Attempted substitution of 85. 
 
 85 X = OH 246, Br 247, I 248 249 
# Serine derivative (equiv) Reagents (equiv) Solvent Result 
1 246 (1) PPh3 (1.2), DIAD (1.2) THF Decomposition 
2 247 (1.2) ― MeCN No reaction 
3 248 (1.2) ― MeCN No reaction 
4 247 (1.1) AgOTf (1.5) MeCN No reaction 
5 248 (1.1) AgOTf (1.5) MeCN Decomposition 
 
The 4-iodoimidazole was first submitted to Mitsunobu conditions using protected serine 246. However, 
these conditions resulted in recovery of 85 and decomposition of 246 (entry 1). Attempts to react 
compound 85 with halo-serines 247 or 248 failed to show any conversion (entries 2 and 3). Adding silver 
triflate in order to exchange the bromine or iodine for a triflate did not result in any conversion in the 
case of 247 (entry 4). In the case of 248 the serine derivative decomposed and most of 85 was recovered 
(entry 5).  
11.3 Intramolecular strategy 
As a solution to the apparent reactivity problem as well as the regio selectivity issues, a modification to 
the above strategy was developed. It was hypothesized that the amino acid part could be connected to 
the phosphorus via a phosphoramidate bond (figure 66).This would position the amino acid side chain in 
such a way that reaction with the correct imidazole nitrogen would go over a six-membered transition 
state, which is favored over the seven-membered transition state for the other nitrogen. More 
importantly, the intramolecular nature of the reaction should increase the effective reactivity of the 
system, solving the reactivity problem of the previous attempts. 
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 250 251 252 253 
Figure 66: Strategy using the phosphoramidate tether. 
To obtain intermediate 251, one benzyl has to be removed from 167, while leaving all other protecting 
groups unaffected. This was accomplished by submitting 167 to DABCO in toluene at 80°C for 20 hours, 
yielding the mono-benzyl DABCO salt (scheme 51) in analogy to a procedure reported by Saady et al.[185] 
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 167 254 
Scheme 51: Synthesis of compound 254. Reagents and conditions: DABCO (2 equiv), toluene, 80°C, 20 h, quantitative. 
In order to investigate the initial P-N coupling, n-butyl amine was used instead of the amino acid 
(scheme 52). The mono-benzyl phosphonate was activated using PyBrOP and n-butyl amine was added. 
NMR and LCMS data clearly showed that there was conversion and suggested that the target molecule 
255 was indeed the product. However, attempts to isolate the compound by column chromatography 
failed. Nevertheless, the reaction seemed to work, thus it was decided to proceed with the amino acid. 
 
 254 255 
Scheme 52: Synthesis of compound 255. Reagents and conditions: n-butyl amine (1.2 equiv), PyBrOP (1.2 equiv), DIPEA (2.4 equiv), DCM-d2, rt, 
20 h. 
The side chain of the protected serine was protected as a tert-butyl dimethyl silyl (TBS) ether, to prevent 
cross reactivity. Even though similar conditions as for the reaction with n-butyl amine were used, no 
product 257 was observed (scheme 53). Fortunately, addition of a catalytic amount of DMAP pushed the 
reaction to completion. It proved impossible to purify the compound by conventional column 
chromatography. Fortunately, by using a reverse-phase C18 sep-pak 14 milligrams of 257 could be 
isolated, corresponding to a 48% yield. 
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 254 256 257 
Scheme 53: Synthesis of compound 257. Reagents and conditions: 256 (1.2 equiv), PyBrOP (1.2 equiv), DMAP (0.1 equiv), DIPEA (2.4 equiv), 
DCM, rt, 2 days, 48%. 
The low yield was a source of worry, as gram amounts of the final compound would be needed for SPPS. 
Therefore, the byproducts of the reaction were further investigated. It was discovered that compound 
258 was a major side product. Pyrrolidine analogue 258 forms due to pyrrolidine exchange between 254 
and PyBrOP. Since no conditions were discovered that suppressed this behavior, some other activators 
were tested. The results are summarized in table 43. 
 
 258 259 
Initially, HATU and HOAt were investigated to activate the phosphonate, but 254 was not reactive under 
these conditions. Even though there was an initiation time of 5 minutes before the amino acid was 
added, compound 259 was the only new compound found in the reaction mixture (entry 1). Reducing 
the amount of HATU and HOAt suppressed the formation of 259 but did not yield any of the target 
product (entry 2). Attempts to make a chlorophosphonate using Vilsmeier conditions,[186] which could 
then be attacked by the amino acid 260 led to complete decomposition of the starting material (entry 
3). 
Table 43: different activating agents in the synthesis of compound 257 
# Activator (equiv) Base Result 
1 HATU (2.4), HOAt (2.4) DIPEA (4.8) No reaction 
2 HATU (1.1), HOAt (1.1) DIPEA (4.8) No reaction 
3 (COCl)2 (1.4), DMF (0.2) ― Decomposition 
 
The small amount of 257 that was obtained using the PyBrOP method (Scheme 53) was used in an 
attempt to remove the TBS group. To this end 257 was dissolved in THF and TBAF was added and the 
mixture was stirred for two hours (Scheme 54). Unfortunately, a complex mixture of unidentified 
products was obtained, none of these products showed a mass consistent with compound 261 on LCMS. 
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 257 261 
Scheme 54: Attempted synthesis of compound 261. Reagents and conditions: TBAF (1.2 equiv), THF, rt, 2 h. 
Since the synthesis of phosphoramidate 257 did not give the product in high yield and the subsequent 
deprotection did not work, it was decided to cease work on this route.  
 
11.4 Outlook 
Making use of the phosphonate as directing group resulted in the formation of the desired 1-pHis 
regioisomer as a 1:1 inseparable mixture with the undesired regioisomer. The protective group strategy, 
unfortunately, did not yield any 1-pHis. Therefore, other strategies will have to be considered. Many 
different strategies toward 1-pHis analogs could be envisioned, one is discussed below. 
The van Leusen imidazole synthesis is a multicomponent reaction (MCR) that gives fast access to a 
variety of substituted imidazoles from simple starting materials (chapter 5.7.2.3). In this method the 
imidazoline is aromatized by elimination of the tosyl group, a method that also works without a electron 
withdrawing group on C-4 (in contrast to, for instance, BrCCl3/DBU aromatization).
[66] The imidazoline 
could be synthesized in one step from the multicompontent reaction between TosMIC (263), an 
aldehyde (264) and an amine (265), in the presence of base.  
 
 242 262 263 264 265 
Figure 67: Van Leusen strategy to synthesize compound 242. 
The protecting groups on the amino acid should likely be the Alloc and allyl ester groups, as they have 
served well in other chemistries discussed in this thesis. Unfortunately, the dibenzyl formylphosphonate 
is not a stable compound.[187] However, the dimethyl equivalent is stable and can be easily synthesized 
from dimethyl phosphonate and formic acetic anhydride.[188] Both methyl groups should be removable 
using TMS bromide,[189] after which they can be reprotected with benzyl groups. Unfortunately, initial 
experiments toward the synthesis of 264 and 265 did not show promising results. If these compounds 
cannot be made or if the reaction does not work due to issues with the imine formation, the imine 268 
might be synthesized separately in advance. 
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This could be achieved by eliminating HCl from chloramine 269 using base. The chloramine itself should 
be available through either a reductive amination between an alpha amino phosphonate (266) and a 
protected 3-oxo-L-alanine (267).[190] Another possibility would be to use a Kabachnick-Fields reaction 
between a phosphite (270), formaldehyde (271) and a protected L-2,3-diaminopropionic acid (272).[191] 
The amine could then be chlorinated using tert-butyl hypochlorite.[192] This method also allows greater 
flexibility with the phosphonate protecting groups. 
 
 
 266 267 
 
 
 268 269 270 271 272 
Figure 68: Alternative access to the imine 268  for the van Leusen strategy. 
 
  
133 
 
 
  
134 
 
 
 
  
135 
 
12 Adenylylated histidine analog 
Apart from phosphorylation, histidine can also undergo methylation or adenylylation.[193] As for the 
phosphohistidine, little is known about the biological function of adenylylated histidine. Since an 
intermediate in the 3-pHis synthesis could serve as a practical handle to prepare an adenylylated 
histidine analog, it was decided to look into the development of a histidine adenylylation toolset as well.  
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Figure 69: Adenylylation of a histidine residue on a protein using ATP. 
It was hypothized that an intermediate in the 3-pHis analog synthesis could be modified to an 
adenylylated histidine analog in line with earlier work in our group.[5, 194] This compound would also be 
used in SPPS to yield antigen peptides for immunization. Therefore, it should contain, the now familiar, 
Fmoc group on the amine and preferably a benzyl on the phosphonate. The sugar moiety of the 
adenosine was protected with an acetal, as the more common ester protecting groups make the 
adenosine decompose under acidic conditions. The purine moiety was di-boc protected to deactivate 
the system further (figure 70).[5, 194] 
It was thought that building block 274 could be obtained by a coupling of protected adenosine 275 
(provided by Michael Albers)[194] and mono benzylphosphonate 273 (figure 70). 273 could be prepared 
by mono deprotection of compound 136, an intermediate of the synthesis of the 3-pHis analog synthesis 
(chapter 8.2). 
 
 
 
 273 
 274 275  
 
 
 
Figure 70: Retrosynthesis for an adenylylated histidine analogue. 136 
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Mono debenzylation of a phosphonate was already done with DABCO on compound 167 (chapter 11), 
and was also successful in this case. The intermediate mono-benzylphosphonate 273 was not isolated 
but adenosine 275  and PyBrOP were added to the crude reaction mixture. Conversion of the mono-
benzylphosphonate 273 was observed, but no 276 was detected. 
 
 136 276 
Scheme 55: Attempted synthesis of compound 276 using PyBrOP. Reagents and conditions: a) DABCO (2 equiv), toluene, 80°C, 16 h. b) 
Adenosine 275 (1.1 equiv), PyBrOP (1.1 equiv), rt, 6 h. 
It was already known from studies on other mono-benzylphosphonates (chapter 11) that it was hard to 
substitute the phosphonate mono-ester. A particular problem for PyBrOP was the exchange of a 
pyrrolidine group from the PyBrOP phosphorus to the phosphonate. Therefore, a better activator was 
needed.  
The combination of 2,4,6-Triisopropylbenzenesulfonyl chloride (TPSCl) and pyridine has been successful 
in coupling phosphonates and alcohols.[195] Thus, it was investigated for this coupling as well. Mono-
benzyl phosphonate 273 and adenosine 275 were dissolved in pyridine and TPSCl was added. The 
mixture was stirred for five days, after which a compound of the correct mass for 276 was detected in 
the LCMS. Unfortunately, many side products were also present and attempts to isolate the target 
compound failed. 
 
 273 276 
Scheme 56: Attempted synthesis of compound 276 using TPSCl. Reagents and conditions: a) Adenosine275 (1.2 equiv), TPSCl (3 equiv), pyridine, 
rt, five days. 
Since DABCO mono debenzylation worked quite well it was clear that the benzyl protecting groups were 
sensitive to nucleophiles. It was hypothesized that the pyridine solvent was responsible for the large 
amount of side products in the TPSCl promoted reaction. To test the hypothesis compound 136 was 
dissolved in pyridine and heated to 80°C for three days. LCMS clearly showed slow mono debenzylation 
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followed by decomposition of 273. The reaction had not gone to completion after three days but it 
became clear that a reaction performed in pyridine was not an option. 
As an alternative method to increase the reactivity of the phosphonate both benzyl groups might be 
removed. It was already known that one free hydroxy group on the phosphonate did not interfere with 
SPPS[194] and a doubly activated phosphonic acid should be more reactive than a mono activated one. 
Thus, it was attempted to remove both benzyl groups without removing any of the other protecting 
groups of 136. Especially the trityl protecting group on the imidazole was a source of concern as it is 
quite acid labile. Several methods were tested, they are summarized in table 44. 
Table 44: Attempts to remove both benzyl protecting groups. 
 
 136 277 
# Reagent (equiv) Solvent Temperature (°C) Result 
1 PhSH (3), KOtBu (3) DMF 40 Deallylation 
2 PhSH (6), KOtBu (6) DMF 80 Deallylation 
3 TMSBr (2.1) DCM rt 273:277 1:1a 
4 TMSBr (3) DCM rt 277: 277-Tr 1:1a 
a: no yield was determined, ratios determined by 1H and/or 31P NMR. 
Initially thiophenol and potassium tert-butoxide were tested.[196] At 40°C fast mono-benzyl removal was 
seen however the resulting compound 273 was slowly deallylated to the free acid over several hours 
(entry 1). Increasing the temperature to 80°C speeded up the reaction to yield fully deallylated product 
in one hour (entry 2). The second benzyl group was not removed during these tests. Secondly 
trimethylsilyl bromide (TMSBr) in DCM was investigated, after five hours a mixture of mono benzyl 
compound 273 and free phosphonic acid 277 were detected (entry 3). Repeating the reaction with 
slightly more TMSBr pushed the reaction to completion but also resulted in a significant amount of free 
phosphonic acid with the trityl group removed (entry 4). NMR analysis of the crude product also 
indicated that the phosphonic acid contained two TMS groups. Explorative reactions suggested that 
these TMS groups could easily be removed using KF in methanol. 
At this point work on this project had to be halted due to a shift in priorities. Future work on this project 
might include fine-tuning of the TMSBr debenzylation reaction to yield the desired product 277 
exclusively, perhaps through the use of a suitable buffer system. The free phosphonic acid could then be 
activated using TPSCl, using 2,6-lutidine instead of pyridine might stop the decomposition problems 
seen with that base. After coupling of the adenosine and 277 the protecting group manipulations to 
obtain the SPPS building block should be straightforward. 
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13 Nδ-methylarginine SPPS building block synthesis 
Arginine methylation is an essential posttranslational modification that plays a role in many 
physiological processes. There are several forms of methylated arginine, the most prevalent is 
asymmetric dimethyl arginine 278, where both methyls are located on the same nitrogen. Less frequent 
are mono-methylated arginine 279 and symmetric dimethylated arginine 280. There was interest to 
discover if monomethylated arginine 281 was also one of the methyl arginine homologues, to aid in the 
investigation antibodies specific for proteins containing 281 had to be raised.[197] 
 
 278 279 280 281 
Figure 71: Different homologs of methyl arginine. 
In order to raise these antibodies, peptides containing Nδ-methylarginine needed to be synthesized. 
Thus a SPPS building block had to be synthesized based on 281. The SPPS building block should have the 
guanidine moiety protected, preferably with a Pbf or with two boc groups. Naturally, Fmoc protection is 
necessary for the amine so the building block can be used in Fmoc based strategies. A retrosynthetic 
analysis of the target building block is shown in Figure 72.   
 
 282 283 284 285 
Figure 72: retrosynthesis of protected Nδ-methyl arginine 282. 
At first glance, synthesis of the Nδ-methylarginine building block 282 seems straightforward. However, 
there are some difficulties to be expected. Protection of the acid moiety as an ester could lead to 
formation of 287 via the attack of the side chain amine on the carbonyl, due to its activation by the 
methyl group (figure  73).  
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 286 287 
Figure 73: Cyclization of 286. 
Two possibilities to prevent the formation of 287 were envisioned: to leave the acid unprotected (1) or 
to reduce the acid to the alcohol first and re-oxidize to the acid as the last step (2). Option 1 was 
investigated first since less synthetic steps were required.  
13.1 The free acid approach 
Thus, final compound 282 was envisioned to be synthesized by reaction of 283[198] and Fmoc protected 
methyl ornithine 284.[199] This compound should be available by two subsequent reductive aminations of 
FmocN-Orn-OH, first using 2,4-dimethoxybenzyl aldehyde (DMBA), then using formaldehyde. The initial 
DMB protection is to prevent di-addition of the formaldehyde; the DMB group will then be removed 
using acidic or oxidative conditions. FmocN-Orn-OH can easily be made from commercially available 285 
in one step.  
Thus, the Boc group was removed from FmocN-Orn(Boc)-OH (285) with TFA: DCM 1:1, giving the TFA 
salt in quantitative yield (scheme 2). The resulting amine was subjected to reductive 
amination conditions using sodium cyanoborohydride and 2,4-dimethoxybenzyl 
aldehyde in methanol. After one hour, para-formaldehyde was added with another 
portion of sodium cyanoborohydride and the mixture was aged overnight.  
Initially, up to 50 percent dimethyl adduct 288 was recovered from the reductive 
amination reactions. Presumably, this was caused by the reduction of 2,4-
dimethoxybenzyl aldehyde by sodium cyanoborohydride. The problem was solved 
by slow addition of reductor, giving 290 in 66 percent yield (scheme 57). Sodium triacetoxyborohydride 
and 30 percent formaldehyde in water were also tested but these reaction conditions were 
unsuccessful. 
 
 285 289 290 
Scheme 57: Synthesis of 290. Reagents and Conditions: a) TFA: DCM 1:1, rt, 5 h, quant. b) 2,4-dimethoxybenzaldehyde (1.1 equiv), sodium 
cyanoborohydride (2 equiv), sodium acetate (2.1 equiv), 3A molsieve, MeOH, rt, 1h. c) para-formaldehyde (4 equiv), sodium cyanoborohydride 
(2 equiv), rt, 16 h, 66% over two steps. 
288 
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Next, conditions were screened to remove the DMB protective group (Table 2). Initial DMB group 
removal with TFA did not result in any conversion. The DMB group proved to be quite stable to acidic 
conditions (entries 1 and 2). Therefore, oxidating conditions were investigated. DDQ was not a strong 
enough oxidizer to oxidize the DMB group (entry 3). However, CAN in 1,4-dioxane and water did 
produce 284 after a long reaction time and with a significant amount of unidentified byproducts (entry 
4). A solvent switch to acetonitrile and water produced compound 284 at 81 percent yield in only an 
hour (entry 5).  
Table 45: DMB deprotection. 
N
DMB
NHFmoc
OH
O
Reagent
Solvent
NH
NHFmoc
OH
O
 
 290 284 
Reagents and conditions: Reagent, solvent, rt, 16 h. 
# Reagent (equiv) Solvent Result 
1 TFA (excess) DCM No reaction 
2 TFA (excess) Water No reaction 
3a DDQ (1.5) DCM No reaction 
4 CAN (3) 1,4-dioxane: water 9:1 Full conversion 
5b CAN (3) MeCN: water 4:1 81% 
a: reaction was performed at 80°C. b: reaction was done in 1 hour. 
Pure 284 was obtained as a brown, sticky, extremely hydrophobic foam and was therefore very hard to 
handle. Due to its unprotected acid moiety it was also very insoluble in organic solvents. For a similar 
compound, Feichtinger et al. reported that a TMS adduct of the acid could be prepared in situ to 
enhance solubility, after which the guadinilation reagent can be added.[199] 
Similar conditions were tested to prepare a TMS ester of 284 in situ (table 3). The initial test used 
bis(trimethylsilyl)acetamide (BSA) as TMS donor. A mixture of 284 suspended in DCM and BSA was 
heated to 45°C for 3 hours, after which no more suspended solid was visible. Then compound 283 and 
triethylamine were added at room temperature and the reaction mixture was stirred overnight. 
Regrettably, only complete decomposition of 284 was observed; a large amount of unreacted 283 was 
still present (entry 1). It might be that formation of the TMS adduct was too slow, allowing for 
decomposition of 284 before protection could be complete. Therefore, a better TMS donor, 
trimethylsyliltrifluoromethanesulfonate (TMSOTf), was used. The addition of TMSOTf to a suspension of 
284 in DCM was done at 0°C to prevent decomposition of the starting material; the mixture was then 
allowed to warm to room temperature and stirred for an hour. After addition of the base and stirring for 
16 hours the compound had again completely decomposed (entry 2). Finally, a reaction of 284 and 283 
without the TMS protection was attempted. DCE was used as solvent to increase the solubility of 284, 
however again no product was obtained (entry 3).[200] 
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Table 46: Guanidine synthesis I. 
 
 284 283 282 
Reagents and conditions: a) TMS donor, solvent, rt, 16 h.b) 283 (1.2 equiv), base. 
# TMS donor (equiv) Base (equiv) Solvent Result 
1a BSA (2.2) Et3N (1.2) DCM Decompostion 
2b TMSOTf (3) DIPEA (3) DCM Decompostion 
3 ― DIPEA (4) DCE Decompostion 
a: reaction was done at 45°C then rt. b: reaction was done at 0°C to rt. 
The reason for the decomposition of the starting material during these reactions is unclear. The Fmoc 
group should be stable to triethylamine and DIPEA. Since, a large amount of 283 was recovered it seems 
unlikely it had a role in the decomposition of 284. Finally, entry 3 also had decomposition of 284 while 
there was no silylating agent present.  
Reactions with compound 283 were not successful; therefore other guanidinylation reagents were 
considered. Guanidines are often made from thioureas by activating the thiourea and substituting the 
sulfur for a nitrogen nucleophile.[201] Thioureas can be synthesized by mixing an isothiocyanate and an 
appropriate amine (figure 74). 
 
 A B C 
Figure 74: guanidine synthesis starting from an isothiocyanate. 
Thus several isothiocyanates were employed in an effort to synthesize derivatives of thiourea 11 (Table 
4).The first test, using potassium isothiocyanate in DMF, did not show any conversion (entry 1). Initially 
no base was added, and the mixture was stirred for an hour. When no conversion of 284 was observed 
by TLC three equivalents of DIPEA were added and the mixture was stirred for several hours. After 
addition of base, no turnover of the starting material was observed. This was somewhat surprising as 
conditions were similar to those in table 3, where complete decomposition was seen in all cases. 
 
 
 
 
143 
 
Table 47: Guanidine synthesis II. 
 
 284 291 
# Thiocyanate (equiv) Base (equiv) R Solvent Result 
1 KSCN (1.2) DIPEA (3) H DMF No reaction 
2 PbfNCS (1.2) DIPEA (2) Pbf DCM Decomposition 
3 PbfNCS (1.3) DIPEA (3) Pbf DCM Trace 
4 PbfNCS (1.2) K2CO3 (3) Pbf DCM Decomposition 
 
Pbf-isothiocyanate would be a suitable isothiocyanate to use as it would lead to a guanidine with the Pbf 
protecting group, which is very amiable to SPPS.[202] However, only a trace of compound with the right 
mass was observed in the LCMS (entry 3), which could not be isolated. The use of potassium carbonate 
as base led to complete decomposition, presumably due to Fmoc removal (entry 4).  
Finally, an attempt was made to turn around the guanidine formation. Instead of preparing thiourea 291 
from an isothiocyanate and 284, followed by attack by a nitrogen nucleophile to obtain the guanidine. It 
was attempted to react compound 284 with a di-Pbf protected thiourea 292 (scheme 58). Following a 
procedure described by Qin et al, 292 was activated with DIPEA and Iodine, followed by addition of 
284.[203] However, this strategy also did not yield the desired product.  
 
 292 284 293 
Scheme 58: attempted synthesis of 293. Reagents and Conditions: Iodine (2.9 equiv), DIPEA (2.9 equiv), THF, rt, 16 h. 
13.2 Protected acid approach 
Due to the solubility problems of 284, the synthetic strategy was revised. A literature search revealed 
that several compounds similar to 284 with an ester protecting group on the acid moiety are known. 
These compounds were reported to be stable and did not spontaneously ring close (figure 75). 
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 294[204] 295[205] X = NH 296, S 297[206] 298[207] 
Figure 75: Stable N-methyl ornithine ester and analogues. 
Therefore, it was decided to synthesize a diprotected analogue of 284. Since the Alloc and allyl ester 
protecting group combination had served well in the past (chapter 8.2), it was used here as well. 
Synthesis started with ornithine, which could be selectively boc protected on the side chain after 
protection of the amino acid as a copper complex.[208] After reaction with Boc anhydride, the copper 
complex was removed with sodium sulfide.[209] The amine and carboxylic acid were protected with an 
Alloc and allyl group respectively, using standard methods (scheme 59). 
 
 299 300 301 
Scheme 59: Synthesis of 301. Reagents and Conditions: a) Copper acetate (0.5 equiv), sodium hydroxide (2 equiv), Boc anhydride (1.3 equiv), 
acetone: water 4:3, rt, 2.5 days. b) sodium sulfide (0.75 equiv), water, rt, 2 h, quantitative over two steps. c) allyl chloroformate (1 equiv), 
sodium carbonate (1 equiv), acetonitrile: water 1:2, rt, 2 days. d) allyl bromide (1.1 equiv), sodium bicarbonate (1 equiv), DMF, rt, 2 days, 68% 
over two steps. 
Removal of the Boc group with TFA and reductive amination, using the same procedure as before 
proceeded as expected. Regrettably, removal of the DMB group with CAN lead to the ring closed 
product. Several attempts were made to perform an in situ guanidinylation after the CAN deprotection 
but only traces of the guanidine were obtained.  
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 301 303 304 
 
    305 
Scheme 60: attempted synthesis of 302. Reagents and Conditions: a) TFA: DCM 1:1, rt, 5 h, quant. b) 2,4-dimethoxybenzaldehyde (1.1 equiv), 
sodium cyanoborohydride (2 equiv), sodium acetate (2.1 equiv), 3A molsieve, MeOH, rt, 1h. c) para-formaldehyde (4 equiv), sodium 
cyanoborohydride (2 equiv), rt, 16 h, 78% over two steps. d) CAN (3 equiv) acetonitrile: water 4:1, rt, 15 minutes. 
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Finally, for future attempts toward compound 282 it would be best to use a strategy similar to the 
method of Marletta et al. although the sequence is much longer than the routes pursued above.[210] 
They first introduced a tosyl group on the Nδ position using the copper protection strategy used above 
for the boc introduction. After adding a protecting group to the primary amine the methyl group was 
established using methyl iodide and all protecting groups were removed. Then they protected the amino 
acid as a boron complex followed by synthesis of the guanidine with N,N’-diboc thiourea. Removal of 
the borane complex can be achieved using weak acid, leaving the boc groups untouched. At this point an 
Fmoc protecting group could be introduced yielding the final product (figure 76). 
 
 
 
 
 299 306 307 308 309  
 
 
 
 
 282 
Figure 76: Alternative synthesis toward 282. 
Alternatively, a strategy centered around compound 310 (figure 77). The alcohol moiety should not give 
the problems related to the acid (bad solubility, hygroscopicity or ring closure) and can be protected as 
an easily handled silyl ether if needed. In contrast to the Fmoc group, the Alloc protecting group is stable 
to acidic and basic conditions, allowing for the introduction of the guanidine without decomposition. 
The Alloc can then be easily removed and an Fmoc installed. This route incorporates lessons learned 
during the previously discussed chemistry allowing quick access to target compound 282. 
 
 282 310 311 299 
Figure 77: Second alternative retrosynthesis toward 282. 
To synthesize compound 310, initial protection of 299 could be performed with the copper methodology 
used before, to introduce the Boc protection. Alloc protection would likewise be done using chemistry 
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mentioned previously. Reduction of the carboxylic acid can be done by first activating it with, for 
instance, PyBrOP or as the asymmetric anhydride, followed by sodium borohydride reduction.[211] Then 
removal of the Boc group followed by the reductive amination procedure detailed above would yield 
compound 310. This could then be guadinylated by any of the methods mentioned above. The final 
compound could then be obtained by oxidation and a protecting group switch. 
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14 Probes 
In this chapter, the design and partial synthesis of a probe to study the synergy between lipidation and 
phosphorylation will be described. In contrast to the other chapters, this probe is not meant to raise 
antibodies but will be used as a MS tag for proteomic studies. To study lipidation and phosphorylation of 
a single protein, a bifunctional probe was developed. 
The probe consisted of three parts. The bottom part, a maleimide, was designed to be attacked by the 
surface cysteine residues of a protein (figure 78, 312) (normal lipidation sites). The middle part, a 
piperazine, was designed to enable easy fragmentation in the mass spectrometer, together with the 
maleimide (313). The top part, a phosphonate, was designed to allow titanium oxide purification, 
together with other phosphate containing proteins. These functions allow the probe to be used in pull-
down experiments where information about proteins that get lipidated and phosphorylated can be 
obtained. 
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 312 313 314 315 
Figure 78: Flow chart to use probe 312. 
The retrosynthetic analysis of the probe 312 starts with a disconnection of the piperazine and the alkyl 
chain. The final product could be obtained using a reductive amination between aldehyde 316 and 
piperazine 318. The aldehyde can be made by hydroboration of 317 and oxidation of the resulting 
alcohol. 317 can be made from an addition of di-tert-butylphosphonate to allyl bromide. Piperazine 318 
should be available through coupling of piperazin-1-amine 319 and maleic anhydride 320. The 
piperazine was protected with a boc protecting group to prevent cross reactivity (figure 79). 
 
 
 
 
150 
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 312 318 319 320 
Figure 79: Retrosynthetic analysis of compound 312. 
14.1 Synthesis of the bottom part 
Thus, synthesis of the piperazine moiety started with N-boc-piperazine, which was aminated using 
sodium nitrite, followed by reduction using zinc and acetic acid.[212] Synthesis of the urea was envisioned 
as a simple condensation between compound 319 and maleic anhydride 320. However, after starting 
the reaction using DIPEA in DCM, the reaction stalled at the intermediate amide stage 321. To make sure 
the urea ring closed an acetic anhydride promoted strategy was pursued, the results are summarized in 
table 48. 
Table 48: synthesis of piperazine 318. 
 
 319 320 321 318 
Reagents and conditions: maleic anhydride 320 (1 equiv), DCM, rt, 2.5 h then: evaporate DCM, reagent, 3 h. 
# Reagent (equiv) Temp (°C)a Resultb 
1c DIPEA (2) 50 321 
2c – rt 321 
3 Ac2O (42)  120 318:byproduct 1:1 
4 Ac2O (42), NaOAc (3) 120 318:byproduct 3:2 
5 Ac2O (42), NaOAc (3) 60 318:byproduct 4:1 
6 Ac2O (42), NaOAc (3) rt 321 
a: temperature for the acetic anhydride promoted ring closing reaction. b: ratios determined by 1H-NMR, no yields were determined. c: no acetic 
anhydride or sodium acetate was added. 
Running the reaction without any acid or base (entry 2) gave the same result as the reaction with DIPEA 
(entry 1). Next the acetic anhydride promoted ring closure reaction was performed by first heating the 
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piperazine 319 and maleic anhydride 320 together to form intermediate 321. Then acetic anhydride was 
added and the mixture was heated to 120°C for three hours. This led to a mixture of target molecule 318 
and an unidentified byproduct, likely an addition product from boc deprotection (entry 3). Adding 
sodium acetate to decrease the acidity of the reaction led to a more favorable ratio of 318 and the 
byproduct (entry 4). Finally, decreasing the temperature to 60°C gave a ratio of 4:1 of 318:byproduct 
(entry 5) as optimal conditions. After chromatographic purification this method delivered compound 
318 in 63 percent yield. Lowering the temperature further to room temperature to prevent the 
formation of the byproduct, only resulted in intermediate 321 (entry 6). It should be noted that after 
introduction of the maleimide moiety, the piperazine ring was present as a mixture of conformations. 
This mixture made NMR interpretation more difficult. In one case one of the conformers was isolated 
successfully; the fact that this is possible shows that there is little exchange between conformers. Since 
these two conformers are the same compound no further attempts were made to separate them. 
Compound 318 could be easily deprotected using a one-to-one mixture of TFA and DCM to yield the 
unprotected piperazine 322 (scheme 61), ready for coupling with the aldehyde 316. 
 
 318 322 
Scheme 61: Boc deprotection using TFA:DCM 1:1. Reagents and conditions: TFA:DCM 1:1, rt, 30 min, quantitative. 
Before moving to the synthesis of the full probe a test probe was  prepared to verify the behavior in the 
mass spectrometer. To this end compound 323 was synthesized, containing a methyl group on top of 
the piperazine. Initially, the attempts were made to methylate compound 323 using a reductive 
amination with formaldehyde or a substitution reaction with methyl iodide. The results are summarized 
in table 49. 
Table  49: attempted synthesis of 323. 
 
 322 323 
# Reagents (equiv) Solvent Result 
1 p-formaldehyde (5), NaBH3CN (5) MeCN Decomposition 
2 p-formaldehyde (5), NaBH3CN (5) EtOH:AcOH 1:1 Decomposition 
3 37 wt% formaldehyde (aq) (2), NaBH3CN (1.2) MeOH Decomposition 
4 MeI (1), DIPEA (1.2) THF Decomposition 
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The reductive amination strategy seemed attractive as it was planned to furnish the final probe 312 in 
the same manner. However, reductive amination using para-formaldehyde let to decomposition of the 
starting material (entries 1 and 2). Using an aqueous formaldehyde solution did not yield a different 
result (entry 3). It might be that the maleimide was susceptible to nucleophilic attack from the 
NaBH3CN, leading to its decomposition. Therefore, methyl iodide and DIPEA were investigated as 
methylation reagents. Unfortunately, a mixture of unidentified products was again obtained (entry 4).  
To obtain target molecule 323 a different strategy was used, instead of functionalizing compound 322. It 
was decided to synthesize 323 starting from commercially available 1-amino-4-methylpiperazine 324 
and maleic anhydride 320 (scheme 62).  
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 324 320 323 
Scheme 62: synthesis of compound 323. Reagents and conditions: maleic anhydride 320 (1 equiv), DCM, rt, 1 h then: evaporate DCM, acetic 
anhydride (42 equiv), sodium acetate (3 equiv), 50°C, 13 h, 94%. 
 Using conditions similar to those for the synthesis of 318 an excellent yield of the target compound 323 
was achieved. In a similar way compound 326 was synthesized from commercial 325, to provide a way 
to the phosphate through 327. 
 
 325 320 326 327 
Scheme 63: synthesis of compound 326. Reagents and conditions: maleic anhydride 320 (1 equiv), DCM, rt, 3.5 h then: evaporate DCM, acetic 
anhydride (42 equiv), sodium acetate (3 equiv), 50°C, 2.5 h, 33%. 
While the initial reaction to yield 326 proceeded albeit in a poor yield, the following deprotection to 
obtain 327 did not work. Several conditions were screened. The results are summarized in table 50. 
Table 50: attempted synthesis of 327. 
# Reagent (equiv) Solvent Result 
1 Cs2CO3 (0.1) MeOH Addition of methoxide 
2 MgOMe (0.1) MeOH Addition of methoxide 
3 H2SO4 (2.2) MeOH Decomposition 
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First the bases cesium carbonate and magnesium methoxide in methanol were investigated but both 
resulted in fast addition of methoxide to the maleimide (entries 1 and 2). Sulfuric acid in methanol led to 
complete decomposition of the starting material. 
Despite a failure to deliver 327 due to deprotection issues, compounds 322 and 323 were successfully 
synthesized to ensure continuation of the project. The next step was the synthesis of the phosphonate 
‘top’ part, required to furnish final probe 312. 
14.2 Synthesis of the top part 
Synthesis of the aldehyde 316 started with the literature synthesis of ditert-butylphosphonate 328 from 
phosphorus trichloride and tert-butanol.[213] Ditert-butylphosphonate 328 was then deprotonated with 
sodium hydride and allowed to react with allyl bromide 329, yielding allyl phosphonate 317 (scheme 64). 
 
 328 329 317 
Scheme 64: synthesis of allyl ditert-butylphosphonate 317. Reagents and conditions: allyl bromide (1.2 equiv), sodium hydride (1.1 equiv), THF, 
0°C to rt, 5 h, 70%. 
Allyl phosphonate was then subjected to hydroboration conditions followed by hydrogen peroxide 
oxidation to obtain the alcohol (scheme 65). Borane in THF was found to be a successful reagent, 
whereas 9-BBN did not result in any product. After oxidative work-up the target alcohol 330 was 
recovered in only 31 percent yield. While this yield is quite low it was decided to test the oxidation to 
the aldehyde before attempting to optimize the yield. 
 
 317 330 
Scheme 65: Hydroboration of 317. Reagents and conditions: a) BH3.THF (2.5 equiv), THF, rt, 1 h. b) MeOH (excess), 3M NaOH (aq) (7.5 equiv), 
30% H2O2 (aq) (22 equiv), 0°C to rt, 2 h, 31%. 
The oxidation of 330 was attempted by swern reaction and with Dess-Martin periodinane. In both cases 
there was full conversion of the starting alcohol and some of the target aldehyde was seen in NMR. 
However, none of the product could be isolated, instead a brown mixture of unidentified products was 
obtained. It seems likely that the target aldehyde 316 is not stable under the reaction conditions. 
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b)DMP  
 330 316 
Scheme 66: Attempted oxidation of 330. Reagents and conditions: a) oxalyl chloride (1.2 equiv), DMSO (2.4 equiv), Et3N (5 equiv), DCM, -78°C to 
rt, 2 h. b) DMP (1.2 equiv), DCM, rt, 4 h. 
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This project was not pursued further due to a shift in priorities. Future research might include the 
coupling of the alcohol 330 with 322 using a Mitsunobu reaction. Alternatively, oxidative cleavage of a 
longer alkene derivative osmium tetroxide and sodium periodate could be used to make related 
aldehydes that might be stable. If no stable aldehyde homolog can be found and other coupling 
methods coupling prove to be unsuccessful, the required molecule could still be made using a different 
strategy (figure 80).  
 
 
 
 331 332 
 
 
 312 333 334 335 
Figure 80: Alternative retrosynthetic analysis of compound 312. 
In this strategy the maleimide is introduced at the end of the sequence after converting protected 334 
into hydrazine 333, using similar conditions as described before (table 48). 334 could be made by metal 
catalyzed coupling of 331 and protected 335,[38] thereby bypassing unstable aldehyde 316. 331 should 
be easily available by reducing the corresponding azide, which can be made from bromide 332. Bromide 
332 can be synthesized by refluxing 1,3-dibromopropane and tri-tert-butylphosphite.[39] Alternatively, 
the bromide might also be accessed by a radical reaction between hydrogen bromide and allyl 
phosphonate 317. 
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15 Concluding remarks 
Post-translational modifications such as phosphorylation, methylation and adenylylation can alter 
protein function in a dynamic way. Phosporylation and dephosphorylation for example, have been 
shown to function as an on/off switch for proteins such as kinases. A good understanding of these 
processes can eventually lead to disease modifying drugs such as illustrated in the anti-cancer drug 
Gleevec. The short life-time of some post-translation modified residues, such as phosphorylated 
histidine, makes it impossible to study these processes using conventional biological methods.  
Synthetic chemistry can be a powerful method to generate tool compounds to better understand 
biological processes as illustrated in the projects described in this thesis. In this thesis, the design and 
synthesis of a stable 3-pHis analog and its incorporation into a peptide has been described. This peptide 
in turn was succsefully used to raise antibodies, which can be used to study phosphorylation of histidine 
in more detail. In addition, major advances have been made in the synthesis of a 1-pHis analog, an 
adenylyated histidine analog and a methylated arginine, which all can be used to raise their respective 
antibodies in the near future. With the completion of these syntheses even more antibodies to 
understand post-translational modifications can be added to the biological toolbox.  
Synthetically, the development of the tool compounds was challenging. Many different synthetic routes 
towards the 3-phis mimic were designed and pursued. The final synthetic strategy toward this mimic 
proved suitable to deliver multigram amounts of the mimic for future peptide synthesis campaigns. The 
synthesis started with cheap starting materials and used several innovative steps to get to the final 
product. Many difficulties have been overcome during the synthesis. The crucial transformations are 
highlighted in figure 81. Azide introduction to yield 66 was succesfully achieved by substitution of a 
triflate using TMGA. The difficulties to remove byproducts from the aza-wittig product, related to 
reagent PPh3, could successfully be circumvented by the use of dppe. Aromatization of the imidazoline 
was achieved using base induced elimination of the tosylate. The imidazole was successfully trityl 
protected using trityl chloride, silver triflate and DBU. Finally, facile protecting group manipulations led 
to the final product. 
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Figure 81: Highlights of the synthesis of 3-pHis mimic 65. 
With this synthetic route available, enough 65 has been synthesized to make a wide range of peptides 
available for antibody generation. The antibodies raised during the course of this project showed very 
good affinity. The high affinity likely reflects the electrostatic similarities of pHis and its stable analog, 
emphasizing the importance of a well thought out design of the mimic. These antibodies can now be 
used to detect the presence of pHis in various biological systems. This will aid in the study of the biology 
of phosphohistidine. 
The synthetic methodology used to prepare the 3-pHis method was further explored to generate a small 
library of 4-phosphonic acid imidazoles. It is expected that such a library will provide a valuable starting 
point for the discovery of inhibitors of phosphohistidine phosphatase.   
As mentioned above, the side projects have all generated important data on which future research can 
be build. Initial studies were performed towards the synthesis of a 1-phosphohistidine analog. It is 
expected that successful completion of this project will provide antibodies that will allow researchers to 
distinguish 1-pHis from 3-pHis containing proteins, thereby discovering the potentially different effects 
they have on biological systems. 
The synthesis of an adenylylated histidine mimic was also investigated. It is expected that only minimal 
efforts will be required to complete the synthesis of this compound. This adenylylated histidine mimic in 
turn can be used to raise antibodies for proteins that are adenylylated on histidine.  
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The work done in the Nδ-methylarginine project provided a first view into the chemistry of this 
unexpectedly hard to synthesize compound. While the synthesis did not result in the target compound, 
the suggested follow-up studies should enable its synthesis with relative ease. 
A version of the piperazine probe was successfully synthesized, allowing for proof of concept studies. 
The complete probe should be available following the suggestions at the end of the chapter and will aid 
proteomic studies focusing on palmitoylation and phosphorylation. 
In conclusion, this thesis provides a clear example of the power of chemical biology. Using rational 
design several tool compounds were designed and synthesized. This led to antibodies that can shed new 
light on important biological processes. The work in thesis also emphasizes that tool compounds needed 
for biological investigation can be difficult to synthesize. Therefore, a good knowledge of chemistry is 
essential for the success of chemical biological studies. 
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16 Experimental Section 
 
16.1 General remarks 
All chemicals were obtained from Acros, Aldrich, Alfa Aesar, Merck or Rapp Polymere and were used 
without further purification except when noted. Solvents were used as received; except 
dichloromethane, which was distilled from CaH2. 
1H, 13C and 31P NMR spectra were recorded on Varian 
Mercury 400- or a Bruker DRX 500 NMR spectrometer. Chemical shifts are reported in δ values relative 
to residual solvent peaks (Abbreviations: s: singlet, bs: broad singlet, d: doublet, dd: doublet of doublets, 
ad: apparent doublet, t: triplet, q: quartet, m: multiplet). Specific optical rotations were measured on a 
Schmidt + Haensch Polartronic HH8 Polarimeter. IR spectra were measured on a Bruker Tensor 27 with 
compounds deposited as a neat film onto the crystal. Column chromatography was performed using 
silica gel for chromatography (0.035-0.070 mm, 60A) purchased from Acros Organic. Compounds on TLC 
were visualized by UV and/or basic KMnO4 staining. High  resolution mass spectra  (HR-MS, 70  eV)  were  
measured  on  a  Thermo  Orbitrap,  coupled  to a Thermo  Accela  nano-HPLC machine,  using  electron  
spray  ionization (ESI).  Analytical  HPLC-MS  data were  recorded  on  an  Agilent  HPLC  (1100  series)  
coupled  to  a  Finnigan  LCQ  ESI spectrometer,  using  a Nucleodur C18 gravity column, ID 4 mm, length 
125 mm, particle size 3 µm from Macherey-Nagel. A gradient was applied beginning at 10% acetonitrile 
and ending at 90% after 15 min, followed by 3 min at 90% acetonitrile; finally, the column was washed 
for 5 min with 100% acetonitrile. The column was equilibrated for 3 min with 10% acetonitrile. All RP-
HPLC solvents contained TFA (0.1% v/v). Residence time (tR) was taken from the UV detector, unless 
otherwise noted. Chiral HPLC was performed on an Agilent 1100 system using a Diacel Chiralpak IA 
column, as mobile phase an isocratic mixture of 15% dichloromethane: ethanol (100:2) in hexanes was 
used, at a flow of 0.5 mL/minute over 60 minutes. 
 
16.2 Compound information 
 
 (S)-2-(((9H-Fluoren-9-yl)methoxy)carbonylamino)-3-(4-(bis(benzyloxy)phosphoryl)-1-trityl-1H-
imidazol-2-yl)propanoic acid (65): Under argon, in a 50 mL schlenk flask, equipped with an egg-shaped 
stirring bar, compound 136 (1.2 g, 1.52 mmol, 1 equiv) was dissolved in anhydrous THF (10 mL) and 
phenylsilane (822 mg, 0.94 mL, 7.6 mmol, 5 equiv) was added, followed by palladium 
tetrakis(triphenylphosphine) (173 mg, 0.15 mmol, 0.1 equiv). Immediately after addition was complete, 
the mixture turns yellow and bubbles are formed. As the mixture ages, it slowly turned black. After 1 
hour the reaction mixture was transferred to a 25 mL round bottom flask and the solvent was 
evaporated in vacuo. The residue was suspended in 4 mL mesitylene and evaporated to dryness on a 
rotary evaporator equipped with a dry ice cooler and an oil pump, this procedure was repeated twice to 
remove excess phenylsilane. The resulting black solid was not purified further and used ‘as is’ in the next 
step. 31P NMR (162 MHz, CDCl3) δ 12.91. Rf: 0.08 (chloroform:methanol 9:1). LC-MS (ESI): tR 7.71 min. 
HRMS (ESI): for [M+H]+ calc.: 658.24653, found: 658.24633. The crude reaction mixture (1.52 mmol) was 
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dissolved in dioxane (9 mL), upon complete dissolution, water (1 mL) was added followed by Fmoc-OSu 
(769 mg, 2.28 mmol 1.5 equiv) and sodium hydrogen carbonate (192 mg, 2.28 mmol, 1.5 equiv). The 
mixture was stirred at room temperature for 16 hours, when a TLC sample (Ethyl acetate or CHCl3 
containing 10% MeOH) indicated complete consumption of the starting material. Water (10 mL) and 
chloroform (10 mL) were added and the mixture was acidified to pH 4 with 0.5 M aqueous potassium 
hydrogen sulfate solution. The layers were separated and the aqueous layer was washed with 3 
additional portions of chloroform (10 mL), the organic layers were combined, washed with brine and 
dried over anhydrous sodium sulfate. Evaporation of the solvent yielded a black foam (2.16 g) that was 
further purified by C18 sep-pak cartridge (loading 100 mg compound per gram C18-material, 100% water 
to 100% acetonitrile in steps of 10%, each step 7 mL solvent per gram C18, compound eluted at 70- to 
90% acetonitrile), removal of the solvent by lyophilization yielded 1.1 g (1.24 mmol, 82%) of a brown 
amorphous solid. 1H NMR (500 MHz, CDCl3) δ 7.77 (d, J = 7.5 Hz, 2H), 7.57 (d, J = 7.2 Hz, 2H), 7.50 (d, J = 
7.2 Hz, 2H), 7.46 – 7.17 (m, 22H), 7.07 – 6.94 (m, 6H), 5.92 (bs, 1H), 5.14 (dd, J = 16.9, 9.0 Hz, 4H), 4.59 – 
4.48 (m, 1H), 4.32 – 4.18 (m, 2H), 4.13 (t, J = 6.9 Hz, 1H), 2.57 (d, J = 17.0 Hz, 1H), 1.80 (dd, J = 17.3, 9.4 
Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 172.18(C=O), 155.28(C=O),  150.38 (d, J = 19.1, C), 143.86 (C), 
141.34, 141.33, 140.50, 135.96 (d, J = 5.5, C), 135.92 (d, J = 5.8, 1xC), 134.34, 134.27, 131.36 (d, J = 35.8, 
CH), 129.81, [128.68, 128.64, 128.59, 128.45, 128.11, 128.07, 127.80, 127.15] this area is unrevolvable, 
125.24 (CH), 125.15 (CH), 120.07 (CH), 76.77 (C), 68.36 (d, J = 23.7, CH2), (d, J = 23.7, CH2), 67.16(CH2), 
51.65 (CH), 47.12 (CH), 34.01 (CH2). 
31P NMR (162 MHz, CDCl3) δ 10.61. Rf: 0.16 (chloroform:methanol 
95:5). LC-MS (ESI): tR = 10.99 min. HRMS (ESI): for [M+H]
+ calc.: 880.31461, found: 880.31426. []
 
+219.3°  (c=0.0023, CHCl3).  
 
 
Dibenzyl 1-azido-2-(4-methylphenylsulfonamido)ethylphosphonate (66): In a 250 mL three-necked, 
round bottom flask containing an egg-shaped stirrer bar, azide 117 (18.3 g, 29.4 mmol, 1 equiv) was 
dissolved in 1,4-dioxane (130 mL). After complete solution of the starting material, water (15 mL) and 
ceric ammonium nitrate (48.4 g, 88.2 mmol, 3 equiv) were added, turning the mixture bright orange. 
After 6.5 hours TLC showed a small amount of starting material remaining, in order to drive the reaction 
to completion, additional portions of ceric ammonium nitrate (2 g,) and water (5 mL) were added. After 
stirring for an additional 15 minutes, TLC indicated complete conversion of the starting material. The 
reaction mixture was partitioned between water (200 mL) and ethyl acetate (200 mL), the aqueous layer 
was washed with additional ethyl acetate (2 x 100 mL), the organic layers were combined, washed with 
brine (100 mL) and dried over anhydrous magnesium sulfate. Evaporation yielded an orange oil that was 
purified by flash column chromatography (toluene:ethyl acetate 24:1 in increasing gradient to 4:1) 
evaporation of the solvent yielded a yellow oil (12 g, 24 mmol, 81%). 1H NMR (500 MHz, CDCl3) δ 7.75 
(ad, J = 8.3, 2H), 7.41 – 7.30 (m, 10H), 7.22 (ad, J = 8.2, 2H), 6.40 (t, J = 6.2, 1H), 5.16 – 5.00 (m, 4H), 3.95 
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– 3.82 (m, 1H), 3.47 – 3.35 (m, 1H), 3.22 – 3.09 (m, 1H), 2.37 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 143.4, 
136.7, 135.3 (d, J = 5.4, 1C), 135.3 (d, J = 5.5, 1C), 129.6, 128.6 (br, 2x2C), 128.5 (br, 2x2C), 128.0 (br, 
2x2C), 126.9, 68.6 (d, J = 6.9, 2C), 57.5 (d, J = 154.1, 1C), 42.3 (d, J = 5.1, 1C), 21.3. 31P NMR (162 MHz, 
CDCl3) δ 20.9. IR ν = 3151 (bw), 3066 (w), 3035 (w), 2894 (bw), 2107 (s), 1598 (w), 1497 (w), 1455 (m), 
1331 (s), 1238 (s), 1157 (s), 1092 (w), 990 (s), 873 (m), 813 (s), 732 (s), 696 (s), 660 (s). Rf: 0.34 
(toluene:ethyl acetate 2:1). LC-MS (ESI): tR = 9.39 min. HRMS (ESI): for [M+H]
+ calc. 501.13560, found 
501.13500. 
 
 (2S)-Allyl 2-(allyloxycarbonylamino)-3-(4-(bis(benzyloxy)phosphoryl)-1-tosyl-4,5-dihydro-1H-imidazol-
2-yl)propanoate (68): Under argon, in a 250 mL, flame dried schlenk flask azide 119 (2.7g, 3.6 mmol, 1 
equiv) was dissolved in anhydrous THF (80 mL), 1,2-Bis(diphenylphosphino)ethane (dppe) (2.2 g, 5.4 
mmol, 1.5 equiv) was added in one portion. The schlenk flask was closed and immersed in an 80oC oil 
bath for 6 hours, after which the reaction mixture was allowed to cool just below boiling. A solution of 
hydrogen peroxide (30% in water) (15 mL) and saturated aqueous sodium hydrogen carbonate (15 mL) 
was added and the mixture was stirred for 10 minutes. When TLC indicated that no trace of un-oxidized 
DPPE remained, the mixture was transferred to a separatory funnel, chloroform (100 mL) and saturated 
aqueous sodium hydrogen carbonate (100 mL) were added, layers separated and the aqueous layer was 
washed with additional portions of chloroform (2 x 75 mL). Organic layers were combined, washed with 
brine (100 mL) and dried over sodium sulfate, evaporation yielded an off-white sticky solid that was 
further purified by filtration through a 4 cm high plug of silica eluting with chloroform:ethyl acetate 3:1, 
yielding 68 as a yellow oil as a mixture of diastereoisomers (1:1.24 by 31P-NMR) (2.5 g, 3.5 mmol, 98%). 
1H NMR (400 MHz, CDCl3) δ 7.84 – 7.66 (m, J = 8.3, 2H), 7.44 – 7.18 (m, 12H), 6.22 – 5.71 (m, 3H), 5.38 – 
5.06 (m, 4H), 5.05 – 4.87 (m, 4H), 4.83 – 4.70 (m, J = 4.3, 9.0, 1H), 4.64 – 4.39 (m, 4H), 4.24 – 4.08 (m, 
1H), 4.05 – 3.74 (m, 2H), 3.55 – 3.34 (m, 1H), 3.14 – 2.93 (m, 1H), 2.45 – 2.35 (m, 3H). 13C NMR (101 
MHz, CDCl3) δ 170.5, 170.3, 159.3, 159.2, 156.2, 156.1, 145.19, 145.15, 136.17, 136.11, 136.06, 136.00, 
134.96, 134.91, 132.8, 131.9, 131.8, 130.4, 128.73, 128.68, 128.65, 128.61, 128.03, 128.01, 127.99, 
127.3, 118.4, 118.3, 118.0, 117.8, 68.78, 68.75, 68.71, 68.69, 68.40, 68.33, 68.26, 68.19, 66.30, 66.12, 
66.05, 65.96, 62.0, 61.9, 60.4, 60.3, 51.1, 50.8, 48.96, 48.92, 48.89, 48.83, 32.5, 32.1, 21.74, 21.73. 31P 
NMR (162 MHz, CDCl3) δ 22.7, 22.2. Rf: 0.36 (chloroform:ethyl acetate 3:1). LC-MS (ESI): tR = 10.61 min. 
HRMS (ESI): for [M+H]+ calc.: 696.21391, found: 696.21318. 
 
N-((1,3-Dioxolan-2-yl)methyl)-4-methylbenzenesulfonamide (69): In a 250 ml round bottom schlenk 
flask, equipped with a large egg-shaped stirring bar, under argon, (1,3-dioxolan-2-yl)methanamine (2.5 
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g, 2.3 mL, 24 mmol, 1 equiv) was dissolved in anhydrous dichloromethane (25 mL), the mixture was 
cooled to 0oC with an ice bath and triethylamine (2.4 g, 3.4 mL, 24 mmol, 1 equiv) was added followed 
by 4-dimethylaminopyridine (30 mg, 0.24 mmol, 0.01 equiv). Tosyl chloride (4.6g, 24 mmol, 1 equiv) was 
dissolved in 25 mL anhydrous dichloromethane containing 1 mL anhydrous THF to aid solvation. The 
tosyl chloride solution was added to the reaction mixture at 0oC, dropwise, over 5 minutes. After 
addition was complete the mixture was allowed to warm to room temperature with the ice bath in 16 
hours. The mixture was added to 50 mL dichloromethane and was washed 3 times with 10% aqueous 
citric acid (100 mL), once with water (100 mL), 3 times with 5% aqueous sodium carbonate (100 mL) and 
once with brine (100 mL). The mixture was dried over anhydrous magnesium sulfate and the solvent was 
evaporated yielding 5.7 g (22 mmol, 93 %) of a white solid. 1H NMR (400 MHz, CDCl3) δ 7.84 – 7.70 (m, 
2H), 7.00 – 6.90 (m, 2H), 4.96 (t, J = 6.3, 1H), 4.89 (t, J = 3.8, 1H), 3.92 – 3.73 (m, 7H), 3.11 (dd, J = 3.8, 
6.4, 2H). 13C NMR (101 MHz, CDCl3) δ 162.94, 131.70, 129.27 (2xCH), 114.27 (2xCH), 101.53, 65.34 
(2xCH2), 55.70, 45.51. Rf: 0.23 (toluene:ethyl acetate 3:1). Melting point: 106.9
oC. LC-MS (ESI): tR = 6.87 
min. The compound is poorly visible in the MS. 
 
Dibenzyl 5-iodo-1-trityl-1H-imidazol-4-ylphosphonate (73):  Under argon, in a 50 mL Schlenk imidazole 
167 (500 mg, 0.88 mmol, 1 equiv) was dissolved in 5 mL THF. The mixture was cooled to -30°C and 1.6M 
butyl lithium in hexanes (0.6 mL, 1.0 mmol, 1.1 equiv) was added dropwise. The mixture was stirred for 
30 minutes, followed by the addition of Iodine (330 mg, 1.3 mmol, 1.5 equiv) dissolved in 1 mL THF until 
the iodine color persisted. The mixture was poured into sat. aqueous sodium thiosulfate solution (15 mL 
and ethyl acetate (15 mL). The aqueous layer was washed with three additional 10 mL portions of ethyl 
acetate, the organic layers were combined, washed with brine (30 mL), dried over magnesium sulfate 
and the solvent was removed in vacuo. The resulting white foam was further purified by flash column 
chromatography (toluene:ethyl acetate 2:1) yielding 0.326 g (0.47 mmol, 53%) of a white foam. 1H NMR 
(400 MHz, CDCl3) δ 7.60 (d, J = 2.6 Hz, 1H), 7.41 – 7.28 (m, 20H), 7.16 – 7.08 (m, 6H), 5.22 – 5.09 (m, 4H). 
31P NMR (162 MHz, cdcl3) δ 11.75. LC-MS (ESI): tR = 10.72 min. HRMS (ESI): for [M+H]
+ calc.: 571.21451, 
found: 571.21491. 
 
 
Dibenzyl 1-amino-2-(tert-butyldimethylsilyloxy)ethylphosphonate (75): Azide 173 (3.7 g, 8.02 mmol, 1 
equiv) was dissolved in 22 mL ethanol and 7 mL water. Ammonium chloride (0.98 g, 18.4 mmol, 2.3 
equiv) was added followed by zinc powder (1.6 g, 24.1 mmol, 3 equiv). After stirring for 30 minutes the 
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reaction was poured into saturated ammonia (50 mL) and ethyl acetate (50 mL). The layers were 
separated and the aqueous phase was washed with 3 additional portion of ethyl acetate (30 mL), the 
organic layers were combined, washed with brine and dried over anhydrous sodium sulfate. Evaporation 
of the solvent yielded 75 as a yellow oil (3.1 g, 7.1 mmol, 89%). 1H NMR (400 MHz, CDCl3) δ = 7.36 – 7.23 
(m, 10H), 5.13 – 4.90 (m, 4H), 3.90 – 3.78 (m, 1H), 3.71 (ddd, J=10.2, 7.5, 6.1, 1H), 3.18 (ddd, J=13.1, 7.5, 
3.7, 1H), 1.58 (s, 2H), 0.84 (s, 9H), 0.00 (s, 3H), -0.00 (s, 3H). 31P NMR (162 MHz, CDCl3) δ = 28.34. LC-MS 
(ESI): tR = 8.47 min. HRMS (ESI): for [M+H]
+ calc.: 436.20675, found: 436.20671. 
  
(S)-Allyl 2-(allyloxycarbonylamino)-4-amino-4-thioxobutanoate (78): under argon, in a 50 mL round 
bottom flask, (S)-allyl 2-(((allyloxy)carbonyl)amino)-4-amino-4-oxobutanoate (494 mg, 1.9 mmol, 1 
equiv) was dissolved in THF (7.5 mL). Lawesson’s reagent (389 mg, 0.96 mmol, 0.5 equiv) was added and 
the mixture was stirred for four hours. The reaction mixture was partitioned between saturated 
aqueous sodium bicarbonate solution (20 mL) and ethyl acetate (20 mL). The layers were separated and 
the aqueous phase was washed with 3 additional portion of ethyl acetate (20 mL), the organic layers 
were combined, washed with brine (20 mL) and dried over anhydrous sodium sulfate. After evaporation 
of the solvent the residue was further purified by flash column chromatography (chloroform:ethyl 
acetate 3:1) yielding 453 mg (1.7 mmol, 88%) of a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 
1H NMR (400 
MHz, CDCl3) δ = 7.47 (bs, 1H), 7.32 (bs, 1H), 6.00 (bd, J=6.5, 1H), 5.91 – 5.75 (m, 2H), 5.35 – 5.10 (m, 4H), 
4.70 – 4.62 (m, 1H), 4.60 (ddd, J=5.8, 2.8, 1.4, 2H), 4.51 (dt, J=5.6, 1.4, 2H), 3.30 – 3.06 (m, 2H). LC-MS 
(ESI): tR = 7.30 min. HRMS (ESI): for [M+H]
+ calc.: 273.09035, found: 273.09052. 
 
Dibenzyl 2-azido-1-(4-methylphenylsulfonamido)ethylphosphonate (90): In a 25 mL round bottom 
flask, containing an egg-shaped stirring bar, aziridine 91 (595 mg, 1.3 mmol, 1 equiv) was dissolved in 8.6 
mL DMF. Sodium azide (106 mg, 1.6 mmol, 1.25 equiv) was added in one batch, changing the clear 
solution to a white suspension. After stirring overnight, a TLC sample indicated complete consumption 
of the starting materials. The DMF was evaporated in vacuo and the residue partitioned between water 
(10 mL) and ethyl acetate (10 mL). The aqueous layer was washed once with 10 mL of ethyl acetate, the 
organic layers were combined, washed with brine (10 mL) and dried over anhydrous magnesium sulfate. 
Evaporation of the solvent yielded a grey oil that was further purified by filtering through a silica plug (3 
cm high, 25% ethyl acetate in toluene) yielding a grey oil (509 mg, 1 mmol, 78%). Rf: 0.24 (toluene:ethyl 
acetate 3:1). 1H NMR (400 MHz, CDCl3) δ 7.77 – 7.61 (m, 2H), 7.33 – 7.05 (m, 12H), 6.06 (dd, J = 3.9, 9.4, 
1H), 5.03 – 4.73 (m, 4H), 3.91 – 3.73 (m, 1H), 3.54 – 3.31 (m, 2H), 2.29 (s, 3H). 13C NMR (101 MHz, CDCl3) 
δ 143.79 (C), 137.90 (C), 135.70 (d, J = 30.3, CH), 135.64 (d, J = 30.6, CH), 129.76 (CH), 128.86 (C), 128.78 
(CH), 128.77 (CH), 128.34 (CH), 128.31 (CH), 127.18 (CH), 68.94 (d, J = 78.3, CH2), 68.87 (d, J = 78.4, CH2), 
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51.32 (CH2), 50.56 (d, J = 163.9, CH), 21.65 (CH3). 
31P NMR (162 MHz, CDCl3) δ 21.94. IR: 3114 (w), 2922 
(w), 2103 (s), 1332 (s), 1235 (s), 1160 (s), 995 (s), 814 (m), 735 (s). LC-MS (ESI): tR = 9.30 min. HRMS (ESI): 
for [M+H]+ calc.: 501.13560, found: 501.13514. 
 
Dibenzyl 1-tosylaziridin-2-ylphosphonate (91): Under argon, a schlenk tube containing a magnetic 
stirring bar was charged with sulphonamide (94) (710 mg, 1.5 mmol, 1 equiv), triphenylphosphine (394 
mg, 1.5 mmol, 1 equiv) and 3 mL anhydrous THF. The solution was cooled to 0oC and 
dimethylazodicarboxylate (219 mg, 1.5 mmol, 1 equiv) was added dropwise, upon complete addition the 
mixture is stirred at 0oC for 30 minutes followed by warming to room temperature over 1 hour. Water (5 
mL) and diethyl ether (5 mL) were added, the layers were separated and the organic layer washed with 
2 additional 5 mL portions of water. The organic layer was washed with brine, dried over anhydrous 
magnesium sulfate and the solvent removed in vacuo. The resulting oil was purified by column 
chromatography (toluene 25% ethyl acetate) yielding 639 mg (1.4 mmol, 93%) of a clear oil. Rf: 0.54 
(toluene:ethyl acetate 1:1). 1H NMR (400 MHz, CDCl3) δ 7.86 – 7.77 (m, 2H), 7.40 – 7.20 (m, 12H), 5.04 – 
4.83 (m, 4H), 2.87 (ddd, J = 4.6, 7.6, 16.4, 1H), 2.67 (dd, J = 7.6, 9.3, 1H), 2.44 (dd, J = 4.6, 9.4, 1H), 2.39 
(s, 3H). 13C NMR (101 MHz, CDCl3) δ 145.31, 135.73 (d, J = 13.4, 1C), 135.67 (d, J = 13.0, 1C), 134.01, 
129.88 (2xCH), 128.79, 128.72 (2xCH), 128.64 (2xCH), 128.62, 128.37 (2xCH), 128.19 (2xCH), 128.04 
(2xCH), 68.64 (d, J = 31.7, 1C), 68.58 (d, J = 31.7, 1C), 31.83 (d, J = 207.5, 1C), 30.26 (d, J = 4.4, 1C), 21.75. 
31P NMR (162 MHz, CDCl3) δ 18.84. LC-MS (ESI): tR = 10.01 min. HRMS (ESI): for [M+H]
+ calc.: 458.11856, 
found: 458.11846. 
 
Dibenzyl 1-hydroxy-2-(4-methylphenylsulfonamido)ethylphosphonate (336): 
Method A: In a 100 mL three-necked round bottom flask, vinyl dibenzylphosphonate (1 g, 3.47 mmol, 1 
equiv) was dissolved in chloroform (17.5 mL). To this mixture chloramine T trihydrate (223 mg, 4.34 
mmol, 1.25 equiv), benzyl triethylammonium chloride (40 mg, 0.17 mmol, 0.05 equiv), water (17.5 mL) 
and osmium tetroxide as a 2.5% solution in tert-butanol (0.44 mL, 0.035 mmol, 0.01 equiv) were 
sequentially added. On addition of the osmium tetroxide the mixture changes from a pink suspension to 
a green clear solution. The mixture was heated to 60oC over 16 hours, after which the mixture turned 
had brown. After confirming complete conversion with a TLC sample, sodium bisulfite (361 mg, 3.47 
mmol, 1 equiv) was added and the mixture stirred for one hour, turning the reaction black. The mixture 
was poured into a separatory funnel, the layers were separated, the organic layer was washed with 
brine (10 mL) and dried over anhydrous magnesium sulfate. Evaporation of the solvent yielded 1.5 g of a 
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brown oil that was purified further by flash column chromatography (toluene : ethyl acetate 1 : 1) 
yielding 0.82 g (1.7 mmol, 50%) of a yellow oil that solidified on standing. 
Method B: In a 100 mL round bottom flask, containing an egg-shaped stirring bar, hydroxysulfonamide 
117 (2 g, 3.36 mmol, 1 equiv) was dissolved in 15.3 mL 1,4-dioxane, water (1.7 mL) was added followed 
by ceric ammonium nitrate (5.5 g, 10.1 mmol, 3 equiv) and the orange mixture was stirred for 8 hours. 
After confirming the complete conversion of the starting material with a TLC sample, the reaction 
mixture was poured into ethyl acetate (30 mL) and water (30 mL). The layers were separated, the 
aqueous layer was washed with two additional 15 mL portions of ethyl acetate, the organic layers were 
combined and washed with brine (50 mL). After drying over anhydrous magnesium sulfate, the solvent 
was evaporated yielding a yellow oil that was purified further by flash column chromatography 
(toluene:ethyl acetate 1:1) yielding 1.28 g (2.7 mmol, 80%) of an orange oil that solidified on standing. 
Rf: 0.28 (toluene:ethyl acetate 1:1). 
1H NMR (400 MHz, CDCl3) δ = 7.70 (d, J=8.2, 2H), 7.37 – 7.25 (m, 
10H), 7.20 (d, J=8.5, 2H), 5.99 (dd, J=7.1, 5.1, 1H), 5.10 – 4.97 (m, 4H), 4.86 (bs, 1H), 4.09 (bs, 1H), 3.42 – 
3.29 (m, 1H), 3.28 – 3.14 (m, 1H), 2.37 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 143.65, 136.86, 136.01 (d, 
J=5.7), 129.94, 128.86, 128.84, 128.81, 128.79, 128.27, 127.33, 68.82 (d, J=7.1), 67.39 (d, J=161.8), 44.71 
(d, J=6.5), 21.72. 31P NMR (162 MHz, CDCl3) δ = 23.72. LC-MS (ESI): tR = 8.82 min. HRMS (ESI): for [M+H]
+ 
calc.: 476.12912, found: 476.12885. 
 
Diethyl 2-azido-1-(4-methylphenylsulfonamido)ethylphosphonate (337):  In a 25 mL round bottom 
flask, containing an egg-shaped stirring bar, 595 mg (1.3 mmol, 1 equiv) of aziridine 91 was dissolved in 
8.6 mL DMF. Sodium azide (106 mg, 1.6 mmol, 1.25 equiv) was added at room temperature and the 
resulting mixture was stirred for 16 hours at room temperature during which the mixture changed from 
a clear solution into a white suspension. A TLC sample confirmed complete consumption of the starting 
material. The DMF was evaporated on a rotary evaporator with a dry ice condenser and an oil pump. 
The residue was partitioned between water (20 mL) and ethyl acetate (20 mL), the aqueous layer was 
washed with two additional 20 mL portions of ethyl acetate, the organic layers were combined, washed 
with brine, dried over anhydrous magnesium sulfate and the solvent was evaporated yielding a yellow 
oil. This was further purified by passing through a short (3 cm) silica column (toluene 25% ethyl acetate) 
yielding a clear oil (509 mg, 1 mmol, 78%). 1H NMR (400 MHz, MeOH-d4) δ 7.82 – 7.75 (m, 2H), 7.44 – 
7.30 (m, 2H), 4.24 – 3.99 (m, 4H), 3.96 – 3.83 (m, 1H), 3.55 – 3.33 (m, 2H), 2.42 (s, 3H), 1.30 (t, J = 7.1, 
3H), 1.28 (t, J = 7.1, 3H). 13C NMR (101 MHz, MeOH-d4) δ 144.97, 140.25, 130.80 (2xCH), 128.23 (2xCH), 
64.90 (d, J = 50.1, 1H), 64.83 (d, J = 50.0, 1H), 52.43 (d, J = 5.9, 1H), 52.36 (d, J = 6.7, 1H), 50.87 (the 
second peak of the doublet is obfuscated by the methanol peak), 21.60, 16.83 (d, J = 10.6, 1H), 16.77 (d, 
J = 10.8, 1H). 31P NMR (162 MHz, MeOH-d4) δ 25.78. IR: 3103 (bw), 2992 (w), 2885 (w), 2099 (s), 1753 
(w), 1666 (w), 1596 (w), 1468 (w), 1441 (w), 1394 (w), 1332 (s), 1304 (w), 1279 (w), 1243 (w), 1225 (s), 
1191 (m), 1157 (s), 1109 (m), 1090 (m), 1025 (s), 984 (s), 953 (s), 921 (s), 846 (w), 823 (s), 798 (m), 761 
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(w), 705 (w), 663 (s). Rf: 0.24 (toluene:ethyl acetate 3:1). LC-MS (ESI): tR = 8.26 min. HRMS (ESI): for 
[M+H]+ calc.: 377.10430, found: 377,10395. 
 
Compound 96: Under argon, in a 5 mL, flame dried, schlenk flask containing an egg-shaped stirring bar, 
Azide 338 (30 mg, 0.08 mmol, 1 equiv) and amino acid 67 (33 mg, 0.09 mol, 1.1 equiv) were dissolved in 
0.4 mL anhydrous dichloromethane. After cooling to 0oC, PyBrOP (42 mg, 0.09 mmol, 1.1 equiv), DIPEA 
(31 mg, 0.24 mmol, 3 equiv) and DMAP (12 mg, 0.1 mmol, 1.25 equiv) were added sequentially. After 
stirring the resulting mixture for 3.5 hours, a TLC confirmed complete conversion of the azide. The 
mixture was poured into 10% citric acid (5 mL), the layers were separated and the aqueous layer was 
washed twice with dichloromethane (5 mL). The organic layers were combined, washed with saturated 
aqueous sodium hydrogen carbonate solution (5 mL), water (5 mL) and brine (5 mL). Drying over 
anhydrous magnesium sulfate, followed by evaporation of the solvent, yielded a yellow oil that was 
purified further by flash column chromatography (Petroleum ether:ethyl acetate 1:1) yielding 13.6 mg 
(0.02 mmol, 28%) of a yellow oil as a mixture of diastereoisomers (1:1 by 31P-NMR). 1H NMR (400 MHz, 
CDCl3) δ 8.01 – 7.76 (m, 2H), 7.36 – 7.28 (m, 2H), 5.99 – 5.56 (m, 3H), 5.27 – 5.07 (m, 4H), 4.55 – 4.31 (m, 
5H), 4.25 – 3.86 (m, 4H), 3.86 – 3.61 (m, 2H), 3.55 – 3.12 (m, 2H), 3.08 – 3.00 (m, 1H), 2.40 – 2.37 (m, 
3H), 1.34 – 1.12 (m, 6H). 31P NMR (162 MHz, CDCl3) δ 21.19, 20.64. 
 
Diethyl (1-azido-2-(4-methylphenylsulfonamido)ethyl)phosphonate (97): in a 5 mL round bottom flask, 
azide 116 (123 mg, 0.25 mmol, 1 equiv) was dissolved in acetonitrile:water 5:1 (1.25 mL). CAN (411 mg, 
0.75 mmol, 3 equiv) was added and the mixture was stirred for 6 hours and poured into ethyl acetate 
(10 mL). The organic phase was washed six times with saturated sodium bisulfite (10 ml) to remove the 
aldehyde. The organic layer was washed with brine (10 mL) and dried over anhydrous magnesium 
sulfate. The solvent was evaporated yielding an orange oil (67 mg, 0.18 mmol, 71%). 1H NMR (400 MHz, 
CDCl3) δ 7.88 – 7.77 (m, 2H), 7.77 – 7.69 (m, 2H), 5.25 – 5.12 (m, 1H), 4.24 – 4.04 (m, 4H), 3.66 (ddd, J = 
11.5, 8.8, 4.9 Hz, 1H), 3.44 – 3.29 (m, 1H), 3.19 – 3.01 (m, 1H), 2.49 – 2.34 (m, 3H), 1.41 – 1.28 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ 144.03, 136.92, 130.02, 127.21, 77.48, 77.37, 77.16, 76.84, 63.67 (d, J = 6.7 
Hz), 63.60 (d, J = 6.5 Hz), 57.03 (d, J = 153.6 Hz), 42.52 (d, J = 3.7 Hz), 21.68, 16.60 (d, J = 5.5 Hz), 16.57 
(d, J = 5.5 Hz). 31P NMR (162 MHz, CDCl3) δ 20.07. 
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Diethyl 1,2-dibromoethylphosphonate (99): In a 100 mL three-necked flask, vinyl diethylphosphonate (1 
g, 6.1 mmol, 1 equiv) was dissolved in chloroform (7.7 mL). Bromine (0.99 g, 6.2 mmol, 1.02 equiv) was 
added dropwise over 5 minutes. The resulting brown solution was stirred for 3 hours, after which it was 
poured into 5% aqueous sodium thiosulfate (20 mL), chloroform (10 mL) was added, the layers were 
separated and the aqueous layer was washed once with an additional 20 mL portion of chloroform, the 
organic layers were combined, washed with brine and dried over anhydrous sodium sulfate. Evaporation 
of the solvent yielded 2.1 g (quantitative yield) of a colorless oil. 1H NMR (400 MHz, CDCl3) δ = 
1H NMR 
(400 MHz, CDCl3) δ = 4.37 – 4.16 (m, 4H), 4.16 – 3.92 (m, 2H), 3.69 – 3.59 (m, 1H), 1.37 (tt, J=7.1, 0.6, 
6H). 13C NMR (126 MHz, CDCl3) δ = 64.19 (d, J=29.8), 64.13 (d, J=29.8), 41.96 (d, J=151.1), 31.94 (d, 
J=2.5), 16.35 (d, J=5.7). 31P NMR (162 MHz, CDCl3) δ = 16.91. LC-MS (ESI): tR = 8.01 min. HRMS (ESI): for 
[M+H]+ (Br2) calc.: 322.90418, found: 322.90514. (
81BrBr) calc.: 324.90214, found: 324.90256. (81Br2) 
calc.: 326.90009, found: 326.90024. 
 
Diethyl (1-bromovinyl)phosphonate (101): In a 5 mL round bottom flask, dibromo compound 99 (30 
mg, 0.09 mmol, 1 equiv) was dissolved in DMF (0.45 mL). Sodium azide (48 mg, 0.74 mmol, 8 equiv) was 
added and the mixture was stirred at room temperature for three hours. The solvent was removed in 
vacuo and the residue was dissolved in water (5 mL) and ethyl acetate (5 mL). The layers were separated 
and the organic layer was washed with brine (5 mL), dried over anhydrous magnesium sulfate and the 
solvent was removed in vacuo yielding 32 mg (full conversion) of a yellow oil that was not purified 
further. 1H NMR (400 MHz, CDCl3) δ 6.90 (dd, J = 14.4, 1.8 Hz, 1H), 6.45 (dd, J = 37.2, 1.8 Hz, 1H), 4.26 – 
4.03 (m, 4H), 1.37 (td, J = 7.1, 0.7 Hz, 6H). 31P NMR (162 MHz, CDCl3) δ 9.12. 
 
Diethyl 1-hydroxy-2-(4-methylphenylsulfonamido)ethylphosphonate (102): In a 250 mL, three necked, 
round bottom flask containing an egg-shaped stirring bar, diethyl vinylphosphonate (5 g, 4.7 mL, 30.5 
mmol, 1equiv) was dissolved in 115 mL tert-butanol and 35 mL water was added. Chloramine-T (10.7 g, 
38.1 mmol, 1.25 equiv) was added in one batch, followed by osmium tetroxide as a 2.5% solution in tert-
butanol (3.8 mL, 0.3 mmol). Resulting mixture is stirred overnight, after which a TLC sample indicated 
complete consumption of the starting material. A solution of sodium hydrogensulfate (4g) in 50 mL 
water was added to reduce the osmium catalyst, after stirring for 2 hours the mixture was transferred to 
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a separatory funnel and extracted with four 100 mL portions of chloroform. The organic layers were 
combined and washed with saturated sodium hydrogencarbonate (100 mL), water (100 mL) and brine 
(100 mL), followed by drying over anhydrous magnesium sulfate and evaporation of the solvent yielding 
a dirty solid. Final purification by flash column chromatography (chloroform 50% ethyl acetate) and 
evaporation of the fractions yielded a white solid (5.1 g, 14.4 mmol, 47%). Rf: 0.38 (chloroform:methanol 
9:1). Melting point: 70.9oC. 1H NMR (400 MHz, CDCl3) δ 7.70 (ad, J = 8.3, 2H), 7.24 (ad, J = 7.9, 2H), 6.05 
(dd, J = 4.9, 7.2, 1H), 5.02 – 4.92 (m, 1H), 4.16 – 4.01 (m, 4H), 4.01 – 3.89 (m, 1H), 3.36 – 3.18 (m, 1H), 
3.18 – 3.00 (m, 1H), 2.36 (s, 3H), 1.25 (dd, J = 7.2, 14.9, 6H). 13C NMR (101 MHz, CDCl3) δ 143.57, 137.00, 
129.88 (2xCH), 127.28 (2xCH), 67.00 (d, J = 162.9, 1H), 63.48 (d, J = 7.9, CH2), 63.40 (d, J = 7.5, CH2), 
44.72 (d, J = 7.1, 1H), 21.67, 16.58 (d, J = 5.6, CH3), 16.57 (d, J = 5.5, CH3). 
31P NMR (162 MHz, CDCl3) δ 
22.93. LC-MS (ESI): tR = 6.87 min. HRMS (ESI): for [M+H]
+ calc.: 352.09782, found: 352.09828.  
 
Diethyl (2-oxido-3-tosyl-1,2,3-oxathiazolidin-5-yl)phosphonate (103): Under argon, in a 50 mL, flame 
dried schlenk flask, alcohol 102 (575 mg, 1.64 mmol, 1 equiv) was dissolved in 3.7 mL anhydrous THF. 
The mixture was cooled to -45C and thionyl chloride (166 µL, 273 mg, 2.29 mmol, 1.4 equiv) was added 
dropwise over 2 minutes. Pyridine (330 µL, 324 mg, 4.1 mmol, 2.5 equiv) was added dropwise over 10 
minutes, after addition was complete the mixture was stirred at the same temperature for one hour, 
before being allowed to warm to rt, the solution changed into a thick white suspension during this time. 
After stirring for an additional hour saturated aqueous sodium bicarbonate (10 mL) was added followed 
by 10 mL ethyl acetate. The layers were separated and the aqueous phase was washed with one 
additional portion of ethyl acetate (10 mL), the organic layers were combined, washed with brine (20 
mL) and dried over anhydrous sodium sulfate. After evaporation of the solvent the residue (633 mg) was 
used in the next reaction without further purification. 1H NMR (400 MHz, CDCl3) δ = 
1H NMR (400 MHz, 
CDCl3) δ = 7.80 – 7.71 (m, 2H), 7.36 – 7.27 (m, 2H), 5.24 (ddd, J=10.7, 6.8, 4.0, 1H), 4.19 – 4.08 (m, 4H), 
3.63 (dddd, J=19.7, 13.0, 8.8, 7.2, 2H), 2.39 (s, 3H), 1.26 (t, J=7.1, 6H). 31P NMR (162 MHz, CDCl3) δ = 
14.75. LC-MS (ESI): tR = 8.57 min. HRMS (ESI): for [M+H]
+ calc.: 398.04916, found: 398.04894. 
 
1-(Diethoxyphosphoryl)-2-(4-methylphenylsulfonamido)ethyl methanesulfonate (107): At -10°C, in a 
round bottom flask alcohol 102 (100 mg, 0.29 mmol, 1 equiv) was dissolved in 1.1 mL dichloromethane. 
Triethylamine (87 mg, 120 µL, 0.86 mmol, 3 equiv) and mesyl chloride (65 mg, 44 µL, 0.57 mmol, 2 
equiv) were sequentially added. The mixture was stirred at the same temperature for 15 minutes and 
then allowed to warm to room temperature over one hour. The mixture was poured into water (5 mL) 
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and dichloromethane (5 mL) was added. The phases were separated and the aqueous phase was 
washed with two additional 5 mL portions of dichloromethane. The organic layers were combined and 
washed with 10% aqueous sodium bicarbonate (10 mL), brine (10 mL) and dried over anhydrous 
magnesium sulfate. The solvent was evaporated yielding 115 mg (0.25 mmol, 85% (corrected for 10 
percent residual starting material by NMR)) of a clear oil that was used in the next reaction without 
further purification. 1H NMR (400 MHz, CDCl3) δ 7.75 – 7.71 (m, 2H), 7.31 – 7.27 (m, 2H), 5.75 (t, J = 6.3 
Hz, 1H), 4.86 (ddd, J = 10.7, 7.9, 3.8 Hz, 1H), 4.28 – 4.06 (m, 4H), 3.51 – 3.27 (m, 2H), 3.17 (s, 3H), 2.40 (s, 
3H), 1.31 (qd, J = 7.1, 0.4 Hz, 6H). 31P NMR (162 MHz, CDCl3) δ 16.13. 
 
 
1-(Diethoxyphosphoryl)-2-(4-methylphenylsulfonamido)ethyl 4-methylbenzenesulfonate ( 108): tosyl 
amide 102 (200 mg, 0,57 mmol, 1 equiv) was dissolved in dichloromethane (2.5 mL). Triethylamine (0.42 
mL, 303 mg, 1.71 mmol, 3 equiv) was added, followed by tosyl chloride (217 mg, 1.14 mmol, 2 equiv). 
The mixture was stirred for two hours and poured into water (20 mL). Dichloromethane (20 mL) was 
added and the layers were separated and the aqueous phase was washed with 3 additional portion of 
dichloromethane (10 mL), the organic layers were combined, washed with saturated aqueous sodium 
bicarbonate solution (20 mL), brine (20 mL) and dried over anhydrous sodium sulfate. The compound 
was obtained as a 1:1 mixture with p-toluenesulfonic acid (303 mg, 0.6 mmol, 96% (corrected)). No 
further purification was performed due to the compounds instability. Rf: . 
1H NMR (400 MHz, CDCl3) δ = 
7.82 – 7.77 (m, 2H), 7.75 – 7.70 (m, 2H), 7.38 – 7.34 (m, 2H), 7.33 – 7.29 (m, 2H), 4.76 – 4.65 (m, 1H), 
4.22 – 3.95 (m, 5H), 3.51 – 3.18 (m, 2H), 2.46 (s, 3H), 2.43 (s, 3H), 1.27 (dtd, J=11.0, 7.1, 0.5, 6H). 13C 
NMR (126 MHz, CDCl3) δ = . 
31P NMR (162 MHz, CDCl3) δ = 16.13. LC-MS (ESI): tR = 8.93 min. HRMS (ESI): 
for [M+H]+ calc.: 506.10667, found: 506.10611. 
 
 
2-(N-(Tert-butoxycarbonyl)-4-methylphenylsulfonamido)-1-(diethoxyphosphoryl)ethyl 
methanesulfonate (109): Under argon, in a 5 mL round bottom schlenk, sulfonyl amide 107 (134 mg, 
0.31 mmol, 1 equiv) was dissolved in 1.24 mL dichloromethane. Boc-anhydride (82 mg, 0.37 mmol, 1.2 
equiv) was added followed by triethylamine (47 µL, 34 mg, 0.34 mmol, 1 equiv) and DMAP (4 mg, 0.031 
mmol, 0.1 equiv). The mixture was stirred until disappearance of the starting material on TLC, diluted 
with 10 mL dichloromethane and poured into 10% aqueous citric acid (20 mL). The layers were 
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separated and the aqueous phase was washed with 3 additional portion of dichloromethane (10 mL), 
the organic layers were combined, washed with saturated aqueous sodium bicarbonate (20 mL), brine 
(20 mL) and dried over anhydrous sodium sulfate. After evaporation of the solvent the residue was 
further purified by flash column chromatography (toluene:ethyl acetate 1:1) yielding 127 mg (0.24 
mmol, 77%) of a clear oil that solidifies on standing. Rf: 0.31 (toluene:ethyl acetate 1:1). 
1H NMR (400 
MHz, CDCl3) δ = 7.87 – 7.77 (m, 2H), 7.37 – 7.29 (m, 2H), 5.32 (ddd, J=10.6, 9.7, 2.5, 1H), 4.50 (ddd, 
J=15.3, 10.7, 5.6, 1H), 4.33 – 4.22 (m, 4H), 4.10 (ddd, J=15.3, 2.5, 1.5, 1H), 3.23 (s, 3H), 2.44 (s, 3H), 1.40 
(t, J=7.1, 6H), 1.36 (s, 9H). 13C NMR (126 MHz, CDCl3) δ = . 
31P NMR (162 MHz, CDCl3) δ = 16.20. LC-MS 
(ESI): tR = 9.29 min. HRMS (ESI): for [M+H]
+ calc.: 530.12780, found: 30.12760. 
 
 
2-(N-(Tert-butoxycarbonyl)-4-methylphenylsulfonamido)-1-(diethoxyphosphoryl)ethyl 4-
methylbenzenesulfonate (110): Under argon, in a 5 mL round bottom schlenk, sulfonyl amide  108 (348 
mg, 0.48 mmol, 1 equiv) was dissolved in 2 mL dichloromethane. Boc-anhydride (126 mg, 0.58 mmol, 1.2 
equiv) was added followed by triethylamine (67 µL, 49 mg, 0.48 mmol, 1 equiv) and DMAP (6 mg, 0.048 
mmol, 0.1 equiv). The mixture was stirred until disappearance of the starting material on TLC, diluted 
with 10 mL dichloromethane and poured into water. The layers were separated and the aqueous phase 
was washed with 3 additional portion of dichloromethane (10 mL), the organic layers were combined, 
washed with brine (20 mL) and dried over anhydrous sodium sulfate. After evaporation of the solvent 
the residue was further purified by flash column chromatography (toluene:ethyl acetate 3:1) yielding 
143 mg (0.24 mmol, 49%) of a clear oil that solidifies on standing. Rf: . 
1H NMR (400 MHz, CDCl3) δ = 7.91 
– 7.82 (m, 4H), 7.35 – 7.28 (m, 4H), 5.43 – 5.32 (m, 1H), 4.40 (ddd, J=15.3, 10.1, 7.9, 1H), 4.23 – 4.03 (m, 
5H), 2.43 (t, J=6.9, 6H), 1.39 – 1.24 (m, 15H). 13C NMR (126 MHz, CDCl3) δ = . 
31P NMR (162 MHz, CDCl3) δ 
= 16.10. LC-MS (ESI): tR = 10.13 min. HRMS (ESI): for [M+H]
+ calc.: 606.15910, found: 606.15970. 
 
Diethyl 1-hydroxy-2-(N-(4-methoxybenzyl)-4-methylphenylsulfonamido)ethylphosphonate (112): In a 
25 mL round bottom flask, tosyl amide 102 (256 mg, 0.54 mmol, 1 equiv) was dissolved in 3 mL DMF. 
Cesium carbonate (352 mg, 1.08 mmol, 2 equiv) was added followed by 4-methoxybenzyl bromide (217 
mg, 1.08 mmol, 2 equiv). The resulting mixture was stirred for three hours and then poured into 
saturated aqueous ammonium chloride (10 mL) and ethyl acetate (10 mL). The layers were separated 
and the aqueous phase was washed with 3 additional portion of ethyl acetate (10 mL), the organic layers 
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were combined, washed with water (10 mL), brine (2x 10 mL) and dried over anhydrous sodium sulfate. 
After evaporation of the solvent the residue was further purified by flash column chromatography 
(chloroform:ethyl acetate 4:1 in increasing gradient to 1:1) yielding 292 mg (0.49 mmol, 91%) of a yellow 
oil that solidifies on standing. Rf: . 
1H NMR (400 MHz, CDCl3) δ = 8.00 (bs, 1H), 7.74 – 7.69 (m, J=6.6, 1.1, 
2H), 7.34 – 7.30 (m, 2H), 7.19 – 7.14 (m, 2H), 6.84 – 6.80 (m, 2H), 4.50 (d, J=14.4, 1H), 4.19 (d, J=14.5, 
1H), 4.14 – 4.00 (m, 4H), 3.77 (s, 3H), 3.77 – 3.76 (m, 1H), 3.46 (ddd, J=12.9, 10.3, 5.2, 1H), 3.40 – 3.30 
(m, 1H), 2.43 (s, 3H), 1.31 – 1.20 (m, 6H). 13C NMR (126 MHz, CDCl3) δ = 
13C NMR (101 MHz, CDCl3) δ = 
159.71, 143.97, 136.37, 130.19, 130.07, 128.81, 127.54, 114.37, 114.17, 67.17 (d, J=160.9), 63.12 (d, 
J=35.0), 63.05 (d, J=34.9), 55.48, 54.96, 53.13, 49.67 (d, J=9.1), 36.67, 21.75, 16.64 (d, J=5.5), 16.60 (d, 
J=5.5). 31P NMR (162 MHz, CDCl3) δ = 22.20. LC-MS (ESI): tR = 8.61 min. HRMS (ESI): for [M+H]
+ calc.: 
472.15534, found: 472.15527. 
OHP
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Dibenzyl 1-hydroxy-2-(N-(4-methoxybenzyl)-4-methylphenylsulfonamido)ethylphosphonate (113): 
Method A: In a 10 mL round bottom flask alcohol 94 (256 mg, 0.54 mmol, 1 equiv) was dissolved in DMF 
(2.7 mL). Cesium carbonate (352 mg, 1.08 mmol, 2 equiv) was added followed by 4-methoxybenzyl 
bromide (217 mg, 1.08 mmol, 2 equiv) and the mixture was vigorously stirred for three hours. It was 
then poured into saturated aqueous ammonium chloride (10 mL) and ethyl acetate (10 mL). The layers 
were separated and the aqueous layer was extracted twice with ethyl acetate (10 mL). The organic 
layers were combined, washed with water (20 mL) and twice with brine (20 mL). The resulting solution 
was dried over anhydrous magnesium sulfate and the solvent was removed in vacuo. The resulting 
yellow oil was purified by column chromatography (chloroform:ethyl acetate 4:1 in increasing gradient 
to 1:1) yielding 292 mg (0.49 mmol, 91%) of a yellow oil that solidified on standing. 
Method B: In a 250 mL three-necked, round bottom flask containing an egg-shaped stirring bar, TMS-
alcohol 129 (36 g, 54 mmol, 1 equiv) was dissolved in methanol (100 mL). Potassium fluoride (6.3 g, 108 
mmol, 2 equiv) was added in one portion, which dissolves completely. After 15 minutes a white solid 
precipitated out of the reaction mixture and an additional 100 mL of methanol was added to ensure 
efficient stirring. After an additional 15 minutes, TLC indicated complete consumption of the starting 
material. The reaction mixture was poured into a separatory funnel containing saturated aqueous 
ammonium chloride (200 mL), ethyl acetate (200 mL) was added and upon shaking all white solid 
dissolved. The layers were split and the aqueous layer was washed with two additional portions of ethyl 
acetate (200 mL), organic layers were combined, washed with saturated aqueous sodium hydrogen 
carbonate (300 mL), water (300 mL) and brine (300 mL), the mixture was dried over anhydrous sodium 
sulfate and evaporation of the solvent yielded a white solid (30.3 g, 50.9 mmol, 94%) that required no 
further purification. 1H NMR (500 MHz, CDCl3) δ 7.67 (ad, J = 8.3, 2H), 7.39 – 7.28 (m, 10H), 7.26 (ad, J = 
8.0, 2H), 7.14 (ad, J = 8.6, 2H), 6.77 (ad, J = 8.6, 2H), 5.10 – 4.93 (m, 4H), 4.49 (d, J = 14.5, 1H), 4.21 (d, J = 
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14.5, 1H), 3.98 (ddd, J = 2.3, 7.9, 10.2, 1H), 3.76 (s, 3H), 3.51 (ddd, J = 5.3, 10.3, 15.5, 1H), 3.45 – 3.37 (m, 
1H), 2.43 (s, 3H), OH is not visible. 13C NMR (126 MHz, CDCl3) δ 159.6, 143.8, 136.4, 136.2 (d, J = 6.5 Hz, 
1C), 136.2 (d, J = 6.7 Hz, 1C), 130.1, 129.9, 128.7 (broad, 2x2C), 128.6, 128.6, 128.1, 128.1, 127.7, 127.5, 
114.3, 68.4 (d, J = 21.6 Hz, 1C), 68.4 (d, J = 21.7, 1C), 67.5 (d, J = 160.1, 1C), 55.4, 52.9, 49.4 (d, J = 9.6, 
1C), 21.7. 31P NMR (162 MHz, CDCl3) δ 22.9. Melting point: 96.3-97.2
oC. Rf: 0.40 (toluene:ethyl acetate 
1:1). LC-MS (ESI): tR = 10.59 min. HRMS (ESI): for [M+H]
+ calc.: 596.18664, found: 596.18603. Rf: 0.40 
(toluene:ethyl acetate 1:1). 
 
 
1-(Diethoxyphosphoryl)-4-(4-methoxyphenyl)-3-tosylbutyl trifluoromethanesulfonate (114): Under 
argon in a flame dried 25 mL schlenk flask equipped with an egg-shaped stirrer bar, alcohol 112 (157 mg, 
0.36 mmol, 1 equiv) was dissolved in anhydrous CH2Cl2 (3.5 mL). Pyridine (57 mg, 58 µL, 0.72 mmol, 2 
equiv) was added in one batch, followed by cooling to -15oC with an ice-salt bath. Dropwise addition of 
triflic anhydride (152 mg, 91 µL, 0.54 mmol, 1.5 equiv) over 5 minutes yielded a yellow solution that 
turned to bright pink within minutes. After stirring at the same temperature for 1.5 hours, TLC 
confirmed complete consumption of the starting material. The mixture was poured into an ice cold 
solution of 5% aqueous citric acid (5 mL), turning the reaction mixture yellow, a few shakes of the 
separatory funnel turned the organic layer bright pink again. The layers were split and the aqueous layer 
was washed with three portions of CH2Cl2 (5 mL). Organic layers are combined, washed with water (10 
mL) and brine (10 mL), dried over anhydrous magnesium sulfate and the solvent was evaporated, 
yielding a pink oil (assumed quantitative). The oil is co-evaporated with toluene twice to remove any 
traces of CH2Cl2, and used in the next reaction without further purification due to its potential instability. 
The yield was assumed quantitative. Rf: 0.21 (toluene:ethyl acetate 3:1). 
1H NMR (400 MHz, CDCl3) δ 
7.72 – 7.68 (m, 2H), 7.34 – 7.30 (m, 2H), 7.06 – 7.01 (m, 2H), 6.82 – 6.77 (m, 2H), 5.07 (td, J = 3.2, 9.4, 
1H), 4.42 (d, J = 14.5, 1H), 4.22 (d, J = 14.5, 1H), 4.19 – 4.06 (m, 4H), 3.77 (s, 3H), 3.70 – 3.57 (m, 1H), 
3.51 (dt, J = 3.2, 15.9, 1H), 2.44 (s, 3H), 1.36 – 1.27 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 159.83 (C), 
144.13 (C), 135.71 (C), 130.72 (CH), 130.02 (CH), 127.74 (CH), 126.31 (C), 116.85 (C), 114.36 (CH), 79.33 
(d, J = 159.8, CH), 64.30 (d, J = 11.8, CH2), 64.23 (d, J = 10.9, CH2), 55.42 CH3), 53.30 (CH2), 47.12 (d, J = 
7.6, CH2), 21.68 (CH3), 16.39 (d, J = 10.2, CH3), 16.33 (d, J = 10.3, CH3). 
31P NMR (162 MHz, CDCl3) δ 13.84. 
19F NMR (377 MHz, CDCl3) δ -74.41. LC-MS (ESI): tR = 10.13 min. HRMS (ESI): for [M+H]
+ calc.:604.10462, 
found: 604.10431. 
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1-(Bis(benzyloxy)phosphoryl)-2-(N-(4-methoxybenzyl)-4-methylphenylsulfonamido)ethyl 
trifluoromethanesulfonate (115): Under argon in a flame dried 250 mL schlenk flask equipped with an 
egg-shaped stirrer bar, alcohol 113 (11.2 g, 18.8 mmol, 1 equiv) was dissolved in anhydrous 
dichloromethane (130 mL). Pyridine (3.0 g, 3.1 mL, 37.6 mmol, 2 equiv) was added in one batch, 
followed by cooling to -15oC with an ice-salt bath. Dropwise addition of triflic anhydride (8.0 g, 4.8 mL, 
28.2 mmol, 1.5 equiv) over 5 minutes yielded a yellow solution that turned to bright pink after a few 
minutes. After stirring at -15°C for 1.5 hours, TLC confirmed complete consumption of the starting 
material. The mixture was poured into an ice cold solution of 5% aqueous citric acid (150 mL). The layers 
were split and the aqueous layer was washed with three portions of dichloromethane (100 mL). Organic 
layers were combined, washed with water (200 mL) and brine (200 mL), dried over anhydrous 
magnesium sulfate and the solvent was evaporated, yielding a pink oil (13.4g, 18.4 mmol, 98%). The oil 
was co-evaporated with toluene twice to remove any traces of dichloromethane, and used in the next 
reaction without further purification due to its instability. 1H-NMR (400 MHz, CDCl3): δ 7.65 – 7.58 (m, 
2H), 7.38 – 7.31 (m, 6H), 7.31 – 7.23 (m, 6H), 6.99 – 6.93 (m, 2H), 6.76 – 6.70 (m, 2H), 5.20 – 5.11 (m, 
1H), 5.04 – 4.92 (m, 4H), 4.35 (d, J = 14.5, 1H), 4.17 (d, J = 14.5, 1H), 3.75 (s, 3H), 3.64 – 3.54 (m, 1H), 
3.52 – 3.43 (m, 1H), 2.43 (s, 3H). 13C NMR (101 MHz, CDCl3, 25°C): δ 159.8, 144.1, 135.7, 135.3 (d, J = 8.2 
Hz, 1C), 135.2 (d, J = 8.5 Hz, 1C), 130.7, 130.0, 129.1 (br, 2x2CH), 128.9 (br, 2x2CH), 128.6, 128.6, 127.8, 
126.3, 114.4, 79.5 (d, J = 160.9, 1C), 69.6 (d, J = 11.6 Hz, 1C), 69.5 (d, J = 11.2 Hz, 1C), 55.5, 53.4, 47.2 (d, J 
= 7.6, CH2)., 21.8. 
31P NMR (162 MHz, CDCl3): δ 14.9. 
19F NMR (377 MHz, CDCl3): δ -74.3. Rf: 0.64 
(toluene:ethyl acetate 3:1). HRMS (ESI): for [M+H]+ calc.: 728.13592, found: 728.13607.  
 
 
Diethyl (1-azido-2-(N-(4-methoxybenzyl)-4-methylphenylsulfonamido)ethyl)phosphonate (116): Under 
argon in a 5 mL round bottom Schlenk, triflate 114 (173 mg, 0.29 mmol, 1 equiv) was dissolved in 1.2 mL 
acetonitrile. TMGA (34 mg, 0.33 mmol, 1.1 equiv) was added and the mixture was stirred for 16 hours. 
The solvent was evaporated, the residue dissolved in water (5 ml) and ethyl acetate (5 mL) and the 
layers were separated. The aqueous layer was washed with two additional portions of ethyl acetate (5 
mL) and the organic layers were combined, washed with saturated aqueous sodium bicarbonate (10 
mL), water (10 mL) and brine (10 mL). After removal of the solvent in vacuo a yellow oil remained that 
was not purified further (123 mg, 0.25 mmol, 86%). 1H NMR (400 MHz, CDCl3) δ 7.71 – 7.62 (m, 2H), 7.26 
(d, J = 7.9 Hz, 2H), 7.16 – 7.06 (m, 2H), 6.81 – 6.72 (m, 2H), 4.33 (d, J = 14.6 Hz, 1H), 4.23 (d, J = 14.6 Hz, 
1H), 4.13 – 3.94 (m, 4H), 3.72 (s, 3H), 3.63 (ddd, J = 13.7, 8.6, 3.1 Hz, 1H), 3.37 (dt, J = 15.2, 2.7 Hz, 1H), 
3.27 – 3.15 (m, 1H), 2.38 (s, 3H), 1.97 (s, 2H), 1.22 (ddd, J = 20.8, 10.8, 6.4 Hz, 6H). 31P NMR (162 MHz, 
CDCl3) δ 19.99. LC-MS (ESI): tR = 9.46 min. 
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Dibenzyl 1-azido-2-(N-(4-methoxybenzyl)-4-methylphenylsulfonamido)ethylphosphonate (117): Under 
an argon atmosphere, in a 250 mL, flame dried schlenk flask, triflate 115 (136.7 g, 50.4 mmol, 1 equiv) 
was dissolved in anhydrous acetonitrile (130 mL). N,N,N’,N’-tetramethylguanidinium azide (8.8 g, 55.4 
mmol, 1.1 equiv) was rapidly weighed (hygroscopic!) and added to the pink solution in one portion. The 
resulting mixture was allowed to stir for 2 hours, after which a TLC confirmed complete consumption of 
the starting material (If the reaction was left to age after completion, yield was diminished). Reaction 
mixture was poured into saturated aqueous sodium hydrogen carbonate (250 mL), layers were 
separated and the aqueous layer was washed with ethyl acetate (3 x 150 mL). The organic layers were 
combined, washed with 10% citric acid (250 mL), water (250 mL), brine (250 mL) and dried over 
anhydrous magnesium sulfate. Evaporation of the solvent yielded a thick orange oil that was purified by 
flash column chromatography (toluene:ethyl acetate 24:1 in increasing gradient to 9:1) yielding a clear 
oil that solidified on standing (21.9 g, 35.2 mmol, 70%). 1H NMR (500 MHz, CDCl3) δ 7.66 (d, J = 8.3, 2H), 
7.45 – 7.30 (m, 10H), 7.27 (d, J = 8.1, 2H), 7.15 (d, J = 8.6, 2H), 6.82 (d, J = 8.7, 2H), 5.12 – 4.92 (m, 4H), 
4.34 (d, J = 14.6, 1H), 4.28 (d, J = 14.6, 1H), 3.82 (ddd, J = 2.6, 10.8, 13.6, 1H), 3.77 (s, 3H), 3.48 – 3.38 (m, 
1H), 3.35 – 3.26 (m, 1H), 2.44 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 159.5, 143.7, 136.1, 135.6 (d, J = 5.8 
Hz, 1C),  135.5 (d, J = 5.7 Hz, 1C), 130.0, 129.8, 128.7, 128.7, 128.7 (br, 2x2C), 128.1, 128.1, 127.4, 127.3, 
114.1, 68.6 (d, J = 12.9 Hz, 1C), 68.6 (d, J = 13.0 Hz, 1C), 57.8 (d, J = 151.8, 1C), 55.2, 53.0, 47.1 (d, J = 7.8, 
1C), 21.5. 31P NMR (162 MHz, CDCl3) δ 20.7. IR ν = 3064 (w), 3032 (w), 2950 (bw), 2836 (w), 2134 (s), 
1611 (m), 1511 (s), 1456 (m), 1371 (w), 1333 (s), 1287 (m), 1246 (s), 1217 (m), 1174 (m), 1155 (s), 1119 
(m), 1101 (m), 1087 (m), 1032 (m), 992 (s), 951 (s), 920 (s), 878 (m), 815 (m), 801 (s), 786 (w) 764 (w), 
741 (s), 697 (s), 653 (s), 636 (w). Melting point: 88.6-89.8oC. Rf: 0.50 (toluene:ethyl acetate 3:1). LC-MS 
(ESI): tR = 10.40 min. HRMS (ESI): for [M+H]
+ calc.: 621.19312, found: 621.19268. 
 
(2S)-Allyl 2-(((allyloxy)carbonyl)amino)-4-(N-(2-azido-2-(diethoxyphosphoryl)ethyl)-4-
methylphenylsulfonamido)-4-oxobutanoate (118): Under argon, in a 5 mL, flame dried, schlenk flask 
containing an egg-shaped stirring bar, Azide 97 (50 mg, 0.13 mmol, 1 equiv) and amino acid 67 (56 g, 
0.15 mol, 1.1 equiv) were dissolved in 0.5 mL anhydrous dichloromethane. After cooling to 0oC, PyBrOP 
(70 g, 0.15 mmol, 1.1 equiv), DIPEA (38 g, 51 µL, 0.15 mmol, 2.2 equiv) and DMAP (18 g, 0.15 mmol, 1.1 
equiv) were added sequentially. After stirring the resulting mixture for 3.5 hours, a TLC confirmed 
complete conversion of the azide. The mixture was poured into 10% citric acid (5 mL), the layers were 
separated and the aqueous layer was washed twice with dichloromethane (5 mL). The organic layers 
were combined, washed with saturated aqueous sodium hydrogen carbonate solution (5 mL), water (5 
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mL) and brine (5 mL). Drying over anhydrous magnesium sulfate, followed by evaporation of the solvent, 
yielded a yellow oil that was purified further by flash column chromatography (petroleum ether:ethyl 
acetate 1:1) yielding 72 mg of a yellow oil that still contained some impurities (73% corrected by NMR) 
and was a mixture of diastereoisomers (1:1 by 31P-NMR). 1H NMR (400 MHz, CDCl3) δ 7.76 – 7.69 (m, 
2H), 7.32 – 7.28 (m, 1H), 7.24 – 7.20 (m, 1H), 5.91 – 5.61 (m, 2H), 5.29 – 5.07 (m, 5H), 4.61 – 4.40 (m, 
5H), 4.27 – 3.90 (m, 7H), 3.37 – 3.21 (m, 2H), 2.39 (s, 2H), 2.35 (s, 1H), 1.32 (td, J = 7.1, 1.9 Hz, 4H), 1.30 – 
1.21 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 171.55, 171.41, 170.38, 156.00, 145.77, 143.53, 137.37, 
135.93, 135.89, 132.89, 132.68, 132.01, 131.61, 131.58, 130.26, 129.83, 127.91, 127.87, 127.22, 118.78, 
118.67, 118.30, 117.91, 117.60, 66.41, 66.22, 66.02, 63.74, 63.67, 63.50, 63.43, 58.17, 57.65, 57.50, 
56.65, 56.15, 56.01, 53.65, 50.74, 50.55, 46.67, 45.74, 45.35, 45.26, 42.68, 42.63, 39.54, 39.46, 36.91, 
26.14, 24.49, 21.83, 21.65, 16.66, 16.61, 16.57. 31P NMR (162 MHz, CDCl3) δ 19.30, 19.28. 
 
(2S)-Allyl 2-(allyloxycarbonylamino)-4-(N-(2-azido-2-(bis(benzyloxy)phosphoryl)ethyl)-4-
methylphenylsulfonamido)-4-oxobutanoate (119): Under argon, in a 250 mL, flame dried, round 
bottom schlenk flask containing an egg-shaped stirring bar, azide 66 (12 g, 24 mmol, 1 equiv) and amino 
acid 67 (7.4 g, 28.8 mol, 1.2 equiv) were dissolved in 120 mL anhydrous dichloromethane. After cooling 
to 0oC, PyBroP (13.4 g, 28.8 mmol, 1.2 equiv), DIPEA (7.4 g, 19 mL, 57.6 mmol, 2.4 equiv) and DMAP (3.5 
g, 28.8 mmol, 1.2 equiv) were added sequentially. After stirring the resulting mixture for 3.5 hours, a TLC 
confirmed complete conversion of the azide. The mixture was poured into 10% citric acid (100 mL), the 
layers were separated and the aqueous layer was washed twice with dichloromethane (100 mL). The 
organic layers were combined, washed with saturated aqueous sodium hydrogen carbonate solution 
(150 mL), water (150 mL) and brine (100 mL). Drying over anhydrous magnesium sulfate, followed by 
evaporation of the solvent, yielded a yellow oil that was purified further by flash column 
chromatography (toluene:ethyl acetate 50:1 in increasing gradient to 12:1) yielding 14.1 g (19 mmol, 
79%) of a yellow oil as a mixture of diastereoisomers (1:1.14 by 31P-NMR). 1H NMR (400 MHz, CDCl3) δ 
7.72 (ad, J = 8.5, 2H), 7.41 – 7.33 (m, 10H), 7.33 – 7.28 (m, 2H), 5.97 – 5.66 (m, 2H), 5.33 – 4.99 (m, 8H), 
4.62 – 4.46 (m, 5H), 4.14 – 3.92 (m, 3H), 3.54 – 3.01 (m, 1H), 2.43 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 
171.4, 171.3, 170.3, 155.9, 145.6, 135.7, 135.6, 135.49, 135.48, 135.47, 135.44, 135.43, 132.6, 131.5, 
131.5, 130.11, 130.10, 128.96, 128.95, 128.93, 128.90, 128.83, 128.82, 128.81, 128.45, 128.41, 128.38, 
127.88, 127.82, 118.7, 118.6, 117.9, 69.16, 69.10, 69.05, 69.04, 69.02, 68.98, 68.95, 66.3, 66.0, 57.9, 
57.7, 56.4, 56.2, 50.4, 45.15, 45.11, 45.06, 45.02, 39.4, 39.3, 21.7. 31P NMR (162 MHz, CDCl3) δ 20.3, 
20.2. IR ν: 3293 (b w), 3034 (w), 2955 (w), 2118 (s), 1719 (s), 1649 (w), 1596 (w), 1500 (m), 1455 (m), 
1362 (s), 1332 (m), 1258 (s), 1209 (s), 1164 (s), 1119 (w), 1087 (m), 989 (s), 813 (m), 777 (w), 733 (s), 697 
(s), 668 (s). Rf: 0.76 (chloroform:ethyl acetate 1:1). LC-MS (ESI): tR = 10:15 min. HRMS (ESI): for [M+H]
+ 
calc.: 740.21498, found: 740.21490. 
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N-(2-Hydroxyethyl)-N-(4-methoxybenzyl)-4-methylbenzenesulfonamide (120): In a 25 mL round 
bottom flask, equipped with a small, egg-shaped stirring bar, N-tosyl-ethanolamine (200 mg, 0.93 mmol, 
1 equiv) was dissolved in three mL DMF and cesium carbonate (333 mg, 1.02 mmol, 1.1 equiv) was 
added. p-methoxybenzyl chloride (153 mg, 0.133 mL, 0.98 mmol, 1.05 eq.) was added dropwise over 1 
minute. The resulting reaction mixture was stirred for two hours after which a TLC sample indicated 
complete conversion. The solvent was evaporated on a rotary evaporator equipped with a dry ice 
condenser and an oil pump, the residue was dissolved in 20 mL ethyl acetate and 20 mL water. The 
layers were separated, the aqueous layer was washed once with 20 mL ethyl acetate, the organic layers 
were combined, washed with brine (20 mL) and dried over anhydrous sodium sulfate. The solvent was 
evaporated yielding a clear oil that was further purified by flash column chromatography (hexanes:ethyl 
acetate 3:1 in increasing gradient to 2:1) yielding 259 mg (0.77 mmol, 83%) of a clear oil that slowly 
solidifies on standing. 1H NMR (400 MHz, CDCl3) δ 7.73 – 7.67 (m, 2H), 7.32 – 7.26 (m, 2H), 7.19 – 7.14 
(m, 2H), 6.82 – 6.77 (m, 2H), 4.25 (s, 2H), 3.73 (s, 3H), 3.42 (t, J = 5.8, 2H), 3.17 (t, J = 5.8, 2H), 2.45 (bs, 
1H), 2.39 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 159.27 (C), 143.50 (C), 136.15 (C), 129.75 (2xCH), 129.65 
(2xCH), 128.10 (C), 127.15 (2xCH), 114.03 (2xCH), 60.78 (CH2), 55.16 (CH3), 52.69 (CH2), 50.12 (CH2), 
21.41 (CH3). Rf: 0.40 (toluene:ethyl acetate 1:1). LC-MS (ESI): tR = 9.01 min. HRMS (ESI): for [M+H]
+ calc.: 
336.12641, found: 336.12671.  
 
N-(4-methoxybenzyl)-4-methyl-N-(2-oxoethyl)benzenesulfonamide (122): 
Method A: Under argon, in a 10 mL round bottom schlenk flask, oxalyl chloride (42 mg, 28 µL, 0.33 
mmol, 1.1 equiv) was dissolved in anhydrous dichloromethane (1 mL) and cooled to -78oC in an acetone-
dry ice bath. Dimethyl sulfoxide (56 mg, 51 µL, 0.72 mmol, 2.4 equiv) was added dropwise over one 
minute and the mixture was stirred at the same temperature for 15 minutes. Alcohol 120 (100mg, 0.3 
mmol, 1 equiv), dissolved in 0.5 mL dichloromethane, was added dropwise over one minute and the 
resulting mixture was stirred 30 minutes before dropwise addition of triethyl amine (152 mg, 209 µL, 1.5 
mmol, 5 equiv) over one minute. After addition was complete the mixture was stirred at -78oC for 30 
minutes followed by removal of the cooling bath and warming to room temperature over 45 minutes. 
Water (5 mL) was added to the resulting white milky solution, turning it clear, the aqueous layer was 
extracted with three 5 mL portions of DCM, organic layers were combined and washed with water (5 
mL), brine (5 mL) and dried over anhydrous sodium sulfate. Evaporation of the solvent yielded 95 mg 
(0.28 mmol, 95%) of a white solid that requires no further purification. Can be recrystallized from ethyl 
acetate:petroleum ether. 
Method B: In a 1 liter round bottom flask, equipped with a large egg-shaped stirring bar, diol 123 (20 g, 
30 mmol, 1 equiv) was dissolved in 400 mL dioxane by sonicating the suspension one hour. The mixture 
was cooled in an ice bath and periodic acid (7.5 g, 33 mmol, 1.1 equiv) was slowly added, a slight 
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exotherm was noticed. Upon complete addition the cooling bath was removed and the mixture was 
stirred for one hour. TLC indicated complete conversion of the starting material. 400 mL of DCM were 
added, followed by about 15 g of anhydrous magnesium sulfate. After stirring for five minutes about 10 
grams of celite were added and, after stirring for an additional 5 minutes, the mixture was filtered 
through a celite plug. The filter cake was washed with two 100 mL portions of DCM, after which the 
filtrate was evaporated to dryness. The residue was redissolved in 250 mL DCM and the volume of the 
solution reduced to about 100 mL, upon addition of 50 mL petroleum ether 40-60 and cooling white 
crystals crystallize out of the solution. The crystals were obtained by filtration and the mother liquor was 
evaporated to dryness and resubmitted to the crystallization conditions for a total of three crops (15.9 g, 
0.9 g, 0.7 g) for a total of 17.5 g of white crystals (50.1 mmol, 83.5%). The aldehyde is sensitive and 
decomposes slowly, even under argon at -18°C. 1H NMR (500 MHz, CDCl3) δ 9.24 (t, J = 1.4, 1H), 7.71 (ad, 
J = 8.3, 2H), 7.33 (ad, J = 8.0, 2H), 7.15 (ad, J = 8.7, 2H), 6.82 (ad, J = 8.7, 2H), 4.24 (s, 2H), 3.76 (s, 3H), 
3.65 (d, J = 1.4, 2H), 2.43 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 198.03, 159.99, 144.21, 135.63, 130.48, 
130.13, 127.61, 126.57, 114.53, 56.21, 55.45, 52.89, 21.74. Rf : 0.51 (toluene:ethyl acetate 3:1). Melting 
point: 117.9-118.4oC. LC-MS (ESI): tR = 7.82 min. HRMS (ESI): for [M+H]
+ calc.:334.11076, 
found:.334.11103  
 
N,N'-((Z)-2,3-Dihydroxybutane-1,4-diyl)bis(N-(4-methoxybenzyl)-4-methylbenzenesulfonamide) (123): 
In a 3-necked 1L round bottom flask, fitted with a condenser and containing a large egg-shaped stirring 
bar, alkene 131 (73.4 g, 116 mmol, 1 equiv) was dissolved in chloroform (500 mL). Water (24 mL) and 
tert-butanol (57 mL) were added and the mixture was stirred vigorously. Osmium tetroxide as a 5% 
solution in water (5.9 mL, 1.16 mmol, 0.01 equiv) (Osmium tetroxide is very toxic and should be handled 
with care) was added via syringe, followed by spoon wise addition of N-methyl morpholine-N-oxide (41 
g, 347 mmol, 3 equiv). After addition was complete the mixture was heated to 50oC in an oil-bath and 
stirred 16 hours, after which a TLC sample indicated complete conversion of the starting material. 
Sodium hydrogen sulphite (6 g, 57.6 mmol, 0.49 equiv) in 40 mL water was added and stirred for an hour 
to reduce excess osmium tetroxide, turning the water layer of the reaction black. The reaction mixture 
was transferred to a separatory funnel, the layers were separated and the aqueous layer was washed 
with three 200 mL portions of chloroform. The organic layers were combined, washed with water (300 
mL, brine (300 mL) and dried over anhydrous sodium sulfate. After evaporation of the solvent the 
resulting yellow foam was dissolved in a minimal amount of methanol and petroleum ether 40-60 was 
added, precipitating a white solid, which was filtered and the residue dried in vacuo, yielding 75.1 g 
(112.3 mmol, 97%) of a white solid. 1H NMR (500 MHz, CDCl3) δ 7.69 (d, J = 8.2, 4H), 7.31 (d, J = 8.0, 4H), 
7.12 (d, J = 8.6, 4H), 6.82 (d, J = 8.6, 4H), 4.29 (d, J = 14.3, 2H), 4.11 (d, J = 14.3, 2H), 3.78 (s, 6H), 3.31 (s, 
2H), 3.10 – 2.94 (m, 4H), 2.43 (s, 8H). 13C NMR (126 MHz, CDCl3) δ 159.60 (2xC), 143.69 (2xC), 136.29 
(2xC), 130.10 (2x2 CH), 129.93 (2x2 CH), 127.90 (2xC), 127.35 (2x2 CH), 114.32 (2x2 CH), 68.39 (2xCH), 
55.39 (2xOCH3), 53.26 (2xCH2), 50.54 (2xCH2), 21.63 (2xCH3). Rf: 0.40 (toluene:ethyl acetate 1:1). Melting 
point: 157.6oC. LC-MS (ESI): tR = 10.63 min. HRMS (ESI): for [M+H]
+ calc.: 669.22988, found: 669.22976.  
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Dibenzyl 2-(N-(4-methoxybenzyl)-4-methylphenylsulfonamido)-1-(trimethylsilyloxy)ethylphosphonate 
(129): Under an argon atmosphere, in a 500 mL flame dried schlenk flask, dibenzylphosphite (11 g, 9.2 
mL, 41.8 mmol, 1.2 equiv) and triethylamine (5 g, 7.0 mL, 50 mmol, 1.44 equiv) were dissolved in 150 mL 
of anhydrous dichloromethane. The resulting mixture was cooled to -20oC with an ice-salt bath, and 
chlorotrimethylsilane (5.4 g, 6.1 mL, 50 mmol, 1.44 equiv) was added dropwise over 5 minutes. After 
addition was complete, the mixture was stirred for one hour at -20°C, and a white precipitate formed. 
The reaction mixture was cooled to -78oC with acetone-dry ice and aldehyde 122, dissolved in 100 mL 
dichloromethane, was added via cannula. Upon addition, the white precipitate dissolved and the 
mixture changes color from clear to slightly yellow. After stirring for 16 hours, complete consumption of 
the aldehyde was confirmed by TLC. The reaction mixture was poured into saturated aqueous NH4Cl 
(250 mL), a white precipitate formed that was dissolved by addition of a small amount of water (15 mL). 
The layers were split and the aqueous layer was washed with three 100 mL portions of 
dichloromethane. The organic layers were combined and sequentially washed with aqueous saturated 
sodium hydrogen carbonate (200 mL), water (200 mL) and brine (200 mL); dried over anhydrous 
magnesium sulfate and the solvent was evaporated. The resulting crude oil was purified by flash column 
chromatography (toluene:ethyl acetate 49:1 in increasing gradient to 9:1) yielding 129 (17g, 26 mmol, 
73%) as colorless oil. Important: the product is unstable and slowly decomposes to the alcohol in 
solution, particularly under acidic conditions. 1H NMR (400 MHz, C6D6) δ 7.67 – 7.62 (m, 2H), 7.24 – 7.00 
(m, 12H), 6.75 – 6.69 (m, 2H), 6.65 – 6.59 (m, 2H), 5.04 – 4.87 (m, 4H), 4.75 (ddd, J = 2.9, 7.0, 9.7, 1H), 
4.54 (d, J = 14.7, 1H), 4.43 (d, J = 14.7, 1H), 3.89 – 3.81 (m, 1H), 3.63 (ddd, J = 8.0, 9.5, 15.1, 1H), 3.26 (s, 
3H), 1.89 (s, 3H), 0.32 (s, 9H). 13C NMR (101 MHz, C6D6) δ 159.8, 142.8, 138.1, 137.1 (d, J = 8.1, C), 137.0 
(d, J = 8.1, C), 130.8, 129.7, 128.8, 128.7, 128.6, 128.56, 128.48, 128.46, 128.4, 128.4, 114.3, 70.4 (d, J = 
161.3, C), 68.2 (d, J = 6.8, C), 67.9 (d, J = 7.0, C), 54.8, 53.5, 50.2 (d, J = 10.2, C)., 21.1, 0.5. 31P NMR (162 
MHz, C6D6) δ 23.4. Rf: 0.44 (toluene:ethyl acetate 3:1). LC-MS (ESI): tR = 11.32 min. HRMS (ESI): for 
[M+H]+ calc.: 668.22616, found: 668.22590. 
 
 (E)-N,N'-(But-2-ene-1,4-diyl)bis(N-(4-methoxybenzyl)-4-methylbenzenesulfonamide) (131): In a 500 
mL round bottom flask charged with a large egg-shaped stirring bar, sulphonamide 125 (73.8 g, 254 
mmol, 2 equiv) was dissolved in DMF (300 mL) and 1,4-dibromo but-2-ene (27.2 g, 127 mmol, 1 equiv) 
was added to the stirring solution. Cesium carbonate (99.4 g, 305 mmol, 2.4 equiv) was added and the 
reaction mixture was stirred at room temperature for 2 hours, after which a TLC sample indicated 
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complete consumption of the starting material. The solvent was evaporated on a rotary evaporator 
equipped with a dry ice condenser and an oil pump, the residue was partitioned between chloroform 
(400 mL) and water (400 mL), the layers were separated and the aqueous layer was washed with five 
100 mL portions of chloroform. The combined organic layers were washed 3 times with brine (100 mL), 
dried over magnesium sulfate and the solvent was evaporated in vacuo.  The residue was triturated with 
diethyl ether (100 mL), precipitating white crystals. The solid was filtered and the residue was dried in 
vacuo overnight. The filtrate was evaporated to dryness and the brown residue was recrystallized from 
chloroform – diethyl ether yielding a total of 73.5 g (116 mmol, 91%) of white crystals. 1H NMR (500 
MHz, CDCl3) δ 7.73 – 7.61 (m, 4H), 7.34 – 7.27 (m, 4H), 7.09 – 7.00 (m, 4H), 6.83 – 6.74 (m, 4H), 5.14 (t, J 
= 3.3, 2H), 4.11 (s, 4H), 3.77 (s, 6H), 3.54 (d, J = 4.5, 4H), 2.42 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 159.33 
(2xC), 143.43 (2xC), 137.39 (2xC), 129.85 (2x2 CH), 129.82 (2x2 CH), 128.99 (2xC), 127.85 (2xC), 127.26 
(2x2 CH), 114.04 (2x2 CH), 55.34 (2xOCH3), 50.16 (2xCH2), 48.03 (2xCH2), 21.59 (2xCH3). Rf: 0.50 
(toluene:ethyl acetate 9:1). Melting point: 134.9oC. LC-MS (ESI): tR = 10.99 min. HRMS (ESI): for [M+H]
+ 
calc.: 635.22440, found: 635.22429.  
 
(2S)-Allyl 2-(allyloxycarbonylamino)-3-(5-(diethoxyphosphoryl)-1-tosyl-4,5-dihydro-1H-imidazol-2-
yl)propanoate (132): In a 5 mL, flame dried pear shaped schlenk, under argon, azide 90 (20 mg, 0.03 
mmol, 1 equiv) was dissolved in anhydrous THF. The reaction mixture was cooled to -41C and triphenyl 
phosphine (13 mg, 0.05 mmol, 1.5 equiv) was added. 5 minutes after addition the schlenk was closed 
and the content heated to 80C and stirred at that temperature for six hours. The solvent was 
evaporated and the residue loaded on a silica column, elution with dichloromethane with 3% methanol 
yielded 30 mg of a yellow oil that still contained a lot of TPP and TPPO (66% product according to 31P-
NMR) in addition to other impurities, a yield was not determined. 31P NMR (162 MHz, CDCl3) δ = 30.13 
(OPPh3), 21.48, 21.32, 15.64 (PPh3). LC-MS (ESI): tR = 8.93 min. HRMS (ESI): for [M+H]
+ calc.: 572.18261, 
found: 572.18286. 
 
(E)-Allyl 2-(((allyloxy)carbonyl)amino)-3-(4-(bis(benzyloxy)phosphoryl)-1-tosyl-4,5-dihydro-1H-
imidazol-2-yl)acrylate (135): Under an argon atmosphere, in a 10 mL round bottom Schlenk, imidazoline 
68 (176 mg, 0.25 mmol, 1 equiv) was dissolved in 1,4-dioxane (1.3 mL). Selenium dioxide (42 mg, 0.38 
mmol, 1.5 equiv) was added and the mixture was heated to 40°C. After stirring for 16 hours the mixture 
was poured into saturated aqueous sodium bicarbonate (5 mL). The aqueous layer was washed three 
times with ethyl acetate (5 mL), the organic layers were combined, washed with brine (10 mL) twice and 
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dried over anhydrous sodium sulfate. The resulting solution was evaporated to dryness and the residue 
was purified by column chromatography (chloroform:ethyl acetate 10:1) yielding a yellow oil (35 mg, 
0.05 mmol, 20%). 1H NMR (400 MHz, CDCl3) δ 7.62 (d, J = 8.4 Hz, 2H), 7.33 – 7.11 (m, 12H), 6.38 (s, 1H), 
6.00 – 5.86 (m, 1H), 5.69 (ddd, J = 16.3, 11.1, 5.2 Hz, 1H), 5.44 – 5.02 (m, 4H), 4.99 – 4.82 (m, 4H), 4.73 
(dd, J = 5.8, 1.3 Hz, 2H), 4.51 – 4.39 (m, 2H), 4.23 (ddd, J = 15.2, 11.5, 8.4 Hz, 1H), 4.00 – 3.73 (m, 2H), 
2.30 (s, 3H). 31P NMR (162 MHz, CDCl3) δ 21.85. LC-MS (ESI): tR = 10.60 min. HRMS (ESI): for [M+H]
+ calc.: 
694.19826, found: 694.19812. 
 
(S)-Allyl 2-(allyloxycarbonylamino)-3-(4-(bis(benzyloxy)phosphoryl)-1H-imidazol-2-yl)propanoate 
(136): Under argon, in a flame dried, 500 mL schlenk flask imidazoline 68 (7 g, 10.1 mmol, 1 equiv) was 
dissolved in 120 mL anhydrous THF. The mixture was cooled to -78oC with acetone-dry ice and KHMDS 
(0.5M in toluene, 60.4 mL, 30.2 mmol, 3 equiv) was added dropwise over 20 minutes, during addition 
the mixture turned orange followed by red after addition of the first equivalent. After addition was 
complete the mixture was stirred for 15 minutes, after which a TLC indicated a small amount of starting 
material remained. To push the reaction to completion an additional 5 mL KHMDS solution (2.5 mmol, 
0.25 equiv) was added. A second TLC taken immediately after addition was complete, showed complete 
conversion of the starting material. The reaction mixture was transferred by cannula to a 500 mL round 
bottom flask, containing an egg-shaped stirring bar and 200 mL of water with acetic acid (3.6 g, 3.5 mL, 
60.4 mmol, 6 equiv) at 0oC, while vigorously stirring. After addition was complete, solid sodium 
hydrogen carbonate was added until the pH was 8. Chloroform (200 mL) was added and the layers were 
separated. The aqueous layer was washed with additional chloroform (2 x 200 mL), the organic layers 
were combined, washed with brine (200 mL) and dried over sodium sulfate. Evaporation yielded 136 as 
colorless oil that was not purified further and used ‘as is’ in the next reaction. 1H NMR (400 MHz, CDCl3) 
δ 12.11 (br s, 0.34H), 11.78 (br s, 0.62H), 11.95 (m, 1H), 7.45 (s, 1H), 7.36 – 7.20 (m, 10H), 6.51 (s, 1H), 
5.78 (m, 2H), 5.30 – 4.95 (m, 8H), , 4.76 – 4.67 (m, 1H), 4.60 – 4.37 (m, 4H), 3.27 (d, J = 5.4, 2H). 13C NMR 
(101 MHz, CDCl3) δ 171.0, 156.3, 136.0, 132.6, 131.5, 128.6, 128.5, 128.0, 127.9, 118.7, 117.9, 68.3, 66.3, 
66.0, 52.9, 30.6. 31P NMR (162 MHz, CDCl3) δ 13.4, 10.2 very broad. Rf: 0.49 (chloroform:methanol 9:1). 
LC-MS (ESI): tR = 9.64 min. HRMS (ESI): for [M+H]
+ calc.: 540.18941, found: 540.18833.  
 
Ethyl 4-(bis(benzyloxy)phosphoryl)-1-tosyl-4,5-dihydro-1H-imidazole-2-carboxylate (138): In a 25 mL 
round bottom flask, containing an egg-shaped stirring bar, azide 66 (500 mg, 1 mmol; 1 equiv) was 
dissolved in 2 mL anhydrous THF. While stirring, DIPEA (259 mg, 0.348 mL, 2 mmol, 2 equiv) and DMAP 
(122 mg, 1 mmol, 1 equiv) were added, followed by chloroethyl oxoacetate (273 mg, 0.223 mL, 2 mmol, 
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2 equiv). Upon addition of the acid chloride a white precipitate formed, turning the reaction to a thick 
suspension. After stirring for 1 hour at room temperature a TLC sample indicated complete conversion 
of the starting azide and the reaction was quenched by addition of 5 mL saturated aqueous sodium 
bicarbonate, this dissolved the white precipitate. The resulting mixture was poured into 10 mL of ethyl 
acetate, the layers were separated and the aqueous layer was washed with 2 additional 10 mL portions 
of ethyl acetate. The organic layers were combined, washed with 10% aqueous citric acid (20 mL), brine 
(20 mL) and dried over anhydrous sodium sulfate. The solvent was removed by evaporation in vacuo 
resulting in a yellow oil. The oil was further purified by column chromatography (toluene:ethyl acetate 
10:1) resulting in 268 mg of a yellow oil (0.45 mmol, 45%) that was unstable and was used in the next 
reaction as soon as possible. 1H NMR (400 MHz, CDCl3) δ = 7.85 – 7.80 (m, 2H), 7.42 – 7.32 (m, 10H), 7.32 
– 7.27 (m, 2H), 5.19 – 4.97 (m, 4H), 4.47 – 4.39 (m, 2H), 4.06 – 3.94 (m, 2H), 3.83 – 3.69 (m, 1H), 2.44 (s, 
3H), 1.42 (t, J=7.2, 3H). 13C NMR (126 MHz, CDCl3) δ = 
13C NMR (101 MHz, CDCl3) δ = 161.77, 161.34, 
146.46, 135.61 (d, J=5.8), 133.98, 130.34, 129.07, 129.06, 128.97, 128.71, 128.50, 128.48, 69.16 (d, 
J=11.4), 69.09 (d, J=11.5), 63.40, 56.39 (d, J=152.2), 43.84 (d, J=9.6), 21.97, 14.01. 31P NMR (162 MHz, 
CDCl3) δ = 19.81. IR: 2983 (w), 2118 (s), 1745 (m), 1694 (s), 1596 (w), 14.96 (w), 1455 (s), 1373 (m), 1318 
(m), 1295 (s), 1261 (s), 1198 (s), 1090 (m), 988 (s), 861 (m), 813 (m), 786 (m), 734 (s), 697 (s), 666 (s), 593 
(s), 546 (s), 486 (s), 436 (s). Rf: 0.65 (chloroform:ethyl acetate 3:1). LC-MS (ESI): tR = 10.41 min. HRMS 
(ESI): for [M+H]+ calc.: 601.15165, found: 601.15201. Under argon a flame dried, 100 mL schlenk flask 
was charged with the azide from the previous reaction (243mg, 0.40 mmol, 1 equiv) and 10 mL 
anhydrous THF. dppe (242 mg, 0.61 mmol, 1.5 equiv) was added and the reaction was heated to 50°C in 
an oil bath, steady bubble formation was noticed. Once bubble formation stopped the oil bath was set 
to 80°C and the schlenk flask was closed. After heating for 16 hours the flask was allowed to cool to 
about 50°C and 7 mL saturated aqueous sodium bicarbonate solution: 30% hydrogen peroxide 1:1 was 
added. The mixture was stirred until a TLC sample confirmed complete oxidation of DPPE. Chloroform 
(20 mL) was added, the layers were separated and the aqueous layer was extracted twice with 5 mL 
portions of chloroform. Organic layers were combined, washed with brine (20 mL) and dried over 
anhydrous sodium sulfate. The solvent was evaporated and the resulting oil was further purified by flash 
column chromatography (chloroform:ethyl acetate 3:1) yielding 166 mg (0.30 mmol, 74%) of a clear oil. 
1H NMR (400 MHz, CDCl3) δ = 7.85 – 7.75 (m, 2H), 7.37 – 7.22 (m, 12H), 5.09 – 4.90 (m, 4H), 4.51 – 4.38 
(m, 3H), 3.92 (dd, J=22.1, 10.0, 2H), 2.39 (s, 3H), 1.40 (t, J=7.2, 3H). 13C NMR (101 MHz, CDCl3) δ = 159.84, 
153.11 (d, J=13.1), 145.41, 135.97 (d, J=5.9), 135.95 (d, J=5.4), 134.29, 130.20, 128.81, 128.80, 128.74, 
128.33, 128.07, 127.97, 68.87 (d, J=35.6), 68.80 (d, J=35.7),  64.22 (d, J=164.3), 63.48, 48.04, 21.86, 
14.04. 31P NMR (162 MHz, CDCl3) δ = 20.98. Rf: 0.15 (chloroform:ethyl acetate 3:1). LC-MS (ESI): tR = 9.88 
min. HRMS (ESI): for [M+H]+ calc.: 557.15058, found: 557.15055. 
 
Ethyl 4-(bis(benzyloxy)phosphoryl)-1H-imidazole-2-carboxylate (139): In a flame dried 10 mL schlenk 
flask, containing an egg-shaped stirring bar, imidazoline 138 (20 mg, 0.036 mmol, 1 equiv) was dissolved 
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in 0.18 mL of anhydrous DMF. The mixture was cooled to 0°C and DBU (82 mg, 81 µL, 0.54 mmol, 15 
equiv) was added. Upon complete addition a TLC was taken to confirm complete conversion of the 
imidazoline, and the reaction mixture was partitioned between chloroform (5 mL) and saturated 
aqueous sodium bicarbonate solution (5 mL). The layers were separated and the aqueous layer was 
washed with two additional 5 mL portions of chloroform, the organic layers were combined, washed 
with brine and dried over anhydrous sodium sulfate. Evaporation of the solvent yielded a yellow oil 
(quantitative) that was used as is in the next reaction. 31P NMR (162 MHz, CDCl3) δ = 11.49, 7.82. Rf: 0.44 
(ethyl acetate). LC-MS (ESI): tR = 8.81 min. HRMS (ESI): for [M+H]
+ calc.: 401.12608, found: 401.12531. 
 
N-(4-Methoxybenzyl)-4-nitrobenzenesulfonamide (141-S1):  In a 250 mL round bottom flask, containing 
a large, egg-shaped stirring bar, 4-nitrobenzene sulfonylchloride (5.87 g, 26.5 mmol, 1 equiv) was 
dissolved in 80 mL of toluene. The yellow mixture was cooled to 0°C and triethylamine (5.35 g, 7.4 mL, 
53 mmol, 2 equiv) was added, followed by stirring for 30 minutes. 4-Methoxybenzyl amine (3.64 g, 26.5 
mmol, 1 equiv) was added dropwise over 5 minutes, forming a white precipitate. The mixture was 
stirred at 0°C for 30 minutes followed by stirring at room temperature for 4 hours, after which about 
half the toluene was removed in vacuo, followed by filtration. The residue was washed with two 20 mL 
portions of ice cold toluene, dissolved in boiling chloroform (200 mL), transferred to a separatory funnel 
and extracted twice with 100 mL hot water, once with hot brine (50 mL), dried over anhydrous sodium 
sulfate and the solvent was removed in vacuo yielding 7.66 g of an off-white solid (23.8 mmol, 90%). 1H 
NMR (500 MHz, CDCl3:MeOD 1:1) δ 8.38 – 8.19 (m, 2H), 8.04 – 7.87 (m, 2H), 7.06 (ad, J = 8.6, 2H), 6.79 – 
6.65 (m, 2H), 4.29 (s, 1H), 4.08 (s, 2H), 3.73 (s, 3H). 13C NMR (126 MHz, CDCl3:MeOD 1:1) δ 159.53, 
150.07, 147.19, 129.58 (2xCH), 128.77, 128.50 (2xCH), 124.37 (2xCH), 114.16 (2xCH), 55.44, 46.83. Rf: 
0.40 (toluene:ethyl acetate 8:1). Melting point: 137.4oC. LC-MS (ESI): tR = 9.41 min. HRMS (ESI): for [M-H]
- 
calc.: 321.05507, found: 321.05450.  
 
(E)-N,N'-(But-2-ene-1,4-diyl)bis(N-(4-methoxybenzyl)-4-nitrobenzenesulfonamide) (141): In a 250 mL 
round bottom flask, containing an egg-shaped stirring bar, the nosyl amine 141-S1 (7.66 g, 23.8 mmol, 2 
equiv) and 1,4-dibromo-2-butene (2.54 g, 11.9 mmol, 1 equiv) were dissolved in 30 mL DMF, resulting in 
an orange solution. Cesium carbonate (9.3 g, 28.6 mmol, 2.4 equiv) was added turning the mixture into a 
dark grey-green suspension that was stirred for four hours, after which a TLC sample showed complete 
conversion of the starting material. 250 mL water was added precipitating a white solid. The mixture 
was filtered and the residue was washed with 100 mL water followed by two 50 mL portions of ethanol 
and two 50 mL portions of diethylether. The solid was dried in vacuo yielding 8.1 g of an off-white solid 
(11.6 mmol, 98%). The product is very insoluble, hot chloroform seems to work best. 1H NMR (400 MHz, 
CDCl3) δ 8.39 – 8.28 (m, 2H), 8.01 – 7.89 (m, 2H), 7.08 – 6.98 (m, 2H), 6.86 – 6.76 (m, 2H), 5.25 – 5.18 (m, 
1H), 4.20 (s, 2H), 3.78 (s, 3H), 3.70 – 3.58 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 159.70, 150.12, 146.14, 
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129.96, 128.93, 128.37, 126.80, 124.61, 114.27, 55.46, 50.74, 48.33. Rf: 0.63 (toluene:ethyl acetate 3:1). 
Mp: 199.4oC (decomp.). LC-MS (ESI): tR = 10.31 min. HRMS (ESI): for [M+Na]
+ calc.: 719.14521, found: 
719.14451. 
 
N,N'-((2S,3S)-2,3-Dihydroxybutane-1,4-diyl)bis(N-(4-methoxybenzyl)-4-nitrobenzenesulfonamide) 
(142-S1): In a 250 mL three-necked, round bottom flask, fitted with a reflux condenser and an egg-
shaped stirring bar, nosyl amide 141 (8.1 g, 11.6 mmol, 1 equiv) was suspended in 100 mL chloroform, 
water (4.8 mL) and tert-butanol (11.4 mL). Osmium tetroxide as a 4 wt% solution in water (0.73 mL, 0.76 
g, 0.12 mmol 0.01 equiv) was added followed by 4-methylmorphonline N-oxide (4.1 g, 34.8 mmol, 3 
equiv), the resulting mixture was vigorously stirred and heated to 50°C. After stirring for 3 days the 
yellow suspension had turned into an orange solution, a TLC sample confirmed complete conversion of 
the starting material. Sodium thiosulfate (5.5 g, 34.8 mmol, 3 equiv) in 60 mL water was added and 
stirred for an hour to reduce excess osmium tetroxide and 4-methylmorphonline N-oxide, turning the 
water layer of the reaction black. The reaction mixture was transferred to a separatory funnel, the layers 
were separated and the aqueous layer was washed with three 40 mL portions of chloroform. The 
organic layers were combined, washed with water (70 mL), brine (50 mL) and dried over anhydrous 
sodium sulfate. After evaporation of the solvent the resulting off-white solid was re-dissolved in a 
minimal amount of hot chloroform (around 80 mL) and petroleum ether 40-60 was added, precipitating 
a white solid, which was filtered and the residue was washed with two 100 mL portions of petroleum 
ether, dried in vacuo, yielding 7.36 g of a white solid, a second crop yielded 0.73 g for a total of 8.09 g 
(11.1 mmol, 95%). 1H NMR (400 MHz, CDCl3) δ 8.34 (d, J = 8.5, 4H), 7.96 (d, J = 8.6, 4H), 7.12 (d, J = 8.3, 
4H), 6.82 (d, J = 8.3, 4H), 4.43 (d, J = 14.2, 2H), 4.13 (d, J = 14.4, 2H), 3.78 (s, 6H), 3.34 – 3.20 (m, 2H), 
3.08 (d, J = 3.3, 4H), 2.42 (d, J = 4.9, 2H). 13C NMR (101 MHz, CDCl3) δ 159.93, 150.20, 145.20, 130.10, 
128.48, 126.96, 124.59, 114.53, 68.02, 55.46, 53.26, 50.47. Rf: 0.31 (toluene:ethyl acetate 3:1). Melting 
point: 96.6-97.8oC. LC-MS (ESI): tR = 9.55 min. HRMS (ESI): for [M+Na]
+ calc.: 753.15068, found: 
753.15054.  
 
N-(4-Methoxybenzyl)-4-nitro-N-(2-oxoethyl)benzenesulfonamide (142): In a 50 mL round bottom flask, 
equipped with an egg-shaped stirring bar, the diol 142-S1 (800 mg, 1.1 mmol, 1 equiv) was dissolved in 
15 mL 1,4-dioxane, slight heating was required to achieve full dissolution of the diol. Periodic acid (275 
mg, 1.2 mmol, 1.1 equiv) was added, turning the clear solution to a white suspension. The mixture was 
stirred for 90 minutes, after which a TLC sample indicated complete conversion of the starting material. 
Eight milliliters of DCM were added followed by about 2 grams of anhydrous magnesium sulfate were 
added, mixture was stirred for 5 minutes and about 2 grams of celite were added. After an additional 5 
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minutes of stirring the mixture was filtered through celite. The filter cake was washed with two 
additional portions of DCM (8 mL) and the filtrate was evaporated to dryness, yielding a yellow solid that 
was purified by crystallization from chloroform-petroleum ether 40-60, white crystals 734 mg (2 mmol, 
92%). 1H NMR (500 MHz, CDCl3) δ 9.29 (s, 1H), 8.39 (d, J = 8.8, 2H), 8.03 (d, J = 8.8, 2H), 7.16 (d, J = 8.6, 
2H), 6.86 (d, J = 8.6, 2H), 4.37 (s, 2H), 3.92 (s, 2H), 3.80 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 196.62, 
160.42, 150.62, 145.40, 130.64, 128.97, 125.95, 124.83, 114.89, 77.66, 77.56, 77.41, 77.15, 55.93, 55.72, 
52.54. Rf: 0.71 (toluene:ethyl acetate 1:1). Melting point: 149.7-150.4°C. The compound doesn’t show 
up in mass detectors. 
 
(2S)-Allyl 2-(((allyloxy)carbonyl)amino)-4-(N-(2-azido-2-(bis(benzyloxy)phosphoryl)ethyl)-4-
nitrophenylsulfonamido)-4-oxobutanoate (143-S1): Under argon, in a 25 mL, flame dried, round 
bottom schlenk flask containing an egg-shaped stirring bar, azide 144 (1 g, 1.9 mmol, 1 equiv) and amino 
acid 67 (0.58 g, 2.26 mol, 1.2 equiv) were dissolved in 10 mL anhydrous dichloromethane. After cooling 
to 0oC, PyBroP (1.1 g, 2.26 mmol, 1.2 equiv), DIPEA (0.58 g, 0.79 mL, 4.5 mmol, 2.4 equiv) and DMAP 
(276 mg, 2.26 mmol, 1.2 equiv) were added sequentially. After stirring the resulting mixture for 3.5 
hours, a TLC confirmed complete conversion of the azide. The mixture was poured into 10% citric acid 
(10 mL), the layers were separated and the aqueous layer was washed twice with dichloromethane (10 
mL). The organic layers were combined, washed with saturated aqueous sodium hydrogen carbonate 
solution (15 mL), water (15 mL) and brine (10 mL). Drying over anhydrous magnesium sulfate, followed 
by evaporation of the solvent, yielded a yellow oil that was purified further by flash column 
chromatography (chloroform:ethyl acetate 8:1 in increasing gradient to 3:1) yielding 658 mg (0.89 
mmol, 47%) of a yellow oil as a mixture of diastereoisomers (1:1.14 by 31P-NMR). 1H NMR (400 MHz, 
CDCl3) δ = 8.39 – 8.28 (m, 2H), 8.13 – 7.97 (m, 2H), 7.49 – 7.29 (m, 10H), 5.92 – 5.58 (m, 3H), 5.33 – 5.00 
(m, 8H), 4.69 – 4.40 (m, 5H), 4.16 – 3.97 (m, 2H), 3.97 – 3.79 (m, 1H), 3.49 – 2.83 (m, 2H). 13C NMR (101 
MHz, CDCl3) δ = 171.44, 170.24, 170.16, 155.96, 150.97, 144.13, 135.56, 135.49, 132.57, 131.45, 129.77, 
129.26, 129.23, 129.21, 129.06, 128.73, 128.65, 128.63, 124.54, 119.02, 118.90, 118.20, 69.42, 69.39, 
69.36, 69.25, 69.18, 66.67, 66.63, 66.20, 58.17, 56.67, 50.51, 45.66, 45.57, 39.26, 39.11. 31P NMR (162 
MHz, CDCl3) δ = 19.73, 19.71. Rf: 0.43 (chloroform:ethyl acetate 3:1). IR: 2119 (N3). LC-MS (ESI): tR = 10.04 
min. HRMS (ESI): for [M+H]+ calc.: 771.18440, found: 771.18515.  
 
 (2S)-Allyl 2-(allyloxycarbonylamino)-3-(4-(bis(benzyloxy)phosphoryl)-1-(4-nitrophenylsulfonyl)-4,5-
dihydro-1H-imidazol-2-yl)propanoate (143): Under argon, in a 50 mL, flame dried schlenk flask the 
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amide 143-S1 (0.77 g, 1 mmol, 1 equiv) was dissolved in anhydrous THF (25 mL), 1,2-
Bis(diphenylphosphino)ethane (DPPE) (0.60 g, 1.5 mmol, 1.5 equiv) was added in one batch. The schlenk 
flask was closed and immersed in an 80oC oil bath for 8 hours, after which the reaction mixture was 
allowed to cool just below boiling. A one-to-one solution of hydrogen peroxide (30% in water) (15 mL) 
and saturated aqueous sodium hydrogen carbonate (15 mL) was added and the mixture was stirred for 
10 minutes. Once TLC indicated no more un-oxidized DPPE remained, the mixture was transferred to a 
separatory funnel, chloroform (50 mL) and saturated aqueous sodium hydrogen carbonate (50 mL) were 
added, layers separated and the aqueous layer was washed with additional portions of chloroform (2 x 
30 mL). Organic layers were combined, washed with brine (50 mL) and dried over sodium sulfate, 
evaporation yielded an off-white sticky solid that was further purified by filtration over a 4 cm high plug 
of silica and elution with chloroform containing 25% ethyl acetate, yielding 143 as a yellow oil as a 
mixture of diastereoisomers (1:1.24 by 31P-NMR) (0.596 g, 0.82 mmol, 82%). 1H NMR (400 MHz, CDCl3) δ 
= 8.33 – 8.21 (m, 1H), 8.03 – 7.94 (m, 1H), 7.42 – 7.16 (m, 5H), 6.18 – 5.73 (m, 1H), 5.38 – 5.10 (m, 2H), 
5.06 – 4.89 (m, 2H), 4.87 – 4.69 (m, 1H), 4.68 – 4.45 (m, 2H), 4.26 – 4.15 (m, 1H), 4.03 – 3.77 (m, 1H), 
3.50 – 2.93 (m, 1H). 13C NMR (101 MHz, CDCl3) δ = 170.28, 158.55, 150.79, 143.57, 135.97, 135.78, 
132.76, 131.85, 129.03, 128.99, 128.92, 128.61, 128.38, 128.17, 128.14, 125.01, 124.99, 124.60, 118.77, 
118.63, 118.28, 118.07, 90.89, 87.85, 77.43, 73.48, 69.02, 68.96, 68.54, 68.45, 68.38, 66.57, 66.42, 
66.25, 62.23, 60.61, 53.58, 51.24, 50.90, 49.17, 34.30, 32.67, 32.25. 31P NMR (162 MHz, CDCl3) δ 22.26, 
21.84. Rf: 0.31 (chloroform:ethyl acetate 3:1). LC-MS (ESI): tR = 9.91 min. HRMS (ESI): for [M+H]
+ calc.: 
727.18334, found: 727.18373. 
 
1-(Bis(benzyloxy)phosphoryl)-2-(N-(4-methoxybenzyl)-4-nitrophenylsulfonamido)ethyl 
trifluoromethanesulfonate (144-S1): Under argon in a flame dried 50 mL schlenk flask equipped with an 
egg-shaped stirrer bar, alcohol 145 (860 mg, 1.37 mmol, 1 equiv) was dissolved in anhydrous CH2Cl2 (13 
mL). Pyridine (217 mg, 221 µL, 2.74 mmol, 2 equiv) was added in one batch, followed by cooling to -15oC 
with an ice-salt bath. Triflic anhydride (465 mg, 277 µL, 1.65 mmol, 1.5 equiv) was added dropwise over 
5 minutes. After stirring at the same temperature for 3 hours, TLC confirmed complete consumption of 
the starting material. The mixture was poured into an ice cold solution of 5% aqueous citric acid (20 mL). 
The layers were split and the aqueous layer was washed with three portions of CH2Cl2 (20 mL). Organic 
layers are combined, washed with water (50 mL) and brine (50 mL), dried over anhydrous magnesium 
sulfate and the solvent was evaporated, yielding a yellow oil (949 mg, 1.25 mmol, 91%).The oil is co-
evaporated with toluene twice to remove any traces of CH2Cl2, and used in the next reaction without 
further purification due to its instability. 1H NMR (300 MHz, CDCl3) δ 8.25 – 8.14 (m, 2H), 7.81 – 7.71 (m, 
2H), 7.45 – 7.23 (m, 10H), 6.94 (ad, J = 8.6, 2H), 6.76 – 6.64 (m, 2H), 5.12 (td, J = 3.3, 9.1, 1H), 5.06 – 4.92 
(m, 4H), 4.50 – 4.39 (m, 1H), 4.33 – 4.20 (m, 1H), 3.74 (s, 3H), 3.70 – 3.46 (m, 2H). 13C NMR (75 MHz, 
CDCl3) δ 160.00, 150.17, 144.74, 135.01 (d, J = 7.1, C), 134.94 (d, J = 7.4, C), 130.51 (2xCH), 129.28, 
128.96 (2x2CH), 128.75 (2xCH), 128.67 (2xCH), 128.60 (2x2CH), 125.52, 124.42 (2xCH), 114.44 (2xCH), 
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78.95 (d, J = 161.7, CH), 69.70 (d, J = 7.1, CH2), 69.60 (d, J = 6.7, CH2), 55.44, 53.17, 47.48 (d, J = 7.8, CH2). 
19F NMR (282 MHz, CDCl3) δ -73.00. 
31P NMR (121 MHz, CDCl3) δ 14.20. Rf 0.62 (toluene:ethyl acetate 
2:1). HRMS (ESI): for [M+H]+ calc.: 759.10535, found: 759.10565.  
 
Dibenzyl (1-azido-2-(N-(4-methoxybenzyl)-4-nitrophenylsulfonamido)ethyl)phosphonate (144-S2): 
Under an argon atmosphere, in a 25 mL, flame dried schlenk flask, the triflate 144-S1 (949 mg, 1.25 
mmol, 1 equiv) was dissolved in anhydrous acetonitrile (5 mL), after care was taken there was no more 
CH2Cl2 present in the triflate by co-evaporation with toluene. After cooling to 0
oC in an ice bath, 
N,N,N’,N’-tetramethylguanidinium azide (TMGA) (153 mg, 1.5 mmol, 1.2 equiv) is rapidly weighed and 
added to the pink solution in one batch (Caution: very hygroscopic, forms explosive, toxic gas (HN3) upon 
contact with acid). The resulting mixture is allowed to warm up to 5oC in the ice bath over 16 hours, 
after which a TLC sample still showed starting material present, an additional 30 mg (0.29 mmol, 0.24 
equiv) of TMGA was added followed two hours later by another 18 mg (0.18 mmol, 0.14 equiv). Thirty 
minutes after the final addition the starting material was consumed. Reaction mixture was poured into 
saturated aqueous sodium hydrogen carbonate (15 mL), layers were separated and the aqueous layer 
was washed with ethyl acetate (3 x 15 mL). The organic layers were combined, washed with 10% citric 
acid (30 mL), water (30 mL), brine (30 mL) and dried over anhydrous magnesium sulfate. Evaporation of 
the solvent yielded a thick orange oil that was purified by flash column chromatography (toluene 
containing 20% ethyl acetate) yielding a clear oil that solidified on standing (0.62 g, 0.96 mmol, 76%). 1H 
NMR (400 MHz, CDCl3) δ = 8.28 – 8.17 (m, 2H), 7.88 – 7.77 (m, 2H), 7.40 – 7.34 (m, 6H), 7.33 – 7.28 (m, 
4H), 7.12 – 7.02 (m, 2H), 6.84 – 6.70 (m, 2H), 5.10 – 4.91 (m, 4H), 4.35 (s, 2H), 3.83 – 3.67 (m, 4H), 3.45 – 
3.27 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 
13C NMR (101 MHz, CDCl3) δ = 159.95, 150.19, 145.38, 135.59 
(d, J=3.9), 130.14, 129.14, 129.13, 128.98, 128.62, 128.53, 128.49, 126.60, 124.50, 114.49, 69.02 (d, 
J=12.0), 68.95 (d, J=12.3), 57.76 (d, J=151.7), 55.52, 52.99, 47.27 (d, J=7.8). 31P NMR (162 MHz, CDCl3) δ 
20.32. Ir: 2917 (w), 2122 (s), 1609 (m), 1526 (s), 1511 (s), 1456 (m), 1346 (s), 1310 (m), 1214 (s), 1178 
(m), 1157 (m), 1104 (s), 1036 (s), 994 (s), 917 (s), 854 (s), 817 (m), 799 (m), 766 (w), 736 (s), 698 (s), 600 
(s), 580 (m), 558 (m), 518 (m), 501 (m), 460 (m). Rf: 0.63 (toluene:ethyl acetate 2:1). LC-MS (ESI): tR = 
10.31 min. HRMS (ESI): for [M+H]+ calc.: 652.16255, found: 652.16263.  
 
Dibenzyl 1-azido-2-(4-nitrophenylsulfonamido)ethylphosphonate (144):In a 25 mL three-necked, round 
bottom flask containing an egg-shaped stirrer bar, the azide 144-S2 (1.4 g, 2.2 mmol, 1 equiv) was 
dissolved in 1,4-dioxane (9 mL). After complete solution of the starting material water (1 mL) and Ceric 
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ammonium nitrate (3.6 g, 6.6 mmol, 3 equiv) were added, turning the mixture bright orange. After 6.5 
hours TLC showed complete conversion of the starting material. The reaction mixture was partitioned 
between water (25 mL) and ethyl acetate (25 mL), the aqueous layer was washed with additional ethyl 
acetate (2 x 25 mL), the organic layers were combined, washed with brine (50 mL) and dried over 
anhydrous magnesium sulfate. Evaporation yielded an orange oil that was purified by flash column 
chromatography (toluene with 4% ethyl acetate gradient 20% ethyl acetate at which point compound 
was eluted) evaporation of the solvent yielded a white solid (941 mg, 1.87 mmol, 85%). 1H NMR (400 
MHz, CDCl3) δ 8.24 – 8.16 (m, 2H), 8.02 – 7.89 (m, 2H), 7.44 – 7.28 (m, 10H), 6.51 – 6.41 (m, 1H), 5.16 – 
4.95 (m, 4H), 3.88 – 3.72 (m, 1H), 3.45 – 3.31 (m, 1H), 3.24 – 3.05 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 
150.24, 145.81, 135.43 (d, J = 5.8, 1C), 135.37 (d, J = 5.9, 1C), 129.27, 129.25, 129.05, 128.51, 128.50, 
128.46, 124.61, 69.33 (d, J = 7.2, 1C), 69.30 (d, J = 7.0, 1C), 57.72 (d, J = 154.4, 1C), 42.69 (d, J = 4.7, 1C). 
31P NMR (162 MHz, CDCl3) δ 20.60. Ir: 3105 (w), 2870 (w), 2102 (s), 1528 (s), 1455 (m), 1342 (s), 1307 
(m), 1238 (s), 1213 (m), 1164 (s), 996 (s), 852 (s), 729 (s). Rf: 0.19 (toluene:ethyl acetate 4:1). Melting 
point: 82.5°C. LC-MS (ESI): tR = 9.28 min. HRMS (ESI): for [M+H]
+ calc.: 532.10503, found: 532.10471. 
 
Dibenzyl (2-(N-(4-methoxybenzyl)-4-nitrophenylsulfonamido)-1-
((trimethylsilyl)oxy)ethyl)phosphonate (145-S1): Under an argon atmosphere, in a 500 mL flame dried 
schlenk flask, dibenzylphosphite (12 g, 10 mL, 45.6 mmol, 1.2 equiv) and triethylamine (5.5 g, 7.6 mL, 55 
mmol, 1.44 equiv) were dissolved in 150 mL of anhydrous dichloromethane. The resulting mixture was 
cooled to 0oC with an ice bath, and chlorotrimethylsilane (6.0 g, 6.8 mL, 55 mmol, 1.44 equiv) was added 
dropwise over 5 minutes. After addition was complete, the mixture was stirred for 1 hour at the same 
temperature. The reaction mixture was cooled to -78oC with acetone-dry ice and 142 (13.8 g, 38 mmol, 1 
equiv), dissolved in 110 mL dichloromethane, was added via cannula. Upon addition the mixture’s 
changes color from clear to slightly yellow. After stirring for 16 hours the complete consumption of the 
reaction is confirmed by TLC. The reaction mixture is poured into saturated aqueous NH4Cl (250 mL), a 
white precipitate forms that was dissolved by addition of a small amount of water (15 mL). The layers 
are split and the aqueous layer was washed with three 100 mL portions of dichloromethane. The organic 
layers are combined and sequentially washed with aqueous saturated sodium hydrogen carbonate (200 
mL), water (200 mL) and brine (200 mL); dried over anhydrous magnesium sulfate and the solvent is 
evaporated. The resulting crude oil was purified by filtration through a short 4 cm silica plug 
(toluene:ethyl acetate 9:1) followed by crystallization from hot methanol yielding a yellow solid (15.3 g, 
29.1 mmol, 57%). 1H NMR (300 MHz, CDCl3) δ 8.15 – 8.01 (m, 2H), 7.73 – 7.61 (m, 2H), 7.40 – 7.27 (m, 
10H), 6.98 – 6.88 (m, 2H), 6.75 – 6.61 (m, 2H), 5.08 – 4.89 (m, 4H), 4.53 (d, J = 15.1, 1H), 4.40 – 4.29 (m, 
2H), 3.73 (s, 3H), 3.56 – 3.26 (m, 2H), 0.18 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 159.65, 149.79, 145.82, 
136.17 (d, J = 5.9), 136.13 (d, J = 5.8), 130.32, 129.17 (toluene), 128.82, 128.77, 128.52, 128.37, 128.34, 
126.99, 125.43 (toluene), 124.11, 114.13, 69.67 (d, J = 163.3), 68.37 (d, J = 16.3), 68.27 (d, J = 16.6), 
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55.42, 53.44, 50.01 (d, J = 10.6), 21.59 (toluene), 0.34. 31P NMR (121 MHz, CDCl3) δ 22.31. Rf: 0.15 
(toluene:ethyl acetate 4:1). Mp: 110.9oC.  
 
Dibenzyl 1-hydroxy-2-(N-(4-methoxybenzyl)-4-nitrophenylsulfonamido)ethylphosphonate (145): In a 
250 mL round bottom flask, containing a larger egg-shaped stirring bar, the TMS protected nosyl amine 
145-S1 (15.3 g, 22 mmol, 1 equiv) was suspended in 140 mL methanol. Potassium fluoride (2.6 g, 44 
mmol, 2 equiv) was added in one batch, after stirring for a few minutes the suspension becomes a clear 
solution. Stirring was continued for an hour, after which a TLC sample indicated complete conversion of 
the starting material. The reaction mixture was poured into a separatory funnel containing saturated 
aqueous ammonium chloride (200 mL); ethyl acetate (200 mL) was added and the layers were 
separated. The aqueous layer was washed with two additional portions of ethyl acetate (200 mL), 
organic layers were combined, washed with saturated aqueous sodium hydrogen carbonate (300 mL), 
water (300 mL) and brine (300 mL), the mixture was dried over anhydrous sodium sulfate and 
evaporation of the solvent yielded a white amorphous solid (12.8 g, 20.4 mmol, 93%) that required no 
further purification. 1H NMR (400 MHz, CDCl3) δ = 8.21 (d, J=8.6, 2H), 7.86 (d, J=8.7, 2H), 7.37 – 7.32 (m, 
6H), 7.32 – 7.27 (m, 4H), 7.08 (d, J=8.5, 2H), 6.74 (d, J=8.6, 2H), 5.09 – 4.90 (m, 4H), 4.44 – 4.33 (m, 2H), 
3.98 (t, J=7.9, 1H), 3.53 (ddd, J=15.6, 10.2, 5.4, 1H), 3.47 – 3.33 (m, 2H). 13C NMR (101 MHz, CDCl3) δ = 
159.84, 150.10, 145.81, 135.97 (d, J=5.8), 130.20, 128.91, 128.90, 128.67, 128.30, 128.26, 126.84, 
124.41, 114.42, 68.69 (d, J=7.0), 68.64 (d, J=7.1), 67.20 (d, J=158.7), 55.48, 52.4548.96 (d, J=10.0). 31P 
NMR (162 MHz, CDCl3) δ = 22.76. Rf: 0.25 (toluene:ethyl acetate 2:1). LC-MS (ESI): tR = 9.65 min. HRMS 
(ESI): for [M+H]+ calc.: 627.15606, found: 627.15621.  
 
Imidazole 148: In a flame dried 10 mL Schlenk flask, under argon, imidazoline 68 (60 mg, 0.086 mmol, 1 
equiv) was dissolved in 1 mL THF. The mixture was cooled to -78°C and KHMDS 0.5 M in toluene (0.52 
mL, 0.26 mmol, 3 equiv) was slowly added. The mixture was stirred for eight hours and halve (0.75 mL) 
of it was removed and worked-up. To the remainder Boc2O (38 mg, 0.17 mmol, 2 equiv) was added in 
0.3 mL THF and the mixture was stirred for three hours while warming to room temperature. The 
mixture was poured into saturated aqueous sodium bicarbonate (5 mL) and the aqueous layer was 
extracted three times with ethyl acetate (5 mL). The organic layers were combined, washed with brine 
(10 mL), dried over anhydrous sodium sulfate and the solvent was removed in vacuo. The residual 
brown oil was not purified further. 1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 1.5 Hz, 1H), 7.26 – 7.09 (m, 
11H), 5.82 – 5.55 (m, 2H), 5.52 (dd, J = 9.9, 4.8 Hz, 1H), 5.21 – 4.82 (m, 8H), 4.55 – 4.30 (m, 4H), 3.82 (dd, 
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J = 15.2, 4.9 Hz, 1H), 3.49 (dd, J = 15.2, 9.9 Hz, 1H), 1.46 (s, 9H), 1.25 (s, 9H). 31P NMR (162 MHz, CDCl3) δ 
11.18. LC-MS (ESI): tR = 10.84 min. 
 
 
(S)-Allyl 2-(allyloxycarbonylamino)-3-(4-(bis(benzyloxy)phosphoryl)-1-trityl-1H-imidazol-2-
yl)propanoate (149): Under an argon atmosphere, crude imidazole 136 (10.1 mmol, assumed) was 
added to a schlenk flask containing a magnetic stirring bar. Anhydrous dichloromethane (55 mL) was 
added, followed by trityl chloride (5.6 g, 20.2 mmol, 2 equiv) and DBU (4.6 g, 4.5 ml, 30.3 mmol, 3 
equiv). To the brown mixture silver triflate (5.7 g, 22.2 mmol, 2.2 equiv) was added in one batch, 
forming a suspension. After stirring for 2 hours a TLC sample indicated complete consumption of the 
starting material, the reaction mixture was filtered through a plug of celite to remove the silver 
precipitates. The resulting filtrate was added to 100 mL saturated aqueous sodium bicarbonate solution. 
The layers were split and the aqueous layer was washed with three 50 mL portions of dichloromethane. 
The organic layers were combined, washed with brine (150 mL) and dried over anhydrous sodium 
sulfate. Evaporation of the solvent in vacuo yielded a brown oil that was purified by flash column 
chromatography (toluene:ethyl acetate 3:1), yielding 6.11 g (7.8 mmol, 77% over two steps) of a brown 
oil.1H NMR (400 MHz, CDCl3) δ 7.47 (s, 1H), 7.40 – 7.20 (m, 19H), 7.11 – 6.96 (m, J = 3.0, 6.5, 6H), 5.95 – 
5.79 (m, 1H), 5.79 – 5.62 (m, 2H), 5.33 – 5.02 (m, 8H), 4.57 – 4.32 (m, 5H), 2.52 (dd, J = 4.8, 17.1, 1H), 
2.04 (dd, J = 4.0, 17.2, 1H). 13C NMR (101 MHz, CDCl3) δ 170.7, 155.9, 149.0 (d, J = 21.6, C), 140.9, 136.4 
(d, J = 6.9, 2C), 132.74, 131.74, 131.5 (d, J = 38.2, CH), 129.8, 128.38, 128.36, 128.31, 127.63, 127.57, 
126.0 (d, J = 247.8, C), 117.9, 117.6, 75.8, 67.9 (d, J = 5.6, 2CH), 65.7, 65.7, 51.4, 32.4.  31P NMR (162 
MHz, CDCl3) δ 12.6. Rf: 0.19 (toluene:ethyl acetate 3:1). LC-MS (ESI): tR = 10.81 min. HRMS (ESI): for 
[M+H]+ calc.: 782.29896, found: 782.29946. []
 +17.6°  (c=0.0095, CHCl3). 
 
 (S)-Tert-butyl 2-(3-(allyloxy)-2-(allyloxycarbonylamino)-3-oxopropyl)-4-(bis(benzyloxy)phosphoryl)-
1H-imidazole-1-carboxylate (150): In a 25 mL round bottom flask, containing an egg-shaped stirring bar, 
crude imidazole 136 (556 mg, 1.03 mmol, 1 equiv) was dissolved in 4.44 mL 1,4-dioxane. DIPEA (133 mg, 
179 µL, 1.03 mmol, 1 equiv) was added followed by 0.56 mL water. The resulting mixture was cooled to 
0oC and boc anhydride (225 mg, 1.03 mmol, 1 equiv) was added. The mixture was stirred for 16 hours 
while warming to room temperature in the ice bath. A TLC sample indicated complete conversion of the 
starting material; the reaction mixture was poured into a saturated aqueous sodium bicarbonate 
solution (10 mL) and ethyl acetate (10 mL). The layers were separated and the aqueous layer was 
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washed with three additional portion of ethyl acetate (10 mL). The organic layers were combined, 
washed with brine (20 mL) and dried over anhydrous sodium sulfate. The solvent was evaporated, 
yielding an oil that was purified by flash column chromatography (chloroform:ethyl acetate:triethyl 
amine 82:17:1) yielded a clear oil (433 mg, 0.68 mmol, 66%). 1H NMR (500 MHz, CDCl3) δ 7.80 (s, 1H), 
7.52 – 7.15 (m, 11H), 5.97 (d, J = 9.1, 1H), 5.85 – 5.65 (m, 2H), 5.28 – 4.97 (m, 9H), 4.88 – 4.77 (m, 1H), 
4.58 – 4.34 (m, 4H), 3.60 (dd, J = 5.7, 16.9, 1H), 3.41 (dd, J = 4.3, 16.8, 1H), 1.54 (s, 9H). 13C NMR (126 
MHz, CDCl3) δ 170.7, 155.9, 149.0 (d, J = 20.2, C), 146.8, 136.04 (d, J = 7.4, C), 136.03 (d, J = 6.8, C), 
132.6, 131.6, 130.0, 128.7 (d, J = 36.1, C), 128.47, 128.45, 128.3, 127.8, 127.8, 118.40, 118.37, 117.8, 
87.1, 77.3, 77.0, 76.8, 68.10 (d, J = 5.5, C), 68.08 (d, J = 5.4, C), 66.1, 65.9, 51.6, 32.3, 27.9. 31P NMR (162 
MHz, CDCl3) δ 10.7. Rf: 0.24 (chloroform:ethyl acetate:triethylamine 5:1:0.01). LC-MS (ESI): tR = 10.61 
min. HRMS (ESI): for [2M+Na] + calc.: 1301.45835, found: 1301.45884. []
 +21.1°  (c=0.01, CHCl3). 
 
 (S)-3-(4-(Bis(benzyloxy)phosphoryl)-1H-imidazol-2-yl)-2-(tert-butoxycarbonylamino)propanoic acid 
(339): Boc-protected imidazole 150 (54 mg, 0.08 mmol, 1 equiv) was dissolved in THF (1 mL), phenyl 
silane (46 mg, 52 µL, 0.42 mmol, 5 equiv) and tetrakis(triphenylphosphine)palladium (9.2 mg, 0.008 
mmol, 0.1 equiv) were added and the resulting mixture was stirred for 2 hours, slowly turning black. 
Mesitylene was added and the mixture was evaporated to dryness, after repeating this twice, the 
residue was dissolved in water and acetonitrile and purified by prep-HPLC obtaining a white amorphous 
solid 27 mg (0.05 mmol, 65%). 1H NMR (400 MHz, CDCl3) δ = 10.95 (bs, 3H), 7.49 (s, 1H), 7.29 (s, 10H), 
6.36 (s, 1H), 5.18 – 5.00 (m, 4H), 4.62 (s, 1H), 3.59 (d, J=13.6, 1H), 3.45 – 3.23 (m, 1H), 1.29 (d, J=9.4, 9H). 
13C NMR (101 MHz, CDCl3) δ = 173.38, 162.53 (d, J=35.5), 156.18, 149.15 (d, J=14.5), 135.26 (d, J=6.3), 
128.98, 128.84, 128.52, 128.42, 128.39, 116.79 (d, J=292.1), 80.47, 69.37 (d, J=5.6), 69.36 (d, J=5.4), 
52.73, 30.08, 28.32. 31P NMR (162 MHz, CDCl3) δ = 6.02. Rf: 0.10 (ethyl acetate). LC-MS (ESI): tR = 8.27 
min. HRMS (ESI): for [M+H]+ calc.: 516.18941, found: 516.18878.  
Prep-HPLC conditions solvent A was water with 0.1 % TFA, solvent B was acetonitrile:  
Time (min) B (%) 
0 10 
1 10 
10 60 
12 100 
14 100 
14.1 10 
17 10 
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(S)-Allyl 2-(allyloxycarbonylamino)-3-(4-(bis(benzyloxy)phosphoryl)-1-(4-methoxybenzyl)-1H-imidazol-
2-yl)propanoate (155): Under an argon atmosphere crude imidazole 136 (2.8 mmol, assumed) was 
added to a schlenk flask containing a magnetic stirring bar. Anhydrous DMF (15 mL) was added, followed 
by 4-methoxybenzyl chloride (657 mg, 570 µL, 4.2 mmol, 1.5 equiv) and potassium carbonate (1.93 g, 14 
mmol, 5 equiv). After stirring for 3 hours a TLC sample indicated complete consumption of the starting 
material, the reaction mixture was added to 50 mL ethyl acetate and 50 mL saturated aqueous sodium 
bicarbonate solution. The layers were split and the aqueous layer was washed with three 50 mL portions 
of ethyl acetate. The organic layers were combined, washed with brine (2 x 150 mL) and dried over 
anhydrous sodium sulfate. Evaporation of the solvent in vacuo yielded a yellow oil that was purified by 
flash column chromatography (chloroform:ethyl acetate 2:1), yielding 155 as a yellow oil that consisted 
of a mixture of regio-isomers (N-1: N-3 protection 5.7:1 by 31P-NMR) 1.56 g (2.4 mmol, 84% over two 
steps). Only the major isomer is reported. 1H NMR (400 MHz, CDCl3) δ = 7.40 – 7.21 (m, 11H), 7.02 (ad, 
J=8.5, 2H), 6.92 – 6.81 (m, 2H), 6.43 (d, J=8.7, 1H), 5.96 – 5.63 (m, 2H), 5.28 – 4.99 (m, 8H), 4.94 (s, 2H), 
4.83 – 4.72 (m, 1H), 4.59 – 4.50 (m, 2H), 4.50 – 4.41 (m, 2H), 3.78 (s, 3H), 3.34 (dd, J=15.9, 5.0, 1H), 3.07 
(dd, J=15.9, 4.7, 1H). 13C NMR (101 MHz, CDCl3) δ = 170.50, 159.82, 156.03, 146.99 (d, J=22.1), 136.44 (d, 
J=7.4, 2C), 132.66, 131.52, 130.21 (d, J=36.8), 128.94, 128.43, 128.12, 128.06 (d, J=247.6),  127.78, 
126.49, 118.48, 117.80, 114.65, 7.85 (d, J=5.5), 67.84 (d, J=5.4), 66.16, 65.89, 55.38, 51.99, 49.73, 28.93. 
31P NMR (162 MHz, CDCl3) δ = 12.65 (N-1), 9.32 (N-3). Rf: 0.71 (chloroform:methanol 9:1). LC-MS (ESI): tR 
= 9.37 min. HRMS (ESI): for [M+H]
 + calc.: 660.24693, found: 660.24661.  
 
(S)-2-(((9H-Fluoren-9-yl)methoxy)carbonylamino)-3-(4-(bis(benzyloxy)phosphoryl)-1-(4-
methoxybenzyl)-1H-imidazol-2-yl)propanoic acid (156): Under argon, in a 50 mL schlenk flask, equipped 
with an egg-shaped stirring bar, imidazole 155 (1.54 g, 2.3 mmol, 1 equiv) was dissolved in anhydrous 
THF (15 mL) and phenylsilane (1.26 g, 1.4 mL, 11.6 mmol, 5 equiv) was added, followed by palladium 
tetrakis(triphenylphosphine) (266 mg, 0.23 mmol, 0.1 equiv). Immediately after addition was complete, 
the mixture turned yellow and bubbles formed. As the mixture aged, it slowly turned black. After 1 hour 
the reaction mixture was transferred to a 100 mL round bottom flask and the solvent was evaporated in 
vacuo. The residue was suspended in 20 mL mesitylene and evaporated to dryness on a rotary 
evaporator equipped with a dry ice cooler and connected to an oil pump; this procedure was repeated 
twice to remove excess phenylsilane. The resulting black solid was not purified further and used ‘as is’ 
immediately in the next step. 31P NMR (162 MHz, CDCl3) δ 13.8 (broad). Rf: 0.04 (chloroform:methanol 
9:1). LC-MS (ESI): tR = 6.75 min. HRMS (ESI): for [M+H]
+ calc.: 536.19450, found: 536.19387. The crude 
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mixture (2.3 mmol, assumed) was dissolved in dioxane (12 mL), upon complete dissolution, water (1.2 
mL) was added followed by Fmoc-OSu (1164 mg, 3.45 mmol 1.5 equiv) and sodium hydrogen carbonate 
(290 mg, 3.45 mmol, 1.5 equiv). The mixture was stirred at room temperature for 16 hours, when a TLC 
sample (Ethyl acetate or CHCl3 containing 10% MeOH) indicated complete consumption of the starting 
material. Water (10 mL) and chloroform (10 mL) were added and the mixture was acidified to pH 4 with 
0.5 M aqueous potassium hydrogen sulfate solution. The layers were separated and the aqueous layer 
was washed with 3 additional portions of chloroform (10 mL), the organic layers were combined, 
washed with brine and dried over anhydrous sodium sulfate. Evaporation of the solvent yielded a black 
foam that was further purified by flash column chromatography (chloroform:methanol 99:1 in 
increasing gradient to 49:1) yielding 0.893 g (1.18 mmol, 51% over two steps) of a dirty brown foam 
solid.1H NMR (400 MHz, CDCl3) δ = 10.85 (s, 1H), 7.74 (d, J=7.5, 2H), 7.57 (t, J=6.9, 2H), 7.41 – 7.34 (m, 
2H), 7.33 – 7.17 (m, 13H), 7.05 (d, J=8.3, 2H), 6.85 (d, J=8.5, 2H), 6.54 (d, J=5.8, 1H), 5.14 – 4.96 (m, 6H), 
4.62 – 4.53 (m, 1H), 4.39 – 4.21 (m, 2H), 4.14 (t, J=7.3, 1H), 3.77 (s, 3H), 3.48 (dd, J=15.7, 4.3, 1H), 3.23 
(dd, J=15.6, 8.0, 1H). 13C NMR (101 MHz, CDCl3) δ = 171.73, 160.31, 156.09, 147.77 (d, J=15.5), 143.93, 
143.69, 141.38, 135.67 (d, J=6.1), 135.61 (d, J=6.0), 134.66, 129.76 (d, J=31.4), 129.68, 128.61, 128.59, 
128.23, 127.88, 127.24, 125.31 (d, J=8.0), 125.02, 120.11, 114.97, 68.75, 68.70, 67.40, 55.48, 52.30, 
50.59, 47.15, 28.94. 31P NMR (162 MHz, CD3CN) δ = 11.93. Rf: 0.12 (chloroform:methanol 9:1). LC-MS 
(ESI): tR = 9.63 min. HRMS (ESI): for [M+H]
+ calc.: 758.26258, found: 758.26231. []
 +18.7°  (c=0.015 
g/mL, CHCl3). 
 
  
 (S)-Allyl 2-(((allyloxy)carbonyl)amino)-3-(5-(bis(benzyloxy)phosphoryl)-1-(2,4-dimethoxybenzyl)-1H-
imidazol-2-yl)propanoate (160): in a 10 mL round bottom flask imidazole 136 (60 mg, 0.11 mmol, 1 
equiv) was dissolved in 3.5 mL dichloromethane. To the mixture DIPEA (23 mg, 31 µL, 0.18 mmol, 1.6 
equiv) and freshly prepared 1,4-dimethoxybenzyl chloride (31 mg 0.17 mmol, 1.5 equiv) were added. 
After stirring for 16 hours the reaction had still not gone to full conversion but work-up was performed 
anyway. The mixture was poured into 5 mL chloroform and 5 mL saturated aqueous sodium bicarbonate 
solution. The layers were split and the aqueous layer was washed with three 5 mL portions of 
chloroform. The organic layers were combined, washed with brine (2 x 150 mL) and dried over 
anhydrous sodium sulfate. Evaporation of the solvent in vacuo yielded a yellow oil that was not purified 
further. 31P NMR (162 MHz, CDCl3) δ 9.22 (160). LC-MS (ESI): tR =  9.39 min (160). 
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(S)-Allyl 2-(allyloxycarbonylamino)-3-(4-(bis(benzyloxy)phosphoryl)-1-(2,4-dimethoxybenzyl)-1H-
imidazol-2-yl)propanoate (161): Under argon, in a flame dried, 50 mL schlenk flask imidazole 136 (2.9 
mmol, 1 equiv) was dissolved in anhydrous DMF (13 mL) and potassium carbonate (2 g, 14.5 mmol, 5 
equiv) was added. To the suspension, freshly prepared 1,4-dimethoxybenzyl chloride (0.65 g, 3.5 mmol, 
1.2 equiv) in 2 mL DMF, was added by syringe. Resulting mixture was stirred for 2 hours, a TLC sample 
indicated there was still starting material left. A second portion of 1,4-dimethoxybenzyl chloride (0.22 g, 
1.16 mmol, 0.4 equiv) in 1 mL DMF was added and the reaction mixture was stirred for 16 hours, after 
which the starting material was consumed. The reaction mixture was transferred to a 100 mL round 
bottom flask and the DMF was evaporated in vacuo on a rotary evaporator equipped with a dry ice 
condenser and an oil pump. The residue was partitioned between ethyl acetate (50 mL) and saturated 
sodium hydrogen carbonate (50 mL), the layers were separated and the aqueous layer was washed with 
additional portions of ethyl acetate (2 x 50 mL). The organic layers were combined and washed with 
brine (100 mL), dried over sodium sulfate and the solvent was evaporated, yielding a yellow oil. Further 
purification was done via flash column chromatography (chloroform with 33% ethyl acetate) yielding a 
yellow oil (1.25 g, 1.8 mmol, 62%), containing 5.6% of the 160. 1H NMR (400 MHz, CDCl3) δ 7.39 (s, 1H), 
7.37 – 7.22 (m, 10H), 6.94 (d, J = 8.7, 1H), 6.50 – 6.41 (m, 2H), 5.95 – 5.80 (m, 1H), 5.80 – 5.66 (m, 1H), 
5.32 – 5.01 (m, 8H), 4.93 – 4.89 (m, 2H), 4.87 – 4.77 (m, 1H), 4.54 (m, 2H), 4.49 (ad, J = 5.6, 2H), 3.80 (s, 
3H), 3.77 (s, 3H), 3.45 (dd, J = 5.0, 16.0, 1H), 3.16 (dd, J = 4.6, 16.1, 1H). 13C NMR (101 MHz, CDCl3) δ 
170.80, 161.81, 158.45, 156.27, 147.22, 147.01, 136.72, 136.64, 134.92, 132.88, 131.77, 130.76, 130.65, 
130.39, 128.68, 128.59, 128.25, 128.12, 128.08, 127.93, 118.56, 117.94, 115.57, 104.72, 99.09, 68.02, 
67.99, 67.96, 67.94, 66.28, 66.05, 55.69, 55.62, 52.13, 45.42, 29.02. 31P NMR (162 MHz, CDCl3) δ 12.94 
(161), 9.22 (160). Rf: 0.70 (chloroform:methanol 9:1). LC-MS (ESI): tR = 9.51 min (161), 9.39 min (160). 
HRMS (ESI): for [M+H]+ calc. 690.25749, found: 690.25666. 
 
 (S)-2-(((9H-Fluoren-9-yl)methoxy)carbonylamino)-3-(4-(bis(benzyloxy)phosphoryl)-1-(2,4-
dimethoxybenzyl)-1H-imidazol-2-yl)propanoic acid (162): Under argon, in a 50 mL schlenk flask, 
equipped with an egg-shaped stirring bar, imidazole 161 (1 g, 1.45 mmol, 1 equiv) was dissolved in 
anhydrous THF (8 mL) and phenylsilane (785 mg, 0.89 mL, 7.25 mmol, 5 equiv) was added, followed by 
palladium tetrakis(triphenylphosphine) (168 mg, 0.15 mmol, 0.1 equiv). Immediately after addition is 
complete, the mixture turns yellow and bubbles are formed. As the mixture ages, it slowly turns black. 
After 1 hour the reaction mixture is transferred to a 25 mL round bottom flask and the solvent in 
evaporated. The residue is suspended in 4 mL mesitylene and evaporated to dryness on a rotary 
evaporator equipped with a dry ice cooler and an oil pump, this procedure is repeated twice to remove 
excess phenylsilane. The resulting black solid is not purified further and used ‘as is’ in the next step. 31P 
NMR (162 MHz, CDCl3) δ 14.08. Rf: 0.08 (chloroform:methanol 9:1). LC-MS (ESI): tR 6.93 min. HRMS (ESI): 
for [M+H]+ calc.: 279.09333, found: 279.09346. In a 25 mL round bottom flask containing an egg-shaped 
stirring bar, the black oil (2.3 mmol, 1 equiv) was dissolved in dioxane (10.8 mL) followed by addition of 
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sodium hydrogen carbonate (290 mg, 3.45 mmol, 1.5 equiv), water (1.2 mL) and Fmoc-OSu (1.16 g, 3.45 
mmol, 1.5 equiv). The resulting mixture was stirred for 16 hours after which a TLC sample indicated full 
consumption of the starting material. The reaction mixture was poured into water (20 mL) and 
chloroform (20 mL) was added. The pH of the water layer was adjusted to pH 4 with 0.5M aqueous 
potassium hydrogen sulfate (approximately 1 mL was added), the layers were separated and the 
aqueous layer was washed with additional chloroform (2 x 15 mL). The organic layers were combined, 
washed with brine (20 mL), dried over anhydrous sodium sulfate and the solvent was removed yielding 
an brown oil; this was further purified by flash column chromatography (chloroform : methanol : 
(methanol : water : acetic acid : ethyl acetate 3:3:2:3) 6:0.24:0.1) yielding 915 mg (1.16 mmol, 50.4% 
over two steps) of a brown oil. 1H NMR (400 MHz, CD3CN) δ 7.76 (d, J = 7.5, 2H), 7.55 (d, J = 4.7, 2H), 
7.43 (s, 1H), 7.35 (t, J = 6.9, 3H), 7.30 – 7.19 (m, 11H), 7.18 – 7.06 (m, 2H), 6.92 (d, J = 7.8, 1H), 6.54 – 
6.38 (m, 2H), 5.09 – 4.92 (m, 6H), 4.73 – 4.60 (m, 1H), 4.30 – 4.01 (m, 3H), 3.73 (s, 3H), 3.69 (s, 3H), 3.54 
– 3.37 (m, 2H). 13C NMR (101 MHz, CD3CN) δ 172.57 (C), 162.99 (C), 159.64 (C), 157.13 (C), [144.95, 
144.86, 142.06, 136.84, 132.32, 129.49, 129.48, 129.08, 129.05, 128.71, 128.13, 126.20] This area is 
unresolvable, 120.96 (2xCH), 115.40 (C), 105.95 (CH), 99.71 (CH), 69.46 (2xCH2), 67.66 (CH2), 56.32 (CH3), 
56.15 (CH3), 53.09 (CH), 47.87 (CH), 47.17 (CH2), 29.03 (CH2). No phosphorus couplings were observed. 
31P NMR (162 MHz, CD3CN) δ 7.97. Rf: 0.15 (chloroform 10% methanol). LC-MS (ESI): tR = 10.08 min. 
HRMS (ESI): for [M+H]+ calc. 788.27314, found: 788.27264. 
 
Dibenzyl (1-azido-2-(N-tosylformamido)ethyl)phosphonate (165): In a flame dried schlenk flask, under 
argon, azide 66 (1.5 g, 3.0 mmol, 1 equiv) was dissolved in THF (15 mL) and cooled to 0°C. 1H-
benzo[d][1,2,3]triazole-1-carbaldehyde 72 (0.88 g, 6 mmol, 2 equiv) was added followed by sodium 
hydride (0.14 g, 3.6 mmol, 1.2 equiv). The mixture was stirred for 30 minutes after which it was poured 
into saturated aqueous sodium bicarbonate (50 mL) and ethyl acetate (50 mL). The layers were 
separated and the aqueous layer was washed with two additional portions of ethyl acetate (50 mL). The 
organic layers were combined, washed with water (100 mL), brine (100 mL) and dried over anhydrous 
sodium sulfate. The solvent was evaporated and the residual oil was purified by column chromatography 
(toluene:ethyl acetate 24:1 in increasing gradient to 4:1) yielding a yellow oil (0.89 g, 1.7 mmol, 76%). 1H 
NMR (400 MHz, CDCl3) δ 9.11 (s, 1H), 7.65 (d, J = 8.4 Hz, 2H), 7.42 – 7.22 (m, 12H), 5.16 – 4.96 (m, 4H), 
4.09 – 3.84 (m, 2H), 3.66 – 3.51 (m, J = 14.4 Hz, 1H), 2.44 (s, 3H). 31P NMR (162 MHz, CDCl3) δ 20.00. Rf: 
0.29 (toluene:ethyl acetate 4:1) 
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Dibenzyl (1-tosyl-4,5-dihydro-1H-imidazol-4-yl)phosphonate (166): In a flame dried, 250 mL round 
bottom Schlenk, containing an argon atmosphere, formamide 165 (887 mg, 1.7 mmol, 1 equiv) was 
dissolved in 40 mL THF. dppe (1016 mg, 2.55 mmol, 1.5 equiv) was added, the mixture was warmed to 
50°C and stirred until no more nitrogen bubble formation was seen. The Schlenk was closed and heated 
to 80°C for eight hours. The mixture was allowed to cool to about 50°C and a 1:1 mixture of 30% 
hydrogen peroxide (aq) and saturated sodium bicarbonate (aq) was added. The mixture was stirred for 
one hour, after which a TLC sample indicated all dppe had been completely oxidized. The mixture was 
poured into water (100 mL) and chloroform (150 mL), the layers were separated and the aqueous layer 
was washed with two additional 50 mL portions of chloroform. The organic layers were combined and 
washed with brine (200 mL). Evaporation of the solvent yielded a sticky white solid that was purified by 
passing through a short silica column (chloroform:ethyl acetate 3:1) yielding a clear oil (720 mg, 1.5 
mmol, 87%). 1H NMR (400 MHz, CDCl3) δ 7.72 – 7.62 (m, 2H), 7.40 (dd, J = 3.6, 2.3 Hz, 1H), 7.37 – 7.20 
(m, 12H), 4.97 (dd, J = 11.4, 8.5 Hz, 4H), 4.43 (dddd, J = 15.7, 11.1, 8.8, 2.3 Hz, 1H), 3.75 – 3.55 (m, 2H), 
2.40 (s, 3H). 31P NMR (162 MHz, CDCl3) δ 21.99. 
 
 
Dibenzyl 1-trityl-1H-imidazol-4-ylphosphonate (167):  
Method A: In a flame dried, argon filled, 10 mL schlenk imidazoline 166 (46 mg, 0.095 mmol, 1 equiv) 
was dissolved in 0.5 mL THF. The mixture was cooled to -78°C and KHMDS 0.5M in toluene (0.38 mL, 
0.19 mmol, 2 equiv) was added drop wise. The mixture was stirred for two hours until all starting 
material was consumed (TLC chloroform:ethyl acetate 3:1). Trityl chloride (40 mg, 0.143 mmol, 1.5 
equiv) was added and the mixture was allowed to warm to room temperature. It was poured into 
saturated aqueous sodium bicarbonate (10 mL) and the aqueous phase was washed with three 10 mL 
portions of chloroform. The organic layers were combined, washed with brine (20 mL) and dried over 
anhydrous sodium sulfate. Removal of the solvent yielded a clear oil that contained 50 percent 167 and 
50 percent the unprotected imidazole, no yield was determined. 
Method B: To a flame-dried, argon filled 500 ml Schlenk flask equipped with a large egg-shaped stirring 
bar was added 4-iodo-1-trityl-1H-imidazole (8.00 g, 18.33 mmol), followed by anhydrous THF (100 mL). 
The suspension was briefly heated to 50°C to complete dissolution. The clear solution was cooled to 0°C 
and i-PrMgCl:LiCl (14.8 mL, 1.3 M in THF, 1.05 equiv 19.25 mmol) was added drop-wise over 10 min. The 
resulting clear reaction was stirred for 20 min at 0°C, followed by another 20 min at room temperature. 
The reaction mixture was cooled to -78°C in a acetone-dry ice bath and bis(diethylamino)phosphine 
chloride (4.76 g, 20.16 mmol, 1.10 equiv) was added drop-wise via a syringe over 10 min. The resulting 
clear reaction mixture was aged for 1 hour at -78°C, then allowed to reach ambient temperature over 2 
hours. The Schlenk-flask was connected at the side arm to a large-bore cold trap and the THF was 
removed via vacuum transfer. After complete removal of THF, benzyl alcohol (10.0 g, 82 mmol, 5.05 
equiv) was added, followed by anhydrous acetonitrile (60 mL) and the resulting pink reaction mixture 
was cooled to 0°C. A solution of tetrazole in acetonitrile (6 mL, 0.3 M, 1.80 mmol, 0.10 equiv) was added 
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in one portion and the reaction mixture was allowed to reach ambient temperature and stirred over 
night (12 hours). Upon aging, the reaction mixture turns pale yellow and a thick precipitate is formed. 
The suspension was cooled to -20°C in an ice-salt bath and ice-cold 30% aq. hydrogen peroxide (8.00 mL, 
70.58 mmol, 3.85 equiv) was added drop wise over 5 min. The reaction mixture was allowed to rise to 
0°C over an hour and stirred at 0°C for another hour, when 5% aq Na2CO3 (100 mL) was added, followed 
by Ethyl acetate (100 mL). The resulting white suspension was stirred in the schlenk tube for 10 min, and 
subsequently transferred to a separatory funnel. The mixture was diluted with another 100 mL of water 
and extracted with additional Ethyl acetate (2x100 mL). The combined organic extracts were washed 
with 5% aq sodium thiosulfate (100 mL), followed by water (200 mL) and brine (2x200 mL), dried over 
Na2SO4 and evaporated to dryness. Traces of MeCN and some BnOH were removed by drying on oil-
pump vacuum for 3 hours. The resulting yellow residue (20 g) was dissolved in a small amount of Ethyl 
acetate (10 mL) and cyclohexane (30 mL) was added. The solution was added to a silica gel pad (diam. 80 
mm, 200 mm length, 20% Ethyl acetate in cyclohexane), the excess of BnOH was eluted at 20:80 ethyl 
acetate: cyclohexane, followed by the product when increasing the gradient stepwise from 20:80 to 
80:20 ethyl acetate: cyclohexane. Evaporation of combined fractions yielded 6.2 g of clear oil, 10.86 
mmol, 59% yield. 1H NMR (400 MHz, CDCl3) δ 7.58 – 7.53 (m, 1H), 7.53 – 7.50 (m, 1H), 7.36 – 7.29 (m, 
4H), 7.29 – 7.15 (m, 15H), 7.10 – 6.97 (m, 6H), 5.20 – 5.04 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 141.42 
(3C), 141.17 (d, J = 22.0, 1C), 135.99 (d, J = 6.6, 2C), 130.67 (d, J = 38.4, 1C), 129.25 (3x2C), 128.62 (d, J = 
247.9, 1C), 128.05 (3x1C & 2x2C), 127.95 (3x2C), 127.81 (2C), 127.48(2x2C), 75.64, 67.46 (d, J = 5.5, 2C). 
31P NMR (162 MHz, CDCl3) δ 13.18. Rf: 0.44 (c-hexane: ethyl acetate 1:4). LC-MS (ESI): tR = 10.99 min. 
HRMS (ESI): for [M+H]+ calc.: 571.21451, found: 571.21389. 
 
Dibenzyl (2-((tert-butyldimethylsilyl)oxy)-1-hydroxyethyl)phosphonate (170): In a 250 mL round 
bottom flask TMS-ether 171 (5.34 g, 10.5 mmol, 1 equiv) was dissolved in 100 mL methanol. Citric acid 
(5.04 g, 26.2 mmol, 2.5 equiv) was added and the mixture was stirred until complete consumption of the 
starting material. It was then added to 2.77 g sodium carbonate in 100 mL water. Ethyl acetate (200 mL) 
was added, the layers were separated and the aqueous layer was washed with two additional 100 mL 
portions of ethyl acetate. The organic layers were combined, washed with brine (200 mL), dried over 
anhydrous sodium sulfate and the solvent was evaporated yielding a yellow oil (4.5 g, 10.3 mmol, 98%). 
1H NMR (400 MHz, CDCl3) δ 7.34 – 7.22 (m, 10H), 5.12 – 4.92 (m, 4H), 4.07 (q, J = 7.1 Hz, 1H), 4.03 – 3.93 
(m, 1H), 3.91 – 3.77 (m, 2H), 2.77 (dd, J = 14.1, 5.8 Hz, 1H), 0.82 (s, 9H), -0.00 (s, 6H). 31P NMR (162 MHz, 
CDCl3) δ 23.97. 
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Dibenzyl (2,2,7,7,8,8-hexamethyl-3,6-dioxa-2,7-disilanonan-4-yl)phosphonate (171): Under an argon 
atmosphere, in a 250 mL flame dried schlenk flask, dibenzylphosphite (4 g, 3.4 mL, 15.3 mmol, 1.2 equiv) 
and triethylamine (1.9 g, 2.56 mL, 18.4 mmol, 1.44 equiv) were dissolved in 50 mL of anhydrous 
dichloromethane. The resulting mixture was cooled to -20oC with an ice-salt bath, and 
chlorotrimethylsilane (2.0 g, 2.27 mL, 18.4 mmol, 1.44 equiv) was added dropwise over 5 minutes. After 
addition was complete, the mixture was stirred for one hour at -20°C, and a white precipitate formed. 
The reaction mixture was cooled to -78oC with acetone-dry ice and (TBS-oxy)acetaldehyde 169, 
dissolved in 50 mL dichloromethane, was added via cannula. Upon addition, the white precipitate 
dissolved. After stirring for 16 hours, complete consumption of the aldehyde was confirmed by TLC. The 
reaction mixture was poured into saturated aqueous NH4Cl (100 mL). The layers were split and the 
aqueous layer was washed with three 50 mL portions of dichloromethane. The organic layers were 
combined and sequentially washed with aqueous saturated sodium hydrogen carbonate (100 mL), water 
(100 mL) and brine (100 mL); dried over anhydrous magnesium sulfate and the solvent was evaporated. 
The resulting crude oil was purified by flash column chromatography (toluene:ethyl acetate 9:1) yielding 
171 (5.34 g, 10.5 mmol, 69%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.39 – 7.24 (m, 10H), 5.13 – 
4.91 (m, 4H), 4.06 (ddd, J = 9.5, 8.1, 2.9 Hz, 1H), 3.90 (ddd, J = 10.9, 5.8, 2.9 Hz, 1H), 3.72 (ddd, J = 10.9, 
8.2, 6.1 Hz, 1H), 0.84 (s, 9H), 0.11 (s, 9H), 0.00 (s, 3H), -0.00 (s, 3H). 31P NMR (162 MHz, CDCl3) δ 23.62. 
 
TBS-protected nosyl phosphonate (172): in a 25 mL round bottom flask, under air, alcohol 170 (100 mg, 
0.23 mmol, 1 equiv) was dissolved in dichloromethane (2.3 mL). 4-nitrobenzene sulphonylchloride (56 
mg, 0.25 mmol, 1.1 equiv) and DMAP (31 mg, 0.25 mmol, 1.1 equiv) were added and the mixture was 
stirred two hours. 10 mL dichloromethane was added and the mixture was poured into 10 % citric acid 
(20 mL). The aqueous layer was extracted once with dichloromethane (15 mL), the organic layers were 
combined, washed with saturated aqueous sodium bicarbonate (20 mL), brine (20 mL) and dried over 
magnesium sulfate. Evaporation of the solvent in vacuo yielded a colorless oil (140 mg, 0.23 mmol, 
98%). 1H NMR (400 MHz, CDCl3) δ = 8.15 – 8.09 (m, 2H), 8.01 – 7.96 (m, 2H), 7.35 – 7.17 (m, 10H), 5.09 – 
4.82 (m, 5H), 4.04 (ddd, J=12.8, 9.8, 3.1, 1H), 3.94 (ddd, J=12.1, 7.3, 4.8, 1H), 0.84 – 0.82 (m, 9H), 0.01 (s, 
3H), -0.00 (s, 3H). 31P NMR (162 MHz, CDCl3) δ = 17.21. LC-MS (ESI): tR = 9.03 min. HRMS (ESI): for [M+H]
+ 
calc.: 525.10911, found: 525.10873. 
 
Dibenzyl 1-azido-2-(tert-butyldimethylsilyloxy)ethylphosphonate (173): Under an argon atmosphere, 
in a 100 mL, flame dried schlenk flask, triflate 174 (5.8 g, 10.3 mmol, 1 equiv) was dissolved in anhydrous 
acetonitrile (34 mL), after taken care there was no more CH2Cl2 present in the triflate by co-evaporation 
with toluene. N,N,N’,N’-tetramethylguanidinium azide (1.26 g, 12.3 mmol, 1.2 equiv) is rapidly weighed 
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and added to the pink solution in one batch (Caution: very hygroscopic, forms explosive, toxic gas upon 
contact with acid). The resulting mixture is stirred at room temperature for 3 hours, after which a TLC 
showed remaining starting material. Another batch of N,N,N’,N’-tetramethylguanidinium azide (0.13 g, 
1.23 mmol, 0.12 equiv) was added and 15 minutes later the starting material was completely consumed. 
Reaction mixture is poured into saturated aqueous sodium hydrogen carbonate (50 mL), layers are 
separated and the aqueous layer is washed with ethyl acetate (3 x 30 mL). The organic layers are 
combined, washed with 10% citric acid (50 mL), water (50 mL), brine (50 mL) and dried over anhydrous 
magnesium sulfate. Evaporation of the solvent yielded a thick pink oil that was purified by filtration 
through a silica plug (toluene:ethyl acetate 6:1) yielding a pink oil (3.93 g, 8.5 mmol, 83%). 1H NMR (400 
MHz, CDCl3) δ 7.43 – 7.29 (m, 10H), 5.22 – 4.98 (m, 4H), 4.03 (ddd, J = 3.2, 8.9, 11.0, 1H), 3.87 (ddd, J = 
4.2, 8.4, 10.9, 1H), 3.64 (ddd, J = 3.2, 8.4, 15.1, 1H), 0.90 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H). 13C NMR (101 
MHz, CDCl3) δ 135.82 (d, J = 9.4, C), 135.77 (d, J = 9.3, C), 128.65 (br, 2x2CH&2xC), 128.14 (2x2CH), 68.43 
(d, J = 17.8, CH2), 68.35 (d, J = 17.8, CH2), 62.44 (d, J = 6.3, CH2), 60.28 (d, J = 155.5, CH), 25.75 (3xCH3), 
18.21, -5.52 (2xCH3). 
31P NMR (162 MHz, CDCl3) δ 21.26. Rf: 0.58 (toluene:ethyl acetate 3:1) IR = 3035 
(w), 2954 (w), 2929 (w), 2885 (w), 2857 (w), 2093 (m), 1498 (w), 1457 (w), 1380 (w), 1314 (w), 1252 (s), 
1213 (m), 1112 (m), 1080 (m), 992 (s), 918 (w), 833 (s), 778 (s), 732 (s), 695 (s), 665 (m), 618 (w). LC-MS 
(ESI): tR = 11.56 min. HRMS (ESI): for [M+H]
+ calc.: 462.19725, found: 462.19718.  
 
1-(Bis(benzyloxy)phosphoryl)-2-((tert-butyldimethylsilyl)oxy)ethyl trifluoromethanesulfonate (174): In 
an argon filled, flame dried 250 mL Schlenk, alcohol 170 (4.5 g, 10.3 mmol, 1 equiv) was dissolved in 100 
mL dichloromethane and cooled to -15°C. Pyridine (1.6 g, 1.65 mL, 20.5 mmol, 2 equiv) and triflic 
anhydride (4.34 g, 2.6 mL, 15.4 mmol, 1.5 equiv) were added and stirred for two hours. The mixture was 
poured into 200 mL ice cold five percent citric acid (aq) and the aqueous layer was washed three times 
with 100 mL dichloromethane. The organic layers were combined, washed with brine (200 mL) and dried 
over anhydrous sodium sulfate. Removal of the solvent in vacuo gave 174 as a yellow oil (5.6 g, 9.9 
mmol, 96%) that required no further purification. 1H NMR (400 MHz, CDCl3) δ 7.41 – 7.27 (m, 10H), 5.05 
(ddd, J = 9.5, 9.0, 6.1 Hz, 5H), 4.02 (ddd, J = 12.3, 5.9, 2.8 Hz, 1H), 3.92 (ddd, J = 12.3, 8.4, 3.8 Hz, 1H), 
0.94 – 0.80 (m, 9H), 0.04 (d, J = 1.3 Hz, 6H). 31P NMR (162 MHz, CDCl3) δ 14.80. 
19F NMR (377 MHz, CDCl3) 
δ -74.79. 
 
 
(2S)-Allyl 2-(((allyloxy)carbonyl)amino)-4-((1-(bis(benzyloxy)phosphoryl)-2-((tert-
butyldimethylsilyl)oxy)ethyl)amino)-4-oxobutanoate (175): In a 100 mL round bottom flask, amino acid 
67 (1.6 g, 6.3 mmol, 1.25 equiv) was dissolved in 26 mL dichloromethane. EDC (1.26 g, 6.6 mmol, 1.3 
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equiv) and DMAP (0.062 g, 0.51 mmol, 0.1 equiv) were added and the mixture was stirred for five 
minutes. Amine 75 (2.2 g, 5.1 mmol, 1 equiv) was added and the mixture was stirred for five hours. The 
mixture was poured into five percent aqueous citric acid (30 mL) and the aqueous layer was washed 
three times with dichloromethane (20 mL). The organic layers were combined, washed with saturated 
aqueous sodium bicarbonate (50 mL), water (50 mL) and brine (50 mL). The mixture was dried over 
anhydrous sodium sulfate and the solvent was removed. The residual oil was purified by column 
chromatography (toluene:ethyl acetate 4:1) resulting in a yellow oil (2.3 g, 3.4 mmol, 67%) as a mixture 
of diastereomers. 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.17 (m, 10H), 6.00 (dd, J = 21.5, 9.0 Hz, 1H), 5.92 – 
5.74 (m, 3H), 5.37 – 5.06 (m, 4H), 5.06 – 4.87 (m, 4H), 4.67 – 4.37 (m, 6H), 4.02 – 3.86 (m, 1H), 3.86 – 
3.67 (m, 1H), 3.02 – 2.79 (m, 1H), 2.64 (ddd, J = 24.0, 16.1, 4.4 Hz, 1H), 0.84 (d, J = 1.6 Hz, 9H), 0.01 (dd, J 
= 3.9, 1.6 Hz, 6H). 31P NMR (162 MHz, CDCl3) δ 24.58, 24.43. LC-MS (ESI): tR = 8.40 min. HRMS (ESI): for 
[M+H]+ calc.: 675.28667, found: 675.28701.  
 
 
(2S)-Allyl 2-(((allyloxy)carbonyl)amino)-4-((1-(bis(benzyloxy)phosphoryl)-2-hydroxyethyl)amino)-4-
oxobutanoate (176): In a 24 mL round bottom flask, TBS protected alcohol 175 (555 mg, 0.82 mmol, 1 
equiv) was dissolved in 4.1 mL wet THF. HF.pyridine (212 mg, 233 µL, 7.35 mmol, 9 equiv) was added 
and the mixture was stirred for four hours. The mixture was poured into saturated aqueous sodium 
bicarbonate (20 mL) and the aqueous layer was extracted three times with ethyl acetate (15 mL). The 
organic layers were combined, washed with brine (20 mL), dried over anhydrous sodium sulfate and the 
solvent was removed in vacuo. The resulting yellow oil required no further purification (454 mg, 0.81 
mmol, 99%). 1H NMR (400 MHz, CDCl3) δ 7.41 – 7.26 (m, 10H), 6.20 – 6.07 (m, 1H), 5.94 – 5.74 (m, 2H), 
5.36 – 4.89 (m, 8H), 4.66 – 4.35 (m, 6H), 4.03 – 3.90 (m, 1H), 3.87 – 3.67 (m, 2H), 2.95 – 2.60 (m, 2H). 31P 
NMR (162 MHz, CDCl3) δ 25.23, 25.08. LC-MS (ESI): tR = 8.44 min. HRMS (ESI): for [M+H]
+ calc.: 
561.200196, found: 561.19988.  
 
Dibenzyl (1,3-dithian-2-yl)(hydroxy)methylphosphonate (178): In a 100 mL three-necked, round 
bottom flask containing an egg-shaped stirring bar, TMS protected alcohol 182 (3.12 g, 6.5 mmol, 1 
equiv) was dissolved in methanol (30 mL). Potassium fluoride (0.76 g, 13 mmol, 2 equiv) was added in 
one batch, dissolving completely. After 30 minutes, TLC indicated complete consumption of the starting 
material. The reaction mixture was poured into a separatory funnel containing saturated aqueous 
ammonium chloride (50 mL) and ethyl acetate (50 mL). The layers were split and the aqueous layer was 
washed with two additional portions of ethyl acetate (30 mL), organic layers were combined, washed 
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with saturated aqueous sodium hydrogen carbonate (30 mL), water (30 mL) and brine (30 mL), the 
mixture was dried over anhydrous sodium sulfate and evaporation of the solvent yielded a white solid 
(2.5 g, 6.09 mmol, 94%) that required no further purification. 1H NMR (400 MHz, CDCl3) δ = 7.40 – 7.28 
(m, 10H), 5.22 – 4.97 (m, 4H), 4.34 – 4.20 (m, 2H), 2.96 – 2.85 (m, 2H), 2.77 – 2.65 (m, 2H), 2.10 – 1.86 
(m, 2H). 13C NMR (126 MHz, CDCl3) δ = 134.32 (d, J = 11.4 Hz), 134.26 (d, J = 11.6 Hz), 126.67, 126.66, 
126.20, 126.15, 125.09, 68.30 (d, J = 164.4 Hz), 66.82 (d, J = 6.7 Hz), 66.29 (d, J = 7.0 Hz), 44.77 (d, J = 4.8 
Hz), 26.24, 25.64, 23.09. 31P NMR (162 MHz, CDCl3) δ 22.61. LC-MS (ESI): tR = 8.68 min. HRMS (ESI): for 
[M+H]+ calc.: 411.08481, found: 411.08504. 
 
(S)-Allyl 2-(((allyloxy)carbonyl)amino)-4-amino-4-oxobutanoate (181): In a 250 mL round bottom flask, 
under air, asparagines monohydrate (5 g, 33.3 mmol, 1 equiv) was dissolved in 100 mL water. Sodium 
bicarbonate (5.6 g, 66.6 g, 2 equiv) was added followed by slow addition of allyl chloroformate (3.7 mL, 
4.2 g, 35 mmol, 1.05 equiv) over six hours while ensuring the mixture is basic the whole time. After 
addition was complete the mixture was stirred for 30 minutes. The mixture was frozen and the solvent 
removed via lyophilization. The white solid residue was suspended in ethanol and filtered; the residue 
was washed three times with ethanol. The combined filtrates were evaporated to dryness in vacuo 
yielding a white foam (quantitative yield). 1H NMR (400 MHz, CD3OD) δ = 6.01 – 5.84 (m, 1H), 5.30 (ddd, 
J=17.3, 3.1, 1.6, 1H), 5.17 (ddd, J=10.5, 2.8, 1.4, 1H), 4.93 (bs, 4H), 4.60 – 4.43 (m, 3H), 2.75 (dd, J=6.0, 
4.1, 2H). LC-MS (ESI): tR = 4.61 min. HRMS (ESI): for [M+H]
+ calc.: 217.08190, found: 217.08203. In a 50 
mL round bottom flask, the mono protected amino acid (500 mg, 2.3 mmol, 1 equiv) was dissolved in 9 
mL DMF. Allyl bromide (339 mg, 242 mL, 2.8 mmol, 1.2 equiv) and cesium carbonate (1.12 g, 3.45 mmol, 
1.5 equiv) were added and the reaction was stirred for eight hours. The mixture was added to 20 mL 1N 
HCl (aq) and the aqueous layer was extracted three ties with ethyl acetate (20 mL). The organic layers 
were combined, washed with brine (50 mL) twice, dried over anhydrous magnesium sulfate and 
evaporated to dryness yielding a clear oil that solidifies on standing to a white solid (514 mg, 2.11 mmol, 
92%). 1H NMR (400 MHz, CDCl3) δ 6.05 – 5.82 (m, 3H), 5.62 (bs, 1H), 5.52 b(s, 1H), 5.38 – 5.16 (m, 4H), 
4.70 – 4.52 (m, 5H), 3.03 – 2.95 (m, 1H), 2.78 (dd, J = 16.2, 4.1 Hz, 1H). LC-MS (ESI): tR = 4.50 min.  
 
Dibenzyl (1,3-dithian-2-yl)(trimethylsilyloxy)methylphosphonate (182): Under an argon atmosphere, in 
a 250 mL flame dried schlenk flask, dibenzylphosphite (4.1 g, 3.45 mL, 15.6 mmol, 1.2 equiv) and 
triethylamine (1.9 g, 2.6 mL, 18.7 mmol, 1.44 equiv) were dissolved in 50 mL of anhydrous 
dichloromethane. The resulting mixture was cooled to -20oC with an ice-salt bath, and 
chlorotrimethylsilane (2.0 g, 2.73 mL, 18.7 mmol, 1.44 equiv) was added dropwise over 5 minutes. After 
addition was complete, the mixture was stirred for one hour at the same temperature. The reaction 
mixture was cooled to -78oC with acetone-dry ice and 1,3-dithiane-2-carbaldehyde (1.93 g, 13 mmol, 1 
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equiv), dissolved in 20 mL dichloromethane, was added via cannula. After stirring for 16 hours the 
complete consumption of the aldehyde was confirmed by TLC. The reaction mixture was poured into 
saturated aqueous NH4Cl (100 mL), the layers were split and the aqueous layer was washed with three 
50 mL portions of dichloromethane. The organic layers were combined and sequentially washed with 
aqueous saturated sodium hydrogen carbonate (100 mL), water (100 mL) and brine (100 mL); dried over 
anhydrous magnesium sulfate and the solvent was evaporated. The resulting crude oil was purified by 
flash column chromatography (toluene:ethyl acetate 9:1) yielding 182 (3.17g, 6.6 mmol, 50%) as a 
colorless oil. 1H NMR (400 MHz, CDCl3) δ = 7.24 – 7.10 (m, 10H), 4.99 – 4.71 (m, J = 25.9, 11.8, 7.5 Hz, 
4H), 4.28 (dd, J = 7.5, 4.4 Hz, 1H), 4.12 (dd, J = 9.2, 4.4 Hz, 1H), 2.78 – 2.58 (m, 4H), 1.94 – 1.80 (m, 1H), 
1.78 – 1.58 (m, 1H), -0.00 (s, 9H). 31P NMR (162 MHz, CDCl3) δ = 22.13. LC-MS (ESI): tR = 8.59 min. HRMS 
(ESI): for [M+H]+ calc.: 483.12434, found: 483.12411. 
O
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Phosphonate (183): At 40°C, sodium periodate (120 mg, 0.56 mmol, 2.3 equiv) was added to a stirring 
solution of dithiane 178 (100 mg, 0.24 mmol, 1 equiv) in dioxane (1 mL) and water (0.6 mL) and stirred 
for 16 hours. The reaction was poured into saturated aqueous sodium bicarbonate solution (10 mL) and 
ethyl acetate (10 mL). The layers were separated and the aqueous phase was washed with 3 additional 
portion of ethyl acetate (10 mL), the organic layers were combined, washed with brine (20 mL) and 
dried over anhydrous sodium sulfate. After evaporation of the solvent the residue was further purified 
by flash column chromatography (chloroform:methanol 15:1) yielding 38 mg (0.086 mmol, 36%) of a 
yellow oil still containing about six percent 184. 1H NMR (400 MHz, CDCl3) δ = 7.39 – 7.25 (m, 11H), 5.25 
– 5.01 (m, 6H), 3.87 (t, J = 2.9 Hz, 1H), 3.63 – 3.49 (m, 1H), 3.01 (td, J = 12.2, 2.6 Hz, 2H), 2.88 – 2.65 (m, 
2H), 2.34 – 2.24 (m, 1H). 13C NMR (126 MHz, CDCl3) δ = 135.98 (d, J = 5.6 Hz), 135.95 (d, J = 5.6 Hz), 
128.88, 128.85, 128.45, 128.44, 128.39, 74.83 (d, J = 5.8 Hz), 69.54 (d, J = 7.4 Hz), 69.18 (d, J = 6.9 Hz), 
64.88 (d, J = 167.5 Hz), 51.16, 46.85, 15.20. 31P NMR (162 MHz, CDCl3) δ = 20.71. LC-MS (ESI): tR = 6.95 
min. HRMS (ESI): for [M+H]+ calc.: 443.07464, found: 443.07454. 
 
 (S)-Tert-butyl 4-(N-((1,3-dioxolan-2-yl)methyl)-4-methylphenylsulfonamido)-2-(tert-
butoxycarbonylamino)-4-oxobutanoate (187): Under an argon atmosphere, a 100 mL round bottom 
schlenk flask containing an egg-shaped stirring bar, was charged with HOAt ester 191 (2.57 g, 6.31 
mmol, 1 equiv) and anhydrous dichloromethane (50 mL). The reaction was cooled to 0oC with an ice 
bath and N-allyl-4-methylbenzenesulfonamide (1.79 g, 6.94 mmol, 1.1 equiv) was added, followed by 
addition of 1,8-diazabicyclo-undec-7-ene (1.44 g, 1.42 mL, 9.46 mmol, 1.5 equiv), which turned the 
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reaction mixture yellow. After stirring for 15 minutes the ice bath was removed and the solution was 
allowed to stand at room temperature for an hour. The mixture was poured into 10 % aqueous citric 
acid (50 mL), the layers were separated and the organic layer was washed with an additional portion of 
10 % aqueous citric acid (50 mL), two 50 mL portions of saturated aqueous sodium hydrogencarbonate 
and 50 mL brine. Drying over anhydrous magnesium sulfate and evaporation of the solvent yielded a 
yellow oil that was purified further by flash column chromatography over silica (Petroleum ether (40-60) 
with 33% ethyl acetate) yielding a white foam (2.34 g,  4.43 mmol, 70%). 1H NMR (400 MHz, CDCl3) δ 
7.83 (ad, J = 8.4, 2H), 7.28 (d, J = 8.4, 2H), 5.43 (d, J = 8.6, 1H), 5.17 (t, J = 4.0, 1H), 4.38 – 4.28 (m, 1H), 
4.06 – 3.90 (m, 4H), 3.90 – 3.79 (m, 2H), 3.25 (dd, J = 4.1, 17.7, 1H), 3.06 (dd, J = 3.8, 17.8, 1H), 2.39 (s, 
3H), 1.38 (s, 9H), 1.25 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 171.69, 169.89, 155.74, 145.02, 136.62, 
129.76 (2xCH), 128.58 (2xCH), 101.74, 82.07, 79.82, 65.29, 65.25, 50.43, 47.96, 39.11, 28.50 (3xCH3), 
27.80 (3xCH3), 21.77. Rf: 0.35 (petroleum ether:ethyl acetate 2:1). Melting point: 87.2-89.1
oC. LC-MS 
(ESI): tR = 10.51 min. HRMS (ESI): for [M+H]
+ calc.: 529.22143, found: 529.22119. 
 
(S)-4-(3H-[1,2,3]Triazolo[4,5-b]pyridin-3-yl) 1-tert-butyl 2-(tert-butoxycarbonylamino)succinate (191): 
In a 50 mL round bottom flask, containing an egg-shaped stirring bar, L-Aspartic acid, N-[(1,1-
dimethylethoxy)carbonyl]-, 1-(1,1-dimethylethyl) ester (1 g, 3.46 mmol, 1 equiv) was dissolved in 20 mL 
dichloromethane. The mixture was cooled to 0oC and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(1 g, 5.2 mmol, 1.5 equiv) was added, followed by spoon wise addition of 1-hydroxyazabenzotriazole 
(612 mg, 4.5 mmol, 1.3 equiv) turning the mixture orange. The mixture was allowed to warm up in the 
ice bath over 16 hours, changing the color to yellow, after which a TLC confirmed complete conversion 
of the starting material. The mixture was poured into 10 % aqueous citric acid (20 mL), the layers were 
separated and the organic layer was washed with two additional portions of 10 % aqueous citric acid (20 
mL), once with brine (20 mL) and dried over anhydrous magnesium sulfate. Evaporation of the solvent 
yielded a white foam (1.2 g, 2.9 mmol, 85%).1H NMR (400 MHz, CDCl3) δ 8.70 (dd, J = 4.5, 1.4 Hz, 1H), 
8.41 (dd, J = 8.4, 1.4 Hz, 1H), 7.44 (dd, J = 8.4, 4.5 Hz, 1H), 5.62 (d, J = 7.4 Hz, 1H), 4.66 (d, J = 6.5 Hz, 1H), 
3.49 (dd, J = 17.1, 4.3 Hz, 1H), 3.39 (dd, J = 17.1, 5.2 Hz, 1H), 1.48 (s, 9H), 1.46 (s, 9H). 
 
 (R)-Tert-butyl 4-(N-allyl-4-methylphenylsulfonamido)-2-(tert-butoxycarbonylamino)-4-oxobutanoate 
(192): Under an argon atmosphere, a round bottom schlenk flask containing an egg-shaped stirring bar, 
was charged with HOAt ester 191 (1 g, 2.45 mmol, 1 equiv) and anhydrous dichloromethane (20 mL). 
The reaction was cooled to 0oC with an ice bath and N-allyl-4-methylbenzenesulfonamide (570 mg, 2.7 
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mmol, 1.1 equiv) was added, followed by addition of 1,8-diazabicyclo-undec-7-ene (560 mg, 0.55 mL, 
3.68 mmol, 1.5 equiv), which turned the reaction mixture yellow. After stirring for 15 minutes the ice 
bath was removed and the solution was allowed to stand at room temperature for an hour. The mixture 
was poured into 10 % aqueous citric acid (20 mL), the layers were separated and the organic layer was 
washed with an additional portion of 10 % aqueous citric acid (20 mL), two 20 mL portions of saturated 
aqueous sodium hydrogencarbonate and 20 mL brine. Drying over anhydrous magnesium sulfate and 
evaporation of the solvent yielded a yellow oil that was purified further by flash column 
chromatography over alumina (toluene 5% ethyl acetate gradient, compound eluted at 10% ethyl 
acetate) yielding a white solid (924 mg, 1.9 mmol, 78%). 1H NMR (400 MHz, CDCl3) δ 7.81 (ad, J = 8.3, 
2H), 7.32 (ad, J = 8.2, 2H), 5.84 (ddd, J = 5.4, 10.4, 15.8, 1H), 5.47 (d, J = 9.0, 1H), 5.32 – 5.17 (m, 2H), 
4.52 – 4.31 (m, 3H), 3.31 (dd, J = 4.3, 17.8, 1H), 3.02 (dd, J = 3.6, 17.9, 1H), 2.42 (s, 3H), 1.41 (s, 9H), 1.30 
(s, 9H). 13C NMR (101 MHz, CDCl3) δ 171.02, 169.90, 155.70, 145.12, 136.42, 132.48, 129.85, 128.31, 
118.55, 82.14, 79.87, 50.42, 48.66, 39.23, 28.44, 27.82, 21.74. Rf: 0.55 (toluene:ethyl acetate 3:1). 
Melting point: 64.1oC. LC-MS (ESI): tR = 10.35 min. HRMS (ESI): for [M+H]
+ calc.: 483.21595, found: 
483.21584. 
 
Dibenzyl 2-iodo-1-(4-methoxybenzyl)-1H-imidazol-4-ylphosphonate (212): At -78°C imidazole 211 (2.23 
g, 5.0 mmol, 1 equiv) was dissolved in 35 mL anhydrous THF. 1.5 M t-butyl lithium in pentane (4.0 mL, 6 
mmol, 1.2 equiv) was slowly added over 5 minutes. The mixture was stirred for 20 minutes, after which 
iodine (1.9 g, 7.5 mmol, 1.5 equiv) in 7 mL THF was slowly added until the iodine color persisted (about 
5.5 mL was added). The reaction was poured into saturated aqueous sodium thiosulfate solution (50 mL) 
and ethyl acetate (50 mL). The layers were separated and the aqueous phase was washed with 3 
additional portion of ethyl acetate (30 mL), the organic layers were combined, washed with brine (50 
mL) and dried over anhydrous sodium sulfate. After evaporation of the solvent the residue consisted of 
three main products, 2-iodoimidazole 212, 5-iodoimidazole and 2,5 diiodoimidazole. The mixture was 
further purified by flash column chromatography (chloroform:methanol 49:1) yielding 487 mg (0.85 
mmol, 17%) of a clear colorless oil. 1H NMR (400 MHz, CDCl3) δ = 7.63 (d, J=2.3, 1H), 7.33 – 7.27 (m, 4H), 
7.26 – 7.17 (m, 6H), 7.02 (t, J=5.9, 2H), 6.87 – 6.77 (m, 2H), 5.16 – 5.01 (m, 4H), 4.99 (s, 2H), 3.74 (s, 3H). 
31P NMR (162 MHz, CDCl3) δ = 11.29. LC-MS (ESI): tR = 8.42 min. HRMS (ESI): for [M+H]
+ calc.: 575.05911, 
found: 575.05901. 
 
16.2.1 General procedure for the synthesis of amides 227a-t 
This procedure was followed in all cases unless stated otherwise. In a 25 mL round bottom flask, 
containing an egg-shaped stirring bar, azide 66 (1 equiv) was dissolved in 2 mL anhydrous THF. While 
stirring, DIPEA (2 equiv) and DMAP (1 equiv) were added, followed by the acid chloride (2 equiv). Upon 
addition of the acid chloride a white precipitate formed, turning the reaction to a thick suspension. After 
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stirring for 1 hour at room temperature, a TLC sample indicated complete conversion of the starting 
azide and the reaction was quenched by addition of 5 mL saturated aqueous sodium bicarbonate, this 
dissolved the white precipitate. The resulting mixture was poured into 10 mL of ethyl acetate, the layers 
were separated and the aqueous layer was washed with 2 additional 10 mL portions of ethyl acetate. 
The organic layers were combined, washed with 10% aqueous citric acid (20 mL), brine (20 mL) and 
dried over anhydrous sodium sulfate. The solvent was removed by evaporation in vacuo and the residue 
was further purified by column chromatography. 
 
2-Azido-2-bis(benzyloxy)phosphoryl-N-acetyl-N-(4-toluenesulfonyl)-ethanamine (227a): In a 10 mL 
pear shaped flask, acetyl chloride (0.109 mL, 1.54 mmol, 2.0 equiv) was added to a solution of 2-azido-2-
bis(benzyloxy)phospholyl-N-bis(4-toluenesulfonyl)-ethanamine 66 (385 mg, 0.77 mmol, 1.0 equiv), 
DIPEA (0.268 mL, 1.54 mmol, 2.0 equiv) in THF (1.5 mL) at 0 °C. Upon addition of the acid chloride a 
white precipitate formed, turning the reaction to a thick suspension. After stirring for 1 hour at room 
temperature, a TLC sample indicated complete conversion of the starting azide and the reaction was 
quenched by addition of 5 mL saturated aqueous sodium bicarbonate, this dissolved the white 
precipitate. The resulting mixture was poured into 10 mL of ethyl acetate, the layers were separated and 
the aqueous layer was washed with 2 additional 10 mL portions of ethyl acetate. The organic layers 
were combined, washed with 10% aqueous citric acid (20 mL), brine (20 mL) and dried over anhydrous 
sodium sulfate. After removal of the solvent in vacuo the residual yellow oil was purified with flash 
column chromatography on silica gel (toluene:ethyl acetate 8:1 in increasing gradient to 5:1) to afford 
227a as a colorless oil (380 mg, 0.70 mmol, 91%). 1H NMR (400 MHz, CDCl3) δ 7.73 (d, J = 8.5 Hz, 2H), 
7.42 – 7.33 (m, 10H), 7.31 (d, J = 8.6 Hz, 2H), 5.22 – 5.01 (m, 4H), 4.20 – 4.01 (m, 3H), 2.43 (s, 3H), 2.28 
(s, 3H). 13C NMR (101 MHz, CDCl3) δ 170.48, 145.41, 136.20, 135.60 (d, J = 5.5 Hz), 130.02, 128.87, 
128.85, 128.80 (d, J = 1.0 Hz), 128.38, 128.36, 128.03, 127.83, 68.92 (d, J = 7.0 Hz), 68.85 (d, J = 7.0 Hz), 
57.29 (d, J = 150.7 Hz), 45.31 (d, J = 9.2 Hz), 24.94, 21.73. 31P NMR (162 MHz, CDCl3) δ 20.47. IR =3034 
(w), 2116 (s), 1702 (s), 1596 (w), 1497 (w), 1456 (m), 1359 (s), 1242 (m), 1187 (m), 1165 (s), 1087 (m), 
990 (s), 909 (s), 813 (m), 729 9s), 696 (s), 652 (s), 619 (w). Rf: 0.35 (chloroform:ethyl acetate 2:1). LC-MS 
(ESI): tR = 9.75 min. HRMS (ESI): for [M+H]
+ calc.: 543.14617, found: 543.14586. 
 
2-Azido-2-bis(benzyloxy)phosphoryl-N-propioyl-N-(4-toluenesulfonyl)-ethanamine (227b): In a 10 mL 
pear shaped flask, propionyl chloride (0.152 mL, 1.81 mmol, 2.0 equiv) was added to a solution of 2-
azido-2-bis(benzyloxy)phospholyl-N-bis(4-toluenesulfonyl)-ethanamine 66 (452 mg, 0.90 mmol, 1.0 
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equiv), DIPEA (0.297 mL, 1.81 mmol, 2.0 equiv), and DMAP (110 mg, 0.91 mmol, 1.0 equiv) in THF (1.5 
mL) at 0 °C. Upon addition of the acid chloride a white precipitate formed, turning the reaction to a thick 
suspension. After stirring for 1 hour at room temperature, a TLC sample indicated complete conversion 
of the starting azide and the reaction was quenched by addition of 5 mL saturated aqueous sodium 
bicarbonate, this dissolved the white precipitate. The resulting mixture was poured into 10 mL of ethyl 
acetate, the layers were separated and the aqueous layer was washed with 2 additional 10 mL portions 
of ethyl acetate. The organic layers were combined, washed with 10% aqueous citric acid (20 mL), brine 
(20 mL) and dried over anhydrous sodium sulfate. After removal of the solvent in vacuo the residual 
yellow oil was purified with flash column chromatography on silica gel (toluene:ethyl acetate 15:1 in 
increasing gradient to 8:1) and washed with 1 N NaOH aq. to afford 227b as a colorless oil (459 mg, 0.82 
mmol: 91% yield).  1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 8.3 Hz, 2H), 7.43 – 7.33 (m, 10H), 7.31 (d, J = 
8.4 Hz, 2H), 5.19 – 5.04 (m, 4H), 4.21 – 4.02 (m, 3H), 2.63 (dq, J = 17.5, 7.2 Hz, 1H), 2.55 – 2.43 (m, 1H), 
2.43 (s, 3H), 1.01 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 174.12, 145.25, 136.40, 135.61 (d, J = 
5.6 Hz), 129.96, 128.87 (d, J = 1.8 Hz), 128.81, 128.40 (d, J = 2.6 Hz), 127.89, 68.94 (d, J = 6.9 Hz), 68.85 
(d, J = 7.0 Hz), 57.48 (d, J = 150.7 Hz), 45.13 (d, J = 9.0 Hz), 29.80, 21.73, 8.77. 31P NMR (162 MHz, CDCl3) 
δ 20.52. IR = 2944 (bw), 2116 (s), 1706 (s), 1596 (w), 1497 (w), 1456 (w), 1356 (s), 1260 (w), 1215 (w), 
1163 (s), 1121 (w), 1087 (w), 989 (s), 910 (m), 813 (m), 729 (s), 696 (s), 665 (m). Rf: 0.20 
(chloroform:ethyl acetate 5:1). LC-MS (ESI): tR = 10.15 min. HRMS (ESI): for [M+H]
+ calc.: 557.16182., 
found: 557.16153.  
 
Aibenzyl 1-azido-2-(3-methyl-N-tosylbutanamido)ethylphosphonate (227c): 500 mg, 1 mmol of the 
azide was used. Column chromatography (toluene:ethyl acetate 10:1 0.1% Et3N) resulting in 443 mg of a 
yellow oil (0.76 mmol, 76%). 1H NMR (400 MHz, CDCl3) δ = 7.79 – 7.68 (m, 2H), 7.40 – 7.33 (m, 10H), 7.32 
– 7.28 (m, 2H), 5.22 – 5.01 (m, 4H), 4.24 – 4.00 (m, 3H), 2.55 – 2.35 (m, 5H), 2.09 (dt, J=13.5, 6.7, 1H), 
0.82 (d, J=6.6, 2H), 0.82 (d, J=6.7, 2H). 13C NMR (126 MHz, CDCl3) δ = 172.79, 145.24, 136.62, 135.64 (d, 
J=5.7), 129.94, 128.90, 128.88, 128.84, 128.83, 128.41, 127.85, 68.94 (d, J=7.6), 68.86 (d, J=7.1), 57.61 
(d, J=150.9), 45.04, 45.03 (d, J=9.0), 25.41, 22.43, 22.28, 21.76. 31P NMR (162 MHz, CDCl3) δ = 20.48. IR: 
2959 (w), 2116 (s), 1703 (m), 1596 (w), 1497 (w), 1456 (w), 1355 (s), 1260 (m), 1215 (m), 1162 (s), 1087 
(m), 988 (s), 813 (m), 732 (s), 696 (s), 668 (s). Rf: 0.43 (toluene:ethyl acetate 3:1). LC-MS (ESI): tR = 10.74 
min.  HRMS (ESI): for [M+H]+ calc.: 585.19312, found: 585.19355. 
 
 
Dibenzyl 1-azido-2-(3,3-dimethyl-N-tosylbutanamido)ethylphosphonate (227d): 500 mg, 1 mmol of the 
azide was used. Column chromatography (toluene:ethyl acetate 10:1 0.1% Et3N) resulting in 442 mg of a 
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yellow oil (0.74 mmol, 74%). 1H NMR (400 MHz, CDCl3) δ = 7.72 (d, J=8.3, 1H), 7.40 – 7.33 (m, 5H), 7.32 – 
7.28 (m, 1H), 5.20 – 5.03 (m, 2H), 4.25 – 4.00 (m, 2H), 2.50 (s, 1H), 2.44 (s, 2H), 0.92 (s, 4H). 13C NMR 
(126 MHz, CDCl3) δ = 172.04, 145.17, 136.83, 135.67 (d, J=5.6), 129.93, 128.91, 128.89, 128.85, 128.44, 
127.87, 68.94 (d, J=8.1), 68.87 (d, J=8.2), 57.65 (d, J=150.6), 47.85, 45.05 (d, J=9.2), 31.77, 29.59, 21.77. 
31P NMR (162 MHz, CDCl3) δ = 20.55. IR: 2955 (w), 2116 (s), 1703 (m), 1597 (w), 1497 (w), 1456 (w), 1354 
(s), 1260 (m), 1216 (m), 1164 (s), 1087 (m), 989 (s), 813 (m), 732 (s), 696 (s), 669 (s). Rf: 0.48 
(toluene:ethyl acetate 3:1). LC-MS (ESI): tR = 11.00 min.  HRMS (ESI): for [M+H]
+ calc.: 599.20877, found: 
599.20931. 
 
 
Dibenzyl 1-azido-2-(N-tosyltetradecanamido)ethylphosphonate (227e): In a 25 mL round bottom flask, 
containing an egg-shaped stirring bar, azide 66 (500 mg, 1 mmol; 1 equiv) was dissolved in 2 mL 
anhydrous THF. While stirring, DIPEA (259 mg, 0.348 mL, 2 mmol, 2 equiv) and DMAP (122 mg, 1 mmol, 
1 equiv) were added, followed by myristoyl chloride (246 mg, 0.271 mL, 1 mmol, 1 equiv). Upon addition 
of the acid chloride a white precipitate formed, turning the reaction to a thick suspension. After stirring 
for 1 hour at room temperature a TLC sample indicated complete conversion of the starting azide and 
the reaction was quenched by addition of 5 mL saturated aqueous sodium bicarbonate, this dissolved 
the white precipitate. The resulting mixture was poured into 10 mL of ethyl acetate, the layers were 
separated and the aqueous layer was washed with 2 additional 10 mL portions of ethyl acetate. The 
organic layers were combined, washed with 10% aqueous citric acid (20 mL), brine (20 mL) and dried 
over anhydrous sodium sulfate. The solvent was removed by evaporation in vacuo resulting in a yellow 
oil. To get rid of any myristoleic acid the oil was dissolved in methanol (10 mL) and a large excess of 
sodium bicarbonate was added. After stirring for an hour, enough isolute was added to absorb all 
solvent. After evaporating the isolute to dryness it was loaded on a silica column and eluted 
(toluene:ethyl acetate 10:1) resulting in a yellow oil (301 mg, 0.42 mmol, 42%). 1H NMR (400 MHz, 
CDCl3) δ = 7.83 – 7.70 (m, 2H), 7.45 – 7.28 (m, 12H), 5.20 – 4.99 (m, 4H), 4.27 – 3.99 (m, 3H), 2.68 – 2.36 
(m, 5H), 1.56 – 1.43 (m, 2H), 1.37 – 1.13 (m, 20H), 0.88 (t, J=6.9, 3H). 13C NMR (101 MHz, CDCl3) δ = 
173.61, 145.33, 136.67, 135.74 (d, J=5.6), 130.06, 128.99, 128.97, 128.93, 128.51, 128.50, 127.98, 77.55, 
77.24, 76.92, 69.04 (d, J=7.7), 68.97 (d, J=7.1), 57.62 (d, J=150.8), 45.21 (d, J=9.0), 36.47, 32.13, 29.89, 
29.86, 29.81, 29.64, 29.57, 29.49, 29.08, 24.73, 22.90, 21.86, 14.33. 31P NMR (162 MHz, CDCl3) δ = 20.51. 
IR: 2917 (s), 2850 (m), 2115 (s), 1705 (s), 1347 (s), 1292 (m), 1247 (s), 1167 (s), 1118 (s), 1090 (m), 996 
(s), 870 (s), 813 (s), 725 (s), 696 (s), 573 (m), 562 (s), 533 (s), 512 (s), 476 (s), 456 (s). Rf: 0.53 
(toluene:ethyl acetate 3:1). LC-MS (ESI): tR = 14.38 min (AD card). HRMS (ESI): for [M+Na]
+ calc.: 
711.33397, found: 711.33418. 
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Dibenzyl 1-azido-2-(N-tosyldodec-11-ynamido)ethylphosphonate (227f): 500 mg, 1 mmol of the azide 
was used, dodec-11-ynoyl chloride was used as acid chloride. Column chromatography (toluene:ethyl 
acetate 10:1 0.1% Et3N) resulting in 586 mg of a yellow oil (0.86 mmol, 86%).
1H NMR (400 MHz, CDCl3) δ 
= 7.73 (ad, J=8.4, 2H), 7.40 – 7.33 (m, 10H), 7.31 (d, J=8.5, 2H), 5.24 – 4.96 (m, 4H), 4.21 – 3.97 (m, 3H), 
2.67 – 2.55 (m, 1H), 2.53 – 2.41 (m, 4H), 2.17 (td, J=7.1, 2.6, 2H), 1.93 (t, J=2.7, 1H), 1.58 – 1.44 (m, 4H), 
1.42 – 1.30 (m, 4H), 1.30 – 1.05 (m, 8H). 13C NMR (101 MHz, CDCl3) δ = 173.57, 145.34, 136.65, 135.74 
(d, J=5.6), 130.07, 128.99, 128.98, 128.93, 128.50, 127.98, 84.94, 69.04 (d, J=7.2), 68.97 (d, J=7.2), 68.32, 
57.62 (d, J=150.7), 45.20 (d, J=8.9), 36.45, 29.44, 29.40, 29.21, 29.03, 28.90, 28.66, 24.71, 21.86, 18.60. 
31P NMR (162 MHz, CDCl3) δ = 20.50. IR: 3295 (w), 2924 (m), 2854 (w), 2117 (s), 1703 (m), 1596 (w), 1496 
(w), 1404 (w), 1351 (s), 1255 (m), 1216 (m), 1164 (s), 1119 (m), 1088 (m), 991 (s), 813 (m), 734 (s), 734 
(s), 697 (s), 666 (s), 641 (m), 585 (s), 560 (s), 543 (s), 527 (s), 484 (m). Rf: 0.52 (toluene:ethyl acetate 3:1). 
LC-MS (ESI): tR = 11.51 min. HRMS (ESI): for [M+H]
+ calc.: 679.27137, found: 679.27271. 
 
 
Dibenzyl 1-azido-2-(N-tosylhexadec-15-ynamido)ethylphosphonate (227g): 500 mg, 1 mmol of the 
azide was used, hexadec-15-ynoyl chloride was used as acid chloride. Column chromatography 
(toluene:ethyl acetate 10:1 0.1% Et3N) resulting in 480 mg of a yellow oil (0.65 mmol, 65%) and 117 mg 
of the starting material recovered (0.23 mmol, 23%). 1H NMR (400 MHz, CDCl3) δ = 7.73 (ad, J=8.3, 2H), 
7.40 – 7.33 (m, 10H), 7.30 (d, J=8.1, 2H), 5.23 – 5.02 (m, 4H), 4.22 – 4.03 (m, 3H), 2.79 – 2.38 (m, 5H), 
2.17 (td, J=7.1, 2.6, 2H), 1.97 – 1.87 (m, 1H), 1.51 (dd, J=14.6, 7.1, 4H), 1.45 – 1.33 (m, 2H), 1.33 – 1.09 
(m, 16H). 13C NMR (101 MHz, CDCl3) δ =  173.60, 145.33, 136.67, 135.75 (d, J=5.6), 130.07, 128.99, 
128.98, 128.93, 128.51, 127.98, 85.02, 77.57, 77.26, 76.94, 69.04 (d, J=7.4), 68.97 (d, J=7.4), 68.27, 57.63 
(d, J=150.7), 45.21 (d, J=9.1), 36.47, 29.82, 29.79, 29.79, 29.71, 29.63, 29.48, 29.32, 29.08, 28.98, 28.72, 
24.73, 21.86, 18.62. 31P NMR (162 MHz, CDCl3) δ = 20.51. IR: 3300 (w), 2924 (s), 2853 (m), 2116 (s), 1703 
(m), 1596 (w), 1497 (w), 1456 (m), 1356 (s), 1260 (s), 1186 (s), 1163 (m), 1120 (m), 1087 (m), 989 (s), 814 
(m), 734 (s), 696 (s), 665 (s), 583 (s), 543 (s), 484 (m). Rf: 0.54 (toluene:ethyl acetate 3:1). LC-MS (ESI): tR 
= 12.52 min. HRMS (ESI): for [M+NH4]
+ calc.: 752.36052, found: 752.36071. 
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Dibenzyl 1-azido-2-(N-tosylcyclopentanecarboxamido)ethylphosphonate (227h): 500 mg, 1 mmol of 
the azide was used, cyclopentanecarbonyl chloride was used as acid chloride. Column chromatography 
(toluene:ethyl acetate 10:1 0.1% Et3N) resulting in 443 mg of a yellow oil (0.74 mmol, 74%). 
1H NMR 
(400 MHz, CDCl3) δ = 7.73 (ad, J=8.3, 2H), 7.40 – 7.33 (m, 10H), 7.32 – 7.28 (m, 2H), 5.10 (m, 4H), 4.25 – 
3.98 (m, 3H), 3.31 – 3.14 (m, 1H), 2.43 (s, 3H), 1.83 – 1.38 (m, 8H). 13C NMR (126 MHz, CDCl3) δ = 177.54, 
145.08, 136.80, 135.65 (d, J=5.9), 129.93, 128.92, 128.90, 128.85, 128.45, 128.43, 127.83, 68.97 (d, 
J=9.9), 68.90 (d, J=10.1), 57.75 (d, J=151.0), 45.04 (d, J=9.2), 44.39, 31.18, 30.85, 26.24, 21.78. 31P NMR 
(162 MHz, CDCl3) δ = 20.46. IR: 2955 (w), 2116 (s), 1699 (m), 1596 (w), 1497 (w), 1454 (m), 1354 (s), 
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1260 (s), 1215 (m), 1162 (s), 1119 (m), 1087 (m), 988 (s), 813 (m), 733 (s), 696 (s), 666 (s). Rf: 0.46 
(toluene:ethyl acetate 3:1).  LC-MS (ESI): tR = 10.81 min. HRMS (ESI): for [M+H]
+ calc.: 597.19312, found: 
597.19341. 
 
Dibenzyl 1-azido-2-(N-tosylcyclohexanecarboxamido)ethylphosphonate (227i): 500 mg, 1 mmol of the 
azide was used, cyclohexanecarbonyl chloride was used as acid chloride. Column chromatography 
(toluene:ethyl acetate 10:1 0.1% Et3N) resulting in  516 mg of a yellow oil (0.84 mmol, 84%). 
1H NMR 
(400 MHz, CDCl3) δ = 7.83 – 7.67 (m, 2H), 7.40 – 7.33 (m, 10H), 7.31 (m, 2H), 5.19 – 5.02 (m, 4H), 4.27 – 
3.98 (m, 3H), 2.93 (m, 1H), 2.43 (s, 3H), 1.60 (m, 5H), 1.46 – 1.23 (m, 2H), 1.23 – 0.99 (m, 3H). 13C NMR 
(126 MHz, CDCl3) δ = 176.99, 145.17, 136.94, 135.67 (d, J=5.7), 129.98, 128.89, 128.88, 128.85, 128.84, 
128.43, 128.42, 127.72, 68.94 (d, J=9.3), 68.82 (s, J=9.5), 57.61 (d, J=151.1), 44.90 (d, J=9.3), 44.40, 
29.51, 29.34, 25.61, 25.58, 25.48, 21.78. 31P NMR (162 MHz, CDCl3) δ = 20.45. IR: 2930 (w), 2856 (w), 
2117 (s), 1698 (m), 1596 (w), 1496 (w), 1453 (m), 1355 (s), 1260 (s), 1215 (m), 1160 (s), 1087 (m), 986 (s), 
813 (m), 731 (s), 696 (s), 667 (s). Rf: 0.54 (toluene:ethyl acetate 3:1). LC-MS (ESI): tR = 11.07 min.  HRMS 
(ESI): for [M+Na]+ calc.: 633.19071, found: 633.19072. 
 
Dibenzyl 1-azido-2-(3-cyclopentyl-N-tosylpropanamido)ethylphosphonate (227j): 500 mg, 1 mmol of 
the azide was used, cyclopentanepropionyl chloride was used as acid chloride. Column chromatography 
(toluene:ethyl acetate 10:1 0.1% Et3N) resulting in 489 mg of a yellow oil (0.76 mmol, 76%). 
1H NMR 
(400 MHz, CDCl3) δ = 7.74 (d, J=8.3, 2H), 7.40 – 7.33 (m, 10H), 7.31 (d, J=8.5, 2H), 5.21 – 5.00 (m, 4H), 
4.23 – 4.01 (m, 3H), 2.55 (m,  2H), 2.44 (s, 3H), 1.71 – 1.38 (m, 9H), 1.08 – 0.91 (m, 2H). 13C NMR (126 
MHz, CDCl3) δ = 173.62, 145.27, 136.58, 135.66 (d, J=5.6), 129.97, 128.90, 128.89, 128.85, 128.42, 
127.93, 68.95 (d, J=8.0), 68.88 (d, J=8.0), 57.54 (d, J=150.6), 45.17 (d, J=9.1), 39.49, 35.72, 32.50, 32.44, 
30.74, 25.19, 21.77. 31P NMR (162 MHz, CDCl3) δ = 20.51. IR: 2947 (w), 2116 (s), 1702 (m), 1596 (w), 
1497 (w), 1455 (w), 1355 (s), 1259 (m), 1215 (m), 1163 (s), 1118 (w), 1087 (m), 988 (s), 813 (m), 732 (s), 
696 (s), 666 (s). Rf: 0.48 (toluene:ethyl acetate 3:1). LC-MS (ESI): tR = 11.36 min. HRMS (ESI): for [M+H]
+ 
calc.: 625.22442, found: 625.22460. 
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Dibenzyl 1-azido-2-(3-phenyl-N-tosylpropanamido)ethylphosphonate (227k): 500 mg, 1 mmol of the 
azide was used, hydrocinnamoyl chloride was used as acid chloride. Column chromatography 
(toluene:ethyl acetate 10:1 0.1% Et3N) resulting in 438 mg of a yellow oil (0.69 mmol, 69%). 
1H NMR 
(400 MHz, CDCl3) δ = 7.69 (d, J=8.3, 2H), 7.39 – 7.33 (m, 10H), 7.28 (d, J=8.0, 2H), 7.25 – 7.15 (m, 3H), 
7.10 – 7.01 (m, 2H), 5.19 – 5.02 (m, 4H), 4.17 – 3.98 (m, 3H), 3.05 – 2.74 (m, 4H), 2.44 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ = 172.62, 145.30, 140.23, 136.36, 135.62 (d, J=5.8), 130.00, 128.90, 128.88, 128.83, 
128.58, 128.41, 128.40, 127.86, 126.37, 68.95 (d, J=9.9), 68.88 (d, J=10.0), 57.47 (d, J=150.6), 45.13 (d, 
J=9.1), 38.00, 30.70, 21.78. 31P NMR (162 MHz, CDCl3) δ =
 20.44. IR: 3031 (w), 2116 (s), 1702 (m), 1596 
(w), 1496 (w), 1454 (w), 1355 (s), 1260 (m), 1215 (m), 1163 (s), 1118 (w), 1087 (w), 987 (s), 909 (m), 812 
(m), 768 (m), 730 (s), 696 (s), 666 (s). Rf: 0.48 (toluene:ethyl acetate 3:1). LC-MS (ESI): tR = 10.77 min. 
HRMS (ESI): for [M+H]+ calc.: 633.19312, found: 633.19344. 
 
2-Azido-2-bis(benzyloxy)phosphoryl-N-benzoyl-N-(4-toluenesulfonyl)-ethanamine (227l): In a 10 mL 
pear shaped flask, benzoyl chloride (0.200 mL, 1.86 mmol, 2.0 equiv) was added to a solution of 2-azido-
2-bis(benzyloxy)phospholyl-N-bis(4-toluenesulfonyl)-ethanamine (465 mg, 0.93 mmol, 1.0 equiv), DIPEA 
(0.323 mL, 1.86 mmol, 2.0 equiv), and DMAP (118 mg, 0.93 mmol, 1.0 equiv) in THF (1.5 mL) at 0 °C. 
Upon addition of the acid chloride a white precipitate formed, turning the reaction to a thick 
suspension. After stirring for 1 hour at room temperature, a TLC sample indicated complete conversion 
of the starting azide and the reaction was quenched by addition of 5 mL saturated aqueous sodium 
bicarbonate, this dissolved the white precipitate. The resulting mixture was poured into 10 mL of ethyl 
acetate, the layers were separated and the aqueous layer was washed with 2 additional 10 mL portions 
of ethyl acetate. The organic layers were combined, washed with 10% aqueous citric acid (20 mL), brine 
(20 mL) and dried over anhydrous sodium sulfate. After removal of the solvent in vacuo the residual 
yellow oil was purified with flash column chromatography on silica gel (toluene:ethyl acetate 15:1 in 
increasing gradient to 8:1) and washed with 1 N NaOH aq. to afford 227l as a colorless oil (521 mg, 0.86 
mmol: 93% yield). 1H NMR (400 MHz, CDCl3) δ 7.67 (d, J = 8.3 Hz, 2H), 7.53 (d, J = 8.3 Hz, 2H), 7.49 (t, J = 
7.5 Hz, 1H), 7.42 – 7.26 (m, 14H), 7.25 (d, J = 8.2 Hz, 2H), 5.19 – 4.91 (m, 4H), 4.27 – 3.90 (m, 3H), 2.42 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ 171.48, 145.30, 135.48 (d, J = 5.7 Hz, 2C), 135.35, 134.67, 132.08, 
129.80, 128.86, 128.84, 128.79, 128.78, 128.75, 128.44, 128.30, 128.28, 77.48, 77.16, 76.84, 68.91 (d, J = 
6.8 Hz), 68.79 (d, J = 7.0 Hz), 57.58 (d, J = 151.9 Hz), 46.30 (d, J = 8.4 Hz),  21.73.  31P NMR (162 MHz, 
CDCl3) δ 19.95. IR = 3065 (w), 3034 (w), 2959 (w), 2350 (bw), 2114 (s), 1689 (s), 1597 (w), 1496 (w), 1454 
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(m), 1359 (s), 1264 (s), 1214 (m), 1187 (s), 1165 (w), 1121 (m), 1088 (s), 989 (s), 964 (w), 924 (w), 845 
(w), 814 (m), 773 (w), 732 (s), 695 (s), 661 (s). Rf: 0.55 (chloroform:ethyl acetate 3:1). LC-MS (ESI): tR = 
10.41 min. HRMS (ESI): for [M+H]+ calc.: 605.16182, found: 605.16205. 
 
Dibenzyl (1-azido-2-(4-methoxy-N-tosylbenzamido)ethyl)phosphonate (227m): 500 mg, 1 mmol of the 
azide was used, 4-methoxybenzoyl chloride was used as acid chloride. Column chromatography 
(toluene:ethyl acetate 10:1 in increasing gradient to 8:1) resulting in 577 mg of a colorless oil (0.91 
mmol, 91%). 1H NMR (400 MHz, CDCl3) 7.65 (m, 4H), 7.39 – 7.26 (m, 10H), 7.24 (d, J = 8.0 Hz, 2H), 6.93 – 
6.82 (m, 2H), 5.14 – 4.94 (m, 4H), 4.11 – 3.95 (m, 3H), 3.85 (s, 3H), 2.41 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 171.31, 163.50, 145.23, 135.66 (d, J = 5.7 Hz), 135.64 (d, J = 5.9 Hz), 132.06, 129.99, 128.96, 
128.91, 128.90, 128.42, 128.40, 128.39, 126.96, 113.80, 69.00 (d, J = 11.2 Hz), 68.93 (d, J = 11.3 Hz), 
57.83 (d, J = 152.2 Hz), 55.68, 46.54 (d, J = 8.2 Hz), 21.86. 31P NMR (162 MHz, CDCl3) δ 20.07. IR: 2957 
(w), 2113 (s), 1683 (m), 1601 (s), 1509 (m), 1456 (m), 1359 (m), 1251 (s), 1163 (s), 1088 (s), 989 (s), 912 
(m), 840 (m), 813 (m), 731 (s), 695 (s), 672 (s). Rf: 0.55 (toluene:ethyl acetate 3:1).  LC-MS (ESI): tR = 10.39 
min. HRMS (ESI): for [M+Na]+ calc.: 657.15433 found: 657.15468. 
 
Dibenzyl (1-azido-2-(4-chloro-N-tosylbenzamido)ethyl)phosphonate (227n): 500 mg, 1 mmol of the 
azide was used, 4-chlorobenzoyl chloride was used as acid chloride. Column chromatography 
(toluene:ethyl acetate 10:1 gradient to 8:1) resulting in 491 mg of a yellow oil (0.77 mmol, 77%). 1H NMR 
(400 MHz, CDCl3) δ 7.66 – 7.57 (m, 2H), 7.55 – 7.44 (m, 2H), 7.39 – 7.27 (m, 12H), 7.27 – 7.23 (m, 2H), 
5.13 – 4.91 (m, 4H), 4.12 – 3.90 (m, 3H), 2.42 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 170.75, 145.64, 
138.75, 135.58 (d, J = 5.7 Hz), 135.55 (d, J = 5.6 Hz), 135.21, 133.26, 130.53, 130.05, 129.05, 128.95, 
128.74, 128.48, 128.45, 69.08 (d, J = 11.9 Hz), 69.01 (d, J = 12.1 Hz), 57.58 (d, J = 152.2 Hz), 46.29 (d, J = 
8.5 Hz), 21.89. 31P NMR (162 MHz, CDCl3) δ 19.88. IR: 3034 (w), 2958 (w), 2113 (s), 1692 (m), 1688 (m), 
1593 (m), 1456 (w), 1360 (s), 1261 (s), 1215 (m), 1187 (s), 1087 (s), 989 (s), 910 (m), 838 (s), 814 (s), 730 
(s), 694 (s), 667 (s). Rf: 0.53 (toluene:ethyl acetate 3:1).  LC-MS (ESI): tR = 10.80 min. HRMS (ESI): for 
[M+H]+ calc.: 639.12285, found: 639.12255. 
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Dibenzyl 1-azido-2-(3,4-dimethoxy-N-tosylbenzamido)ethylphosphonate (227o): 500 mg, 1 mmol of 
the azide was used, 3,4-dimethoxybenzoyl chloride was used as acid chloride. Column chromatography 
(toluene:ethyl acetate 10:1 0.1% Et3N) resulting in 530 mg of a yellow oil (0.80 mmol, 80%). 
1H NMR 
(400 MHz, CDCl3) δ = 7.63 (d, J=8.1, 2H), 7.39 – 7.27 (m, 11H), 7.24 (d, J=8.5, 2H), 7.17 (d, J=1.4, 1H), 6.82 
(d, J=8.4, 1H), 5.13 – 4.96 (m, 4H), 4.10 – 3.99 (m, 3H), 3.91 (s, 3H), 3.85 (s, 3H), 2.41 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ = 
13C NMR (101 MHz, CDCl3) δ = 171.23, 153.10, 148.79, 145.14, 135.53 (d, J=5.7), 
135.50 (d, J=5.6), 135.24, 129.86, 128.87, 128.81, 128.79, 128.35, 128.30, 128.28, 126.83, 124.10, 
112.24, 110.14, 68.90 (d, J=10.5), 68.84 (d, J=10.6), 57.74 (d, J=152.6), 56.16, 56.09, 46.56 (d, J=8.2), 
21.74. 31P NMR (162 MHz, CDCl3) δ =
 20.02. IR: 2960 (w), 2117 (s), 1682 (m), 1596 (m), 1513 (s), 1415 
(m), 1358 (m), 1265 (s), 1216 (s), 1163 (s), 11.39 (s), 1087 (s), 989 (s), 911 (s), 866 (m), 813 (m), 768 (m), 
728 (s), 696 (s), 674 (s). Rf: 0.25 (toluene:ethyl acetate 3:1). LC-MS (ESI): tR = 10.13 min. HRMS (ESI): for 
[M+Na]+ calc.: 687.16489, found: 687.16529. 
 
2-Azido-2-bis(benzyloxy)phosphoryl-N-pentafluorobenzoyl-N-(4-toluenesulfonyl)-ethanamine (227p): 
In a 10 mL pear shaped flask, pentafluorobenzoyl chloride (0.246 mL, 1.78 mmol, 2.0 equiv) was added 
to a solution of 2-azido-2-bis(benzyloxy)phospholyl-N-bis(4-toluenesulfonyl)-ethanamine (446 mg, 0.89 
mmol, 1.0 equiv), DIPEA (0.323 mL, 1.86 mmol, 2.0 equiv) in THF (2 mL) at 0 °C. Upon addition of the 
acid chloride a white precipitate formed, turning the reaction to a thick suspension. After stirring for 1 
hour at room temperature, a TLC sample indicated complete conversion of the starting azide and the 
reaction was quenched by addition of 5 mL saturated aqueous sodium bicarbonate, this dissolved the 
white precipitate. The resulting mixture was poured into 10 mL of ethyl acetate, the layers were 
separated and the aqueous layer was washed with 2 additional 10 mL portions of ethyl acetate. The 
organic layers were combined, washed with 10% aqueous citric acid (20 mL), brine (20 mL) and dried 
over anhydrous sodium sulfate. After removal of the solvent in vacuo the residual yellow oil was purified 
with flash column chromatography on silica gel (toluene:ethyl acetate 15:1 gradient 10:1) to afford 227p 
as a yellow oil (584 mg, 0.84 mmol: 94% yield). 1H NMR (400 MHz, CDCl3) δ 7.57 (d, J = 8.4 Hz, 2H), 7.43 – 
7.32 (m, 8H), 7.28 (d, J = 8.5 Hz, 2H), 5.15 (ddd, J = 11.5, 8.8, 2.9 Hz, 2H),  5.07 (ddd, J = 11.5, 8.8, 2.9 Hz, 
2H), 4.26 – 3.96 (m, 3H), 2.45 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 158.67, 146.49, 145.0 – 143.9 (br), 
142.5 – 141.2 (br), 139.1 – 138.4 (bs), 136.5 – 135.7 (bs), 135.41 (d, J = 5.8 Hz), 134.25, 130.09, 128.96 
(d, J = 1.5 Hz), 128.82, 128.38, 128.17, 111.6 – 110.9, 69.11 (d, J = 6.9 Hz), 69.00 (d, J = 7.0 Hz), 57.27 (d, J 
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= 152.5 Hz). 21.76. 19F NMR (377 MHz, CDCl3) δ -140.16 (d, J = 844.6 Hz), -149.92 (s), -160.36 (d, J = 113.6 
Hz).31P NMR (162 MHz, CDCl3) δ 19.68. IR = 3035 (w), 2122 (s), 1696 (m), 1655 (w), 1595 (w), 1521 (m), 
1505 (s), 1456 (w), 1432 (w), 1374 (s), 1329 (m), 1238 (m), 1215 (m), 188 (w), 1170 (s), 1142 (w), 1089 
(w), 992 (s), 907 (s), 840 (w), 813 (m), 728 (s), 697 (s), 666 (s), 648 (s). Rf: 0.55 (chloroform:ethyl acetate 
5:1). LC-MS (ESI): tR = 10.69 min. HRMS (ESI): for [M+H]
+ calc.: 695.11471, found: 605.11507. 
 
Dibenzyl 1-azido-2-(4-nitro-N-tosylbenzamido)ethylphosphonate (227p): 500 mg, 1 mmol of the azide 
was used, 3,3-dimethylbutyryl chloride was used as acid chloride. Column chromatography 
(toluene:ethyl acetate 10:1 0.1% Et3N) resulting in 533 mg of a yellow oil (0.82 mmol, 82%). 
1H NMR 
(400 MHz, CDCl3) δ = 8.16 (m, 2H), 7.60 (m, 4H), 7.43 – 7.19 (m, 12H), 5.17 – 4.95 (m, 4H), 4.17 – 3.89 
(m, 3H), 2.44 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 169.76, 149.52, 146.12, 140.74, 135.51 (d, J=5.6), 
135.45 (d, J=5.6), 134.94, 130.21, 129.62, 129.13, 128.98, 128.96, 128.53, 128.50, 128.43, 123.48, 77.57, 
77.25, 76.94, 69.14 (d, J=6.8), 69.07 (d, J=6.9), 57.23 (d, J=152.1), 45.94 (d, J=7.6), 21.93. 31P NMR (162 
MHz, CDCl3) δ = 19.75. IR: 3034 (w), 2957 (w), 2113 (s), 1690 (m), 1597 (w), 1524 (s), 1496 (w), 1455 (w), 
1346 (s), 1260 (s), 1215 (m), 1188 (w), 1166 (s), 1087 (m), 987 (s), 851 (s), 814 (m), 732 (s), 711 (s), 695 
(s), 665 (s), 593 (s), 571 (s), 544 (m), 517 (m), 485 (m), 459 (m). Rf: 0.46 (toluene:ethyl acetate 3:1). LC-
MS (ESI): tR = 10.30 min. HRMS (ESI): for [M+H]
+ calc.: 650.14690, found:650.14698. 
 
Dibenzyl (1-azido-2-(3,5-dinitro-N-tosylbenzamido)ethyl)phosphonate (227q): 500 mg, 1 mmol of the 
azide was used, 3,5-dinitrobenzoyl chloride was used as acid chloride. Column chromatography 
(toluene:ethyl acetate 10:1 gradient to 8:1) resulting in 653 mg of a yellow oil (0.94 mmol, 94%). 1H NMR 
(400 MHz, CDCl3) δ 9.01 (t, J = 2.1 Hz, 1H), 8.59 (d, J = 2.1 Hz, 2H), 7.65 – 7.43 (m, 2H), 7.45 – 7.30 (m, 
10H), 7.30 – 7.21 (m, 2H), 5.20 – 4.96 (m, 4H), 4.21 – 3.96 (m, 3H), 2.43 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 167.29, 147.87, 146.55, 138.31, 135.31 (d, J = 7.5 Hz), 135.27 (d, J = 7.4 Hz), 134.19, 130.32, 
129.02, 128.95, 128.91, 128.76, 128.75, 128.42, 128.33, 128.32, 128.21, 127.99, 120.98, 6968.98 (d, J = 
6.8 Hz), 68.95 (d, J = 7.0 Hz), 56.57 (d, J = 152.0 Hz), 45.47 (d, J = 7.0 Hz), 21.69. 31P NMR (162 MHz, 
CDCl3) δ 19.74. IR: 3092 (w), 2116 (s), 1692 (m), 1626 (w), 1595 (w), 1542 (s), 1496 (w), 1456 (m), 1343 
(s), 1260 (s), 1165 (s), 1084 (m), 989 (s), 912 (s), 814 (s), 728 (s), 697 (s), 665 (s). Rf: 0.48 (toluene:ethyl 
acetate 3:1).  LC-MS (ESI): tR = 10.44 min. HRMS (ESI): for [M+NH4]
+ calc.: 712.15852, found: 712.15921. 
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16.2.2 General procedure for the synthesis of amides 228a-r 
This procedure was followed in all cases unless stated otherwise. Under argon a flame dried, 100 mL 
schlenk flask was charged with the azide (1 equiv) and 20 mL anhydrous THF. dppe (1.5 equiv) was 
added and the reaction was heated to 50°C in an oil bath, steady bubble formation was noticed. Once 
bubble formation stopped the oil bath was set to 80°C and the schlenk flask was closed. After heating 
for 16 hours the flask was allowed to cool to about 50°C and 7 mL saturated aqueous sodium 
bicarbonate solution: 30% hydrogen peroxide 1:1 was added. The mixture was stirred until a TLC sample 
confirmed complete oxidation of dppe. Chloroform (20 mL) was added, the layers were separated and 
the aqueous layer was extracted twice with 5 mL portions of chloroform. Organic layers were combined, 
washed with brine (20 mL) and dried over anhydrous sodium sulfate. The solvent was evaporated and 
the resulting sticky solid was further purified by flash column chromatography. 
N
NP
O
BnO
BnO
Ts  
4-Bis(benzyloxy)phosphoryl-4,5-dihydro-2-methyl-1-(4-toluenesulfonyl)-1H-imidazole (228a): Azide 
227a (340 mg, 0.63 mmol, 1.0 equiv) was used. Column chromatography (toluene:ethyl acetate 2:1 
gradient 1:1) to afford 228a as a colorless oil (233 mg, 0.47 mmol; 74% yield). 1H NMR (400 MHz, CDCl3) 
δ 7.69 (d, J = 8.3 Hz, 2H), 7.44 – 7.19 (m, 10H), 5.09 – 4.86 (m, 4H), 4.27 – 4.15 (m, 1H), 4.06 – 3.86 (m, 
2H), 2.40 (s, 3H), 2.22 (dd, J = 3.3, 1.6 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ  158.79 (d, J = 13.4 Hz), 
144.90, 136.08 (d, J = 5.7 Hz), 136.01 (d, J = 5.4 Hz), 135.38, 130.19, 128.66, 128.60, 128.57, 128.09, 
127.97, 127.17, 77.48, 77.16, 76.84, 68.34 (d, J = 6.7 Hz), 61.07 (d, J = 166.3 Hz), 49.14, 21.67, 16.72 (d, J 
= 1.9 Hz). 31P NMR (162 MHz, CDCl3) δ 23.01. Rf: 0.40 (toluene:ethyl acetate 2:1). LC-MS (ESI): tR = 9.15 
min. HRMS (ESI): for [M+H]+ calc.: 499.145511, found: 499.11458. 
 
4-Bis(benzyloxy)phosphoryl-4,5-dihydro-2-ethyl-1-(4-toluenesulfonyl)-1H-imidazole (228b):  Azide 
227b (384 mg, 0.69 mmol, 1 equiv) was used. Column chromatography (toluene:ethyl acetate 8:1 
gradient 5:1) to afford 228b as a colorless oil (306 mg, 0.60 mmol; 87% yield). 1H NMR (400 MHz, CDCl3) 
δ 7.69 (d, J = 8.2 Hz, 2H), 7.39 – 7.20 (m, 12H), 5.14 – 4.87 (m, 4H), 4.32 – 4.13 (m, 1H), 4.10 – 3.82 (m, 
2H), 2.75 – 2.59 (m, 1H), 2.59 – 2.45 (m, 1H), 2.39 (s, 3H), 1.17 (t, J = 7.3 Hz, 2H). 13C NMR (101 MHz, 
CDCl3) δ 163.06 (d, J = 13.2 Hz), 144.78, 136.13 (d, J = 6.0 Hz), 136.06 (d, J = 5.5 Hz), 135.49, 130.14, 
128.53 (d, J = 2.1 Hz), 127.97, 127.93, 127.14, 68.40 (d, J = 6.8 Hz), 68.26 (d, J = 6.9 Hz), 61.20 (d, J = 
165.7 Hz),  49.20, 23.37 (d, J = 1.6 Hz), 21.65, 10.81. 31P NMR (162 MHz, CDCl3) δ 23.00. Rf: 0.20 
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(chloroform:ethyl acetate 5:1). LC-MS (ESI): tR = 9.91 min. HRMS (ESI): for [M+H]
+ calc.: 513.16076, 
found: 513.16039. 
 
Dibenzyl 2-isobutyl-1-tosyl-4,5-dihydro-1H-imidazol-4-ylphosphonate (228c):  Azide 227c (406 mg, 0.69 
mmol, 1 equiv) was used. Column chromatography (chloroform:ethyl acetate 3:1) yielded 318 mg (0.59 
mmol, 85%) of a yellow oil.  1H NMR (400 MHz, CDCl3) δ = 7.69 (ad, J=8.3, 2H), 7.42 – 7.20 (m, 12H), 5.08 
– 4.89 (m, 4H), 4.30 – 4.11 (m, 1H), 2.54 – 2.45 (m, 2H), 2.40 (s, 3H), 2.16 (dp, J=13.4, 6.7, 1H), 0.93 (t, 
J=7.1, 6H). 13C NMR (101 MHz, CDCl3) δ = 161.54 (d, J=13.4), 144.94, 136.26 (d, J=5.8), 136.22 (d, J=5.3), 
135.59, 130.28, 128.78, 128.72, 128.70, 128.21, 127.36, 77.57, 77.26, 76.94, 68.57 (d, J=6.7), 68.36 (d, 
J=7.0), 61.42 (d, J=166.2), 49.20, 38.54, 26.82, 22.70, 22.62, 21.81. 31P NMR (162 MHz, CDCl3) δ = 23.15. 
Rf: 0.30 (chloroform:ethyl acetate 3:1). LC-MS (ESI): tR = 10.31 min. HRMS (ESI): for [M+H]
+ calc.: 
541.19206, found: 541.19171. 
 
Dibenzyl 2-neopentyl-1-tosyl-4,5-dihydro-1H-imidazol-4-ylphosphonate (228d): Azide 227d (408 mg, 
0.68 mmol, 1 equiv) was used. Column chromatography (chloroform:ethyl acetate 3:1) yielding 349 mg 
(0.63 mmol, 93%) of a yellow oil.  1H NMR (400 MHz, CDCl3) δ = 7.68 (m, 2H), 7.39 – 7.22 (m, 12H), 5.10 – 
4.88 (m, 4H), 4.25 – 4.09 (m, 1H), 3.92 (m, 2H), 2.82 – 2.69 (m, 1H), 2.57 – 2.46 (m, 1H), 2.40 (s, 3H), 1.03 
(s, 9H). 13C NMR (101 MHz, CDCl3) δ = 160.55 (d, J=14.0), 144.90, 136.24 (d, J=5.7), 136.22 (d, J=5.4), 
135.52, 130.27, 128.78, 128.71, 128.27, 128.19, 127.41, 77.57, 77.25, 76.93, 68.59 (d, J=6.7), 68.27 (d, 
J=7.0), 61.51 (d, J=167.4), 48.79, 41.36, 41.34, 32.30, 32.28, 29.84, 21.81. 31P NMR (162 MHz, CDCl3) δ = 
23.32. Rf: 0.40 (chloroform:ethyl acetate 3:1). LC-MS (ESI): tR = 10.65 min. HRMS (ESI): for [M+H]
+ calc.: 
555.20771, found: 555.20736. 
Dibenzyl 1-tosyl-2-tridecyl-4,5-dihydro-1H-imidazol-4-ylphosphonate (228e) and Dibenzyl 2-(4-
methylphenylsulfonamido)-1-tetradecanamidoethylphosphonate (230):  Azide 227e (301 mg, 0.42 
mmol, 1 equiv) was used. Column chromatography (chloroform:ethyl acetate 3:1) yielded 116 mg (0.17 
mmol, 41%) of a clear oil (228e) and 73 mg (0.11 mmol, 25%) of a clear oil that solidified on standing 
(230). 
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228e: 
1H NMR (400 MHz, CDCl3) δ = 7.75 – 7.64 (m, 2H), 7.34 – 7.22 (m, 12H), 5.08 – 4.92 (m, 4H), 4.30 – 
4.15 (m, 1H), 4.09 – 3.80 (m, 2H), 2.67 – 2.45 (m, 2H), 2.40 (s, 3H), 1.72 – 1.56 (m, 2H), 1.36 – 1.16 (m, 
20H), 0.88 (t, J=6.9, 3H). 13C NMR (101 MHz, CDCl3) δ = 162.40 (d, J=13.3), 144.92, 136.29 (d, J=5.7), 
136.23 (d, J=5.6), 130.28, 128.77, 128.70, 128.68, 128.15, 128.11, 127.34, 68.51 (d, J=12.1), 68.44 (d, 
J=12.4), 61.38 (d, J=165.6), 49.37, 32.14, 29.92, 29.90, 29.88, 29.76, 29.57, 29.56, 29.49, 26.75, 22.91, 
21.81, 14.34. 31P NMR (162 MHz, CDCl3) δ = 23.05. Rf: 0.69 (chloroform:ethyl acetate 3:1). LC-MS (ESI): tR 
= 14.24 min. HRMS (ESI): for [M+H]
+ calc.: 667.33291, found: 667.33275. 
 
230: 1H NMR (400 MHz, CDCl3) δ = 7.74 (d, J=8.2, 2H), 7.38 – 7.15 (m, 12H), 7.01 (d, J=9.5, 1H), 6.55 (t, 
J=6.6, 1H), 5.11 – 4.88 (m, 4H), 4.72 (ddt, J=18.4, 9.5, 4.6, 1H), 3.38 – 3.17 (m, 2H), 2.38 (s, 3H), 2.23 – 
2.04 (m, 2H), 1.61 – 1.43 (m, 2H), 1.38 – 1.11 (m, 20H), 0.88 (t, J=6.9, 3H). 13C NMR (101 MHz, CDCl3) δ = 
173.82 (d, J=6.1), 143.49, 137.23, 135.93 (d, J=16.5), 135.87 (d, J=16.5)129.89, 128.86, 128.84, 128.76, 
128.28, 128.08, 127.35, 68.71 (d, J=44.8), 68.64 (d, J=44.8), 45.04 (d, J=157.9), 43.33 (d, J=1.5), 36.48, 
32.15, 29.92, 29.90, 29.89, 29.75, 29.63, 29.58, 29.54, 25.73, 22.91, 21.71, 14.34. 31P NMR (162 MHz, 
CDCl3) δ = 24.17. Rf: 0.26 (chloroform:ethyl acetate 3:1). LC-MS (ESI): tR = 12.44 min. HRMS (ESI): for 
[M+H]+ calc.: 685.34347, found: 685.34435. 
 
Dibenzyl 1-tosyl-2-(undec-10-ynyl)-4,5-dihydro-1H-imidazol-4-ylphosphonate (228f): Azide 227f (523 
mg, 0.77 mmol, 1 equiv) was used. Column chromatography (chloroform:ethyl acetate 3:1) yielded 489 
mg (0.77 mmol, 100%) of a clear oil.  1H NMR (400 MHz, CDCl3) δ = 7.75 – 7.62 (m, 2H), 7.42 – 7.22 (m, 
12H), 5.10 – 4.91 (m, 4H), 4.32 – 4.15 (m, 1H), 4.08 – 3.83 (m, 2H), 2.67 – 2.44 (m, 2H), 2.40 (s, 3H), 2.17 
(td, J=6.9, 2.6, 2H), 1.93 (t, J=2.7, 1H), 1.73 – 1.56 (m, 2H), 1.56 – 1.44 (m, 2H), 1.44 – 1.16 (m, 10H). 13C 
NMR (101 MHz, CDCl3) δ = 162.29 (d, J=13.3), 144.85136.19 (d, J=6.1), 136.13 (d, J=5.5), 130.19, 128.69, 
128.61, 128.60, 128.06, 128.02, 127.25, 84.87, 68.42 (d, J=12.9), 68.35 (d, J=13.1), 68.23, 61.28 (d, 
J=165.8), 49.28, 29.84, 29.46, 29.37, 29.34, 29.19, 28.84, 28.60, 26.63, 21.73, 18.52. 31P NMR (162 MHz, 
CDCl3) δ = 23.06. Rf: 0.46 (chloroform:ethyl acetate 3:1). LC-MS (ESI): tR = 11.31 min. HRMS (ESI): for 
[M+H]+ calc.: 635.27031, found: 635.27046. 
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Dibenzyl 2-(pentadec-14-ynyl)-1-tosyl-4,5-dihydro-1H-imidazol-4-ylphosphonate (228g): Azide 227g 
(410 mg, 0.56 mmol, 1 equiv) was used. Column chromatography (chloroform:ethyl acetate 3:1) yielded 
372 mg (0.54 mmol, 96%) of a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.70 (ad, J=8.0, 2H), 7.40 – 7.21 
(m, 12H), 5.14 – 4.91 (m, 4H), 4.32 – 4.15 (m, 1H), 4.11 – 3.82 (m, 2H), 2.67 – 2.44 (m, 2H), 2.40 (s, 3H), 
2.21 – 2.11 (m, 2H), 1.93 (td, J=2.6, 0.8, 1H), 1.69 – 1.56 (m, 2H), 1.52 (dt, J=14.5, 7.0, 2H), 1.48 – 1.10 
(m, 18H). 13C NMR (101 MHz, CDCl3) δ = 
13C NMR (101 MHz, CDCl3) δ = 162.33 (d, J=13.3), 144.84136.20 
(d, J=6.0), 136.15 (d, J=5.7), 130.20, 128.69, 128.62, 128.60, 128.07, 128.03, 127.26, 84.94, 68.43 (d, 
J=12.4), 68.36 (d, J=12.7), 68.17, 61.28 (d, J=165.7), 49.28, 29.86, 29.77, 29.74, 29.66, 29.65, 29.46, 
29.40, 29.25, 28.90, 28.64, 26.66, 21.73, 18.54. 31P NMR (162 MHz, CDCl3) δ = 23.06. Rf: 0.45 
(chloroform:ethyl acetate 3:1). LC-MS (ESI): tR = 12.49 min. HRMS (ESI): for [M+H]
+ calc.: 691.33291, 
found: 691.33322. 
 
Dibenzyl 2-cyclopentyl-1-tosyl-4,5-dihydro-1H-imidazol-4-ylphosphonate (228h): Azide 227h (443 mg, 
0.74 mmol, 1 equiv) was used. Column chromatography (chloroform:ethyl acetate 3:1) yielded 343 mg 
(0.62 mmol, 84%) of a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.70 (ad, J=8.3, 2H), 7.39 – 7.20 (m, 12H), 
5.12 – 4.89 (m, 4H), 4.21 (ddd, J=14.6, 11.4, 7.8, 1H), 4.08 – 3.84 (m, 2H), 3.39 – 3.23 (m, 1H), 2.40 (s, 
3H), 2.01 – 1.45 (m, 8H). 13C NMR (101 MHz, CDCl3) δ = 
13C NMR (101 MHz, CDCl3) δ = 166.29 (d, J=13.0), 
144.73, 136.21 (d, J=5.9), 136.18 (d, J=5.5), 135.68, 130.15, 128.67, 128.58, 128.02, 127.23, 77.48, 77.16, 
76.84, 68.41 (d, J=9.9), 68.35 (d, J=10.3), 61.22 (d, J=165.2), 49.52, 38.91, 38.89, 32.25, 32.23, 31.81, 
25.82, 25.75, 21.72. 31P NMR (162 MHz, CDCl3) δ = 23.04. Rf: 0.40 (chloroform:ethyl acetate 3:1). LC-MS 
(ESI): tR = 10.51 min. HRMS (ESI): for [M+H]
+ calc.: 553.19206, found: 553.19166. 
 
Dibenzyl 2-cyclohexyl-1-tosyl-4,5-dihydro-1H-imidazol-4-ylphosphonate (228i): Azide 227i (464 mg, 
0.76 mmol, 1 equiv) was used. Column chromatography (chloroform:ethyl acetate 3:1) yielded 392 mg 
(0.69 mmol, 91%) of a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.72 – 7.67 (m, 2H), 7.40 – 7.21 (m, 12H), 
5.09 – 4.87 (m, 4H), 4.31 – 4.11 (m, 1H), 4.08 – 3.80 (m, 2H), 2.93 (t, J=10.7, 1H), 2.40 (s, 3H), 1.97 – 1.61 
(m, 5H), 1.55 – 1.09 (m, 5H). 13C NMR (101 MHz, CDCl3) δ = 166.32 (d, J=13.2), 144.78, 136.20 (d, J=6.0), 
136.19 (d, J=5.4), 135.65, 130.15, 128.66, 128.57, 128.08, 128.05, 127.20, 77.48, 77.16, 76.84, 68.39 (d, 
J=7.0), 68.38 (d, J=6.7), 61.38 (d, J=165.3), 49.28, 38.23, 31.58, 31.56, 31.23, 31.22, 26.05, 26.03, 25.91, 
21.71. 31P NMR (162 MHz, CDCl3) δ = 23.01. Rf: 0.37 (chloroform:ethyl acetate 3:1). LC-MS (ESI): tR = 
10.69 min. HRMS (ESI): for [M+H]+ calc.: 567.20771, found: 567.20739. 
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Dibenzyl 2-(2-cyclopentylethyl)-1-tosyl-4,5-dihydro-1H-imidazol-4-ylphosphonate (228j): Azide 227j 
(455 mg, 0.73 mmol, 1 equiv) was used. Column chromatography (chloroform:ethyl acetate 3:1) yielded 
396 mg (0.68 mmol, 93%) of a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.70 (m, 2H), 7.44 – 7.25 (m, 
12H), 5.13 – 4.88 (m, 4H), 4.29 – 4.13 (m, 1H), 4.10 – 3.84 (m, 2H), 2.68 – 2.47 (m, 2H), 2.40 (s, 3H), 1.84 
– 1.39 (m, 9H), 1.13 – 0.96 (m, 2H). 13C NMR (101 MHz, CDCl3) δ = 162.54 (d, J=13.3), 144.95, 136.28 (d, 
J=5.7), 136.23 (d, J=5.4), 135.67, 130.28, 128.78, 128.70, 128.69, 128.14, 128.10, 127.34, 77.60, 77.28, 
76.96, 68.50 (d, J=9.1), 68.43 (d, J=9.3), 61.36 (d, J=165.7), 49.39, 39.91, 32.93, 32.59, 32.57, 29.25, 
25.35, 21.81. 31P NMR (162 MHz, CDCl3) δ = 23.07. Rf: 0.43 (chloroform:ethyl acetate 3:1). LC-MS (ESI): tR 
= 11.04 min. HRMS (ESI): for [M+H]
+ calc.: 581.22336, found: 581.22317. 
 
Dibenzyl 2-phenethyl-1-tosyl-4,5-dihydro-1H-imidazol-4-ylphosphonate (228k): Azide 227k (396 mg, 
0.63 mmol, 1 equiv) was used. Column chromatography (chloroform:ethyl acetate 3:1) yielded 283 mg 
(0.48 mmol, 76%) of a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.73 – 7.62 (m, 2H), 7.44 – 7.23 (m, 14H), 
7.23 – 7.15 (m, 3H), 5.09 – 4.89 (m, 4H), 4.32 – 4.18 (m, 1H), 4.11 – 3.82 (m, 2H), 3.06 – 2.77 (m, 4H), 
2.40 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 161.44 (d, J=13.3), 144.93, 140.85, 136.16 (d, J=5.8), 136.11 
(d, J=5.1), 135.37, 130.23, 128.71, 128.64, 128.62, 128.57, 128.56, 128.06, 128.02, 127.23, 126.30, 
77.48, 77.16, 76.84, 68.43 (d, J=13.1), 68.36 (d, J=13.2), 61.34 (d, J=165.9), 49.33, 32.58, 31.62, 31.61, 
21.72. 31P NMR (162 MHz, CDCl3) δ = 22.89. Rf: 0.37 (chloroform:ethyl acetate 3:1). LC-MS (ESI): tR = 
10.47 min. HRMS (ESI): for [M+H]+ calc.: 589.19206, found: 589.19184. 
N
NP
O
BnO
BnO
Ts  
4-Bis(benzyloxy)phosphoryl-4,5-dihydro-2-phenyl-1-(4-toluenesulfonyl)-1H-imidazole (228l): Azide 
227l (450 mg, 0.74 mmol, 1 equiv) was used. Column chromatography (toluene:ethyl acetate 5:1) to 
afford 228l as a colorless oil (386 mg, 0.69 mmol; 93% yield). 1H NMR (400 MHz, CDCl3) δ 7.57 (d, J = 7.1 
Hz, 2H), 7.48 (t, J = 7.5 Hz, 1H) 7.43 – 7.23 (m, 14H), 7.18 (d, J = 8.2 Hz, 1H), 5.22 – 4.85 (m, 4H), 4.36 – 
3.96 (m, 3H), 2.38 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 161.90 (d, J = 15.4 Hz), 144.94, 136.09 (d, J = 5.7 
Hz), 136.01 (d, J = 5.5 Hz), 134.82, 131.32, 129.93, 129.91, 129.75, 128.72, 128.69, 128.66, 128.19, 
128.11, 122.75, 127.66. 68.58 (d, J = 6.8 Hz), 68.43 (d, J = 6.8 Hz), 62.65 (d, J = 168.6 Hz), 50.45, 21.73. 31P 
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NMR (162 MHz, CDCl3) δ 22.94. Rf: 0.25 (chloroform:ethyl acetate 5:1). LC-MS (ESI): tR = 9.92 min. HRMS 
(ESI): for [M+H]+ calc.: 560.16076, found: 560.16046. 
 
Dibenzyl 2-(4-methoxyphenyl)-1-tosyl-4,5-dihydro-1H-imidazol-4-ylphosphonate (228m): Azide 227m 
(541 mg, 0.85 mmol, 1 equiv) was used. Column chromatography (chloroform:ethyl acetate 3:1) yielded 
456 mg (0.77 mmol, 91%) of a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.60 (m, 2H), 7.39 (ad, J=8.2, 2H), 
7.35 – 7.23 (m, 10H), 7.19 (ad, J=8.1, 2H), 6.88 (m, 2H), 5.00 (m, 4H), 4.27 – 4.04 (m, 2H), 3.97 (m, 1H), 
3.86 (s, 3H), 2.38 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 162.34, 161.80 (d, J=15.9), 145.00, 136.21 (d, 
J=7.4), 136.15 (d, J=7.3), 134.89, 131.95, 130.05, 128.81, 128.77, 128.74, 128.72, 128.27, 128.19, 127.73, 
122.10, 113.29, 77.59, 77.28, 76.96, 68.67 (d, J=6.8), 68.47 (d, J=6.8), 62.63 (d, J=169.7), 55.59, 50.66, 
21.83. 31P NMR (162 MHz, CDCl3) δ = 23.26. Rf: 0.23 (chloroform:ethyl acetate 3:1). LC-MS (ESI): tR = 9.94 
min. HRMS (ESI): for [M+H]+ calc.: 591.17132, found: 591.17104. 
 
Dibenzyl 2-(4-chlorophenyl)-1-tosyl-4,5-dihydro-1H-imidazol-4-ylphosphonate (228n): Azide 227n (455 
mg, 0.73 mmol, 1 equiv) was used. Column chromatography (chloroform:ethyl acetate 3:1) yielded 396 
mg (0.68 mmol, 93%) of a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.52 (m, 2H), 7.44 – 7.24 (m, 14H), 
7.21 (ad, J=8.3, 2H), 5.01 (m, 4H), 4.25 – 3.97 (m, 3H), 2.39 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 161.07 
(d, J=15.5), 145.27, 137.71, 136.11 (d, J=7.7), 136.05 (d, J=7.4), 134.72, 131.38, 131.37, 130.16, 128.85, 
128.82, 128.81, 128.28, 128.22, 127.69, 77.59, 77.27, 76.96, 68.67 (d, J=11.8), 68.60 (d, J=11.8), 62.84 (d, 
J=168.9), 50.58 (d, J=1.1), 21.86. 31P NMR (162 MHz, CDCl3) δ = 22.80. Rf: 0.22 (toluene:ethyl acetate 
2:1). LC-MS (ESI): tR = 10.39 min. HRMS (ESI): for [M+H]
+ calc.: 595.12178, found: 595.12191. 
 
Dibenzyl 2-(3,4-dimethoxyphenyl)-1-tosyl-4,5-dihydro-1H-imidazol-4-ylphosphonate (228o): Azide 
227o (492 mg, 0.74 mmol, 1 equiv) was used. Column chromatography (chloroform:ethyl acetate 3:1) 
yielded 399 mg (0.64 mmol, 87%) of a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.42 – 7.36 (m, 2H), 7.35 
– 7.24 (m, 11H), 7.21 – 7.16 (m, 2H), 7.13 (d, J=2.0, 1H), 6.85 (d, J=8.4, 1H), 5.12 – 4.94 (m, 4H), 5.09 – 
4.97  (m, 2H), 4.06 – 3.88 (m, 4H), 3.84 (s, 3H), 2.38 (s, 3H). 13C NMR (101 MHz, CDCl3) δ =  161.82 (d, 
J=16.0), 151.91, 148.23, 145.00, 136.19 (d, J=8.2), 136.13 (d, J=8.2), 135.01, 130.00, 128.81, 128.77, 
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128.75, 128.73, 128.27, 128.19, 127.74, 123.91, 122.10, 113.11, 110.17, 77.57, 77.26, 76.94, 68.69 (d, 
J=6.8), 68.47 (d, J=6.8), 62.64 (d, J=169.7), 56.18, 50.82 (d, J=1.4), 21.82. 31P NMR (162 MHz, CDCl3) δ = 
23.29. Rf: 0.18 (chloroform:ethyl acetate 3:1). LC-MS (ESI): tR = 9.63 min. HRMS (ESI): for [M+H]
+ calc.: 
621.18189, found: 621.18154. 
 
4-Bis(benzyloxy)phosphoryl-4,5-dihydro-2-pentafluorophenyl-1-(4-toluenesulfonyl)-1H-imidazole 
(228p): Azide 227p (451 mg, 0.65 mmol, 1 equiv) was used. Column chromatography (toluene:ethyl 
acetate 5:1) to afford 228p as a colorless oil (297 mg, 0.46 mmol; 70% yield). 1H NMR (400 MHz, CDCl3) 
1H NMR (400 MHz, CDCl3) δ 7.55 (d, J = 8.3 Hz, 2H), 7.39 – 7.23 (m, 12H), 5.11 – 4.88 (m, 5H), 4.49 (ddd, J 
= 16.7, 11.7, 8.6 Hz, 1H), 4.21 – 3.98 (m, 1H), 2.41 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 148.7 - 148.4 (br), 
146.6 – 146.2 (br), 145.82, 144.6 – 143.6 (br), 142.0 – 141.5 (br), 139.2 – 138.7 (br), 136.6 – 136.2, 
135.97 (d, J = 2.3 Hz), 135.91 (d, J = 2.7 Hz), 134.03, 130.25, 128.75, 128.73, 128.71, 128.25, 128.08, 
127.53, 106.7 – 106.2 (br), 77.36, 68.89 (d, J = 6.9 Hz), 68.53 (d, J = 6.9 Hz), 63.46 (d, J = 164.9 Hz). 48.79, 
21.75. 19F NMR (377 MHz, CDCl3) δ -137.86 (dd, J = 79.6, 22.2 Hz), -150.16 (t, J = 20.8 Hz), -161.41 (dtd, J 
= 51.6, 21.5, 7.9 Hz).  31P NMR (162 MHz, CDCl3) δ 20.97. Rf: 0.40 (toluene:ethyl acetate 2:1). LC-MS (ESI): 
tR = 10.31 min. HRMS (ESI): for [M+H]
+ calc.: 651.11365, found: 651.11360. 
 
Dibenzyl 2-(4-nitrophenyl)-1-tosyl-4,5-dihydro-1H-imidazol-4-ylphosphonate (228q): Azide 227q (464 
mg, 0.71 mmol, 1 equiv) was used. Column chromatography (chloroform:ethyl acetate 3:1) yielded 371 
mg (0.61 mmol, 86%) of a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 
1H NMR (400 MHz, CDCl3) δ = 8.21 (d, 
J=8.7, 2H), 7.69 (d, J=8.7, 2H), 7.45 – 7.17 (m, 14H), 5.10 – 4.93 (m, 4H), 4.26 – 4.04 (m, 3H), 2.42 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ = 160.06 (d, J=15.3), 149.42, 145.55, 135.91 (d, J=6.9), 135.89, 135.87 (d, 
J=9.3), 134.39, 130.87, 130.86, 130.24, 128.84, 128.80, 128.76, 128.22, 128.19, 127.55, 122.95, 68.65 (d, 
J=6.9), 68.63 (d, J=6.8), 63.17 (d, J=168.3), 50.40, 21.80. 31P NMR (162 MHz, CDCl3) δ = 22.33. Rf: 0.31 
(chloroform:ethyl acetate 3:1). LC-MS (ESI): tR = 10.13 min. HRMS (ESI): for [M+H]
+ calc.: 606.14583, 
found: 606.14580. 
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Dibenzyl 2-(3,5-dinitrophenyl)-1-tosyl-4,5-dihydro-1H-imidazol-4-ylphosphonate (228r): Azide 227r 
(581 mg, 0.84 mmol, 1 equiv) was used. Column chromatography (toluene:ethyl acetate 3:1) yielded 396 
mg (0.61 mmol, 72%) of a yellow oil.  1H NMR (400 MHz, CDCl3) δ = 9.11 (t, J=2.1, 1H), 8.66 (d, J=2.1, 2H), 
7.46 – 7.40 (m, 2H), 7.39 – 7.27 (m, 12H), 5.03 (m, 4H), 4.25 – 4.00 (m, 3H), 2.44 (s, 3H). 13C NMR (101 
MHz, CDCl3) δ = 158.06 (d, J=15.4), 147.99, 146.09, 135.76 (d, J=5.5), 135.74 (d, J=5.2), 134.20, 133.54 (d, 
J=2.2), 130.57, 129.59, 128.96, 128.86, 128.84, 128.77, 128.19, 127.38, 120.80, 68.79 (d, J=6.8), 68.72 (d, 
J=6.8), 63.47 (d, J=168.5), 50.35 (d, J=1.2), 21.81. 31P NMR (162 MHz, CDCl3) δ = 21.94. Rf: 0.17 
(toluene:ethyl acetate 3:1). LC-MS (ESI): tR = 10.05 min. HRMS (ESI): for [M+H]
+ calc.: 651.13091, 
found:651.13096. 
16.2.3 General procedure for the synthesis of amides 231a-q 
This procedure was followed in all cases unless stated otherwise. In a flame dried 50 mL schlenk flask, 
containing an egg-shaped stirring bar, the imidazoline (1 equiv) was dissolved in 3-8 mL anhydrous THF. 
The resulting mixture was cooled to -78°C with a dry-ice/acetone bath and 0.5 M KHMDS in toluene (3 
equiv) was added dropwise over 5 minutes. At the start of addition color changes were usually seen. 
After addition of roughly two thirds of the KHMDS solution the reaction mixture stayed clear yellow 
during the addition of the remaining KHMDS. Upon complete addition a TLC was taken to confirm 
complete conversion of the imidazoline (if some imidazoline remained an additional 10% KHMDS 
solution was charged), and the reaction mixture was transferred by cannula to a 100 mL round bottom 
flask containing a vigorously stirred mixture of 20 mL of water containing acetic acid (6 equiv). Following 
the transfer saturated aqueous sodium bicarbonate solution was added until the mixture was pH 8, 50 
mL of chloroform was added and the resulting mixture was vigorously stirred for five minutes. The layers 
were separated and the aqueous layer was washed with two additional 10 mL portions of chloroform, 
the organic layers were combined, washed with brine and dried over anhydrous sodium sulfate. 
Evaporation of the solvent yielded an oil that was used ‘as is’ in the next reaction. 
 
4-bBis(benzyloxy)phosphoryl-2-methyl-1H-imidazole (231a): Imidazoline 228a (160 mg, 0.32 mmol, 1.0 
equiv) was used. 31P NMR (162 MHz, CDCl3) δ 13.64 (br). Rf: 0.20 (chloroform:methanol 10:1). LC-MS 
(ESI): tR = 6.23 min. HRMS (ESI): for [M+H]
+ calc.: 343.12061, found: 343.12098. 
 
4-Bis(benzyloxy)phosphoryl-2-ethyl-1H-imidazole (231b): Imidazoline 228b (200 mg, 0.39 mmol, 1 
equiv) was used. 31P NMR (162 MHz, CDCl3) δ 14.32 (br), 11.01 (br). Rf: 0.55 (chloroform:methanol 10:1). 
LC-MS (ESI): tR = 5.93 min. HRMS (ESI): for [M+H]
+ calc.: 357.13626, found: 357.13647. 
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Dibenzyl 2-isobutyl-1H-imidazol-4-ylphosphonate (231c): Imidazoline 228c (283 mg, 0.52 mmol, 1 
equiv) was used. 31P NMR (162 MHz, CDCl3) δ = 12.16. Rf: 0.22 (ethyl acetate). LC-MS (ESI): tR = 6.91 min. 
HRMS (ESI): for [M+H]+ calc.: 385.16756, found:385.16934. 
 
Dibenzyl 2-neopentyl-1H-imidazol-4-ylphosphonate (231d): Imidazoline 228d (315 mg, 0.57 mmol, 1 
equiv) was used. 31P NMR (162 MHz, CDCl3) δ = 12.36. Rf: 0.09 (chloroform:ethyl acetate 3:1). LC-MS 
(ESI): tR = 7.33 min. HRMS (ESI): for [M+H]
+ calc.: 399.18321, found: 399.18214. 
 
Dibenzyl 2-tridecyl-1H-imidazol-4-ylphosphonate (231e): Imidazoline 228e (106 mg, 0.16 mmol, 1 
equiv) was used. 31P NMR (162 MHz, CDCl3) δ = 13.11. Rf: 0.56 (ethyl acetate). LC-MS (ESI): tR = 11.01 min. 
HRMS (ESI): for [M+H]+ calc.: 511.30841, found: 511.30832. 
 
Dibenzyl 2-(undec-10-ynyl)-1H-imidazol-4-ylphosphonate (231f): Imidazoline 228f (410 mg, 0.65 mmol, 
1 equiv) was used. 31P NMR (162 MHz, CDCl3) δ = 13.58, 11.96. Rf: 0.58 (ethyl acetate). LC-MS (ESI): tR = 
8.60 min. HRMS (ESI): for [M+H]+ calc.: 479.24581, found: 479.24527. 
 
Dibenzyl 2-(pentadec-14-ynyl)-1H-imidazol-4-ylphosphonate (231g): Imidazoline 228g (323 mg, 0.47 
mmol, 1 equiv) was used. 31P NMR (162 MHz, CDCl3) δ = 11.62. Rf: 0.5 (ethyl acetate). LC-MS (ESI): tR = 
9.94 min. HRMS (ESI): for [M+H]+ calc.: 535.30841, found: 535.30770. 
224 
 
 
Dibenzyl 2-cyclopentyl-1H-imidazol-4-ylphosphonate (231h): Imidazoline 228h (304 mg, 0.55 mmol, 1 
equiv) was used. 31P NMR (162 MHz, CDCl3) δ = 11.88. Rf: 0.29 (ethyl acetate). LC-MS (ESI): tR = 7.09 min. 
HRMS (ESI): for [M+H]+ calc.: 397.16756, found: 397.16640. 
 
Dibenzyl 2-cyclohexyl-1H-imidazol-4-ylphosphonate (231i): Imidazoline 228i (349 mg, 0.62 mmol, 1 
equiv) was used.  31P NMR (162 MHz, CDCl3) δ = 12.31. Rf: 0.24 (ethyl acetate). LC-MS (ESI): tR = 7.27 min. 
HRMS (ESI): for [M+H]+ calc.: 411.18321, found: 411.18324. 
 
Dibenzyl 2-(2-cyclopentylethyl)-1H-imidazol-4-ylphosphonate (231j): Imidazoline 228j (357 mg, 0.61 
mmol, 1 equiv) was used. 31P NMR (162 MHz, CDCl3) δ = 12.36. Rf: 0.29 (ethyl acetate). LC-MS (ESI): tR = 
7.73 min. HRMS (ESI): for [M+H]+ calc.: 425.19886, found: 425.19746. 
 
Dibenzyl 2-phenethyl-1H-imidazol-4-ylphosphonate (231k): Imidazoline 228k (251 mg, 0.43 mmol, 1 
equiv) was used. 31P NMR (162 MHz, CDCl3) δ = 11.80. Rf: 0.25 (ethyl acetate). LC-MS (ESI): tR = 7.59 min. 
HRMS (ESI): for [M+H]+ calc.: 433.16756, found: 433.16632. 
 
4-Bis(benzyloxy)phosphoryl-2-phenyl-1H-imidazole (231l): Imidazoline 228l (302 mg, 0.54 mmol, 1 
equiv) was used. 31P NMR (162 MHz, CDCl3) δ 14.50, 10.61. Rf: 0.30 (chloroform:methanol 20:1). LC-MS 
(ESI): tR = 8.24 min. HRMS (ESI): for [M+H]
+ calc.: 405.13626, found: 405.13563. 
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Dibenzyl 2-(4-methoxyphenyl)-1H-imidazol-4-ylphosphonate (231m): Imidazoline 228m (423 mg, 0.72 
mmol, 1 equiv) was used. 31P NMR (162 MHz, CDCl3) δ = 11.59. Rf: 0.09 (chloroform:ethyl acetate 3:1). 
LC-MS (ESI): tR = 8.38 min. HRMS (ESI): for [M+H]
+ calc.: 435.14682, found: 435.114655. 
 
Dibenzyl 2-(4-chlorophenyl)-1H-imidazol-4-ylphosphonate (231n): Imidazoline 228n (353 mg, 0.59 
mmol, 1 equiv) was used. 31P NMR (162 MHz, CDCl3) δ = 13.60, 10.43. Rf: 0.10 (toluene:ethyl acetate 
1:1). LC-MS (ESI): tR = 9.31 min. HRMS (ESI): for [M+H]
+ calc.: 439.09728, found: 439.09728. 
 
Dibenzyl 2-(3,4-dimethoxyphenyl)-1H-imidazol-4-ylphosphonate (231o): Imidazoline 228o (378 mg, 
0.61 mmol, 1 equiv) was used. 31P NMR (162 MHz, CDCl3) δ = 10.79. Rf: 0.19 (ethyl acetate). LC-MS (ESI): 
tR = 7.93 min. HRMS (ESI): for [M+H]
+ calc.: 465.15738, found: 465.15651. 
 
4-Bis(benzyloxy)phosphoryl-2-pentafluorophenyl-1H-imidazole (231p): Imidazoline 228p (253 mg, 0.39 
mmol, 1 equiv) was used. 19F NMR (377 MHz, CDCl3) δ 140.13, 152.33, 161.47. 
31P NMR (162 MHz, CDCl3) 
δ 11.55, 8.40. Rf: 0.30 (chloroform:methanol 10:1). LC-MS (ESI): tR = 8.98 min. HRMS (ESI): for [M+H]
+ 
calc.: 495.08915, found: 495.08855. 
 
Dibenzyl 2-(4-nitrophenyl)-1H-imidazol-4-ylphosphonate (231q): In a flame dried 10 mL schlenk flask, 
containing an egg-shaped stirring bar, imidazoline 228q (20 mg, 0.033 mmol, 1 equiv) was dissolved in 
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0.16 mL of anhydrous DMF. The mixture was cooled to 0°C and DBU (75 mg, 74 µL, 0.50 mmol, 15 equiv) 
was added turning the solution bright red. After stirring to 1 hour a TLC was taken to confirm complete 
conversion of the imidazoline, and the reaction mixture was partitioned between ethyl acetate (5 mL) 
and saturated aqueous sodium bicarbonate solution (5 mL). The layers were separated and the aqueous 
layer was washed with two additional 5 mL portions of ethyl acetate, the organic layers were combined, 
washed with brine and dried over anhydrous sodium sulfate. Evaporation of the solvent yielded a yellow 
oil that was used as is in the next reaction. 31P NMR (162 MHz, CDCl3) δ = 13.58, 9.71. Rf: 0.44 (ethyl 
acetate). LC-MS (ESI): tR = 9.61min. HRMS (ESI): for [M+H]
+ calc.: 450.12133, found: 450.12085. 
 
16.2.4 General procedure for the synthesis of amides 229a-q 
This procedure was followed in all cases unless stated otherwise. In a flame dried, 25 mL round bottom 
schlenk, containing an egg-shaped stirring bar and an argon atmosphere, the unprotected imidazole (1 
equiv, assumed 100% yield in previous reaction) was dissolved in 2-3 mL DCM. Trityl chloride (2 equiv), 
DBU (3 equiv) and silver triflate (2.2 equiv) were sequentially added. After addition of the silver triflate a 
grey solid precipitated out of the solution. After one hour a TLC sample confirmed complete conversion 
and an additional 5 mL of DCM was added followed by one scoop of celite. The resulting mixture was 
filtered through celite, the filtrate was reduced in volume in vacuo and poured into saturated aqueous 
sodium bicarbonate solution (10 mL). The aqueous layer was washed with two additional portions of 
DCM (10 mL), the organic layers were combined, washed with brine and dried over anhydrous sodium 
sulfate. The solvent was evaporated yielding a foam that was further purified by flash column 
chromatography. 
 
4-Bis(benzyloxy)phosphoryl-2-methyl-1-triphenylmethyl-1H-imidazole (229a): Imidazole 231a (0.30 
mmol, 1.0 equiv, assumed) was used. Column chromatography (toluene:ethyl acetate 2:1 gradient 1:1) 
afforded a yellow oil (77 mg, 0.13 mmol; 54% over two steps from 228a). 1H NMR (400 MHz, CDCl3) δ 
7.42 – 7.27 (m, 19H), 7.18 – 6.97 (m, 6H), 5.21 – 5.04 (m, 4H), 1.65 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 
150.01 (d, J = 22.4 Hz), 141.63, 136.61 (d, J = 6.5 Hz), 131.38 (d, J = 38.6 Hz), 129.99, 128.45, 128.31, 
128.22, 128.18, 128.08, 127.33, 124.84, 75.83, 67.76 (d, J = 5.5 Hz),17.51. 31P NMR (162 MHz, CDCl3) δ 
14.38. Rf: 0.40 (toluene:ethyl acetate 1:1). LC-MS (ESI): tR = 10.52 min. HRMS (ESI): for [M+H]
+ calc.: 
585.23016, found: 585.23032.  
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4-Bis(benzyloxy)phosphoryl-2-ethyl-1-triphenylmethyl-1H-imidazole (229b): Imidazole 231b (0.28 
mmol, 1.0 equiv, assumed) was used. Column chromatography (toluene:ethyl acetate 2:1) afforded a 
brown oil that solidified on standing (105 mg, 0.17 mmol; 74% over two steps from 228b). 1H NMR (400 
MHz, CDCl3)
 1H NMR (400 MHz, CDCl3) δ 7.41 – 7.23 (m, 19H), 7.14 – 6.98 (m, 5H), 5.31 – 5.02 (m, 4H), 
1.94 (q, J = 7.4 Hz, 2H), 0.75 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 154.59 (d, J = 22.1 Hz), 
141.94, 136.71 (d, J = 6.6 Hz), 130.80 (d, J = 38.8 Hz), 129.86, 128.43, 128.29, 128.14, 128.12, 128.07, 
127.35, 124.86, 126.11 (d, J = 250.0 Hz), 75.54, 67.81 (d, J = 5.4 Hz), 24.23, 11.86. 31P NMR (162 MHz, 
CDCl3) δ 14.60. Rf: 0.25 (toluene:ethyl acetate 2:1). LC-MS (ESI): tR = 10.89 min. HRMS (ESI): for [M+H]
+ 
calc.: 599.24581, found: 599.24553.  
 
Dibenzyl 2-isobutyl-1-trityl-1H-imidazol-4-ylphosphonate (229c): Imidazole 231c (0.52 mmol, 1 equiv, 
assumed) was used. Column chromatography (chloroform:ethyl acetate 3:1) yielded a yellow foam (255 
mg, 0.41 mmol, 78% over two steps from 228c). The compound is unstable and slowly reverts back to the 
unprotected imidazole. 1H NMR (400 MHz, CDCl3) δ = 7.43 (s, 1H), 7.42 – 7.37 (m, 4H), 7.36 – 7.29 (m, 
15H), 7.18 – 6.99 (m, J=6.4, 2.7, 6H), 5.23 – 5.13 (m, 4H), 2.02 – 1.90 (m, 1H), 1.77 (d, J=7.0, 2H), 0.59 (d, 
J=6.6, 6H). 13C NMR (101 MHz, CDCl3) δ = 152.51 (d, J=22.0), 141.72, 136.62 (d, J=6.8), 131.02 (d, J=38.8), 
129.92, 128.32, 128.13, 128.03, 128.00, 127.88, 125.66 (d, J=249.4), 75.51, 67.78 (d, J=5.4), 39.16, 26.25, 
22.24. 31P NMR (162 MHz, CDCl3) δ = 14.45. Rf: 0.57 (chloroform:ethyl acetate 3:1). LC-MS (ESI): tR = 
11.58 min. HRMS (ESI): for [M+H]+ calc.: 627.27711, found: 627.27788. 
 
Dibenzyl 2-neopentyl-1-trityl-1H-imidazol-4-ylphosphonate (229d): Imidazole 231d (0.57 mmol, 1 
equiv, assumed) was used. Column chromatography (chloroform:ethyl acetate 18:1 gradient 9:1) yielded 
a yellow foam (209 mg, 0.33 mmol, 57% over two steps from 228d). The compound is unstable and 
slowly turns back into the unprotected imidazole.
 1H NMR (400 MHz, CDCl3) δ = 7.50 (s, 1H), 7.39 (dd, 
J=7.8, 1.6, 4H), 7.36 – 7.29 (m, 16H), 7.15 – 7.09 (m, 5H), 5.29 – 5.16 (m, 4H), 1.85 (s, 2H), 0.77 (s, 8H). 
13C NMR (101 MHz, CDCl3) δ = 
13C NMR (126 MHz, CDCl3) δ = 151.47 (d, J=22.4), 141.79, 136.69 (d, J=7.1), 
130.89 (d, J=38.6), 129.94, 128.33, 128.13, 127.98, 127.95, 127.69, 125.23 (d, J=248.6), 75.52, 67.88 (d, 
J=5.5), 42.79, 31.55, 29.61. 31P NMR (162 MHz, CDCl3) δ = 13.99. Rf: 0.58 (chloroform:ethyl acetate 6:1). 
LC-MS (ESI): tR = 11.97 min. HRMS (ESI): for [M+H]
+ calc.:641.29276, found: 641.29448. 
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Dibenzyl 2-tridecyl-1-trityl-1H-imidazol-4-ylphosphonate (229e): Imidazole 231e (0.16 mmol, 1 equiv, 
assumed) was used. Column chromatography (chloroform:ethyl acetate 9:1) yielded a clear oil (89 mg, 
0.12 mmol, 74% over two steps from 228e).1H NMR (400 MHz, CDCl3) δ = 
1H NMR (400 MHz, CDCl3) δ = 
7.43 – 7.23 (m, 20H), 7.14 – 6.98 (m, 6H), 5.21 – 5.08 (m, 4H), 2.01 – 1.87 (m, 2H), 1.42 – 1.01 (m, 20H), 
1.01 – 0.76 (m, 7H). 13C NMR (126 MHz, CDCl3) δ = 
13C NMR (101 MHz, CDCl3) δ = 153.88 (d, J=21.9), 
142.05, 136.80 (d, J=6.6), 130.87 (d, J=38.7), 130.01, 128.54, 128.39, 128.26, 128.22, 128.18, 126.09 (d, 
J=249.6), 75.71, 67.94 (d, J=5.4), 32.15, 31.15, 29.91, 29.88, 29.85, 29.78, 29.63, 29.60, 29.58, 29.44, 
27.82, 22.92, 14.35. 31P NMR (162 MHz, CDCl3) δ = 14.52. Rf: 0.22 (chloroform:ethyl acetate 9:1). LC-MS 
(ESI): tR = does not run. HRMS (ESI): for [M+H]
+ calc.: 753.41796, found: 753.41884. 
 
Dibenzyl 1-trityl-2-(undec-10-ynyl)-1H-imidazol-4-ylphosphonate (229f): Imidazole 231f (0.65 mmol, 1 
equiv, assumed) was used. Column chromatography (chloroform:ethyl acetate 9:1) yielded a yellow 
foam (336 mg, 0.47 mmol, 72% over two steps from 228f). 1H NMR (400 MHz, CDCl3) δ = 7.45 – 7.19 (m, 
20H), 7.17 – 7.00 (m, 6H), 5.20 – 5.06 (m, 4H), 2.21 – 2.09 (m, 2H), 2.01 – 1.80 (m, 3H), 1.48 (dt, J=14.7, 
7.1, 2H), 1.36 – 1.23 (m, 2H), 1.23 – 1.00 (m, 6H), 1.00 – 0.78 (m, 4H). 13C NMR (126 MHz, CDCl3) δ = 
153.81 (d, J=22.0), 142.06, 136.81 (d, J=6.6), 130.87 (d, J=38.7), 130.01, 128.53, 128.39, 128.25, 128.21, 
128.17, 126.13 (d, J=249.7), 84.97, 75.68, 68.29, 67.91 (d, J=5.4), 31.14, 29.53, 29.42, 29.34, 29.18, 
28.88, 28.68, 27.78, 18.61. 31P NMR (162 MHz, CDCl3) δ = 14.56. Rf: 0.34 (chloroform:ethyl acetate 6:1). 
LC-MS (ESI): tR = 8.37 min. HRMS (ESI): for [M+H]
+ calc.: 721.35536, found: 721.35623. 
 
Dibenzyl 2-(pentadec-14-ynyl)-1-trityl-1H-imidazol-4-ylphosphonate (229g): Imidazole 231g (0.47 
mmol, 1 equiv, assumed) was used. Column chromatography (chloroform:ethyl acetate 9:1) yielded a 
yellow foam (277 mg, 0.37 mmol, 76% over two steps from 228g). 1H NMR (400 MHz, CDCl3) δ = 7.39 – 
7.20 (m, 20H), 7.14 – 7.00 (m, 6H), 5.21 – 5.07 (m, 4H), 2.18 (td, J=7.1, 2.6, 2H), 2.00 – 1.82 (m, 3H), 1.59 
– 1.46 (m, 2H), 1.46 – 1.33 (m, J=14.3, 6.9, 2H), 1.33 – 1.00 (m, 14H), 1.00 – 0.76 (m, 4H). 13C NMR (126 
MHz, CDCl3) δ = 153.84 (d, J=22.0), 142.08, 136.82 (d, J=6.6), 131.07, 130.87 (d, J=38.8), 128.53, 128.38, 
128.24, 128.20, 128.17, 126.14 (d, J=249.7), 85.01, 75.68, 68.28, 67.91 (d, J=5.4), 31.16, 29.81, 29.81, 
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29.76, 29.73, 29.62, 29.59, 29.44, 29.33, 28.99, 28.72, 27.82, 18.63. 31P NMR (162 MHz, CDCl3) δ = 14.59. 
Rf: 0.45 (chloroform:ethyl acetate 6:1). LC-MS (ESI): tR = 10.47 min. HRMS (ESI): for [M+H]
+ calc.: 
777.41796, found: 777.41885. 
 
Dibenzyl 2-cyclopentyl-1-trityl-1H-imidazol-4-ylphosphonate (229h): Imidazole 231h (0.55 mmol, 1 
equiv, assumed) was used. Column chromatography (chloroform:ethyl acetate 6:1) yielded a yellow 
foam (274 mg, 0.43 mmol, 78% over two steps from 228h). 1H NMR (500 MHz, CDCl3) δ = 
1H NMR 7.41 
(d, J=2.0, 2H), 7.39 (d, J=1.5, 2H), 7.36 (s, 1H), 7.36 – 7.30 (m, 15H), 7.15 – 7.02 (m, 6H), 5.19 (d, J=8.1, 
4H), 2.49 – 2.38 (m, 1H), 1.69 – 1.59 (m, 2H), 1.59 – 1.47 (m, 2H), 1.22 – 1.10 (m, 2H), 1.03 – 0.94 (m, 
2H). 13C NMR (126 MHz, CDCl3) δ = 
13C NMR (126 MHz, CDCl3) δ = 158.32 (d, J=21.8), 142.15, 136.70 (d, 
J=6.7), 130.31 (d, J=38.9), 129.79, 128.35, 128.19, 128.05, 127.97, 127.96, 126.04 (d, J=248.2), 75.31, 
67.78 (d, J=5.3), 40.81, 33.51, 25.73. 31P NMR (162 MHz, CDCl3) δ = 14.70. Rf: 0.54 (chloroform:ethyl 
acetate 3:1). LC-MS (ESI): tR = 11.75 min. HRMS (ESI): for [M+H]
+ calc.: 639.27711, found: 639.27767. 
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Dibenzyl 2-cyclohexyl-1-trityl-1H-imidazol-4-ylphosphonate (229i): Imidazole 231i (0.62 mmol, 1 equiv, 
assumed) was used. Column chromatography (chloroform:ethyl acetate 3:1) yielded a brown foam (326 
mg, 0.50 mmol, 81% over two steps from 228i). 1H NMR (400 MHz, CDCl3) δ = 7.46 (s, 1H), 7.45 – 7.37 
(m, 4H), 7.37 – 7.24 (m, 15H), 7.23 – 7.06 (m, 6H), 5.26 – 5.08 (m, 4H), 2.09 (t, J=11.3, 1H), 1.52 – 1.32 
(m, 5H), 1.11 (dt, J=13.0, 8.1, 1H), 0.79 (d, J=12.9, 2H), 0.74 – 0.57 (m, 2H). 13C NMR (126 MHz, CDCl3) δ = 
157.52 (d, J=21.6), 141.97, 136.66 (d, J=6.6), 130.11 (d, J=38.9), 129.64, 128.32, 128.14, 128.03, 127.99, 
127.86, 125.94 (d, J=248.1), 75.31, 67.74 (d, J=5.3), 39.35, 31.77, 26.42, 25.60. 31P NMR (162 MHz, CDCl3) 
δ = 14.80. Rf: 0.50 (chloroform:ethyl acetate 3:1). LC-MS (ESI): tR = 7.17 min. HRMS (ESI): for [M+H]
+ calc.: 
653.29276, found: 653.29320. 
 
Dibenzyl 2-(2-cyclopentylethyl)-1-trityl-1H-imidazol-4-ylphosphonate (229j): Imidazole 231j (0.61 
mmol, 1 equiv, assumed) was used. Column chromatography (chloroform:ethyl acetate 3:1) yielded a 
yellow foam (357 mg, 0.54 mmol, 88% over two steps from 228j). 1H NMR (400 MHz, CDCl3) δ = 7.43 – 
7.23 (m, 20H), 7.16 – 7.00 (m, 6H), 5.14 (d, J=8.4, 4H), 1.98 – 1.88 (m, 2H), 1.51 – 1.25 (m, 7H), 1.15 (dt, 
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J=10.9, 7.6, 2H), 0.83 – 0.61 (m, 2H). 13C NMR (101 MHz, CDCl3) δ = 
13C NMR (101 MHz, CDCl3) δ = 153.88 
(d, J=22.0), 142.02, 136.74 (d, J=6.5), 130.81 (d, J=38.7), 129.92, 128.44, 128.30, 128.16, 128.10, 126.02 
(d, J=249.8), 75.6167.81 (d, J=5.4), 40.03, 33.84, 32.24, 30.32, 25.09. 31P NMR (162 MHz, CDCl3) δ = 
14.69. Rf: 0.62 (chloroform:ethyl acetate). LC-MS (ESI): tR = 12.23 min. HRMS (ESI): for [M+H]
+ calc.: 
667.30841, found: 667.30935. 
 
Dibenzyl 2-phenethyl-1-trityl-1H-imidazol-4-ylphosphonate (229k): Imidazole 231k (0.43 mmol, 1 
equiv, assumed) was used. Column chromatography (chloroform:ethyl acetate 3:1) yielded a brown 
foam (217 mg, 0.32 mmol, 75% over two steps from 228k). 1H NMR (500 MHz, CDCl3) δ = 7.43 (d, J=7.0, 
4H), 7.39 (s, 1H), 7.38 – 7.29 (m, 15H), 7.19 – 7.10 (m, 3H), 7.08 (dd, J=8.1, 1.0, 6H), 6.85 (d, J=7.0, 2H), 
5.22 (d, J=8.3, 4H), 2.59 – 2.48 (m, 2H), 2.34 – 2.23 (m, 2H). 13C NMR (101 MHz, CDCl3) δ =  152.54 (d, 
J=22.1), 141.82, 141.22, 136.58 (d, J=6.5), 130.89 (d, J=38.8), 129.77, 128.53, 128.39, 128.30, 128.12, 
127.97, 127.91, 126.16 (d, J=249.9), 125.16, 75.57, 67.79 (d, J=5.4), 33.70, 32.76 (there is some overlap 
in the aromatic region). 31P NMR (162 MHz, CDCl3) δ = 14.47. Rf: 0.15 (chloroform:ethyl acetate 3:1). LC-
MS (ESI): tR = 11.41 min. HRMS (ESI): for [M+H]
+ calc.: 675.27711, found: 675.27897. 
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4-Bis(benzyloxy)phosphoryl-2-phenyl-1-triphenylmethyl-1H-imidazole (229l): Imidazole 231l (0.47 
mmol, 1 equiv, assumed) was used. Column chromatography with (toluene:ethyl acetate 5:1 gradient 
2:1) afforded a brown oil that solidified on standing (224 mg, 0.35 mmol, 87% over two steps from 228l). 
1H NMR (400 MHz, CDCl3) δ 7.70 (s, 1H), 7.44 – 7.35 (m, 4H), 7.35 – 7.13 (m, 15H), 7.04 (d, J = 6.9 Hz, 
6H), 6.96 (t, J = 7.4 Hz, 1H), 6.79 (t, J = 7.5 Hz, 2H), 6.67 (d, J = 7.8 Hz, 2H), 5.32 – 5.06 (m, 4H). 13C NMR 
(101 MHz, CDCl3) δ 151.98 (d, J=22.4), 141.81, 136.76 (d, J=6.4), 132.59, 132.31 (d, J=38.2), 130.63, 
130.57, 128.58, 128.29, 128.19, 128.16, 128.10, 127.88, 126.99, 125.95 (P(O)C) the other peak of this 
doublet is obscured by the other aromatic peaks), 76.85, 68.02 (d, J=5.5). 31P NMR (162 MHz, CDCl3) δ 
13.75. Rf: 0.25 (toluene:ethyl acetate 3:1). LC-MS (ESI): tR = 11.17 min. HRMS (ESI): for [M+H]
+ calc.: 
647.24581, found: 647.24584. 
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Dibenzyl 2-(4-methoxyphenyl)-1-trityl-1H-imidazol-4-ylphosphonate (229m): Imidazole 231m (0.72 
mmol, 1 equiv, assumed) was used. Column chromatography (chloroform:ethyl acetate 6:1 gradient 3:1) 
yielded a yellow foam (397 mg, 0.57 mmol, 81% over two steps from 228m). 1H NMR (500 MHz, CDCl3) δ 
= 7.72 (s, 1H), 7.41 (d, J=6.5, 4H), 7.37 – 7.14 (m, 13H), 7.14 – 7.00 (m, 6H), 6.62 (d, J=8.7, 2H), 6.35 (d, 
J=8.6, 2H), 5.31 – 5.14 (m, 4H), 3.64 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 
13C NMR (126 MHz, CDCl3) δ = 
158.97, 151.69 (d, J=22.5), 141.70, 136.57 (d, J=6.4), 132.03 (d, J=38.2), 131.79, 130.32, 128.37, 128.08, 
127.96, 127.94, 127.90, 126.78 (d, J=248.5), 124.82, 112.31, 76.54, 67.81 (d, J=5.5), 55.13. 31P NMR (162 
MHz, CDCl3) δ = 13.86. Rf: 0.36 (chloroform:ethyl acetate 3:1). LC-MS (ESI): tR =  8.17 min. HRMS (ESI): for 
[M+H]+ calc.: 677.25637, found: 677.25705. 
 
Dibenzyl (2-(4-chlorophenyl)-1-trityl-1H-imidazol-4-yl)phosphonate (229n): Imidazole 231n (0.59 
mmol, 1 equiv, assumed) was used. Column chromatography (chloroform:ethyl acetate 6:1 gradient 3:1) 
yielded a yellow foam (282 mg, 0.41 mmol, 70% over two steps from 228n). 1H NMR (400 MHz, CDCl3) δ 
= 7.71 (d, J = 0.9 Hz, 1H), 7.38 (dt, J = 4.7, 2.8 Hz, 4H), 7.35 – 7.16 (m, 15H), 7.07 – 6.97 (m, 6H), 6.82 – 
6.71 (m, 2H), 6.66 – 6.56 (m, 2H), 5.20 (d, J = 8.6 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ = 150.54 (d, J = 
22.5 Hz), 141.43, 136.42 (d, J = 6.3 Hz)9, 133.90, 132.12 (d, J = 38.1 Hz), 131.69, 130.77, 130.29, 128.39, 
128.16, 128.00, 127.95, 126.95, 126.60 (d, J = 114.5 Hz), 76.68, 67.88 (d, J = 5.5 Hz). 31P NMR (162 MHz, 
CDCl3) δ = 13.48. Rf: 0.21 (toluene:ethyl acetate 2:1). LC-MS (ESI): tR = 11.50 min. HRMS (ESI): for [M+H]
+ 
calc.: 681.20683, found: 681.20700. 
 
Dibenzyl 2-(3,4-dimethoxyphenyl)-1-trityl-1H-imidazol-4-ylphosphonate (229o): Imidazole 231o (0.61 
mmol, 1 equiv, assumed) was used. Column chromatography (chloroform:ethyl acetate 3:1) yielded a 
yellow foam (342 mg, 0.48 mmol, 79% over two steps from 228o). 1H NMR (500 MHz, CDCl3) δ = 7.75 (s, 
1H), 7.41 (d, J=2.0, 3H), 7.40 (d, J=1.5, 2H), 7.36 – 7.21 (m, 16H), 7.13 – 7.02 (m, 6H), 6.35 – 6.22 (m, 3H), 
5.28 – 5.14 (m, 4H), 3.73 (s, 3H), 3.40 (s, 3H). 13C NMR (126 MHz, CDCl3) δ = 151.54 (d, J=22.5), 148.47, 
146.84, 141.68, 136.54 (d, J=6.4), 131.87 (d, J=38.1), 130.29, 128.35, 128.07, 127.94, 127.90, 127.87, 
126.81 (d, J=249.4), 124.87, 123.62, 113.62, 109.72, 76.44, 67.79 (d, J=5.5), 55.77, 55.23. 31P NMR (162 
MHz, CDCl3) δ = 13.82. Rf: 0.55 (ethyl acetate). LC-MS (ESI): tR = 10.49 min. HRMS (ESI): for [M+H]
+ calc.: 
707.26694, found: 707.26948. 
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4-Bis(benzyloxy)phosphoryl-2-pentafluorophenyl-1-triphenylmethyl-1H-imidazole (229p): Imidazole 
231p (0.29 mmol, 1 equiv, assumed) was used. Column chromatography (toluene:ethyl acetate 8:1 
gradient 5:1) afforded a brown oil that solidified on standing (124 mg, 0.17 mmol, 56% over two steps 
from 228p). 1H NMR (400 MHz, CDCl3) δ 7.51 (s, 1H), 7.40 – 7.16 (m, 18H), 7.08 (d, J = 7.7 Hz, 6H), 5.32 – 
4.94 (m, 4H). 13C NMR (101 MHz, CDCl3) 
13C NMR (101 MHz, CDCl3) δ 145.8 – 145.5 (br), 143.3 – 142.9 
(br), 140.93, 138.6 – 138.2 (br), 136.66 (d, J = 23.8 Hz), 136.23 (d, J = 6.4 Hz), 136.2 – 135.5 (br), 135.44 
(d, J = 36.5 Hz), 135.26, 130.46, 130.34, 128.69, 128.54, 128.35, 127.97, 127.83, 109.10, 78.52, 68.13 (d, 
J = 5.4 Hz). 19F NMR (377 MHz, CDCl3) δ -135.12 (dd, J = 24.4, 6.3 Hz), -152.98 (t, J = 20.9 Hz), -163.40 (td, 
J = 21.8, 6.3 Hz). 31P NMR (162 MHz, CDCl3) δ 11.64. Rf: 0.30 (toluene:ethyl acetate 5:1). LC-MS (ESI): tR = 
9.17 min. HRMS (ESI): for [M+H]
+ calc.: 737.19870, found: 737.19920.  
 
Dibenzyl 2-(4-nitrophenyl)-1-trityl-1H-imidazol-4-ylphosphonate (229q): Imidazole 231q (0.19 mmol, 1 
equiv, assumed) was used. Column chromatography (chloroform:ethyl acetate 18:1 gradient to 6:1) 
yielded a clear oil (88 mg, 0.13 mmol, 67% over two steps from 228q). 1H NMR (400 MHz, CDCl3) δ = 7.69 
(d, J=0.9, 1H), 7.67 – 7.62 (m, 2H), 7.41 – 7.19 (m, 19H), 7.06 – 7.00 (m, 6H), 6.94 – 6.88 (m, 2H), 5.18 (d, 
J=8.7, 4H). 13C NMR (126 MHz, CDCl3) δ = 149.41 (d, J=22.6), 146.90, 141.39, 138.74, 136.52 (d, J=6.1), 
132.71 (d, J=38.1), 131.42, 130.51, 128.68, 128.63, 128.43, 128.36, 128.36 (d, J=249.8), 128.19, 121.94, 
77.17, 68.16 (d, J=5.5). 31P NMR (162 MHz, CDCl3) δ = 12.93. Rf: 0.47 (chloroform:ethyl acetate 3:1). LC-
MS (ESI): tR = 10.86 min. HRMS (ESI): for [M+H]
+ calc.: 692.23088, found: 692.23166. 
 
Dibenzyl 1H-imidazol-4-ylphosphonate (234): Trityl imidazole 167 (500 mg, 0.88 mmol, 1 equiv) was 
dissolved in acetic acid (5 mL), triisopropyl silane  (278 mg, 359 µL, 1.75 mmol, 2 equiv)  and 
trifluoroacetic acid (100 mg, 67 µL, 0.88 mmol, 1 equiv) were added and the mixture was stirred for 16 
hours. TLC sample indicated conversion was not complete, a further 150 µL of TFA was added, after a 
further two hours stirring at room temperature the conversion was complete. The mixture was 
evaporated to dryness, partitioned between 0.5 M aqueous potassium hydrogen sulfate (10 mL) and 
methyl tert-butyl ether (10 mL). The organic phase was washed with 2 additional 5 mL portions of 0.5 M 
aqueous potassium hydrogen sulfate, the aqueous layers were combined, pH was adjusted to 8.5 with 
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sodium hydrogen carbonate and extracted with five 10 mL portions of chloroform. Evaporation of the 
solvent yielded an off-white oil (187 mg, 0.57 mmol, 65%). 1H NMR (400 MHz, CDCl3) δ 7.69 (s, 1H), 7.51 
(s, 1H), 7.34 – 7.21 (m, 11H), 5.16 – 5.00 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 142.37 (CH), 138.86 (d, J = 
22.5, CH), 136.04 (d, J = 6.9, 2xC), 129.01 (d, J = 162.9, C), 128.61 (2xCH), 128.47 (2xCH), 127.92 (2xCH), 
68.11 (d, J = 5.4, 2xCH2). 
31P NMR (162 MHz, CDCl3) δ 13.54 (br). Rf: 0.72 (chloroform : methanol : (ethyl 
acetate:methanol:acetic acid:water 3:3:3:2) 9:2:1). LC-MS (ESI): tR = 6.65 min. HRMS (ESI): for [M+H]
+ 
calc.: 329.10496, found: 329.10507.  
 
Benzyl hydrogen 1-trityl-1H-imidazol-4-ylphosphonate (254): A 25 mL round bottom flask, containing 
an egg-shaped stirring bar, was charged with imidazole 167 (426 mg, 0.75 mmol, 1 equiv) and toluene (4 
mL). The mixture was stirred and DABCO (167 mg, 1.5 mmol, 2 equiv) was added in one batch. The 
mixture was heated to 80°C for 3 hours, after which a TLC sample (cyclohexane: ethyl acetate 1:4) 
showed complete consumption of the starting material. The solvent was evaporated in vacuo, the 
resulting solid was dissolved in 50 mM aqueous ammonium bicarbonate (ca. 3 mL) and a minimal 
amount of acetonitrile (ca. 1 mL) and purified over a C18 sep-pak cartridge (loading 100 mg per gram, 
100% water to 100% acetonitrile in steps of 10%, each step 7 mL solvent per gram C18, compound came 
at 30 - 50 % acetonitrile), removal of the solvent by lyophilization yielded 399 mg of a white fluffy solid 
(assumed quant.). 1H NMR (400 MHz, CDCl3) δ 7.62 – 7.50 (m, 2H), 7.38 (s, 1H), 7.34 – 7.07 (m, 17H), 
7.07 – 6.95 (m, 6H), 5.89 (s, 1H), 5.01 (s, 2H), 4.75 (d, J = 6.5 Hz, 2H), 3.66 – 3.54 (m, 6H), 2.94 (t, J = 7.3 
Hz, 6H). 31P NMR (162 MHz, CDCl3) δ 5.57. LC-MS (ESI): tR = 7.73 min. HRMS (ESI): for [M+H]
+ calc.: 
481.16756, found: 481.16716. 
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Imidazole (257): In a 5 ml, flame dried round bottom Schlenk, imidazole 254 (20 mg, 0.042 mmol, 1 
equiv) was dissolved in 0.5 mL dichloromethane. NH2-Ser(TBS)-OAll (16 mg, 0.063 mmol, 1.5 equiv) was 
added followed by PyBroP (23 mg, 0.05 mmol, 1.2 equiv) and DIPEA (22 µL, 16 mg, 0.126 mmol, 3 equiv). 
The mixture was stirred for 20 hours, the solvent was evaporated and the residue loaded on a C18 sep-
pak cartridge (0.5 g). Elution was done with a gradient of 50 mM aqueous ammonium carbonate and 
acetonitrile (100% 50 mM aqueous ammonium carbonate to 100% acetonitrile in steps of 10%). Fraction 
nine and ten contained product, lyophilization of the solution yielded 14.2 mg (0.02 mmol, 48%) of a 
white amorphous solid. 1H NMR (400 MHz, CDCl3) δ = 7.62 – 7.32 (m, 16H), 7.21 – 7.04 (m, 6H), 6.00 – 
5.80 (m, 1H), 5.41 – 5.04 (m, 4H), 4.60 (ddd, J=10.4, 6.7, 4.3, 2H), 4.23 (bs, 1H), 4.15 – 3.64 (m, 4H), 3.24 
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– 3.17 (m, 1H), 0.97 – 0.75 (m, 9H), 0.15 – -0.09 (m, 6H). 31P NMR (162 MHz, CDCl3) δ = 16.06, 15.87. LC-
MS (ESI): tR =  11.84 min. HRMS: calc: 722.31736, found: 722.31722. 
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 (S)-benzyl 2-(3-(allyloxy)-2-(allyloxycarbonylamino)-3-oxopropyl)-1-trityl-1H-imidazol-4-
ylphosphonate 1-benzyl-4-aza-1-azoniabicyclo[2.2.2]octane salt (273): In a 5 mL, flame dried pear-
shaped schlenk, containing a stirring bar and an argon atmosphere, imidazole 136 (39 mg, 0.05 mmol, 1 
equiv) was dissolved in 0.5 mL of anhydrous toluene. DABCO (11.2 mg, 0.1 mmol, 2 equiv) was added 
and the mixture was stirred overnight. The solvent was evaporated yielding an off white, amorphous 
solid. 1H NMR (400 MHz, CDCl3) δ = 7.38 – 7.13 (m, 20H), 7.13 – 7.03 (m, 6H), 6.83 (d, J=8.8, 1H), 5.84 – 
5.68 (m, 2H), 5.21 – 5.06 (m, 4H), 5.02 – 4.80 (m, 4H), 4.50 – 4.37 (m, 4H), 4.33 – 4.22 (m, 1H), 3.60 (t, 
J=7.3, 6H), 2.95 (t, J=7.2, 6H), 2.52 (dd, J=16.9, 5.8, 1H), 2.10 – 1.99 (m, 1H). 31P NMR (162 MHz, CDCl3) δ 
= 6.98. Rf: Doesn’t run. LC-MS (ESI): tR = 9.25 min. HRMS (ESI): for [M+H]
+ calc.: 692.25201, found: 
692.25243. 
 
(S)-2-(((9H-Fluoren-9-yl)methoxy)carbonylamino)-5-(methylamino)pentanoic acid (284): In a 100 mL 
round bottom flask, containing an egg-shaped stirring bar, FmocNH-Orn(DMB, Me)-OH (30 mg, 0.06 
mmol, 1 equiv) was dissolved in 0.8 mL acetonitrile and 0.2 mL water. CAN (132 mg, 0.24 mmol, 4 equiv) 
was added and the resulting orange mixture was stirred for one hour. The reaction mixture was 
evaporated; the residue was put on a silica column and eluted with chloroform: methanol: (acetic 
acid:ethyl acetate:methanol:water 3:3:3:2) 18:2:1 yielding 18 mg (0.05 mmol, 81%) of a brown, 
extremely hygroscopic foam. 1H NMR (400 MHz, CDCl3) δ = 7.63 (d, J = 7.5 Hz, 2H), 7.50 (d, J = 5.7 Hz, 
2H), 7.27 (t, J = 7.3 Hz, 2H), 7.24 – 7.11 (m, 2H), 7.11 – 6.99 (m, 1H), 4.20 – 3.98 (m, 4H), 2.91 (bs, 2H), 
2.59 (s, 3H), 1.90 – 1.54 (m, 4H). LC-MS (ESI): tR = 6.10 min. HRMS (ESI): for [M+H]
+ calc.: 369.18088, 
found: 369.18100. 
N
DMB
NHFmoc
OH
O
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(S)-2-(((9H-Fluoren-9-yl)methoxy)carbonylamino)-5-((2,4-dimethoxybenzyl)(methyl)amino)pentanoic 
acid (290): In a 50 mL, flame dried schlenk flask, containing and argon atmosphere, FmocHN-Orn(TFA)-
OH (1.1 mmol, 1 equiv) was dissolved in 30 mL anhydrous methanol. Molsieve (1 g) was added followed 
by 2,4- dimethoxybenzaldehyde (199 mg, 1.2 mmol, 1.1 equiv) and sodium acetate (189 mg, 2.3 mmol, 
2.1 equiv). To the clear solution sodium cyanoborohydride (138 mg, 2.2 mmol, 2 equiv) was added batch 
wise, over one hour, turning it into a white suspension. After stirring for an additional hour 
paraformaldehyde (132 g, 4.4 mmol, 4 equiv) and a second portion of sodium cyanoborohydride (0138 
mg, 2.2 mmol, 2 equiv) were added and the resulting mixture was stirred for 16 hours. The reaction 
mixture was acidified to pH 5 with acetic acid, evaporated to dryness and loaded on a silica column, the 
compound was eluted with chloroform:methanol:(acetic acid:ethyl acetate:methanol:water 3:3:3:2) 
18:2:1 yielding 376 mg (0.73 mmol, 66%) of a clear oil that solidifies on standing. 1H NMR (400 MHz, 
CDCl3) δ = 7.65 (d, J=7.5, 2H), 7.55 (dd, J=14.3, 7.3, 2H), 7.29 (t, J=7.4, 2H), 7.23 – 7.15 (m, 3H), 6.45 – 
6.30 (m, 2H), 6.19 (bs, 1H), 4.32 – 3.96 (m, 6H), 3.68 (s, 6H), 3.15 – 2.66 (m, 2H), 2.50 (s, 3H), 2.01 – 1.63 
(m, 4H). 13C NMR (126 MHz, CDCl3) δ = 175.74, 162.44, 159.52, 159.50, 155.95, 144.18, 143.95, 141.26, 
141.23, 134.23, 127.62, 127.04, 125.31, 125.22, 119.90, 109.39, 105.05, 98.70, 77.32, 77.06, 76.81, 
66.69, 55.45, 55.44, 55.27, 47.24, 38.98, 29.92, 20.26.(Some signals inferred from HSQC & HMBC). LC-
MS (ESI): tR = 6.69 min. HRMS (ESI): for [M+H]
+ calc.: 519.24896, found: 519.24844. 
 
(S)-Allyl 2-(allyloxycarbonylamino)-5-(tert-butoxycarbonylamino)pentanoate (301): In a 250 mL round 
bottom flask NH2-Orn(Boc)-OH (59.3 mmol, assumed) was dissolved in 30 mL acetonitrile and 60 mL 
water. Sodium carbonate (6.3 g, 59.3 mmol, 1 equiv) was added followed by slow addition of 6.3 mL allyl 
chloroformate (7.1 g, 59.3 mmol, 1 equiv) over 5 hours. The resulting mixture was stirred for 16 hours 
after addition was complete, at which time a TLC sample showed complete conversion of the starting 
material. The acetonitrile was removed in vacuo followed by removal of the water by lyophilization. The 
resulting white solid was dissolved in 60 mL anhydrous DMF and sodium hydrogen carbonate (4.98 g, 
59.3 mmol, 1 equiv) was added followed by allyl bromide (5.6 mL, 7.9 g, 65.2 mmol, 1.1 equiv). Resulting 
mixture was stirred for one day, the DMF was removed in vacuo and the residue was partitioned 
between ethyl acetate (50 mL) and water (50 mL). The organic layer was washed with three portions of 
water (30 mL), two portions of brine (30 mL) and dried over anhydrous sodium sulfate. The solvent was 
evaporated yielding 14.39 g (40.36 mmol, 68%) of a yellow oil that solidifies on standing. 1H NMR (400 
MHz, CDCl3) δ = 6.05 – 5.80 (m, 2H), 5.40 – 5.13 (m, 4H), 4.72 – 4.48 (m, 4H), 4.37 (s, 1H), 3.13 (d, J=6.2, 
2H), 1.95 – 1.83 (m, J=10.7, 6.0, 1H), 1.77 – 1.62 (m, 1H), 1.62 – 1.48 (m, 2H), 1.43 (s, 9H). LC-MS (ESI): tR 
= 8.80 min. HRMS (ESI): for [M+H]
+ calc.: 357.20201, found: 357.20268. 
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(S)-Allyl 2-(allyloxycarbonylamino)-5-aminopentanoate (303): In a 50 mL round bottom flask, 
containing an egg-shaped stirrer bar, Boc-protected Orthinine 301 (4 g, 11.2 mmol, 1 equiv) was 
dissolved in 6 mL anhydrous dichloromethane. 6 mL trifluoroacetic acid was added and the resulting 
mixture was stirred for 30 minutes. A TLC sample taken at this time confirmed complete conversion of 
the starting material. 24 mL toluene was added, followed by evaporating to dryness, another 24 mL 
toluene was added and the mixture was evaporated to dryness again to ensure all TFA was evaporated. 
After the final evaporation an orange oil remained 5.75 g (quant.) that was not purified further but used 
in the next reaction ‘as is’. 1H NMR (400 MHz, CDCl3) δ =  8.00 (s, 3H), 5.95 – 5.76 (m, 3H), 5.42 – 5.11 (m, 4H), 
4.73 – 4.39 (m, 4H), 4.39 – 4.08 (m, 1H), 2.98 (s, 2H), 2.09 – 1.64 (m, 4H). 13C NMR (101 MHz, CDCl3) δ = 175.20, 
175.08, 172.02, 162.34 (q, J=34.7,TFA), 156.50, 132.65, 131.53, 119.28, 118.03, 66.47, 66.19, 53.63, 39.51, 29.34, 
23.73. Rf: 0.10 (toluene:ethyl acetate 2:1). LC-MS (ESI): tR = 5.36 min. HRMS (ESI): for [M+H]
+ calc.: 
257.14958, found: 257.14964. 
 
(S)-Allyl 2-(allyloxycarbonylamino)-5-((2,4-dimethoxybenzyl)(methyl)amino)pentanoate (304): In a 100 
mL, flame dried round bottom schlenk, containing a magnetic stirring bar and an argon atmosphere, 
diprotected orthinine  303 (2.57 g, 5 mmol, 1 equiv) was dissolved in 37 mL anhydrous methanol. 5 g 3 A 
molsieve was added followed by sodium acetate (861 mg, 10.5 mmol, 2.1 equiv) and 2,4-
dimethoxybenzaldehyde (831 mg, 5 mmol, 1 equiv). Sodium cyanoborohydride (620 mg, 10 mmol, 2 
equiv) was added portion-wise over 2 hours, followed by an additional 2 hours of stirring. 
Paraformaldehyde (606 mg, 20 mmol, 4 equiv) was added followed by another portion of sodium 
cyanoborohydride (620 mg, 10 mmol, 2 equiv). The resulting mixture was stirred overnight, 5 g of celite 
was added and the suspension was filtered through celite. The filtrate was evaporated to dryness, and 
redissolved in chloroform (50 mL) and water (50 mL).  The layers were separated and the aqueous phase 
was washed with 3 additional portion of chloroform (30 mL), the organic layers were combined, washed 
with brine and dried over anhydrous sodium sulfate. After evaporation of the solvent the residue was 
further purified by flash column chromatography (chloroform:methanol 99:1 gradient 24:1) yielding 1.63 
g (3.9 mmol, 78%) of a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.16 (d, J=8.9, 1H), 6.63 (s, 1H), 6.51 – 
6.37 (m, J=5.6, 2.3, 2H), 5.97 – 5.77 (m, 2H), 5.35 – 5.11 (m, 4H), 4.60 (d, J=5.7, 2H), 4.53 (d, J=4.6, 2H), 
4.25 (d, J=4.7, 1H), 3.78 (d, J=1.1, 7H), 3.57 – 3.43 (m, 2H), 2.44 (t, J=6.5, 2H), 2.20 (s, 3H), 1.91 – 1.53 (m, 
4H).13C NMR (126 MHz, CDCl3) δ = 172.29, 160.51, 159.00, 156.20, 132.91, 131.96, 131.78, 118.71, 
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117.54, 117.40, 104.03, 98.47, 65.80, 65.57, 56.52, 55.37, 55.30, 53.97, 41.54, 30.17, 22.87. LC-MS (ESI): 
tR = 6.05 min. HRMS (ESI): for [M+H]
+ calc.: 421.23331, found: 421.23262. 
 
Di-tert-butyl allylphosphonate (317): In a 50 mL, flame dried, round bottom schlenk, containing an egg-
shaped stirring bar and an argon atmosphere, di-tert-butyl phosphite (1 g, 5.15 mmol, 1 equiv) was 
dissolved in 20 mL anhydrous THF. The mixture was cooled to 0°C and sodium hydride 60% dispersion in 
mineral oil (227 mg, 5.7 mmol, 1.1 equiv) was added. The reaction mixture was stirred at 0°C for 3 
minutes, after which allyl bromide (0.54 mL, 748 mg, 6.18 mmol, 1.2 equiv) was added and the cooling 
bath was removed. The resulting white suspension was stirred for 5 hours, after which an LCMS sample 
confirmed complete conversion of the starting material. Acetic acid (0.1 mL) was added to quench 
excess base, followed by 50 mL of water and 50 mL of ethyl acetate. The layers were separated, the 
aqueous layer was washed with 2 additional 25 mL portions of ethyl acetate, the organic layers were 
combined, washed with brine (40 mL) and dried over anhydrous sodium sulfate. Evaporation of the 
solvent yielded 1.1 g of a clear liquid. The liquid was further purified over a silica column 
(chloroform:ethyl acetate 6:1) yielding 847 mg (3.6 mmol, 70%) of a clear liquid. 1H NMR (400 MHz, 
CDCl3) δ = 5.78 (dddd, J=24.7, 13.8, 9.5, 7.3, 1H), 5.17 – 5.04 (m, 2H), 2.50 (ddt, J=21.4, 7.3, 1.3, 2H), 1.49 
(s, 18H). 31P NMR (162 MHz, CDCl3) δ = 20.06. LC-MS (ESI): tR = 8.67 min. HRMS (ESI): for [M+H]
+ calc.: 
235.14576, found: 235.14601. 
 
Tert-butyl 4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)piperazine-1-carboxylate (318): In a 100 mL round 
bottom flask, hydrazine 319 (1.76 g, 8.78 mmol, 1 equiv) and maleic anhydride (861 mg, 8.78 mmol, 1 
equiv) were dissolved dichloromethane (30 mL). The mixture was stirred for 1.5 hours at room 
temperature, while the reaction was monitored by 1H-NMR. When the starting material was completely 
consumed, the solvent was evaporated and the residue was dissolved in acetic anhydride (40 mL) and 
sodium acetate (2.16 g, 26.3 mmol, 3 equiv) was added. The resulting mixture was stirred for 2.5 hours 
at 50°C, after which the solvent was evaporated. The residual brown solid was purified by column 
chromatography (toluene:ethyl acetate 20:1) to afford a yellow solid (1.55g, 5.52 mmol, 63%). 1H NMR 
(400 MHz, CDCl3) δ = 7.20 (d, J=5.4, 1H), 6.20 (d, J=5.4, 1H), 3.53 (dq, J=6.7, 3.7, 8H), 1.47 (s, 9H). Rf: 0.40 
(toluene:ethyl acetate 3:1). LC-MS (ESI): tR = 8.81 min. HRMS (ESI): for [M+H]
+ calc.: 282.14483, found: 
282.14494. 
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1-(Piperazin-1-yl)-1H-pyrrole-2,5-dione (322): In a 50 mL round bottom flask a solution of N-Boc amine 
318 (152.3 mg, 0.54 mmol, 1 equiv) in dichloromethane (3 mL) was exposed to TFA (3 mL). After stirring 
for 30 minutes at room temperature the starting material was consumed (TLC) and the solvent was 
evaporated yielding a yellow solid that required no further purification (quantitative as the TFA salt). 1H 
NMR (400 MHz, CDCl3) δ 8.89 (s, 2H), 7.24 (d, J = 5.5 Hz, 1H), 6.34 (d, J = 5.5 Hz, 1H), 3.82 – 3.70 (m, 4H), 
3.40 (s, 4H).  
 
1-(4-Methylpiperazin-1-yl)-1H-pyrrole-2,5-dione (323): In a 500 mL round bottom flask, 4-
methylpiperazin-1-amine (5.03 g, 43.7 mmol, 1 equiv) and maleic anhydride (4.3 g, 43.7 mmol, 1 equiv) 
were dissolved dichloromethane (150 mL). The mixture was stirred for one hours at room temperature, 
while the reaction was monitored by 1H-NMR. When the starting material was completely consumed, 
the solvent was evaporated and the residue was dissolved in acetic anhydride (300 mL) and sodium 
acetate (10.8 g, 131 mmol, 3 equiv) was added. The resulting mixture was stirred for 12.5 hours at 50°C, 
after which the solvent was evaporated. The residual brown solid was purified by column 
chromatography (toluene:ethyl acetate 10:1) to afford a yellow oil (8.0 g, 41.1 mmol, 94%). 1H NMR (400 
MHz, CDCl3) δ = 7.17 (d, J=5.4, 1H), 6.14 (d, J=5.4, 1H), 3.61 – 3.54 (m, 4H), 2.55 – 2.50 (m, 4H), 2.30 (s, 
3H). LC-MS (ESI): tR = 1.31 min. HRMS (ESI): for [M+H]
+ calc.: 196.10805, found: 196.10811. 
 
2-(4-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)piperazin-1-yl)ethyl acetate (326): In a 50 mL round bottom 
flask, maleic anhydride (338 mg, 3.44 mmol, 1 equiv) was added to a solution of 2-(4-aminopiperazin-1-
yl)ethyl acetate (500 mg, 3.44 mmol, 1 equiv) in dichloromethane (20 mL). The mixture was stirred for 
3.5 hours, after which the solvent was evaporated. The residue was dissolved in acetic anhydride (15 
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mL) and sodium acetate (847 mg, 10.3 mmol, 3 equiv) was added. The mixture was stirred at 50°C for 
2.5 hours, and poured into saturated aqueous sodium bicarbonate (30 mL). The aqueous layer was 
extracted with three 30 mL portions of ethyl acetate, the organic layers were combined, washed with 
brine (50 mL) and dried over anhydrous magnesium sulfate. The solvent was evaporated and the 
residual brown oil was purified by column chromatography (cyclohexane:ethyl acetate 2:1 gradient 1:1) 
to afford a yellow oil (303 mg, 1.13 mmol, 33%). 1H NMR (400 MHz, CDCl3) δ = 7.18 (d, J = 5.4 Hz, 1H), 6.16 
(d, J = 5.4 Hz, 1H), 4.20 (t, J = 5.8 Hz, 2H), 3.62 – 3.52 (m, 4H), 2.71 – 2.58 (m, 7H), 2.07 (s, 3H). LC-MS (ESI): tR = 
1.80 min. HRMS (ESI): for [M+H]+ calc.: 268.12918, found: 268.12913. 
 
Di-tert-butyl 3-hydroxypropylphosphonate (330): In a flame dried, 100 mL round bottom schlenk, 
containing an egg-shaped stirring bar and an argon atmosphere, di-tert-butyl allylphosphonate (500 mg, 
2.13 mmol, 1 equiv) was dissolved in THF (10 mL). Borane in THF (1M, 5.3 mL, 5.3 mmol, 2.5 equiv) was 
added dropwise over five minutes; after stirring for two hours a TLC sample showed complete 
conversion of the starting material. The reaction mixture was cooled to 0°C and methanol (10 mL was 
added) followed by addition of 3 M aqueous sodium hydroxide solution (5.75 mL, 17.3 mmol, 7.5 equiv) 
and 30% aqueous hydrogen peroxide (5.2 mL, 50.6 mmol, 22 equiv). The ice bath was removed and the 
reaction mixture was stirred at room temperature for two hours. The mixture was transferred to a 
separatory funnel containing 30 mL of saturated aqueous sodium bicarbonate solution and 30 mL of 
ethyl acetate, the layers were split and the aqueous layer was washed with two additional 10 mL 
portions of ethyl acetate. The organic layers were combined washed with brine, dried over anhydrous 
sodium sulfate and the solvent was removed in vacuo, yielding a clean oil that was further purified by 
flask column chromatography (toluene:ethyl acetate 1:1 gradient ethyl acetate: methanol 95:5) yielding 
167 mg of a clear oil (0.66 mmol, 31%). 1H NMR (400 MHz, CDCl3) δ = 3.69 (t, J=5.9, 2H), 3.05 (s, 1H), 
1.91 – 1.66 (m, 4H), 1.49 (s, 18H). 13C NMR (101 MHz, CDCl3) δ = 82.08 (d, J=8.6), 62.96 (d, J=12.7), 30.64 
(d, J=3.9), 28.33, 27.58 (d, J=151.9). 31P NMR (162 MHz, CDCl3) δ = 26.00. Rf: 0.14 (ethyl acetate). LC-MS 
(ESI): tR = 6.85 min. HRMS (ESI): for [M+H]
+ calc.: 253.15632, found: 253.15638. 
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16.3 Fmoc Solid Phase Peptide Synthesis (Fmoc SPPS) 
An Applied Biosystems automated peptide synthesizer was used for the automated portions of the 
syntheses of the peptides. Tentagel-RAM-Cys(Trt) was used as solid phase. Each coupling step employed 
10 equiv amino acid and 10 equiv HBTU. The pHis analogue was coupled manually, using the following 
procedure:  
The resin was pre-swollen in DCM, washed five times with DMF and deprotected with 20 % piperidine in 
DMF (3 x 10 min). The resin was washed five times with DMF followed by addition of 2 equiv pHis 
analogue, 2 equiv HATU, 2 equiv HOAt and 6 equiv DIPEA in DMF. The mixture was shaken for 16 h at rt 
and subsequently washed 5 times with DMF. N-terminal acetylation was achieved by treatment of the 
unprotected N-terminus with a 1:1 mixture of 50 equiv DIPEA with 50 equiv acetic anhydride and DMF 
for 30 min at rt. After finishing the peptide sequence the resin was washed with DMF, DCM, methanol 
and diethyl ether (5 times each). Cleavage from the resin and parallel global deprotection was achieved 
with a cleavage mixture, consisting of 2.5 % water, 2.5 % TIPS-H and 2.5 % ethanedithiol in TFA. 
Cleavage was carried out by shaking the resin 1.5 hours with the cleavage mixture, followed by two 
times 30 minutes with a fresh amount of cleavage mixture, at room temperature. Afterwards, the 
cleavage solution was evaporated to dryness, the remaining solid was triturated with diethyl ether and 
subsequently dissolved in water containing as much acetonitrile as necessary for complete dissolution. 
After lyophilization the solid was re-dissolved in water/MeCN and purified by preparative HPLC. 
16.3.1 Preparative HPLC purifications 
The peptides, both those containing the pHis analogue and the ones with normal histidine, were purified 
by preparative HPLC with an Agilent 1100 series instrument, connected to an Agilent MSD VL mass 
spectrometer and a fraction collector. As mobile phase water with 0.1 % TFA (solvent A) and acetonitrile 
(solvent B) were used. Peptides were eluted from a C18 column using the following program at a flow 
rate of 25 ml min-1: 
Time (min) B (%) 
0 5 
1 5 
20 30 
25 100 
27 100 
26 5 
29 5 
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16.3.2 Peptide data 
 
Ac-GAKRH*RKVLRGC-NH2 (216): Synthesis by Fmoc-based SPPS automated and manual coupling at 0.09 
mmol scale. Yield: 49.6 mg, 0.033 mmol, 37% (based on resin loading). 31P NMR (162 MHz, D2O) δ -2.9. 
LC-MS (ESI): tR = 1.08 min (AD card). HRMS: for [M+3H]
3+ calc: 501.27305, found: 501.27285. 
 
Ac-VQFGH*AGAGC-NH2 (217): Synthesis by Fmoc-based SPPS automated and manual coupling at 0.05 
mmol scale. Yield: 28.5 mg; 0.027 mmol; 53% (based on resin loading). 31P NMR (162 MHz, D2O) δ -3.1. 
HRMS: [M+2H]2+ : calculated: 534.21006, found: 534.21036. 
 
Ac-ADQELMTYSH*DNIIC-NH2 (218): Synthesis by Fmoc-based SPPS automated and manual coupling at 
0.05 mmol scale. Yield: 1.7 mg, 0.0009 mmol, 1.8% (based on resin loading). There was not enough 
compound available for 31P NMR. LC-MS (ESI): tR = 5.65 min. HRMS: [M+2H]
2+ : calculated: 937.37845, 
found: 937.37879. 
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Ac-FRQVRLKH*RKLREQCG-NH2 (219): Synthesis by Fmoc-based SPPS automated and manual coupling at 
0.05 mmol scale. Yield: 54.5 mg; 0.025 mmol; 50% (based on resin loading). 31P NMR (162 MHz, D2O) δ -
3.0. HRMS: [M+3H]3+ : calculated: 726.06058, found: 726.05984. 
 
Ac-GH*G-PEG-C-NH2 (220): Synthesis by Fmoc-based SPPS automated and manual coupling at 0.044 
mmol scale. Yield: 12.9 mg; 0.019 mmol; 42% (based on resin loading). 31P NMR (162 MHz, D2O) δ -2.68. 
HRMS: [M+H]+ : calculated: 697.23750, found: 697.23692. 
 
 
Ac-GAKRHRKVLRGC-NH2 (221): Synthesis by Fmoc-based SPPS automated coupling at 0.1 mmol scale. 
Yield: 100 mg, 0.07 mmol, 70% (based on resin loading). LC-MS (ESI): tR = 1.28 min (AD card). HRMS: for 
[M+4H]4+ calc: 356.21502, found: 356.21527. 
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Ac-VQFGHAGAGC-NH2 (222): Synthesis by Fmoc-based SPPS automated coupling at 0.05 mmol scale. 
Yield: 28.5 mg; 0.027 mmol; 53% (based on resin loading). HRMS: [M+H]+ : calculated: 987.44651, found: 
987.44665. 
 
Ac-ADQELMTYSHDNIIC-NH2 (223): Synthesis by Fmoc-based SPPS automated and manual coupling at 
0.05 mmol scale. Yield: 8.8 mg, 0.049 mmol, 9.8% (based on resin loading). LC-MS (ESI): tR = 5.37 min. 
HRMS: [M+2H]2+ : calculated: 897.39529, found: 897.39536. 
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Ac-FRQVRLKHRKLREQCG-NH2 (224): Synthesis by Fmoc-based SPPS automated coupling at 0.05 mmol 
scale. Yield: 57.2 mg; 0.027 mmol; 55% (based on resin loading). HRMS: [M+3H]3+ : calculated: 
699.40513, found: 699.40339. 
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Ac-GHG-PEG-C-NH2 (225): Synthesis by Fmoc-based SPPS automated at 0.138 mmol scale. Yield: 55 mg; 
0.075 mmol; 55% (based on resin loading). LC-MS (ESI): tR = 1.57 min. HRMS: for [M+Na]
+ calc: 
639.25312, found: 639.25221. 
 
  
245 
 
 
  
246 
 
 
  
247 
 
17 References 
[1] C. T. Walsh, S. Garneau-Tsodikova, G. J. Gatto, Angew. Chem. Int. Ed. 2005, 44, 7342-7372. 
[2] G. Manning, D. B. Whyte, R. Martinez, T. Hunter, S. Sudarsanam, Science 2002, 298, 1912-1934. 
[3] C. Harrison, Nat Rev Drug Discov 2012, 11, 21-21. 
[4] K. Hubel, T. Lessmann, H. Waldmann, Chem. Soc. Rev. 2008, 37, 1361-1374. 
[5] C. Smit, J. Bluemer, M. F. Eerland, M. F. Albers, M. P. Mueller, R. S. Goody, A. Itzen, C. Hedberg, 
Angewandte Chemie-International Edition 2011, 50, 9200-9204. 
[6] a) P. A. Levene, C. L. Alsberg, J. Biol. Chem. 1906, 2, 127-133; b) F. A. Lipman, P. A. Levene, J. Biol. 
Chem. 1932, 98, 0109-0114. 
[7] P. Cohen, Trends Biochem. Sci 2000, 25, 596-601. 
[8] a) P. Cohen, Annu. Rev. Biochem 1989, 58, 453-508; b) T. Hunter, Cell 2000, 100, 113-127. 
[9] A. W. Frank, Crc Critical Reviews in Biochemistry 1984, 16, 51-101. 
[10] a) E. K. Dolence, G. Mayer, B. D. Kelly, Tetrahedron: Asymmetry 2005, 16, 1583-1594; b) M. K. 
Tarrant, P. A. Cole, in Annu. Rev. Biochem, Vol. 78, Annual Reviews, Palo Alto, 2009, pp. 797-825; 
c) L. N. Johnson, Biochem. Soc. Trans. 2009, 37, 627-641. 
[11] J. Ciesla, T. Fraczyk, W. Rode, Acta Biochim. Pol. 2011, 58, 137-147. 
[12] a) C. C. Chen, B. B. Bruegger, C. W. Kern, Y. C. Lin, R. M. Halpern, R. A. Smith, Biochemistry 1977, 
16, 4852-4855; b) C.-C. Chen, D. L. Smith, B. B. Bruegger, R. M. Halpern, R. A. Smith, 
Biochemistry 1974, 13, 3785-3789; c) B. T. Wakim, P. S. Grutkoski, A. T. M. Vaughan, G. L. 
Engelmann, J. Biol. Chem. 1995, 270, 23155-23158. 
[13] L. S. Smith, C. W. Kern, R. M. Halpern, R. A. Smith, Biochem. Biophys. Res. Commun. 1976, 71, 
459-465. 
[14] M. E. Wilson, R. A. Consigli, Virology 1985, 143, 516-525. 
[15] S. E. Severin, R. J. Judelovitch, Biokhimiya 1947, 12, 105-110. 
[16] M. Deluca, P. D. Boyer, J. B. Peter, R. W. Moyer, K. E. Ebner, G. Kreil, D. E. Hultquist, 
Biochemische Zeitschrift 1963, 338, 512-&. 
[17] H. R. Matthews, K. Pesis, Y. Wei, Federation Proceedings 1987, 46, 2161-2161. 
[18] Hultquis.De, R. W. Moyer, P. D. Boyer, Biochemistry 1966, 5, 322-&. 
[19] a) S. Klumpp, G. Bechmann, A. Mäurer, D. Selke, J. Krieglstein, Biochem. Biophys. Res. Commun. 
2003, 306, 110-115; b) N. A. Elshourbagy, J. C. Near, P. J. Kmetz, G. M. Sathe, C. Southan, J. E. 
Strickler, M. Gross, J. F. Young, T. N. Wells, P. H. Groot, J. Biol. Chem. 1990, 265, 1430-1435. 
[20] a) S. Srivastava, P. Choudhury, Z. Li, G. Liu, V. Nadkarni, K. Ko, W. A. Coetzee, E. Y. Skolnik, 
Molecular Biology of the Cell 2006, 17, 146-154; b) S. Srivastava, Z. Li, K. Ko, P. Choudhury, M. 
Albaqumi, A. K. Johnson, Y. Yan, J. M. Backer, D. Unutmaz, W. A. Coetzee, E. Y. Skolnik, 
Molecular cell 2006, 24, 665-675. 
[21] a) F. Cuello, R. A. Schulze, F. Heemeyer, H. E. Meyer, S. Lutz, K. H. Jakobs, F. Niroomand, T. 
Wieland, J. Biol. Chem. 2003, 278, 7220-7226; b) A. Mäurer, T. Wieland, F. Meissl, F. Niroomand, 
R. Mehringer, J. Krieglstein, S. Klumpp, Biochem. Biophys. Res. Commun. 2005, 334, 1115-1120. 
[22] J. A. Latham, S. Y. R. Dent, Nat Struct Mol Biol 2007, 14, 1017-1024. 
[23] A. Xu, J. Hao, Z. Zhang, T. Tian, S. Jiang, J. Hao, C. Liu, L. Huang, X. Xiao, D. He, Lung Cancer 2010, 
67, 48-56. 
[24] S. Klumpp, J. Krieglstein, Sci. Signal. 2009, 2, 13. 
[25] P. G. Besant, E. Tan, P. V. Attwood, The International Journal of Biochemistry & Cell Biology 
2003, 35, 297-309. 
[26] P. Ek, G. Pettersson, B. Ek, F. Gong, J. P. Li, O. Zetterqvist, Eur. J. Biochem. 2002, 269, 5016-5023. 
[27] R. D. Busam, A.-G. Thorsell, A. Flores, M. Hammarström, C. Persson, B. M. Hallberg, J. Biol. 
Chem. 2006, 281, 33830-33834. 
248 
 
[28] R. Ma, E. Kanders, U. B. Sundh, M. Geng, P. Ek, Ö. Zetterqvist, J.-P. Li, Biochem. Biophys. Res. 
Commun. 2005, 337, 887-891. 
[29] P. V. Attwood, Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics. 
[30] J. A. Hoch, T. J. Silhavy, Two-component signal transduction, 1995. 
[31] C. Grefen, K. Harter, Planta 2004, 219, 733-742. 
[32] a) V. L. Robinson, A. M. Stock, Structure 1999, 7, R47-R53; b) H. R. Matthews, Pharmacology & 
Therapeutics 1995, 67, 323-350; c) P. V. Attwood, M. J. Piggott, X. L. Zu, P. G. Besant, Amino 
Acids 2007, 32, 145-156. 
[33] J. B. Stock, A. M. Stock, J. M. Mottonen, Nature 1990, 344, 395-400. 
[34] N. K. Dhillon, S. Sharma, G. K. Khuller, Critical Reviews in Microbiology 2003, 29, 259-275. 
[35] A. Kanavarioti, M. T. Rosenbach, J. Org. Chem. 1991, 56, 1513-1521. 
[36] Hultquis.De, Biochim. Biophys. Acta 1968, 153, 329-&. 
[37] B. Duclos, S. Marcandier, A. J. Cozzone, Methods Enzymol. 1991, 201, 10-21. 
[38] Y. Tsuji, K. T. Huh, Y. Ohsugi, Y. Watanabe, J. Org. Chem. 1985, 50, 1365-1370. 
[39] B. Basnar, M. Litschauer, S. Abermann, E. Bertagnolli, G. Strasser, M.-A. Neouze, Chem. 
Commun. 2011, 47, 361-363. 
[40] C. Schenkels, B. Erni, J.-L. Reymond, Bioorg. Med. Chem. Lett. 1999, 9, 1443-1446. 
[41] M.-a. Kakimoto, M. Kai, K. Kondo, Chem. Lett. 1982, 11, 525-526. 
[42] J.-M. Kee, T. W. Muir, ACS Chemical Biology 2011, 7, 44-51. 
[43] G. S. Singh, M. D'Hooghe, N. De Kimpe, Chem. Rev. 2007, 107, 2080-2135. 
[44] M.-a. Kakimoto, M. Kai, K. Kondo, T. Hiyama, Chem. Lett. 1982, 11, 527-528. 
[45] E. Marsault, K. Benakli, S. Beaubien, C. Saint-Louis, R. Déziel, G. Fraser, Bioorg. Med. Chem. Lett. 
2007, 17, 4187-4190. 
[46] T. Y. Zakharian, L. Di Costanzo, D. W. Christianson, Organic & Biomolecular Chemistry 2008, 6, 
3240-3243. 
[47] Z. Jin, Natural Product Reports 2011, 28, 1143-1191. 
[48] L. D. Luca, Current Medicinal Chemistry 2006, 13, 1-23. 
[49] a) P. Wasserscheid, W. Keim, Angewandte Chemie-International Edition 2000, 39, 3772-3789; b) 
R. Sheldon, Chem. Commun. 2001, 2399-2407. 
[50] a) W. A. Herrmann, Angewandte Chemie-International Edition 2002, 41, 1290-1309; b) V. Cesar, 
S. Bellemin-Laponnaz, L. H. Gade, Chem. Soc. Rev. 2004, 33, 619-636. 
[51] a) M. P. Sammes, A. R. Katritzky, in Adv. Heterocycl. Chem., Vol. Volume 35 (Ed.: R. K. Alan), 
Academic Press, 1984, pp. 413-450; b) C. J. Moody, C. W. Rees, R. G. Young, J. Chem. Soc., Perkin 
Trans. 1 1991, 335-339; c) M. Casey, C. J. Moody, C. W. Rees, J. Chem. Soc., Perkin Trans. 1 1987, 
1389-1393; d) M. R. Grimmett, in Comprehensive Heterocyclic Chemistry II (Eds.: R. K. Editors-in-
Chief:  Alan, W. R. Charles, C. W. R. Eric F.V. ScrivenA2 - Editors-in-Chief:  Alan R. Katritzky, F. V. 
S. Eric), Pergamon, Oxford, 1996, pp. 77-220. 
[52] J. A. Joule, K. Mills, Heterocyclic Chemistry, fifth ed., Wiley, 2009. 
[53] a) A. Warshel, G. Naray-Szabo, F. Sussman, J. K. Hwang, Biochemistry 1989, 28, 3629-3637; b) A. 
Warshel, P. K. Sharma, M. Kato, Y. Xiang, H. Liu, M. H. M. Olsson, Chem. Rev. 2006, 106, 3210-
3235. 
[54] a) H. Du, Y. He, R. Sivappa, C. J. Lovely, Synlett 2006, 2006, 0965-0992; b) F. Bellina, R. Rossi, Adv. 
Synth. Catal. 2010, 352, 1223-1276. 
[55] H. Debus, Justus Liebigs Annalen der Chemie 1858, 107, 199-208. 
[56] a) X. Deng, N. S. Mani, Org. Lett. 2005, 8, 269-272; b) N. J. Liverton, J. W. Butcher, C. F. 
Claiborne, D. A. Claremon, B. E. Libby, K. T. Nguyen, S. M. Pitzenberger, H. G. Selnick, G. R. 
Smith, A. Tebben, J. P. Vacca, S. L. Varga, L. Agarwal, K. Dancheck, A. J. Forsyth, D. S. Fletcher, B. 
Frantz, W. A. Hanlon, C. F. Harper, S. J. Hofsess, M. Kostura, J. Lin, S. Luell, E. A. O'Neill, C. J. 
249 
 
Orevillo, M. Pang, J. Parsons, A. Rolando, Y. Sahly, D. M. Visco, S. J. O'Keefe, J. Med. Chem. 1999, 
42, 2180-2190. 
[57] a) S. E. Wolkenberg, D. D. Wisnoski, W. H. Leister, Y. Wang, Z. Zhao, C. W. Lindsley, Org. Lett. 
2004, 6, 1453-1456; b) S. Balalaie, M. M. Hashemi, M. Akhbari, Tetrahedron Lett. 2003, 44, 1709-
1711. 
[58] a) N. D. Kokare, J. N. Sangshetti, D. B. Shinde, Synthesis-Stuttgart 2007, 2007, 2829-2834; b) G. 
V. M. Sharma, Y. Jyothi, P. S. Lakshmi, Synthetic Communications: An International Journal for 
Rapid Communication of Synthetic Organic Chemistry 2006, 36, 2991 - 3000. 
[59] V. Zuliani, G. Cocconcelli, M. Fantini, C. Ghiron, M. Rivara, J. Org. Chem. 2007, 72, 4551-4553. 
[60] A. A. Gridnev, I. M. Mihaltseva, Synth. Commun. 1994, 24, 1547-1555. 
[61] a) Y. Matsuoka, Y. Ishida, D. Sasaki, K. Saigo, Tetrahedron 2006, 62, 8199-8206; b) M. C. Perry, X. 
H. Cui, M. T. Powell, D. R. Hou, J. H. Reibenspies, K. Burgess, J. Am. Chem. Soc. 2003, 125, 113-
123; c) W. L. Bao, Z. M. Wang, Y. X. Li, J. Org. Chem. 2003, 68, 591-593; d) E. Beccalli, G. Broggini, 
A. Contini, I. De Marchi, G. Zecchi, C. Zoni, Tetrahedron-Asymmetry 2004, 15, 3181-3187; e) A. R. 
Chianese, R. H. Crabtree, Organometallics 2005, 24, 4432-4436. 
[62] F. Kunckell, Berichte Der Deutschen Chemischen Gesellschaft 1901, 34, 637-642. 
[63] T. L. Little, S. E. Webber, J. Org. Chem. 1994, 59, 7299-7305. 
[64] N. Ando, S. Terashima, Tetrahedron 2010, 66, 6224-6237. 
[65] Ł. Albrecht, L. K. Ransborg, A. Albrecht, L. Lykke, K. A. Jørgensen, Chemistry – A European Journal 
2011, 17, 13240-13246. 
[66] A. M. Van Leusen, J. Wildeman, O. H. Oldenziel, J. Org. Chem. 1977, 42, 1153-1159. 
[67] a) X. Beebe, V. Gracias, S. W. Djuric, Tetrahedron Lett. 2006, 47, 3225-3228; b) V. Gracias, D. 
Darczak, A. F. Gasiecki, S. W. Djuric, Tetrahedron Lett. 2005, 46, 9053-9056; c) V. Gracias, A. F. 
Gasiecki, S. W. Djuric, Org. Lett. 2005, 7, 3183-3186; d) V. Gracias, A. F. Gasiecki, T. G. Pagano, S. 
W. Djuric, Tetrahedron Lett. 2006, 47, 8873-8876; e) J. Sisko, A. J. Kassick, M. Mellinger, J. J. 
Filan, A. Allen, M. A. Olsen, J. Org. Chem. 2000, 65, 1516-1524; f) B.-C. Chen, R. Zhao, M. S. 
Bednarz, B. Wang, J. E. Sundeen, J. C. Barrish, J. Org. Chem. 2004, 69, 977-979; g) J. C. Boehm, J. 
M. Smietana, M. E. Sorenson, R. S. Garigipati, T. F. Gallagher, P. L. Sheldrake, J. Bradbeer, A. M. 
Badger, J. T. Laydon, J. C. Lee, L. M. Hillegass, D. E. Griswold, J. J. Breton, M. C. Chabot-Fletcher, 
J. L. Adams, J. Med. Chem. 1996, 39, 3929-3937; h) C. Almansa, J. Alfón, A. F. de Arriba, F. L. 
Cavalcanti, I. Escamilla, L. A. Gómez, A. Miralles, R. Soliva, J. Bartrolí, E. Carceller, M. Merlos, J. 
García-Rafanell, J. Med. Chem. 2003, 46, 3463-3475; i) L. Wang, K. W. Woods, Q. Li, K. J. Barr, R. 
W. McCroskey, S. M. Hannick, L. Gherke, R. B. Credo, Y.-H. Hui, K. Marsh, R. Warner, J. Y. Lee, N. 
Zielinski-Mozng, D. Frost, S. H. Rosenberg, H. L. Sham, J. Med. Chem. 2002, 45, 1697-1711. 
[68] S. K. Samanta, I. Kylanlahti, J. Yli-Kauhaluoma, Bioorg. Med. Chem. Lett. 2005, 15, 3717-3719. 
[69] a) D. A. Horne, K. Yakushijin, G. Buchi, Heterocycles 1994, 39, 139-153; b) D. A. Heerding, G. 
Chan, W. E. DeWolf Jr, A. P. Fosberry, C. A. Janson, D. D. Jaworski, E. McManus, W. H. Miller, T. 
D. Moore, D. J. Payne, X. Qiu, S. F. Rittenhouse, C. Slater-Radosti, W. Smith, D. T. Takata, K. S. 
Vaidya, C. C. K. Yuan, W. F. Huffman, Bioorg. Med. Chem. Lett. 2001, 11, 2061-2065. 
[70] a) P. Molina, C. Conesa, M. Desamparados Velasco, Synthesis-Stuttgart 1996, 1996, 1459-1462; 
b) P. M. Fresneda, P. Molina, Synlett 2004, 2004, 1-17. 
[71] Y.-B. Nie, L. Wang, M.-W. Ding, J. Org. Chem. 2011, 77, 696-700. 
[72] Y.-B. Nie, Z. Duan, M.-W. Ding, Tetrahedron 2012, 68, 965-971. 
[73] Y. G. Gololobov, N. I. Gusar, M. P. Chaus, Tetrahedron 1985, 41, 793-799. 
[74] P. Loos, M. Riedrich, H.-D. Arndt, Chem. Commun. 2009, 1900-1902. 
[75] a) P. Molina, M. J. Vilaplana, Synthesis-Stuttgart 1994, 1994, 1197-1218; b) M. Riedrich, PhD 
Thesis, TU dortmund (Dortmund), 2009. 
[76] D. R. Williams, P. D. Lowder, Y.-G. Gu, D. A. Brooks, Tetrahedron Lett. 1997, 38, 331-334. 
250 
 
[77] a) H. Xie, J. Zhu, Z. Chen, S. Li, Y. Wu, J. Org. Chem. 2010, 75, 7468-7471; b) S.-L. You, J. W. Kelly, 
Org. Lett. 2004, 6, 1681-1683; c) S. Lauwagie, R. Millet, J. Pommery, P. Depreux, J.-P. Henichart, 
Heterocycles 2006, 68, 1149-+. 
[78] I. Mohammadpoor-Baltork, M. A. Zolfigol, M. Abdollahi-Alibeik, Synlett 2004, 2004, 2803-2805. 
[79] P. K. Martin, H. R. Matthews, H. Rapoport, Thyagara.G, J. Org. Chem. 1968, 33, 3758-&. 
[80] J. L. Hughey, S. Knapp, H. Schugar, Synthesis-Stuttgart 1980, 489-490. 
[81] a) Y. Amemiya, D. D. Miller, F. L. Hsu, Synth. Commun. 1990, 20, 2483-2489; b) D. Gennet, S. Z. 
Zard, H. Zhang, Chem. Commun. 2003, 1870-1871. 
[82] T. Dockner, A. Frank, BASF A.-G., Fed. Rep. Ger. . 1979, p. 12 pp. 
[83] D. H. Huh, H. Ryu, Y. G. Kim, Tetrahedron 2004, 60, 9857-9862. 
[84] a) M. E. Campos, R. Jimenez, F. Martinez, H. Salgado, Heterocycles 1995, 40, 841-849; b) M. 
Abdollahi-Alibeik, I. Mohammadpoor-Baltork, M. A. Zolfigol, Bioorg. Med. Chem. Lett. 2004, 14, 
6079-6082; c) I. Mohammadpoor-Baltork, M. A. Zolfigol, M. Abdollahi-Alibeik, Tetrahedron Lett. 
2004, 45, 8687-8690. 
[85] K. C. Nicolaou, C. J. N. Mathison, T. Montagnon, Angew. Chem. Int. Ed. 2003, 42, 4077-4082. 
[86] M. Ishihara, H. Togo, Synlett 2006, 2006, 227-230. 
[87] a) Y. Huang, X. Zu, F. Wu, J. Xu, X. Wu, H. Yao, Tetrahedron 2012, 68, 3123-3128; b) S. Haneda, A. 
Okui, C. Ueba, M. Hayashi, Tetrahedron 2007, 63, 2414-2417. 
[88] A. de la Hoz, Á. Díaz-Ortiz, M. del Carmen Mateo, M. Moral, A. Moreno, J. Elguero, C. Foces-
Foces, M. L. Rodríguez, A. Sánchez-Migallón, Tetrahedron 2006, 62, 5868-5874. 
[89] T. Horneff, S. Chuprakov, N. Chernyak, V. Gevorgyan, V. V. Fokin, J. Am. Chem. Soc. 2008, 130, 
14972-14974. 
[90] a) S.-H. Lee, K. Yoshida, H. Matsushita, B. Clapham, G. Koch, J. Zimmermann, K. D. Janda, J. Org. 
Chem. 2004, 69, 8829-8835; b) S. Laufer, G. Wagner, D. Kotschenreuther, Angew. Chem. Int. Ed. 
2002, 41, 2290-2293. 
[91] a) L. Preti, O. A. Attanasi, E. Caselli, G. Favi, C. Ori, P. Davoli, F. Felluga, F. Prati, Eur. J. Org. Chem. 
2010, 2010, 4312-4320; b) O. A. Attanasi, E. Caselli, P. Davoli, G. Favi, F. Mantellini, C. Ori, F. 
Prati, Org. Lett. 2009, 11, 2840-2843; c) O. A. Attanasi, P. Davoli, G. Favi, P. Filippone, A. Forni, G. 
Moscatelli, F. Prati, Org. Lett. 2007, 9, 3461-3464. 
[92] S. Li, Z. Li, Y. Yuan, D. Peng, Y. Li, L. Zhang, Y. Wu, Org. Lett. 2012, 14, 1130-1133. 
[93] T. Benincori, E. Brenna, F. Sannicolo, J. Chem. Soc., Perkin Trans. 1 1993, 675-679. 
[94] a) M. A. Honey, R. Pasceri, W. Lewis, C. J. Moody, J. Org. Chem. 2012, 77, 1396-1405; b) W. Li, Y. 
Lam, J. Comb. Chem. 2005, 7, 644-647; c) D. E. Frantz, L. Morency, A. Soheili, J. A. Murry, E. J. J. 
Grabowski, R. D. Tillyer, Org. Lett. 2004, 6, 843-846. 
[95] a) C. Kanazawa, S. Kamijo, Y. Yamamoto, J. Am. Chem. Soc. 2006, 128, 10662-10663; b) M.-A. 
Bonin, D. Giguère, R. Roy, Tetrahedron 2007, 63, 4912-4917. 
[96] M. E. Voss, C. M. Beer, S. A. Mitchell, P. A. Blomgren, P. E. Zhichkin, Tetrahedron 2008, 64, 645-
651. 
[97] S. Zaman, K. Mitsuru, A. D. Abell, Org. Lett. 2005, 7, 609-611. 
[98] S. Petit, C. Fruit, L. Bischoff, Org. Lett. 2010, 12, 4928-4931. 
[99] C. H. Soh, W. K. Chui, Y. Lam, J. Comb. Chem. 2006, 8, 464-468. 
[100] H. Bredereck, G. Theilig, Chem. Ber. Recl. 1953, 86, 88-96. 
[101] J. J. Garcia, P. Zerecero-Silva, G. Reyes-Rios, M. G. Crestani, A. Arevalo, R. Barrios-Francisco, 
Chem. Commun. 2011, 47, 10121-10123. 
[102] V. Kumar, A. Anand, M. P. Mahajan, Synlett 2006, 2006, 2199-2202. 
[103] B. Hu, Z. Wang, N. Ai, J. Zheng, X.-H. Liu, S. Shan, Z. Wang, Org. Lett. 2011, 13, 6362-6365. 
[104] a) M. McLaughlin, R. M. Mohareb, H. Rapoport, J. Org. Chem. 2002, 68, 50-54; b) Y.-L. Zhong, J. 
Lee, R. A. Reamer, D. Askin, Org. Lett. 2004, 6, 929-931. 
251 
 
[105] M. Gwiazda, H.-U. Reissig, Synlett 2006, 2006, 1683-1686. 
[106] C. Kison, T. Opatz, Chemistry – A European Journal 2009, 15, 843-845. 
[107] R. B. Sparks, A. P. Combs, Org. Lett. 2004, 6, 2473-2475. 
[108] I. Lantos, W. Y. Zhang, X. Shui, D. S. Eggleston, J. Org. Chem. 1993, 58, 7092-7095. 
[109] a) C. J. Helal, J. C. Lucas, Org. Lett. 2002, 4, 4133-4134; b) L. De Luca, G. Giacomelli, A. 
Porcheddu, J. Comb. Chem. 2005, 7, 905-908. 
[110] K.-i. Nunami, M. Yamada, T. Fukui, K. Matsumoto, J. Org. Chem. 1994, 59, 7635-7642. 
[111] a) M. R. Grimmett, in Comprehensive Heterocyclic Chemistry (Eds.: R. K.   Editors-in-Chief:  Alan, 
W. R. Charles), Pergamon, Oxford, 1984, pp. 457-498; b) N. Xi, Q. Huang, L. Liu, in 
Comprehensive Heterocyclic Chemistry III (Eds.: R. K. Editors-in-Chief:  Alan, A. R. Christopher, F. 
V. S. Eric, J. K. T. Richard), Elsevier, Oxford, 2008, pp. 143-364. 
[112] J.-M. Kee, B. Villani, L. R. Carpenter, T. W. Muir, J. Am. Chem. Soc. 2010, 132, 14327-14329. 
[113] J. M. Van der Eijk, R. J. M. Nolte, J. W. Zwikker, J. Org. Chem. 1980, 45, 547-548. 
[114] a) K. Moonen, I. Laureyn, C. V. Stevens, Chem. Rev. 2004, 104, 6177-6216; b) I. Billault, A. 
Vasella, Helv. Chim. Acta 1999, 82, 1137-1149. 
[115] N. Shibata, J. E. Baldwin, A. Jacobs, M. E. Wood, Synlett 1996, 519-520. 
[116] J. E. Baldwin, A. C. Spivey, C. J. Schofield, J. B. Sweeney, Tetrahedron 1993, 49, 6309-6330. 
[117] K. A. Kumar, K. M. L. Rai, K. B. Umesha, Tetrahedron 2001, 57, 6993-6996. 
[118] a) E. Herranz, K. B. Sharpless, J. Org. Chem. 1978, 43, 2544-2548; b) K. B. Sharpless, A. O. Chong, 
K. Oshima, J. Org. Chem. 1976, 41, 177-179. 
[119] A. A. Thomas, K. B. Sharpless, J. Org. Chem. 1999, 64, 8379-8385. 
[120] a) E. K. Dolence, J. B. Roylance, Tetrahedron-Asymmetry 2004, 15, 3307-3322; b) A. Bisai, G. 
Pandey, M. K. Pandey, V. K. Singh, Tetrahedron Lett. 2003, 44, 5839-5841. 
[121] D. Ellis, Tetrahedron-Asymmetry 2001, 12, 1589-1593. 
[122] C. I. Sainz-Diaz, E. Galvez-Ruano, A. Hernandez-Laguna, J. Bellanato, J. Org. Chem. 1995, 60, 74-
83. 
[123] Z. Han, D. Krishnamurthy, P. Grover, Q. K. Fang, X. Su, H. S. Wilkinson, Z.-H. Lu, D. Magiera, C. H. 
Senanayake, Tetrahedron 2005, 61, 6386-6408. 
[124] B. Aguilera, A. Fernandez-Mayoralas, Chem. Commun. 1996, 127-128. 
[125] G. C. G. Pais, R. A. Fernandes, P. Kumar, Tetrahedron 1999, 55, 13445-13450. 
[126] K. K. Andersen, M. G. Kociolek, J. Org. Chem. 1995, 60, 2003-2007. 
[127] a) A. J. Papa, J. Org. Chem. 1966, 31, 1426; b) I. P. Beletskaya, A. V. Cheprakov, Coord. Chem. 
Rev. 2004, 248, 2337-2364. 
[128] a) Y. Génisson, N. L.-d. Viguerie, C. André, M. Baltas, L. Gorrichon, Tetrahedron: Asymmetry 
2005, 16, 1017-1023; b) A. Isidro-Llobet, M. Alvarez, F. Albericio, Chem. Rev. 2009, 109, 2455-
2504. 
[129] M. Bendikov, H. M. Duong, E. Bolanos, F. Wudl, Org. Lett. 2005, 7, 783-786. 
[130] a) A. I. Meyers, F. Tavares, Tetrahedron Lett. 1994, 35, 2481-2484; b) A. I. Meyers, F. X. Tavares, 
J. Org. Chem. 1996, 61, 8207-8215; c) K. Yamamoto, Y. G. Chen, F. G. Buono, Org. Lett. 2005, 7, 
4673-4676; d) J. A. Mayoral, S. Rodríguez-Rodríguez, L. Salvatella, Chemistry – A European 
Journal 2008, 14, 9274-9285. 
[131] a) T. K. M. Shing, Yeung, P. L. Su, Org. Lett. 2006, 8, 3149-3151; b) B. B. Snider, L. Han, C. Xie, J. 
Org. Chem. 1997, 62, 6978-6984. 
[132] X.-h. Cai, H.-j. Yang, G.-l. Zhang, Can. J. Chem. 2005, 83, 273-275. 
[133] F. Camps, J. Coll, A. Parente, Synthesis-Stuttgart 1978, 1978, 215-216. 
[134] W.-D. Woggon, F. Ruther, H. Egli, J. Chem. Soc., Chem. Commun. 1980, 706-708. 
[135] T. M. Nicoletti, C. L. Raston, M. V. Sargent, J. Chem. Soc., Perkin Trans. 1 1990, 133-138. 
[136] Lundquist, A. D. Satterfield, J. C. Pelletier, Org. Lett. 2006, 8, 3915-3918. 
252 
 
[137] M. F. Eerland, C. Hedberg, J. Org. Chem. 2012, 77, 2047-2052. 
[138] K. C. Nicolaou, A. A. Estrada, M. Zak, S. H. Lee, B. S. Safina, Angew. Chem. Int. Ed. 2005, 44, 1378-
1382. 
[139] V. V. Sureshbabu, B. Vasantha, H. P. Hemantha, Synthesis-Stuttgart 2011, 1447-1455. 
[140] M. Mori, H. Wakamatsu, N. Saito, Y. Sato, R. Narita, Y. Sato, R. Fujita, Tetrahedron 2006, 62, 
3872-3881. 
[141] a) J. E. Mathieson, J. J. Crawford, M. Schmidtmann, R. Marquez, Organic & Biomolecular 
Chemistry 2009, 7, 2170-2175; b) D. Brückner, Tetrahedron 2006, 62, 3809-3814. 
[142] H. Firouzabadi, N. Iranpoor, S. Sobhani, Tetrahedron 2004, 60, 203-210. 
[143] Y. Wan, A. N. Kurchan, L. A. Barnhurst, A. G. Kutateladze, Org. Lett. 2000, 2, 1133-1135. 
[144] a) A. Padwa, J. D. Ginn, J. Org. Chem. 2005, 70, 5197-5206; b) A. Padwa, A. G. Waterson, J. Org. 
Chem. 2000, 65, 235-244; c) D. Craig, N. P. King, A. N. Shaw, Tetrahedron Lett. 1997, 38, 8599-
8602. 
[145] N. R. Curtis, H. J. Diggle, J. J. Kulagowski, C. London, S. Grimwood, P. H. Hutson, F. Murray, P. 
Richards, A. Macaulay, K. A. Wafford, Bioorg. Med. Chem. Lett. 2003, 13, 693-696. 
[146] a) S. Cardani, C. Gennari, C. Scolastico, R. Villa, Tetrahedron 1989, 45, 7397-7404; b) C. A. M. 
Afonso, M. T. Barros, C. D. Maycock, Tetrahedron 1999, 55, 801-814. 
[147] A. I. Meyers, R. C. Strickland, J. Org. Chem. 1972, 37, 2579-2583. 
[148] A. S. Thompson, E. J. J. Grabowski, Merck and Co., Inc., USA . 1995, p. 43 pp. 
[149] K. C. K. Swamy, N. N. B. Kumar, E. Balaraman, K. V. P. P. Kumar, Chem. Rev. 2009, 109, 2551-
2651. 
[150] Z. Gultekin, H. Bayrak, W. Frey, Asian J. Chem. 2006, 18, 1474-1480. 
[151] a) S. Yoshida, H. Yorimitsu, K. Oshima, Org. Lett. 2009, 11, 2185-2188; b) R. C. Cambie, G. R. 
Clark, S. R. Gallagher, P. S. Rutledge, M. J. Stone, P. D. Woodgate, J. Organomet. Chem. 1988, 
342, 315-337. 
[152] M. Ginisty, C. Gravier-Pelletier, Y. Le Merrer, Tetrahedron: Asymmetry 2006, 17, 142-150. 
[153] P. A. Grieco, Y. Yokoyama, G. P. Withers, F. J. Okuniewicz, C. L. J. Wang, J. Org. Chem. 1978, 43, 
4178-4182. 
[154] a) M. Miyashita, A. Yoshikoshi, P. A. Grieco, J. Org. Chem. 1977, 42, 3772-3774; b) R. Sterzycki, 
Synthesis-Stuttgart 1979, 1979, 724-725. 
[155] a) K. S. Kim, Y. H. Song, B. H. Lee, C. S. Hahn, J. Org. Chem. 1986, 51, 404-407; b) S. E. Sen, S. L. 
Roach, J. K. Boggs, G. J. Ewing, J. Magrath, J. Org. Chem. 1997, 62, 6684-6686. 
[156] H. M. Walborsky, R. H. Davis, D. R. Howton, J. Am. Chem. Soc. 1951, 73, 2590-2594. 
[157] K. Tanemura, T. Suzuki, T. Horaguchi, J. Chem. Soc., Chem. Commun. 1992, 979-980. 
[158] K. M. Brummond, H. Chen, B. Mitasev, A. D. Casarez, Org. Lett. 2004, 6, 2161-2163. 
[159] W. Yu, Y. Mei, Y. Kang, Z. Hua, Z. Jin, Org. Lett. 2004, 6, 3217-3219. 
[160] L. D. Arnold, J. C. G. Drover, J. C. Vederas, J. Am. Chem. Soc. 1987, 109, 4649-4659. 
[161] S. Van der Jeught, C. V. Stevens, Chem. Rev. 2009, 109, 2672-2702. 
[162] a) B. Iddon, N. Khan, J. Chem. Soc., Perkin Trans. 1 1987, 1445-1451; b) B. Iddon, N. Khan, J. 
Chem. Soc., Perkin Trans. 1 1987, 1453-1455; c) B. Iddon, N. Khan, B. L. Lim, J. Chem. Soc., Perkin 
Trans. 1 1987, 1437-1443. 
[163] M. Bahnous, C. Mouats, Y. Fort, P. C. Gros, Tetrahedron Lett. 2006, 47, 1949-1951. 
[164] a) C. J. Lovely, H. Du, R. Sivappa, M. R. Bhandari, Y. He, H. V. R. Dias, J. Org. Chem. 2007, 72, 
3741-3749; b) N. Matsunaga, T. Kaku, A. Ojida, A. Tasaka, Tetrahedron-Asymmetry 2004, 15, 
2021-2028. 
[165] T. Tschamber, F. Gessier, M. Neuburger, Sudagar S. Gurcha, Gurdyal S. Besra, J. Streith, Eur. J. 
Org. Chem. 2003, 2003, 2792-2798. 
[166] T. Hirao, T. Masunaga, Y. Ohshiro, T. Agawa, Tetrahedron Lett. 1980, 21, 3595-3598. 
253 
 
[167] a) D. Gelman, L. Jiang, S. L. Buchwald, Org. Lett. 2003, 5, 2315-2318; b) C. Huang, X. Tang, H. Fu, 
Y. Jiang, Y. Zhao, J. Org. Chem. 2006, 71, 5020-5022; c) T. Hirao, T. Masunaga, N. Yamada, Y. 
Ohshiro, T. Agawa, Bull. Chem. Soc. Jpn. 1982, 55, 909-913. 
[168] M. Kalek, J. Stawinski, Organometallics 2007, 26, 5840-5847. 
[169] a) S. Doussin, N. Birlirakis, D. Georgin, F. Taran, P. Berthault, Chemistry-a European Journal 2006, 
12, 4170-4175; b) B. Punji, J. T. Mague, M. S. Balakrishna, Inorg. Chem. 2007, 46, 10268-10275. 
[170] a) D. S. Carver, S. D. Lindell, E. A. SavilleStones, Tetrahedron 1997, 53, 14481-14496; b) M. 
Abarbri, J. Thibonnet, L. Berillon, F. Dehmel, M. Rottlander, P. Knochel, J. Org. Chem. 2000, 65, 
4618-4634. 
[171] R. M. de Figueiredo, S. Thoret, C. Huet, J. Dubois, Synthesis-Stuttgart 2007, 2007, 529-540. 
[172] a) S. Tabanella, I. Valancogne, R. F. W. Jackson, Organic & Biomolecular Chemistry 2003, 1, 4254-
4261; b) M. Kruppa, G. Imperato, B. König, Tetrahedron 2006, 62, 1360-1364. 
[173] a) C. Han, S. L. Buchwald, J. Am. Chem. Soc. 2009, 131, 7532-7533; b) J. E. Milne, S. L. Buchwald, 
J. Am. Chem. Soc. 2004, 126, 13028-13032. 
[174] A. J. Ross, H. L. Lang, R. F. W. Jackson, J. Org. Chem. 2009, 75, 245-248. 
[175] V. F. Slagt, A. H. M. de Vries, J. G. de Vries, R. M. Kellogg, Organic Process Research & 
Development 2009, 14, 30-47. 
[176] L. Jin, H. Zhang, P. Li, J. R. Sowa, A. Lei, J. Am. Chem. Soc. 2009, 131, 9892-9893. 
[177] M. G. Organ, S. Avola, I. Dubovyk, N. Hadei, E. A. B. Kantchev, C. J. O'Brien, C. Valente, Chemistry 
– A European Journal 2006, 12, 4749-4755. 
[178] J. E. Utas, B. Olofsson, B. Åkermark, Synlett 2006, 2006, 1965-1967. 
[179] D. A. Evans, T. Bach, Angew. Chem. 1993, 105, 1414-1415. 
[180] Y.-C. Wu, J. Zhu, Org. Lett. 2009, 11, 5558-5561. 
[181] M. D. Smith, C. G. Sudhahar, D. Gong, R. V. Stahelin, M. D. Best, Molecular BioSystems 2009, 5, 
962-972. 
[182] B. H. Rotstein, V. Rai, R. Hili, A. K. Yudin, Nat. Protocols 2010, 5, 1813-1822. 
[183] a) G. Basarab, J. Eyermann, M. Gowravaram, O. Green, L. MacPherson, M. Morningstar, T. 
Nguyen, Astrazeneca AB, Swed. . 2003, p. 240 pp; b) D. Chen, C. L. Franklin, P. R. Guzzo, L. S. Lin, 
M. M. C. Lo, R. P. Nargund, I. K. Sebhat, Merck & Co., Inc., USA . 2008, p. 165pp; c) S. Daninos-
Zeghal, M. A. Al, A. Ahond, C. Poupat, P. Potier, Tetrahedron 1997, 53, 7605-7614; d) J. M. Kelly, 
A. Afonso, Schering Corporation, USA . 2007, p. 247pp; e) L. Roumen, J. W. Peeters, J. M. A. 
Emmen, I. P. E. Beugels, E. M. G. Custers, G. M. de, R. Plate, K. Pieterse, P. A. J. Hilbers, J. F. M. 
Smits, J. A. J. Vekemans, D. Leysen, H. C. J. Ottenheijm, H. M. Janssen, J. J. R. Hermans, J. Med. 
Chem. 2010, 53, 1712-1725; f) P. K. Suryadevara, S. Olepu, J. W. Lockman, J. Ohkanda, M. Karimi, 
C. L. M. J. Verlinde, J. M. Kraus, J. Schoepe, V. W. C. Van, A. D. Hamilton, F. S. Buckner, M. H. 
Gelb, J. Med. Chem. 2009, 52, 3703-3715; g) A. G. Taveras, R. J. Doll, A. B. Cooper, J. A. Ferreira, 
T. Guzi, D. F. Rane, V. M. Girijavallabhan, C. J. Aki, J. Chao, C. Alvarez, J. M. Kelly, T. Lalwani, J. A. 
Desai, J. J. s. Wang, Schering Corporation, USA . 2002, p. 215 pp. 
[184] A. Malanda Kimbonguila, S. Boucida, F. Guibé, A. Loffet, Tetrahedron 1997, 53, 12525-12538. 
[185] M. Saady, L. Lebeau, C. Mioskowski, J. Org. Chem. 1995, 60, 2946-2947. 
[186] A. B. Smith, III, L. Ducry, R. M. Corbett, R. Hirschmann, Org. Lett. 2000, 2, 3887-3890. 
[187] P. Savignac, B. Iorga, Modern Phosphonate Chemistry, first ed., CRC Press, 2003. 
[188] A. Vaseila, R. Voeffray, Helv. Chim. Acta 1982, 65, 1953-1964. 
[189] a) S. Andreae, E. Schmitz, J. Prakt. Chem./Chem.-Ztg. 1994, 336, 366-368; b) J. S. Arora, N. Kaur, 
O. I. V. Phanstiel, J. Org. Chem. 2008, 73, 6182-6186; c) K. C. Calvo, J. Org. Chem. 1987, 52, 3654-
3658; d) C. Sun, R. Bittman, J. Org. Chem. 2004, 69, 7694-7699. 
[190] C. V. Stevens, E. V. Meenen, Y. Eeckhout, B. Vanderhoydonck, W. Hooghe, Chem. Commun. 
2005, 4827-4829. 
254 
 
[191] W. Pan, C. Ansiaux, S. P. Vincent, Tetrahedron Lett. 2007, 48, 4353-4356. 
[192] M. Kawase, T. Kitamura, Y. Kikugawa, J. Org. Chem. 1989, 54, 3394-3403. 
[193] T. W. Grebe, J. B. Stock, Advances in Microbial Physiology, Vol 41 1999, 41, 139-227. 
[194] M. F. Albers, B. van Vliet, C. Hedberg, Org. Lett. 2011, 13, 6014-6017. 
[195] C. D. Warren, I. Y. Liu, A. Herscovics, R. W. Jeanloz, J. Biol. Chem. 1975, 250, 8069-8078. 
[196] G. W. Daub, E. E. Van Tamelen, J. Am. Chem. Soc. 1977, 99, 3526-3528. 
[197] M. T. Bedford, S. G. Clarke, Molecular cell 2009, 33, 1-13. 
[198] T. J. Baker, M. Tomioka, M. Goodman, Org. Synth. 2002, 78, No pp. given. 
[199] K. Feichtinger, C. Zapf, H. L. Sings, M. Goodman, J. Org. Chem. 1998, 63, 3804-3805. 
[200] R. Zhu, M. Xie, F. Wang, Q. Liu, T. Kang, Chin. J. Chem . 2010, 28, 1508-1509. 
[201] a) J. Li, J. Kou, X. Luo, E. Fan, Tetrahedron Lett. 2008, 49, 2761-2763; b) R. G. S. Berlinck, A. C. B. 
Burtoloso, A. E. Trindade-Silva, S. Romminger, R. P. Morais, K. Bandeira, C. M. Mizuno, Natural 
Product Reports 2010, 27, 1871-1907; c) T. Suhs, B. Koenig, Mini-Reviews in Organic Chemistry 
2006, 3, 315-331. 
[202] S. Flemer, Jr., J. S. Madalengoitia, Synthesis-Stuttgart 2007, 1848-1860. 
[203] C. Qin, J. Li, E. Fan, Synlett 2009, 2465-2468. 
[204] a) D. Obrecht, P. Ermert, S. Oumouch, F. Lach, A. Luther, K. Marx, K. Moehle, Polyphor AG, Switz. 
2011, 528; b) D. Obrecht, P. Ermert, S. Oumouch, F. Lach, A. Luther, K. Marx, K. Moehle, 
Polyphor AG, Switz. . 2011, 720. 
[205] S. Bertrand, O. Duval, J.-J. Hélesbeux, G. Larcher, P. Richomme, Tetrahedron Lett. 2010, 51, 
2119-2122. 
[206] L. R. Reddy, B. V. S. Reddy, E. J. Corey, Org. Lett. 2006, 8, 2819-2821. 
[207] E. Morera, F. Pinnen, G. Lucente, Org. Lett. 2002, 4, 1139-1142. 
[208] S. Wiejak, E. Masiukiewicz, B. Rzeszotarska, Chemical & Pharmaceutical Bulletin 2001, 49, 1189-
1191. 
[209] S. Nowshuddin, A. R. Reddy, Tetrahedron Lett. 2006, 47, 5159-5161. 
[210] S. D. Luzzi, M. A. Marletta, Bioorganic &amp; Medicinal Chemistry Letters 2005, 15, 3934-3941. 
[211] a) S. Rapireddy, L. Nhon, R. E. Meehan, J. Franks, D. B. Stolz, D. Tran, M. E. Selsted, D. H. Ly, J. 
Am. Chem. Soc. 2012, 134, 4041-4044; b) B. Nottelet, M. Patterer, B. François, M.-A. Schott, M. 
Domurado, X. Garric, D. Domurado, J. Coudane, Biomacromolecules 2012, 13, 1544-1553; c) M. 
J. Crawford, S. Rapireddy, R. Bahal, I. Sacui, D. H. Ly, Journal of Nucleic Acids 2011, 2011. 
[212] E. Boman, R. Dahl, N. G. J. Delaet, J. Ernst, C. Lum, L. Sebo, J. Urban, Kemia, Inc., USA . 2006, p. 
235pp. 
[213] V. Mark, J. R. V. Wazer, J. Org. Chem. 1964, 29, 1006-1008. 
 
 
 
 
  
255 
 
 
  
256 
 
 
  
257 
 
18 Acknowledgements 
First of all I would like to thank Christian for believing in me enough to hire me and then teach me the 
art of organic chemistry.  Your support, especially during the beginning of my PhD, was paramount in 
making me the chemist I am today. 
Secondly, Prof. Dr. Waldmann, thank you for accepting me into your group and giving me a place to 
work. The stimulating environment that you have created at the MPI played a major part in the 
successful completion of my thesis work. 
I would also like to thank my second ‘Gutachter’ Prof. Dr. Christmann for taking the time to get 
acquainted with my thesis work and be a part of the committee. 
Additionally, the third committee member Dr. Monika Wyszogrodzka is thanked for taking the time to 
be part of my thesis committee. 
I would like to thank the people in the group of Prof. Robert Schneider, especially Bircu Biterge for 
performing the biological experiments related to my thesis. 
Thanks to my students, Tobias and Momotaro, you will both recognize some of your work in this thesis. 
It was a joy to work with the both of you. 
Big thanks to the analytics team: Dr. Petra Janning, Andreas Brockmeyer, Evelyne Merten, Jens Warmers 
and especially Chantale Sevenich for measuring an ungodly amount of HRMS samples. 
Thanks to the other people in the Hedberg group, Martijn, Michael, Samy, Cornelis, Mihail and Jan. It 
was fun to work with you! 
Thanks to the people from A3.12 before it became the Hedberg lab: Bruno, Sureshan, Anouk, Wei Lui, 
Julia, Patrick, Timo and Charlotte.  
Thanks to all other people from department IV, both old and new, especially: Patrick, Robin, Bjoern, 
Heiko, Nancy, Ushi and Katja. I will definitely miss you guys.  
Thanks to Anouk for correcting my thesis, it was improved immensely by your suggestions! Also thanks 
to Michael for translating my Abstract into German and Bjoern for making sure that translation was as 
good as I expected. 
Thanks to my Dutch friends. Steven, Stefan, Bart, Marloes, Remko, Suus, Jeroen, Lidewij, thank you guys 
for your willingness to accept only seeing me once or twice a year and still being awesome friends! 
Thanks to Anouk’s family: Fred, Sven, Mirte, Wout and the rest, for their support, good times and being 
all around nice!  
A HUGE thanks to my family, whom I have spend too little time with: Guido, zonder je constante steun 
en hulp had ik het nooit gehaalt. Je zorgde dat er altijd een fijn thuis om naar terug te komen in de soms 
zware tijden. Mark, binnenkort zijn we allebei deel van de hard werkende echte wereld. Jij hebt je eigen 
258 
 
uitdagingen bedwongen terwijl ik in Duitsland was, ik ben er trots op je broer te zijn! Iris, met je goede 
kleding smaak en je gezelligheid heb je thuis komen altijd extra lekker gemaakt. Ik hoop dat we de kans 
krijgen elkaar wat vaker te zien nu ik klaar ben! 
Anouk, the love of my live, you are the best thing to come out of my PhD. These last few years together 
have been amazing. Ik kan niet wachten tot dat we weer lekker samen wonen! Ik hou van je! 
 
 
 
  
259 
 
 
  
260 
 
 
 
 
  
261 
 
19 Declaration/Eidesstattliche Erklärung 
Hiermit versichere ich an Eides statt, dass ich die vorliegende Arbeit selbständig und nur mit den 
angegeben Hilfsmittln angefertigt habe. 
I hereby declare that I performed the work presented independently and did not use any other but the 
indicated aids. 
Dortmund, Dezember 2012 
 
 
Bart van Vliet 
